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Abstract
Molecular interaction motifs in a system-wide network context: Computationally
charting transient kinase-substrate phosphorylation events
by Ralph Patrick
Protein phosphorylation is the most ubiquitous of post-translational modifications, regulating
a wide variety of essential functions from cell-cycle progression through to DNA damage repair.
Phosphorylation is regulated by the kinases – a super-family of proteins that comprise the
third largest protein family in the human genome. While advances in high-throughput mass
spectrometry have resulted in the identification of hundreds of thousands of phosphorylation
sites, the identification of the kinases that regulate these phosphorylation events has largely
remained elusive. Understanding the kinases responsible for phosphorylation events is often
crucial for understanding the function of the modification, however the transient nature of
kinase binding means that identifying genuine kinase-binding events in vivo is both difficult
and expensive.
The vast majority of methods for computationally predicting kinase binding targets rely pri-
marily on sequence features. A lack of specificity in many kinase-binding motifs means that
valid binding patterns can be found randomly throughout the proteome – leaving such meth-
ods susceptible to high false-positive rates. However, the determinants of phosphorylation are
not limited to the sequence; kinases are regulated through various cellular processes including
mediating/activating proteins, localisation and cell cycle-specific expression. While such infor-
mation has increasingly become accessible through proteomic databases, incomplete coverage,
variable certainty and the heterogeneous nature of context and sequence information means
that the integration of relevant features into a computational model is non-trivial.
In this thesis I present a method for the probabilistic integration of these two aspects of kinase
regulation – context and sequence – into a Bayesian network model that can accurately predict
kinase substrates. In the first part of the thesis I demonstrate how a model that incorporates
knowledge of kinase-substrate phosphorylation, protein interactions and protein abundance
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across the cell cycle can be used to classify kinase substrates. The model achieves high level
of prediction accuracy as determined by cross-validation, obtaining an average AUC of 0.86
across all kinases tested. When applying the model to complement sequence-based kinase-
specific phosphorylation site prediction using previously published methods, I find it improves
prediction performance for most comparisons made. As a validation of these ideas, I also show
how protein interaction networks can be coupled with gene expression data to predict changes
in phosphorylation status in response to varying cell treatment conditions.
To integrate kinase-binding affinity into the modelling framework, I present a method for
classifying kinase-binding sites from sequence, which captures features from the linear motifs
surrounding known kinase-specific phosphorylation sites. This method incorporates observed
position-specific amino acid frequencies and counts of co-occurring neighbouring amino acids
into a Bayesian network model. The model is trained to discriminate between a kinase’s bind-
ing profile, that of its family members, and a phosphorylation background. I show how this
sequence model can be integrated as a module into the larger context model, allowing for a
comprehensive description of the factors that influence kinase binding. This seamless integra-
tion of context and sequence increases kinase-substrate prediction accuracy, when compared
to the first context model, by over 50% at low false-positive levels. I find that this system
of predicting kinase substrates, coupled with predicting kinase binding sites from sequence,
convincingly outperforms existing kinase-specific phosphorylation site classifiers; a comparison
of prediction accuracy at strict specificity levels shows that my method predicts kinase-specific
phosphorylation sites with an average of 9-22% greater sensitivity (at a strict specificity level
of 99.9%) than the alternatives. The method, named PhosphoPICK, has been made freely
available as a web-service.
Possessing a predictor that ably integrates the context and sequence conditions that regulate
phosphorylation allows an approach to problems in phosphorylation that were not feasible
previously. Non-synonymous single nucleotide polymorphisms (nsSNPs) have the potential to
disrupt (or introduce) kinase binding sites through the modification of key amino acids that
mediate kinase activity. To validate that PhosphoPICK accurately represents the biological
characteristics determining phosphorylation occurrence, I developed a method applying Phos-
phoPICK to predict variant-causing phosphorylation loss and gain. The method quantifies the
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expected effect of a nsSNP on phosphorylation based on predictions from the sequence model,
and the probability that a query kinase will target the variant protein. Employing distributions
of predicted variants across the proteome, the method can provide a measure of the significance
of novel variants. Evaluating the method on known examples of variants causing phosphoryla-
tion loss or gain from the literature, I show that PhosphoPICK can detect the positive examples
at strict specificity levels.
While the methodology presented in this work was developed for phosphorylation, it should
be considered a framework that could be applied to alternative biological processes. Sequence
motifs and protein interactions are necessary elements for a spectrum of biology, including
post-translational modifications other than phosphorylation. The short ubiquitin-like modifier
(SUMO), for example, operates on defined sequence motifs, but is also highly dependent on the
context factors that SUMO substrates operate in. The methods I describe allow an approach to
alternative protein prediction problems, such as SUMOylation, where the integration of context
and sequence characteristics can provide a comprehensive description of the relevant regulatory
features.
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Chapter 1
Introduction and overview
1.1 Introduction
Advanced “omics” technologies are rapidly transforming the proteomic research landscape, with
a variety of proteomic and genomic databases recording hundreds of thousands of molecular
interactions (1–3), post-translational modifications (4–9) and functional annotations (10–13).
This increasingly massive and diverse amount of data requires development of computational
methods that can integrate and analyse complex biological data – thus allowing for the kind of
observations and hypothesis testing that only a systems approach to biology allows.
Many important biological processes and functions involve, or are regulated by a variety of
post-translational modifications. For example, acetylation is a co-regulator of major cellular
functions including chromatin remodelling, nuclear transport and protein degradation (14, 15)
while glycosylation is involved in protein folding, localisation and trafficking amongst other
things (16). Protein phosphorylation is the most ubiquitous post-translational modification and
has regulatory roles in a wide array of biologically important functions from DNA damage repair
(17) through to the control of cell-cycle progression. As a consequence of this, there has been
great interest in identifying protein phosphorylation events, with advanced phosphoproteomic
technologies successful in identifying hundreds of thousands of phosphorylation sites across
multiple proteomes. The protein enzymes – kinases – responsible for these modifications have
generally remained elusive; however it is the assignment of kinases to phosphorylation sites that
can give insight into the biological pathway that a site may be involved in. This has resulted
in many attempts to build computational methods for predicting phosphorylation sites and the
kinases that are responsible for them (18).
1
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Broadly speaking, there are two domains of information that need to be considered when seek-
ing to understand the regulation of kinase-mediated phosphorylation. The first is linear motifs
– short regions of amino acids that allow interactions between proteins and are necessary for
kinases to bind their target substrates. The second domain of information concerns what may
be termed the “context factors” that regulate kinase activity at the wider cellular level. Given
the highly specific functions that kinases regulate, it is essential that the activity of kinases
themselves be tightly controlled (19). Kinases are subject to a range of regulatory mechanisms,
such as activating or mediating proteins (20), cell cycle stage-specific expression and sub-cellular
localisation (21). Furthermore, “cross-talk” between post-translational modifications adds an-
other element of regulatory complexity; for example, phosphorylation can act as a promoter
or inhibitor of ubiquitiniation (22), and likewise glycosylation can act as an inhibitor of phos-
phorylation (16). These diverse factors, in concert with the sequence-specificity of kinases, all
contribute towards ensuring kinase-substrate fidelity.
The majority of existing methods for predicting kinase-specific phosphorylation sites have pri-
marily focussed on modelling features within the linear motifs that surround phosphorylation
sites. However, many motifs are non-specific and can be found at random in protein sequences,
leading to the identification of numerous false-positives. In addition to motifs, there are several
examples of predictors complementing the sequence data with other types of information con-
tained within the protein. Protein features such as disorder (23) and surface accessibility (24)
have been shown to improve model accuracy for predicting phosphorylation sites, while protein
structure has been used to both inform the design of predictive methods (25), and supplement
motif-based predictions of phosphorylation (26). While such approaches can identify valid ki-
nase binding locations within a protein, even the presence of a perfect kinase binding motif is no
guarantee that a kinase will come into contact with the protein (27). Despite these limitations,
there has been very little work invested in developing methods to analyse the context factors
that regulate kinases.
There are numerous examples of context information, with high coverage across the proteome,
that could be leveraged to build computational methods for predicting kinase substrates.
Protein-protein interactions (PPIs) are relevant to essentially all biological processes, and huge
numbers of them have been recorded in databases. In particular, PPI networks are an excellent
source of information on the molecular context that proteins operate in. PPI networks contain
a unique capacity to identify proteins that interact with, and perhaps mediate between, kinases
and their substrates. Other information concerning the “association” between proteins can be
gleaned from gene co-expression studies, which are incorporated into the STRING database
(2). Similarly, as phosphorylation is involved in cell cycle-specific processes, the incorporation
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of information relating to cell-cycle progression would be useful in identifying cell cycle-specific
kinase activity (28). The increasing availability of such proteome-wide data in publicly avail-
able databases provides a unique opportunity to leverage such information in computational
methods.
The challenge here is two-fold. Firstly, the context information that could be used to describe a
kinase’s regulation at the systems level is highly diverse, and the information will not be avail-
able for all proteins. Secondly, modelling the context that a kinase operates in, and modelling
its binding specificity are two very different problems. Therefore, the integration of context
and sequence into a single model of phosphorylation is non-trivial.
This thesis proposes a novel computational framework based on probabilistic modelling to
bridge the gap between these diverse sequence and context aspects of kinase regulation. I show
that Bayesian networks are an ideal tool for such a task, allowing for the seamless integration of
diverse types of information, and the handling of uncertain or missing data. The method works
across species, with the ability to predict kinase substrates with high accuracy in three model
organisms: human, mouse and yeast. While this work describes a method for the integration
of information relevant to phosphorylation, the framework that I propose should be considered
generic, with the potential to be applied to alternative post-translational modifications, or other
biological functions where both linear motifs and context factors are relevant.
1.2 Kinase-mediated phosphorylation
Protein phosphorylation was first described as an enzyme-regulated process in 1954, when a liver
enzyme was observed to catalyse the phosphorylation of caesin (29). Since then, the many stud-
ies involving phosphorylation have pointed to the modification as a central control mechanism
underlying every essential biological process that cells undertake (30). While earlier studies es-
timated that approximately 30% of human proteins could be phosphorylation substrates, more
recent work in phosphoproteomics has indicated a much higher figure of at least 70% (28),
making phosphorylation a highly ubiquitous post-translational modification. A consequence
of the central importance and pervasive nature of phosphorylation is that many diseases and
cancers are related to aberrant phosphorylation events, with kinases having emerged as key
drug targets (31).
Kinases are a protein superfamily containing over 500 identified members in human, and com-
prising the third most populated family of proteins (32). Kinases phosphorylate their target
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substrates through the transfer of a phosphate group from an adenosine triphosphate (ATP)
donor to (primarily) a serine (S), threonine (T) or tyrosine (Y) residue on the protein sub-
strate. It is well documented that histidine residues also undergo phosphorylation in bacterial
cells (33), though this is not known to be a common occurrence in eukaryotes. As the focus of
this work is on eukaryotic phosphorylation, only S/T/Y phosphorylation will be considered.
Phosphorylation is likely a significant factor in understanding complex organisms, with phos-
phorylation of eukaryotic proteins showing a significant increase compared to prokaryotes in
terms of numbers of phosphorylation sites (6). Indeed, the presence of large numbers of phos-
phorylation sites on a protein can result in high levels of regulatory flexibility, with a protein
containing n phosphorylation sites having 2n potential phosphorylation “states” that it can
exist in (34). There are a plethora of examples of complex biological processes that could be
explored to illustrate the important regulatory role of phosphorylation. The mitotic cell cycle
is particularly illustrative example of regulation by kinase-meditated phosphorylation, and has
been well studied (35).
1.2.1 Phosphorylation as a key regulator of the cell cycle
The mitotic cell-cycle is a highly regulated process in multi-cellular organisms, where correct
cell numbers must be maintained and damaged cells restrained from replicating. Indeed, the
definition of cancer is the situation where this process has become impaired, with cells containing
irreparable DNA damage continuing to replicate unchecked. The cell cycle is divided up in to 5
main cell-cycle stages, the progression through which are controlled tightly by phosphorylation
and mediated by a variety of kinases. The main drivers of the cell cycle are the cyclin-dependent
kinases (CDKs), which perform key (though potentially overlapping) functions at specific stages
of the cell cycle (36). There are a variety of other kinases that at specific stages, or under specific
conditions, act to inhibit or activate the CDKs; there are further kinases that respond to damage
and enable the organisation of the cell prior to the completion of mitosis.
The initial phase is the growth 1 (G1) phase, where the cell increases in size in preparation
of DNA replication. G1 progression is mediated by the CDK4 and CDK6 kinases (37). The
transition between G1 and synthesis (S) phase is crucial. A key driver of the G1/S phase
transition is CDK2 in complement with cyclin E (38). As the cell transitions into S phase the
expression of cyclin E decreases and cyclin A increases – forming the cyclin A-CDK2 complex
that phosphorylates the DNA replication machinery. As S phase involves the duplication of the
chromosomes, a highly delicate process, the DNA can suffer damage during replication (39).
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In situations of DNA damage during replication the ATR kinase interacts with the replication
machinery to halt S phase progression (40). The phase following S phase, growth 2 (G2),
specifically checks the newly replicated DNA for damage prior entry into M phase There are
a number of kinases that regulate the DNA damage response during G2, but key kinases are
ATR and ATM, which activate Checkpoint kinase 1 (CHK1) and CHK2.
Phosphorylation is particularly ubiqitous during mitosis where many complex operations are
required to take place in order to separate sister chromatid into separating cells. Various
processes to facilitate this such as spindle formation, centrosome maturation/separation and
chromosome attachment to the spindle are controlled by kinases (41, 42). The central driver
behind mitosis is the cyclin B1-CDK1 kinase complex, whose activity can trigger different
mitotic events (43). The number of cyclin B1-CDK1 complexes increases prior to mitosis, but
they are kept inactive by the phosphorylation of CDK1 by the MYT1 and WEE1 kinases.
The rapid dephosphorylation of CDK1 by phosphatases is a key signal for the start of mitosis,
causing the complex to activate Polo kinase 1 (PLK1), the most tightly periodically expressed
gene in the genome (44), which is essential for mitotic progression (if DNA damage is detected
PLK1 will be deactivated until the damage is repaired). There are several other kinases such
as Aurora kinases A and B that are involved in ordering and condensing chromosomes, and
organising the mitotic spindle (45).
Even this brief overview of the role of phosphorylation in cell cycle progression should illustrate
the fact that kinase activity must be highly specific, with kinases maintaining tight selectivity
for target selection. While there is some level of redundancy that can be tolerated, aberrant
functioning of several kinases has been linked to cancers – particularly kinases involved in
DNA damage repair pathways (such as ATM/ATR) and those involved in arresting cell–cycle
progression in case of irreparable DNA damage. The consequences of kinase malfunction should
further underline the importance of understanding kinase activity and selectivity. I now turn
to consider how it is that kinase-substrate specificity is maintained.
1.2.2 Kinase specificity and regulation
Given the role of kinases in regulating a wide array of biological processes through phosphoryla-
tion, it is critical that the kinases themselves be strictly regulated to maintain substrate fidelity.
There are several characteristics of kinases and the wider cell that contribute to ensuring that
kinases phosphorylate the correct substrates under the correct conditions. For the purpose of
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this work, I specify two main categories of interest: the binding affinity of kinases for their
substrates and the context factors that regulate kinase activity.
HIPK2
DYRK1A
DYRK
2
GSK3B
GSK3A JNK
1
JN
K2
P38A
P38B
ER
K1ERK2 ER
K5
CDK9CD
K4
CD
K6
CDK7
CD
K5
CD
K1
CDK2
CDK3
CDK2
CD
K1
ERK2ERK1
GS
K3
B
P38A
JNK1 CDK5
JNK2
CD
K7G
SK
3A
CD
K4
P3
8B
HIPK2
DYRK1A
CDK9
DYRK2
ERK
5
CD
K6
CDK3
(a) (b)
Figure 1.1: Dendrograms showing sequence similarity of kinases from their catalytic do-
mains (a), and binding-specificity from their target peptides (b). Kinase domains were
sourced from Uniprot (www.uniprot.org) and phosphorylation peptides were sourced from
PhosphoSitePlusr (4). Kinases have been coloured according to the four sub-families clus-
tered by catalytic domain sequence similarity (a).
Kinase-substrate binding affinity concerns the propensity of kinases to preferentially phospho-
rylate sites on proteins that contain a short pattern of amino acids, what is often termed a
linear motif. The preference for a kinase to bind to a linear motif is determined by the catalytic
domain of the kinase. Analysis of the 3D structure of kinases has shown that kinases contain
short catalytic domains that bind to certain sequences on substrate proteins (46). Sequence
similarity between kinases in these domains allows them to be organised into families and sub-
families (32), with closely related kinases having a tendency to bind to similar sites. Figure 1.1
shows dendrograms of kinases within the CMGC family. In Figure 1.1(a) the kinases have been
clustered according to the sequence similarity in their binding domains, and coloured accord-
ing to sub-family. Figure 1.1(b) shows a dendrogram where the kinases have been clustered
according to sequence similarity in their known phosphorylation target peptides. While there
is not a perfect overlap between the two dendrograms, they demonstrate that kinases within
the same sub-family will have a tendency to bind to similar sequence patterns.
Figure 1.2 shows examples of sequence logos for various kinase binding sites and the surrounding
amino acids. Some kinase binding motifs appear to be unspecific – the proline-dependent kinases
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such as CDK1 and ERK1 have a proline in the +1 position after the phosphorylation sites as
their main recognition symbol. An [S/T]P motif can easily be found at random throughout the
proteome, with almost 90% of human proteins containing the motif. Protein kinase A (PKA),
which appear to preferentially bind to a motif of the form [RK][RK]X[ST] can be found in 53%
of human proteins. The ATM motif, with a glutamine at the +1 position, can be found in 88%
of humans proteins. The AurB motif, which appears to have a preference for an arginine at the
-2 position, is seen in 87% of proteins. While a fixed motif is not the ideal way to predict kinase
binding sites (as explored in Section 1.5), this illustrates the fact that amino acid motifs that
could represent valid kinase binding sites can be found in a large proportion of the proteome.
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Figure 1.2: Sequence logos representing various kinase binding specificities in a 15 residue
window surrounding the phosphorylation site (position 0). Phosphorylation peptides were
sourced from PhosphoSitePlusr (4) and logos were generated using WebLogo 3 (47). Logos
are listed alphabetically according to kinase name.
The presence of a valid kinase binding site on a protein is no guarantee that a kinase will come
into contact with the protein however (27). It has long been recognised that the activity of ki-
nases can be regulated through upstream processes. The activation of kinases can be controlled
through interacting proteins, complex formation, or phosphorylation events (48). Protein-
protein interaction (PPI) networks can influence phosphorylation, or themselves be regulated
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by phosphorylation, in a variety of ways. For example, kinase activity can be regulated by
mediating proteins that help target their substrates (27, 49). In addition, phosphorylation can
act as a switch within PPI networks, to enable or disable specific protein-protein interactions
within a network (50). Phosphorylation has previously been found to be associated with pro-
teins at the centre of PPI “hubs”, with a broad array of interaction partners (51). There is also
a wide variety of processes throughout the cell to activate or mediate kinases. Cell-cycle control
kinases are activated at specific stages in the cell cycle, with the cell cycle-specific expression
of cyclins coupled to the activation of their cyclin dependent kinase (CDK) counterparts to
regulate their activity at the correct cell-cycle stage (52). An example of proteins that mediate
the interaction between kinases and their substrates can be seen in scaffold proteins, which
are integral to intracellular signalling networks and phosphorylation – in particular through
coordinating kinase cascades (20).
In Section 1.2.1 I described the importance of kinase activity over the cell cycle, and some of
the regulatory mechanisms involved in ensuring cell cycle stage-specific kinase activation and
deactivation. In addition to protein interactions and the cell cycle, sub-cellular localisation
plays a role in regulating kinase activity. Kinase CK2, which has large numbers of identified
substrates, regulates different processes depending on its location in the cell (53). Critical
cellular functions like apoptosis can be associated with kinase sub-cellular location. CDK2
has been shown to localise to the nucleus in proliferating cells, and to the cytoplasm in cells
undergoing apoptosis (54). Sub-cellular localisation can also act in concert with cell-cycle
progression to regulate kinase activity – for example the sub-cellular localisation of Wee1 kinase
is dependent on cell-cycle stage (55).
There are many examples of context factors that regulate kinase activity. The ones that have
been described here have the capacity to be modelled, using the available data: huge numbers
of protein-protein interactions across multiple species have been catalogued in databases such
as BioGRID (1), and less direct “associations” in the STRING database (56). Protein-protein
interaction (or association) networks can feasibly be used to model the “interaction” context
that kinases and their substrates operate it. Furthermore, the sub-cellular activity of kinases
could be indirectly captured through the interaction networks of a kinase and its substrates.
1.3 Experimental identification of phosphorylation
There are two separate problems to consider when attempting to identify the phosphorylation
status of a protein. The first is identifying whether a “phosphorylateable” residue actually
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undergoes a phosphorylation modification. The second is the identification of the kinase that
catalyses the modification. As is outlined below, while the identification of phosphorylated
residues has become easier, and therefore the data extensive, the same has generally not oc-
curred for the identification of kinases. This has lead to a large disparity between the number
of known phosphorylation sites, and the sites that are annotated with a kinase. As phosphory-
lation is reversible, another consideration is the phosphatases that are responsible for removing
phosphorylation modifications. However, the focus in my work will be on the identification of
phosphorylation and kinase targets.
In initial studies on phosphorylation, protein phosphorylation sites were detected using 32P
labelling – a radioactive isotope of phosphorous. An alternative method for detecting phospho-
rylation sites is phospho-antibodies, which can recognise the phosphorylated form of a protein.
In recent years however, the introduction of high-throughput mass spectrometry has resulted
in phosphoproteomic studies that have identified tens of thousands of phosphorylation sites
(28, 57).
While the identification of in vivo phosphorylation sites has become easier, identifying the ki-
nases responsible for regulating the sites has in most cases remained elusive. Many experiments
to identify the kinases regulating phosphorylation sites are performed using in vitro assays.
Such experiments generally involve purifying the kinase and potential substrate to be tested
and adding them in solution with ATP. Phosphorylated forms of the potential substrate can
then be tested for using anti-bodies (for phosphorylation-specific forms of a protein or peptide)
or mass spectrometry. For example, putative ATM substrates were identified through mutage-
nesis experiments on a known substrate to characterise the kinase’s optimal binding motif (58).
This motif was then used to identify proteins containing similar motifs, and again subjected
to in vitro assays to confirm that they can be phosphorylated by the kinase. While in vitro
experiments certainly provide valuable information about the likely kinases to be catalysing a
phosphorylation modification, they are no guarantee that the kinase will phosphorylate the site
in vivo.
There are several methods for using a combination of in vivo and in vitro experiments to detect
kinase targets. Kinases can be transfected with the protein under study, and the phosphoryla-
tion levels measured; if inhibition of the kinase leads to a reduction in phosphorylation, this is
a strong indication that the site is phosphorylated by the kinase (59). Another related method
used frequently is to show through an in vitro assay that a kinase binds to the site of interest,
then show in vivo that when the kinase is inactivated (through the use of a kinase inhibitor or
transfection of kinase-specific siRNA for example), the target site does not get phosphorylated
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(60–63). Alternative or additional evidence that can be provided is to demonstrate that the
kinase interacts with the putative substrate in vivo – something that can be shown through
co-immunoprecipitation experiments (64–67). There are also kinase phosphorylation-specific
antibodies that can be used, through immunoprecipitation experiments, to identify whether a
specific phosphorylation event occurs (68). Such experiments can also be combined with kinase
inhibitors to confirm that the site is down-phosphorylated in the absence of the kinase.
There are also examples of “global” screening for kinase substrates across the proteome. Such
methods can include in vitro screening of kinases simply for the purpose of deciphering their
binding specificity (69). There are also methods that aim to identify putative kinase substrates.
One method takes advantage of a small genetic modification of a kinase that allows it to use
bulky ATP that wild-type kinases would not be able to bind to. Mass spectrometry can then
be used to identify peptides that contain the heavier phosphate form. This method has been
employed using in vitro kinase assays with cell lysates to identify putative substrates for CDK2
(70), and a similar method has been employed for CDK1 in both a human cell line (71) and
in yeast (72). Such methods are useful for the identification of putative substrates, but require
further work to confirm that the kinase targets the substrates and sites in vivo.
1.4 Phosphorylation databases
The inherent difficulty associated with identifying in vivo kinase substrates means that while
phosphorylation sites are regularly detected, the kinase responsible generally remained un-
known. For databases that catalogue phosphorylation sites, there is a substantial gap between
the number of phosphorylation sites, and the number of phosphorylation sites annotated with
a kinase. I present here a brief overview of the main eukaryotic phosphorylation databases,
and their data collection for phosphorylation sites and kinase annotations. Figure 1.3 shows
counts for four different databases that catalogue phosphorylation sites. PhosphoGRID is a
yeast-specific phosphorylation site database, Phospho.ELM catalogues vertebrate phosphoryla-
tion sites, HPRD catalogues human modifications and PhosphoSitePlus contains modifications
from a variety of mammalian organisms.
The Phospho.ELM, HPRD and PhosphoGRID databases collate phosphorylation data from
the primary literature. The PhosphoGRID data collection process involves searching abstracts
identified through a PubMed search using phosphorylation-related keywords (73). An exam-
ination of the experimental technique used for identifying the phosphorylation site (or sites)
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Figure 1.3: Counts of the total number of phosphorylation sites, and the number of sites
annotated with a kinase for the four databases used in this work. Databases shown are
PhosphoGRID (73), Phospho.ELM (74), HPRD (7) and PhosphoSitePlusr (4)
informs the confidence assigned to a particular phosphorylation sites; phosphorylation sites
recorded in PhosphoGRID typically have multiple examples of experimental evidence support-
ing their inclusion. Where a kinase has been experimentally shown to target the site, that
information is included.
Phospho.ELM also compiles phosphorylation sites (and kinase annotations) through manual
searches of the literature. In addition, the database web-site contains the capacity for re-
searchers to upload their phosphorylation data for inclusion in the database. HPRD collates
large amounts of human protein information, including protein-protein interactions, sub-cellular
localisation data, as well as multiple PTMs. Similar to the previous database, the information
in HPRD is manually curated through the search and analysis of the primary literature. The
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PhosphoSitePlus database, while also relying on the manual curation of phosphorylation sites
and kinase interactions, contains a far larger number of phosphorylation sites compared to the
alternatives (Figure 1.3). The PhosphoSitePlusr database has grown substantially as a result
of phosphorylation data generated through high-throughput mass spectrometry. Cell signalling
Technology (CST), which operates PhosphoSitePlus, also generates its own phosphoproteomic
data that is incorporated into the database. The phosphorylation sites contained in Phospho-
SitePlus are all recorded with the experimental techniques used to identify them, and whether
the experiments were performed in vitro or in vivo. Where kinases are known for the sites, the
experimental methodology is also listed. This ensures that users can choose what data they are
willing to trust, based on the methods of experimental validation.
As can be seen from Figure 1.3, there is a large disparity between the number of phosphorylation
sites recorded in these databases, and the number of sites that are annotated with a kinase.
The number of kinase-specific phosphorylation sites in PhosphoSitePlus is barely 5% of the
total number of phosphorylation sites, and for Phospho.ELM the percentage is 10%. Due to the
expansive gap between known phosphorylation sites and their kinase annotations, there has been
a great interest in developing computational methods that can not only predict phosphorylation
sites, but also the kinases that mediate the modification.
1.5 Computational prediction of phosphorylation
Since Blom and colleagues published their phosphorylation site predictor, NetPhos, in 1999
(75), the field of computational eukaryotic phosphorylation prediction has grown tremendously,
with over 50 methods published to date (Figure 1.4). While some methods aim only to predict
phosphorylation sites (75–77), the majority of these predictors are kinase-specific. That is,
the predictor scans a potential phosphorylation substrate to identify the most likely positions
for some query kinase to bind to. As the focus of this thesis is on predicting kinase targets,
rather than phosphorylation sites generally, this section will focus on the methods for predicting
phosphorylation sites in a kinase-specific manner. The different methods have various coverage
of kinases, with the approach and the training data impacting what kinases are available to the
method. Some methods will make predictions for kinase families or sub-families in addition to,
or instead of, individual kinases.
Typically, phosphorylation site predictors, whether kinase-specific or not, are primarily sequence-
based – that is, the predictor mostly relies on sequence information in the form of motifs sur-
rounding phosphorylation sites to make predictions. In some cases however, there are methods
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that complement the amino acid sequence with additional information such as structure, disor-
der or context. In addition to the variety of information types, there have been different kinds
of tools that have been employed for predicting phosphorylation sites. In this section I give an
overview of how these tools have been applied to build the various phosphorylation predictors,
and how different types of information have been used. Table 1.1 contains a summary of the
available kinase-specific phosphorylation prediction tools, with information concerning their
availability and usability.
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Figure 1.4: Count of eukaryotic phosphorylation prediction methods published between
1999 and 2015.
1.5.1 Scoring matrices
There are several kinds of sequence scoring matrices that have been used in phosphorylation site
prediction – position specific scoring matrices (PSSMs), position weight matrices (PWM) and
substitution matrices. A substitution matrix is a 20× 20 matrix representing all possible pair-
wise combinations of amino acids, and is used to score the substitution of one amino acid for
another. A classic example is the BLOSUM62 matrix often used to calculate sequence similarity.
The original Group Phosphorylation Site predictor (GPS 1.0) used the BLOSUM62 substitution
matrix to make predictions (78). The method relies on the hypothesis that phosphorylation
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sites with high sequence similarity in the surrounding peptides are more likely to be targeted by
the same kinase (or kinase family). They define a “Phosphorylation Site Peptide”, or PSP(m,n)
to represent a phosphorylation site with m residues upstream and n residues downstream from
the site. To score a putative phosphorylation site for a given kinase, they take the known
phosphorylation sites of the kinase and its immediate family. A similarity score is calculated
between the putative site PSP and the known binding sites by summing the substitution scores
from the BLOSUM62 matrix that occur in each position of the PSP(m,n). In an updated
version of the method (GPS 2.0), the authors used matrix mutation to modify the BLOSUM62
matrix and found increased sensitivity and specificity in the performance of the method (79).
In the current version of the method (GPS 2.1), the authors optimised the number of upstream
and downstream residues that are used for the PSP(m,n) (80). Instead of a fixed m and n, the
values were optimised for each kinase family.
A different kind of scoring matrix is the position weight matrix (PWM). A PWM is a 20 ×
m matrix, where each row in the matrix represents an amino acid and m is the length of
some sequence motif. Each value in the matrix represents the weight – based on observed
frequencies in training data – that an amino acid contributes towards classification at a given
position. An example of a method that uses PWMs is Predikin, which guides its generation of
PWMs based on an understanding of kinase structure and substrate-binding sites from X-ray
structures of kinase-bound phosphorylation substrates (25). Predikin is based on the concept of
specificity determining residues (SDRs): conserved sequence regions in the binding domain of
kinases that determine whether they will bind to certain substrates. Given a kinase, Predikin
identifies other kinases with similar substrate binding sites. Substrates and phosphorylation
sites for these kinases are identified from the Predikin database PredikinDB (81, 82), which itself
sources kinase substrates from UniProt (83). A frequency matrix is constructed by counting the
occurrences of amino acids in a heptapeptide (7 residue window) centred on the phosphorylation
sites, and is converted into a PWM. Predikin is therefore able to build PWMs for any kinase if
it has a binding region similar to a kinase in the PredikinDB, giving it a wide scope over many
kinases.
The MIMP (mutation impact on phosphorylation) predictor was implemented as part of a
method for scoring the expected effect of protein variants on phosphorylation (84). The au-
thors collected kinase-specific phosphorylation data from a variety of databases, and constructed
kinase-specific PWMs by calculating amino acid frequencies at each position within a 15 residue
window around the phosphorylation site. To optimise the performance of their PWMs the au-
thors performed an iterative refinement process, whereby they constructed an initial PWM
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based on the full set of positive samples. Based on random sampling of negatives, they gener-
ated distributions of scores using the PWM, scoring both the negatives and the positives used
to generate the PWM. If a positive sample fell within the 90th percentile of the negative dis-
tribution, it was discarded, and a new PWM was built based on the remaining set of positives.
This process was repeated until positives were no longer discarded (subject to a lower bound
of ten positive sequences remaining).
The above methods use phosphorylation data from known kinase-protein targets to train their
algorithms, but an alternative method is to estimate the binding specificity of kinases from
in vitro peptide array experiments. Scansite scores kinase binding locations on proteins using
kinase-specific PSSMs constructed from data generated in peptide library experiments (85).
These experiments involve incubating a kinase domain of interest with peptides that have
a fixed phosphorylatable (S/T/Y) residue and sequencing the peptides that are found to be
phosphorylated (86). These experiments yield relative levels of amino acid at positions relative
to the central phosphorylation residue, which can be normalised and converted into a PSSM
(87). The NetPhorest predictor (88) also builds PSSMs from in vitro peptide array data, though
its scoring matrices are complemented with artificial neural network classifiers (discussed below).
Due to the fixed structure of PSSMs, they train PSSMs on the peptide array data that is unlikely
to offer information regarding relationships between residues.
There are several drawbacks to using scoring matrices for predicting kinase targets. Firstly, on
account of their fixed structure, scoring matrices do not have the capacity to recognise subtle
sequence patterns; co-occurrence of certain amino acids acids would not be picked up by a
scoring matrix for example. Secondly, on account of only considering the linear motifs, scoring
matrices are blind to additional factors both within the substrate (e.g. surface accessibility),
and outside the protein, which could have an important regulatory impact on the kinases that
target it. Due to these issues, many phosphorylation predictors use machine learning methods
that are not only able to detect patterns in the sequences surrounding kinase binding sites, but
have the capacity to incorporate information in addition to that contained in the amino acid
sequence.
1.5.2 Machine learning methods
There are several machine learning methods that have been applied to phosphorylation pre-
diction. By far the most popular method is the support vector machine (SVM), though there
have been several examples of the use of neural networks. In addition, hidden Markov models
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Table 1.1: Table of kinase-specific phosphorylation site predictors. For tools with multiple
versions published, the most recent is cited. Availability specifies whether the tool can be
used through the web (Webtool), with a downloadable graphical user interface (GUI), or with
a downloadable command line (CL) tool that can be operated through a terminal. If there is
no available tool, or if a method’s website is no longer accessible, it is listed as “unavailable”;
alternatively, the authors may offer a downloadable dataset. Batch specifies whether users can
feasibly input and run large numbers (e.g. over one thousand) of protein sequences through the
tool. Some tools (e.g. Scansite) instead have options to search an existing sequence database,
instead up a large upload. The methods have been listed according to year published.
Name Availability Batch Website Year Ref.
Scansite Web No scansite3.mit.edu 2003 (87)
NetPhosK Web No cbs.dtu.dk/services/NetPhosK 2004 (16)
PPSP Web No ppsp.biocuckoo.org 2006 (89)
KinasePhos Web No kinasephos2.mbc.nctu.edu.tw 2007 (90)
CRPhos CL tool Yes (CL) ptools.ua.ac.be/CRPhos 2008 (91)
NetPhorest Web, CL tool Yes (CL) netphorest.info 2008 (88)
Phos3D Web No phos3d.mpimp-golm.mpg.de 2009 (26)
PredPhospho Unavailable N/A N/A 2009 (92)
Musite Web, GUI Yes (GUI) musite.net 2010 (93)
N/A dataset N/A bioinfo.bjmu.edu.cn/phospho 2010 (94)
Predikin Web, CL tool Yes (Web/CL) predikin.biosci.uq.edu.au 2011 (95)
GPS Web, GUI Yes (GUI) gps.biocuckoo.org 2011 (80)
PhosK3D Web No csb.cse.yzu.edu.tw/PhosK3D 2013 (24)
PKIS Web No bioinformatics.ustc.edu.cn/pkis 2013 (96)
NetworKIN Web, CL tool Yes (CL) networkin.info 2014 (97)
MIMP Web, CL tool Yes (CL) mimp.baderlab.org 2015 (84)
(HMMs) and conditional random fields have been employed. In this section I firstly give a
review of the use of support vector machines in kinase-specific phosphorylation site prediction;
this is followed by an overview of the additional tools that have been employed.
Support vector machines
The most popular machine learning method that has been applied to phosphorylation is the
support vector machine (SVM). An SVM is a discriminatory method of binary classification,
that solves an optimisation problem to separate two labelled sets of inputs (98). A key concept
in SVM training is the use of kernel functions to transform training data into more easily sepa-
rable dimensions. This is useful for the classification of high dimensional data, such as protein
sequences. The other key concept in SVMs is margins. SVMs use decision boundaries to sepa-
rate classes, such that a margin separating the data points in the two classes is maximised; often
the data points associated with the classes will not be perfectly separable however. The idea of
a “soft margin” SVM is to allow some flexibility in the margin around the decision boundary,
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whereby points close to the decision boundary are ignored – allowing for the placement of a
decision boundary that provides greater separation of the two classes.
SVMs have been applied to phosphorylation prediction in several ways. The simplest involves a
binary encoding of amino acid occurrences at positions within a window surrounding a phospho-
rylation site; other methods provide more sophisticated profiles of the amino acid content of the
motifs. There are also publications demonstrating how SVMs can be used to incorporate into a
model different types of protein information, such as protein disorder, evolutionary information
(in a kinase-generic predictor) and 3D structure, to supplement sequence data (90, 93, 99).
PredPhospho is an SVM phosphorylation predictor that was developed as part of a database for
scoring the potential effect of missense mutations on protein phosphorylation (92). The authors
represented phosphorylation site motifs using a binary encoding of amino acid occurrence within
some m length window surrounding the phosphorylation site. Amino acids were encoded using
a vector of length 20 where, for example, methionine was encoded as 10000000000000000000,
isoleucine as 010...000 and so forth. A motif was therefore represented as a vector of such binary
vector encodings. The vectors were used as input features for training SVM models in a kinase-
specific manner. Another method for encoding kinase binding peptides for use in an SVM is the
composition of monomer spectrum (CMS) technique, used by the protein kinase identification
server (PKIS) (96). Given some phosphorylated peptide, a single monomer spectrum is defined
as a vector of amino acid counts for that peptide; i.e. the peptide sequence EQEESPLRR could
be encoded as the vector 01000300110000201000, where each position in the vector represents
the count of an amino acid occurrence in the peptide. The CMS method encodes the sequence
information in an m length sequence window by computing monomer spectrum vectors for all
windows from size 3 to m, where the window is centred on the phosphorylation site.
KinasePhos2 (90) is the successor to the hidden Markov model (HMM) methodology of Ki-
nasePhos (100), and incorporates information on sequence content and protein-coupling pat-
terns from phosphorylation motifs into SVM classifiers. For the KinasePhos2 predictor, a kinase
binding motif (taken as a 9-residue window surrounding the phosphorylation site) is represented
by two features: an encoding of the protein sequence in the motif, and a profile of amino acid
couplings. Given some pair of amino acids X and Z, and a distance d between them, Wong
and colleagues defined an amino acid coupling, CXdZ , as the frequency of XdZ divided by the
frequency of Z, as observed in training data. In order to select couplings relevant for phospho-
rylation, they calculated the difference in values of CXdZ for both the set of phosphorylation
sites and a background set of all phosphorylatable residues. If the difference in CXdZ passed a
certain threshold it was used as a feature in the SVM model. In addition to amino acid coupling
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profiles, the authors defined three different encodings of the amino acid content of the phospho-
rylation motifs: (1) an encoding based on the row numbers of amino acids in the BLOSUM62
matrix, (2) a reduced alphabet based on the amino acid properties (hydrophobicity, polarity
etc.) and (3) a vector encoding where each amino acid was defined using a 20-dimensional
vector.
The SVM methods described so far use a variety of motif representations as input features
in SVM classifiers. However, SVMs are able to perform classification on the basis of multiple
protein characteristics – in addition to the sequence – when these are represented as numerical
values in feature vectors. This is something taken advantage of by the Musite predictor, which
combines k-nearest neighbour (KNN) scores (representing the distance between the motif sur-
rounding a query site and positive or negative examples of phosphorylation) with amino acid
frequencies and protein disorder scores into SVM classifiers (93). Given positive and negative
phosphorylation data, a distance metric is calculated between a query site and the sites within
the positive and negative data sets. Some k number of the top scoring neighbours in both
positive and negative sets are then identified, and a ratio of positives to negatives is calculated.
The authors defined five increasing levels of k such that the KNN score for a phosphorylation
site is represented as a vector of 5 elements. Amino acid frequencies were calculated within
at 13 residue window around the phosphorylation site, and represented as a size 20 vector of
frequencies. Disorder predictions for query proteins were made using the VSL2b disorder pre-
dictor (101), and disorder scores for a phosphorylation peptide (as defined by some m length
window around the phosphorylation site) were defined as the average VSL2b disorder prediction
across the residues contained in the peptide. The authors define 3 values of m (1, 5 and 13) to
calculate disorder scores for a peptide. These scores were included as inputs into the feature
vectors used to train the SVM.
The Phos3D predictor proposed that some elements of kinase-substrate recognition may lie
in amino acids that are spatially close, though sequence distant, from phosphorylation sites
(26). They used sequence content from phosphorylation motifs encoded with physical-chemistry
properties (hydrophobicity, disorder indices, solvent accessibility etc.), and supplemented this
with spatial data from 3D structures. To incorporate spatial information into the model they
identified amino acids that were in a range of 2 to 10 A˚ to the phosphorylation residue. For each
amino acid they calculated a ratio between the number of times the amino acid was in range
of the phosphorylation site, and all other amino acids that were in range. They were therefore
able to build a profile of amino acid frequencies in spatial closeness to the phosphorylation
site. After comparing the prediction accuracy of their model using just sequence features verse
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the combination of sequence and spatial information, they found that the inclusion of spatial
information increased prediction accuracy by approximately 5%.
Separate (though similarly named) to the Phos3D predictor is the PhosK3D predictor, which
also incorporates amino acid motifs and spatial information from PDB structures into kinase-
specific SVM models (24). The authors incorporated several sequence characteristics into SVM
models. After extracting phosphorylation peptides of length 13 from around phosphorylation
sites, the authors constructed PWMs to represent the raw sequence content of the motifs. In
addition, they calculated surface area accessibility of the residues within the phosphorylation
peptides with the tool RVP-Net (102), and secondary structure using PSIPRED (103). Similar
to Phos3D they used the 3D protein structures to calculate spatial amino acid frequencies,
though the authors of PhosK3D calculated amino acid frequencies at varying distances from
the phosphorylation site, ranging from 3 to 12 A˚. Su and colleagues found that a model in-
corporating spatial and sequence information obtained an average 10% increase in prediction
accuracy over using sequence alone, up from the 5% increase seen with the Phos3D predictor.
The results from the Phos3D and PhosK3D methods demonstrate that spatial information im-
proves phosphorylation prediction accuracy over using linear motifs alone; however, a major
drawback is the lack of availability of 3D structure information for many proteins. This imposes
restrictions both for the proteins that predictions can be made on, and the kinases that the
method can make predictions for; there needs to be 3D structures available for a kinase’s sub-
strates in order to train a kinase-specific predictor. The PhosK3D predictor offers prediction
for 127 kinases or kinase sub-families using its sequence method, but only 21 for the method
incorporating spatial information. This illustrates a drawback of using SVMs to train phospho-
rylation predictors on selectively available data: they are unable to handle proteins where that
data is missing.
The SVM methods presented in this section have an advantage over scoring matrices in that
they allow for more flexible representations of the phosphorylation peptides, and have the ca-
pacity to incorporate multiple information types. There are limitations to using SVMs for
phosphorylation prediction, however, as seen by the restraints of data availability imposed on
the Phos3D and PhosK3D methods. An additional limitation concerns the discriminatory ap-
proach of SVMs, which make them unsuitable for problems that are not of a binary classification
nature. As was shown in Section 1.2.2, kinases within the same family can share binding site
characteristics; indeed one phosphorylation site can be targeted by multiple kinases. The bind-
ing preference of kinases is therefore not best represented as a binary discrimination problem,
as it will be in an SVM model.
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Additional methods
While scoring matrices and SVMs are the tools underlying the majority of phosphorylation
predictors, there are several alternative methods that have been proposed. Neural networks
(NN) are an earlier machine learning method that have been applied in phosphorylation site
prediction. A NN is a network consisting of layers of nodes, with input at the top of the
layer and output at the bottom. Weights associated with the inputs and subsequent layers
of nodes – set using training data – can potentially learn non-linear sequence features, such
as relationships between positions in a motif. The kinase-generic phosphorylation predictor
NetPhos (75), its kinase-specific successor NetPhosK (16), as well as the Yeast-specific (though
kinase-generic) variation NetPhosYeast (104) each train three layer neural networks to predict
phosphorylation sites on the basis of sequence data. NetPhos and NetPhosK represent motifs
surrounding a phosphorylation site as a vector of binary encodings of amino acids (105), similar
to that described for the PredPhos method previously; i.e. an encoding of an amino acid takes
on the form 100..000. The phosphorylation peptides represented using the binary encoding
scheme were then presented as feature vectors for training the NN models.
As mentioned previously, the NetPhorest predictor has an alternate approach to either building
PSSMs or training neural networks depending on the type of phosphorylation data being con-
sidered (88). In vitro peptide array data, which offers a quantitative representation of amino
acid frequencies, but can not be used to glean correlations between positions in a motif, was
used to construct PSSMs. The protein phosphorylation data generally used for training phos-
phorylation predictors was applied to training NNs. They trained NNs by representing the
phosphorylation peptide data using the binary amino acid encoding scheme employed by Blom
and colleagues (75), and used cross-validation testing to optimise several parameters (peptide
window size, number of hidden neurons in the model and the learning rate) for the kinase-
specific models.
KinasePhos (the predecessor to the SVM-based predictor KinasePhos2 described above) trained
profile hidden markov models (profile HMMs) to predict kinase-specific phosphorylation sites
(100). HMMs are a form of graphical modelling used for labelling sequential data, and profile
HMMs are a specialisation whereby a sequence alignment is used to build a position-specific
scoring model. The authors sourced phosphorylation data from the PhosphoBase (106) and
Uniprot (83) databases. The phosphorylation sites were labelled according to kinase anno-
tations, with non-phosphorylated S/T/Y sites contained in the substrate sequences used as
negative. Extracted phosphorylation peptides were then used to construct the profile HMMs
on a kinase-specific basis.
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Dang and colleagues proposed that conditional random fields (CRFs) could be used to model
the amino acid characteristics in kinase binding sites (91). CRFs are similar to HMMs in that
they are used for labelling sequential data and are a form of graphical modelling. In contrast to
HMMs however, CRFs use a conditional probability approach to assign labels to observations.
The authors used phosphorylation data from Phospho.ELM to construct sets of kinase-specific
phosphorylation peptides (using a window of length 9 centred around the phosphorylation site).
They built feature vectors representing a variety of amino acid characteristics in the motif, such
as co-occurrence of amino acids, and co-occurrence of grouped amino acids according to chemical
classes defined by Wong and colleagues (90). For each kinase, a set of feature vectors from the
positive phosphorylation examples was used to build a CRF model, and the negative data used
to obtain false-positive rate thresholds for predictions made by the model.
Another methodology that has been proposed is Bayesian decision theory, which was employed
in the PPSP (prediction of PK-specific phosphorylation site) predictor (89). Xue and col-
leagues defined two classes, C1(phosphorylated) and C2 (unphosphorylated). The application
of Bayesian decision theory in this scenario is given some unclassified sample x, x will be
considered phosphorylated (i.e. belonging to class C1) if P (C1|x) > P (C2|x), and unphos-
phorylated otherwise. The authors obtained kinase-specific phosphorylation sites from Phos-
pho.ELM, and as with other methods defined negatives to be S/T/Y sites within the retrieved
proteins that were not phosphorylated. From these sequences, peptides of length 9 were re-
trieved. They defined a sample peptide as ~x = (x1, x2, ..., x9) and used Bayes theorem to denote
P (C1|xj) = P (xi|C1)P (C1)P (xj) , where j ∈ [1, 2, ..., 9] positions in the motif. The values in the equa-
tion are therefore determined based on observations in the training data. In addition to an
error function calculated on the basis of bio-chemical similarities between amino acids from a
BLOSUM62 matrix, they were able to use the above function to predict the phosphorylation
status of given peptides based on the known phosphorylation examples.
The methods described so far only rely on information that is contained within a protein. There
are many different ways that the sequence context within a phosphorylation site motif can be
represented. Typically some m length window around a phosphorylation site is chosen and the
amino acid content of the resulting peptide can then be represented in several ways. The amino
acid content can be modelled in a position specific manner as in scoring matrices or in some
machine learning methods such as NetPhosK and KinasePhos. Alternatively, or additionally,
the amino acid content can be modelled in a non-position specific manner, for example the
composition of monomer spectrum approach used by PKIS. As we have seen, machine learning
classifiers also allow for additional information contained in the protein (such as structure) to
be incorporated as features in predictive models.
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As was outlined in Section 1.2.2, the factors that determine kinase substrates are not limited to
those contained in the protein. While the methods outlined here may be able to ascertain the
validity of a kinase binding location on a protein, they cannot say anything about the probability
of a kinase coming into contact with the protein in the first place. A separate problem, and
one that cannot be addressed by modelling the binding characteristics of kinases alone, is
how phosphorylation substrates come into contact with the required kinase (27). The cellular
context that the protein exists in needs to be considered to determine candidate kinases. In
the following section I describe the previous work that has been carried out in applying context
information to phosphorylation prediction.
1.5.3 Context-based methodology
While the vast majority of phosphorylation predictors only consider information contained in
the protein, there have been three studies that have supplemented models of phosphorylation
motifs with context information. One of the studies, by Li and colleagues, attempted to inte-
grate phosphorylation motifs with a variety of different functional or context annotations (94);
this approach was also adopted by Fan and colleagues, and applied to additional kinase families
(107). The context and functional information included protein-protein association scores from
the STRING database, gene ontology (GO) annotations (molecular functions, cellular compo-
nents and biological processes), and other structural or pathway data. Li and colleagues used
SVMs to build classifiers for 8 kinase families and compared prediction accuracy between using
sequence alone, and sequence with various other data sources. Sourcing phosphorylation data
from Phospho.ELM, they generated feature vectors representing peptides from a 9 residue win-
dow surrounding phosphorylation sites using the binary encoding scheme employed by Blom
and colleagues (16).
The authors experimented with adding a variety on functional data types to their SVM classi-
fier. Most relevant to the issue of context is their use of protein-protein associations obtained
from the STRING database, and labelling of protein cellular components from gene ontology
(GO) annotations. STRING contains binary protein-protein “association scores” – a prob-
ability of two proteins being functionally related, if not interacting directly, on the basis of
various sources such as gene co-expression data, literature searching and protein-protein inter-
actions (108). To incorporate STRING data into their model they identified proteins in the
STRING database that were over-represented (based on a hypergeometric test) in their pos-
itive data compared to the negative unphosphorylated data. The STRING associations were
also encoded using a binary format; if a query substrate interacted with a protein according to
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STRING it was designated a 1, and 0 otherwise. Comparing the accuracy of phosphorylation
prediction using sequence alone against incorporating STRING, the authors’ results show that
the use of STRING scores resulted in virtually no average increase in prediction accuracy. While
one kinase family (PKC) obtained a moderate increase in accuracy from 78.26% to 83.46%, on
average they obtained an accuracy of 87.33% using sequence alone, and 87.98% when the se-
quence was supplemented with STRING scores. As the STRING database contains a range
of scored protein-protein associations, from low confidence to high confidence, converting all
occurrences to a binary format is likely to introduce a large amount of noise, perhaps partially
explaining the results. Similar to their results with STRING, there appeared to be one kinase
family (GSK3) that benefitted from the cellular component annotations, with an increase of
accuracy from 77.69% to 87.24%. However, if the GSK3 kinase is excluded, the cellular com-
ponent annotations actually result in an average decrease in accuracy, from 78.34% to 77.62%.
While the authors found their addition of context information useful in some regards, it appears
that their approach has little generalisability among kinase families. This should illustrate that
modelling the context that kinases operate in is not a trivial exercise, and an ad hoc approach
of simply adding various sources to a model is unlikely to result in a system with generalised
predictive power.
To date, the most promising approach to using context information to improve kinase-specific
phosphorylation prediction was made with the NetworKIN predictor (109). NetworKin im-
proved upon motif based scoring by including a “context score”, which was calculated on the
basis of protein-protein association scores contained in the STRING database (108). The origi-
nal NetworKIN algorithm consisted of two main stages. In the first stage, one or more proteins
were submitted along with known, or suspected, phosphorylation sites. Using PSSMs and NN-
based sequence prediction (i.e. the NetPhorest methodology described earlier), one or more
kinase families were assigned to the sites. In the second stage, candidate kinases from the fam-
ilies predicted in the first stage are scored on the basis of an “association network” constructed
using the STRING database. As STRING associations are represented with a probability
based on the strength of the underlying data, a network of protein-protein associations can be
constructed with varying path lengths. To calculate a context score on the basis of such an
association network, the Floyd-Warshall algorithm was used to find the shortest path between
the query protein and a kinase that is a member of the predicted kinase families. The final
score was the product of the STRING and sequence scores.
The latest version of NetworKIN updated the distance algorithm used to assign a kinase to a
potential substrate (97). The current score includes penalties based on path length, and the
number of connections in intermediate association hubs. In addition, rather than pre-screening
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the query substrates to identify potential kinases from sequence, the sequences are scanned
separately with NetPhorest (88) to allow a probability to be assigned for any kinase. The final
score for a kinase-specific phosphorylation site is a naive Bayes product of the sequence and
context scores. In contrast to the method by Li and colleagues described above, Linding and
colleagues showed that their use of the STRING network provides a more generalised level of
increased phosphorylation prediction accuracy over using sequence alone. They evaluated their
method for its ability to correctly predict kinase-specific phosphorylation sites on a set of 38
kinases for which 10 or more phosphorylation sites were known. This evaluation yielded an
average area under the curve (AUC) of 0.78 using sequence (NetPhorest) alone, and an average
of 0.83 when NetPhorest was complemented with STRING scores. Despite this, 12 out of the 38
kinases recorded a decrease in AUC when the STRING score was included, and an additional 4
recorded an AUC increase of under 0.01, meaning that for over 40% of the kinases the STRING
score resulted in a negligible or negative impact on prediction accuracy.
The methods described here have used context data to supplement sequence scores, but the
factors that contribute towards a kinase targeting a protein at the systems level are complex.
The context that surrounds a phosphorylation event will likely be more sophisticated than
what can be represented with a shortest path search; indeed it appears that there are strong
limitations in how much accuracy can be gained through the sequence and context models
described above. There are three problems that need to be addressed: (1) modelling how
kinases come into contact with their substrates, (2) modelling the binding of kinases to target
sites and (3) integrating these divergent elements into a unifying model of phosphorylation.
While much work has been done on (2), even the little work that has been done on (1) and (3)
has focussed less on modelling context to understand how kinases target substrates, but rather
using context as a supplement to sequence scores.
1.6 Research aims and project overview
The computational methods described in Section 1.5 rely almost exclusively on information
that is contained within the protein. These predictors primarily model amino acid content
within a fixed window surrounding a phosphorylation site, though some incorporate additional
information such as protein disorder or 3D structure. The NetworKIN method, though it is
the first step towards the use of context information, essentially identifies the “closest” kinase
to a protein substrate it can find in the STRING database. Furthermore, separating out the
problem of the sequence specificity of kinases and the context factors that regulate their activity
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means that potential influences between the two domains of information will be neglected. A
comprehensive model of phosphorylation would provide a seamless integration of the context
and sequence factors that influence how kinases target their substrates. My hypothesis is that
by integrating of two aspects of kinase regulation, context and sequence, I can build methods
that predict kinase substrates with greater accuracy than if considering context or sequence in
isolation.
The general aim of this project was to develop a framework for integration of cellular con-
text data such as protein-protein interaction information with sequence data in order to solve
biological problems where these two domains of information are of high relevance. As phos-
phorylation is an event regulated both through the sequence binding affinity of kinases, and
mediating protein interactions, it has been a prime candidate for this study. In the final part of
the study, the prediction tool was applied to a biological problem: detecting the effect of single
nucleotide polymorphisms (SNPs) on protein phosphorylation status. The more specific aims
of the project are outlined below.
1. Integrate cellular context information in the form of protein-protein interactions, cell-cycle
progression and kinase-specific phosphorylation events into a model that can classify the
kinase, or kinases, responsible for phosphorylating a putative phosphorylation substrate.
As part of this aim I also address the following questions:
(a) Can the model be used to improve sequence-based phosphorylation site prediction
through combining its output with that of existing phosphorylation predictors?
(b) Can context can be used to predict phosphorylation status change in proteins (part
of an sbv IMPROVER competition)?
2. Develop a probabilistic model for predicting kinase binding sites from sequence. Incorpo-
rate this sequence model into the context model.
(a) How generalisable is the modelling approach when applied to kinases from different
species?
(b) How accurate is the model at predicting kinase-specific phosphorylation sites com-
pared to alternative methods?
3. The final aim is to apply the model to a biological problem: detecting the effect of nsSNPs
on protein phosphorylation status.
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(a) Is context an important contributor for understanding the effect of nsSNPs on phos-
phorylation?
(b) How reliable is the system for detecting known examples of variant-causing differen-
tial phosphorylation?
The first part of the project, described in Chapter 2, focussed on understanding the context
that kinases operate in and how to leverage available data in order to design a method that
could predict kinase substrates based on context. This chapter describes the design and imple-
mentation of a Bayesian network model that incorporates experimentally confirmed instances
of kinase-substrate phosphorylation, protein-protein interaction/association data and cell-cycle
data in order to predict kinase substrates. Through cross-validation evaluation I show that
the model obtains reliable prediction accuracy, with an average AUC of 0.86 across the 59 ki-
nases tested. Chapter 2 also demonstrates that the accuracy of previously-published sequence-
operating methods for predicting kinase-specific phosphorylation sites can be improved by com-
plementing their scores with context-based predictions from the Bayesian network. The method
has been implemented as a tool accessible to the scientific community. The web server of Phos-
phoPICK (Phosphorylation in a Protein Interaction Context for Kinases) is publicly available
at http://bioinf.scmb.uq.edu.au/phosphopick.
I had the opportunity to participate in the sbv IMPROVER (systems biology verification for
Industrial Methodology for PROcess VErification in Research) species translation challenge.
The purpose of the challenge was to the predict protein phosphorylation status change in re-
sponse to varying treatment conditions, given gene expression data as measured under the
same conditions. The first sub-challenge was to develop a method for predicting phosphory-
lation status change in rat cells, and the second sub-challenge was to predict phosphorylation
status change in human cells using data from rat cells. The challenge allowed me to investigate
whether a phosphorylation model based on protein-protein interaction data could use condition-
dependent knowledge of protein expression levels to predict changes in protein phosphorylation.
Chapter 3 describes a method for overlaying the protein-protein interaction networks of phos-
phoproteins with gene expression data in order to predict phosphorylation status change. The
method obtained promising prediction accuracy, being ranked 6 out of 21 competitors in the
first sub-challenge, and 7 out of 13 in the second sub-challenge.
While Aim 1 focussed on the problem of modelling context to predict kinase substrates, Aim
2 focussed on developing an algorithm for predicting kinase binding sites from sequence, and
incorporating this algorithm into the larger context model. to obtain a more complete model of
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kinase-protein phosphorylation. Chapter 4 describes a method that considers position-specific
amino acid frequencies and the occurrence of co-occurring neighbouring amino acids (specifi-
cally dimers and trimers) within a window surrounding a phosphorylation site. The model was
defined using a Bayesian network structure that allows the model to discriminate between a
kinase’s binding pattern, that of it’s family members, and a phosphorylation background. In-
corporating the sequence and context models enabled this “combined model” to predict kinase
substrates with higher accuracy than by using context alone. The final system employed by
PhosphoPICK involves using the combined model to obtain a prediction for whether a kinase
will phosphorylate a substrate, and the sequence model to score the potential binding sites
within the protein. When comparing the ability of PhosphoPICK and alternative methods
to predict kinase-specific phosphorylation sites, I found that PhosphoPICK outperformed the
alternatives for most comparisons made; PhosphoPICK obtained an average increase in sensi-
tivity of between 9 and 22% over the alternatives at a 99.9% specificity level. Employing this
system, PhosphoPICK is currently able to make predictions for 107 human kinases.
While I have primarily been working on human data, I was interested in testing PhosphoPICK
on additional species. After obtaining phosphorylation data for mouse and yeast, I was able to
build models for mouse covering 24 kinases, and models for yeast covering 26 kinases. When
testing the mouse and Yeast models for predicting kinase substrates, I found that the combined
model offered greater performance gains over using context alone than for the human version.
This likely reflects the diminished availability of context data for mouse and yeast – protein
abundance information over the cell-cycle was not available like it was for human, and the
protein-protein interaction networks are smaller than for human.
Non-synonymous SNPs (nsSNPs) have the potential to cause loss or gain of protein phospho-
rylation sites through amino acid variants that either disrupt, or introduce, kinase-substrate
binding sites. The final aim of the project was to use PhosphoPICK to build a method for pre-
dicting the effect of nsSNPs on phosphorylation. This method is described in Chapter 5. Using
the Bayesian network models presented in Chapter 4, I build distributions of predicted variant
effects over all protein-altering variants contained in the UniProt database. These distribution
could then be used to quantify the significance of a novel variant’s effect on phosphorylation.
Using a set of phosphorylation-loss or phosphorylation gain-causing variants collected from the
primary literature, I show that the method is able to detect known phosphorylation-altering
variants at high levels of specificity.

Chapter 2
PhosphoPICK: Modelling cellular
context to map kinase-substrate
phosphorylation events1
2.1 Abstract
The determinants of kinase-substrate phosphorylation can be found both in the substrate se-
quence and the surrounding cellular context. Cell cycle progression, interactions with mediating
proteins and even prior phosphorylation events are necessary for kinases to maintain substrate
specificity. While much work has focussed on the use of sequence-based methods to predict
phosphorylation sites, there has been very little work invested into the application of systems
biology to understanding phosphorylation. Lack of specificity in many kinase substrate binding
motifs means that sequence methods for predicting kinase binding sites are susceptible to high
false-positive rates.
We present here a model that takes into account protein-protein interaction information, and
protein abundance data across the cell cycle to predict kinase substrates for 59 human kinases
that are representative of important biological pathways. The model shows high accuracy for
substrate prediction (with an average AUC of 0.86) across the 59 kinases tested. When using the
model to complement sequence-based kinase-specific phosphorylation site prediction, we found
that the additional information increased prediction performance for most comparisons made,
particularly on kinases from the CMGC family. We then used our model to identify functional
1Chapter reproduced from the paper published in Bioinformatics, 2015
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overlaps between predicted CDK2 substrates and targets from the E2F family of transcription
factors. Our results demonstrate that a model harnessing context data can account for the
short-falls in sequence information and provide a robust description of the cellular events that
regulate protein phosphorylation.
2.2 Introduction
Regulation of cellular processes occurs on multiple levels, with epigenetic modifiers and tran-
scription factors (TFs) controlling gene expression, while various post-translational modifi-
cations regulate many protein functions (14–16). The most ubiquitous of post-translational
modifications is phosphorylation, with at least 70% of human proteins estimated to be phos-
phorylation substrates (28). Phosphorylation is likely a significant factor in regulating the
function of complex organisms, with a significant increase in the numbers of phosphorylation
sites in eukaryotic compared to prokaryotic proteins (6). Phosphorylation is known to have
numerous regulatory roles across the cell cycle, and specific kinases have been implicated in
the regulation of G1 phase (110), the G1/S phase transition (111) and DNA replication and
damage repair (112). Phosphorylation is particularly ubiquitous during mitosis where many
complex operations such as spindle formation, centrosome maturation/separation and chromo-
some attachment to the spindle are controlled by kinases (41).
While advanced phosphoproteomic technologies have succeeded in identifying thousands of
phosphorylation sites across multiple proteomes (28, 113), there has been an ever widening
gap between known phosphorylation sites and the kinases responsible for those sites (114).
Currently just over 10% of the phosphorylation sites recorded in the eukaryotic phosphoryla-
tion site database Phospho.ELM are annotated with a kinase. There have been examples of
in vitro studies identifying kinase-substrate binding events (69), and while these studies offer
interesting insights into the consensus motifs of kinase binding sites, it is unknown whether the
binding events observed in vitro would occur in vivo. Determining kinase-substrates in vivo is
non-trivial however, though there have been promising results from combining in vitro kinase
detection assays with in vivo phosphoproteomics (115). As a result of the inherent difficulty in
determining in vivo kinase substrates, there has been a great interest in developing computa-
tional tools to predict kinase-specific phosphorylation sites, with over forty phosphorylation site
prediction methods published (18). While some methods aim only to predict phosphorylation
sites (75, 104), the majority predict kinase-specific phosphorylation sites.
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Historically, phosphorylation site predictors have operated primarily on protein amino acid
sequences, relying on the information contained in the sequence region surrounding phospho-
rylation sites. It has long been recognised that short sequence motifs alone are insufficient for
achieving respectable accuracy in predicting kinase-specific phosphorylation sites. As a result,
prediction methods have often complemented sequence information with other types of data
such as knowledge of 3D structure (26, 81), sequence disorder (93) and kinase family similarity
(80). While such additional data typically improves prediction performance to an extent, they
do not reflect the wider cellular regulatory mechanisms that cause kinases to target their correct
substrates – a protein with an appropriate kinase binding site will not necessarily come into
contact with that kinase (27).
The phosphorylation of a target substrate by a kinase is not determined solely by its binding
affinity, but by various context factors that determine how a kinase comes into contact with its
substrates (46). This is recognised by the NetworKIN predictor (97), which combines sequence-
based scores with a score generated on the basis of a STRING network (108). Context factors
can include cellular location (21), mediating and activating proteins such as scaffold proteins
(20), cyclins (116), and cell cycle-specific expression of kinases and their substrates. Protein-
protein interaction data can certainly be used to represent such context factors; though while
there is vast amounts of protein-protein interaction data currently available in databases such
as BioGRID (1) and STRING, incomplete coverage and variable certainty means that the
integration of context features into a model is non-trivial.
In this work we explore a probabilistic model to accommodate missing values, seamless com-
bination of protein interactions and cell-cycle expression, and to provide flexible options for
querying potential kinase substrates. The model we present here, named PhosphoPICK (Phos-
phorylation in a Protein Interaction Context for Kinases), integrates known kinase-substrate
relationships, protein-protein interactions (PPI), and cell-cycle data to predict kinase substrates
for 59 human kinases. PhosphoPICK shows high prediction accuracy, with a mean AUC of 0.86
across the 59 kinases. We then demonstrate how our method can boost the prediction accuracy
of kinase-specific phosphorylation site prediction by combining PhosphoPICK predictions with
the phosphorylation site predictions from three previously published methods. We find that
PhosphoPICK improves kinase-specific phosphorylation site prediction for most comparisons
made, though greater performance increases were noticed on CMGC kinases – in particular cy-
clin dependant kinases (CDKs), where we observed substantial performance gains as measured
by AUC50. We show that proteins predicted to be CDK2 substrates by PhosphoPICK have GO
terms consistent with known CDK2 substrates, and investigate the functional overlap between
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known and predicted CDK2 substrates, and the targets of specific E2F TFs using ChIP-Seq
data.
2.3 Methods
2.3.1 Bayesian network model
We used a Bayesian network (BN) to design our model. Bayesian networks differ from machine
learning tools that have previously been used for phosphorylation site prediction in several
important ways. Bayesian networks are transparent, allowing for an understanding of how
the variables in the model influence the final outcome (117). Furthermore, the probabilistic
nature of a Bayesian network means that even in the absence of missing data, the model can
still infer the most likely value of the unknown variables on the basis of the known data (118,
119). We represent observations about protein interactions, kinase-specific phosphorylation
events and cell-cycle profiles as Boolean variables in a BN model (Figure 2.1). The model
represents observations about a phosphorylation substrate - the kinases that bind to it, protein
interactions, and whether it is up-regulated during the cell-cycle phases. The kinase nodes are
linked to protein-protein interaction events that are believed to be relevant for the kinase to
phosphorylate substrates. A latent variable is used to capture information from the cell-cycle
data, and the kinase nodes are then conditioned on this latent variable.
2.3.2 Data resources
Known kinase-substrate relationships.
We obtained kinase substrates from Phospho.ELM and HPRD, after converting HPRD IDs to
Uniprot identifiers. In order to identify protein interactions between kinases and their sub-
strates, we selected kinases for which we found greater than 10 substrates. In total, we use 59
human kinases along with a total of 1,210 substrates. Table 2.1 shows the numbers of substrates
that were identified for each of the 59 kinases. The 1,210 substrates contained 2,964 unique
phosphorylation sites that were annotated with at least one kinase.
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Figure 2.1: The PhosphoPICK Bayesian network model. Each of the kinase (K ) nodes,
representing a phosphorylation event by that kinase, are conditioned on a latent variable
incorporating protein abundance across four stages of the cell cycle: Mitosis (M), G1, S
and G2. The “leaf” nodes represent protein-interaction (P) events between the proteins
represented in the nodes and a potential substrate. These nodes are conditioned on relevant
kinase-specific phosphorylation events.
Protein-protein interaction and association data.
To identify and model interaction networks of kinases and their substrates, we used PPI data.
In cases where physical interaction data is unavailable, associations inferred on the basis of
other sources such as gene co-expression or literature mining may be informative, and such
information is available in the STRING database. PPI information was taken from the Bi-
ological General Repository for Interaction Datasets (BioGRID) (1) by selecting entries that
were of type “direct interaction” or “physical association”. As protein-protein interactions are
represented in binary format, this information was incorporated into the model as a Boolean
value. The STRING database scores an association probability between two proteins, with a
score of 0.4 defined as medium confidence. To convert this probability into a Boolean value
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we defined cut-off probabilities, such that given some cut-off θ, any association with a proba-
bility ≥ θ was classified as true, and any association with a probability < θ was classified as
false. We tested three cut-off probabilities, starting at the medium confidence level of 0.4 and
increasing in increments of 0.2. We found that a cut-off probability of 0.6 provided the best
overall performance (Table A.1), and is the cut-off used in this work.
To identify relevant connections between kinases and protein-protein interaction events, the
following steps were taken. Substrates were first grouped according to their kinase (one sub-
strate could be assigned to multiple kinases). BioGRID was then searched for proteins that
interacted both with a substrate and with its kinase – these proteins were added to a pool
of potential protein interaction connections. For each kinase, the proteins in the pool were
ranked in descending order according to the number of interactions that were observed with
the kinase’s substrates. An observation is defined as a substrate-protein interaction occurring
in BioGRID and/or the STRING database. A count c was defined, so that for each kinase
only the top c protein-interactions were used to form connections. To ensure that there would
be enough observations of substrate-protein interactions for setting model parameters, a lower
bound of 10 was set such that for a given kinase, at least 10 substrate-protein observations
were required for the protein to be considered as a connection to that kinase. We tested three
different upper-bounds of c: 25, 40 and 50 to determine the effect of varying sized interaction
networks on prediction performance.
Protein cell-cycle data.
In order to model the availability of substrates during the cell cycle, we used data obtained from
the experiments by (28), who measured the abundance of proteins at six stages throughout the
cell cycle - M phase, G1 phase, the transition between G1 and S phase (G1/S), early S phase,
late S phase and G2 phase. An asynchronous population of cells was also measured, and the
signal used to log2 normalise the measurements from the cells arrested during the six stages.
A protein with a value of 0 during a stage of the cell cycle has an abundance equivalent to
the asynchronous population, while a negative value indicates down-regulation and a positive
value indicates up-regulation. To avoid fitting the model too strongly to data generated from
a single cell type, we represented proteins’ cell-cycle profiles in a simple binary format across
four stages – M, G1, S and G2. We collapsed the G1 and G1/S stages in to the single variable
“G1” and the early S and late S stages into the variable “S”. If a protein has a value greater
than 0 that stage is labelled as true; otherwise it is labelled as false. The G1 and S variables
were set to true if at least one of their respective collapsed stages had a value greater than 0.
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2.3.3 Model parameters and training
The variables in the network were represented with two kinds of probability tables. A condi-
tional probability table (CPT) represents all possible values that a variable X can take given
the set of parents, pa(X), it is conditioned on. Parameters are set during training by calculating
the frequency of occurrence of all possible configurations of pa(X). If X does not have parents,
the CPT simply represents the observed frequency from training data of X being true.
For situations where a variable is conditioned on greater than six parents, we used a variation of
the Noisy-OR approximation (120). In order to set the parameters of the Noisy-OR table during
training, each row (representing a parent variable) in the table was calculated as follows: each
training sample where the parent is observed as being true was identified. A weighted frequency
for each parent pa was calculated such that
freq(pa) =
1
n
n∑
i=1
(
t
(t+ f)pconfi
)
, (2.1)
where n is the number of configurations of parent variables where pa is observed to be true,
pconfi is the number of parents set to true in configuration i, t is the count of the variable the
Noisy-OR node is representing being true during the ith configuration of parents, and f is the
count of it being false.
For the latent variable, and variables that are conditioned on it, parameters are calculated using
the expectation-maximisation (EM) algorithm on a training set (121).
2.3.4 Evaluation and definition of negative test sets
A common problem to phosphorylation-site prediction is that of defining a negative test set
(18). However, as our model is not trained using sequence data, we were able to use a sequence-
scoring method to define negative test sets for each of the 59 kinases in the model. To score
protein sequences for kinase binding sites we used the Predikin web server (95) to obtain
position weight matrices (PWMs) for 53 of the kinases in the model. For the remaining six,
we constructed PWMs using phosphorylation sites from curated data (Section 2.3.5). For a
given kinase, we scored each substrate in the training data-set by obtaining the highest scoring
potential phosphorylation site. We then ranked the substrates based on the highest-scoring site
from lowest to highest, and assigned an equal number of positive and negative substrates for
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that kinase. As very low scores indicate a protein that the kinase cannot phosphorylate, this
gives us a high-confidence negative test set for each of the kinases in the model.
We evaluated the model for each kinase for its ability to correctly predict known substrates
compared to the negative set. To score the probability of a kinase phosphorylating a query
protein, all nodes in the network were set according to the relevant data for the query protein
except for the kinase that we were inferring. Model performance was evaluated using receiver
operating characteristic (ROC) analysis by calculating the area under the ROC curve (AUC)
(122). We used 15-fold cross-validation, and performed the cross-validation 10 times with
different data-set splits. To avoid the possibility of the model gaining information about the
test data during training, we ensured that each protein interaction variable was only connected
to a kinase if, within the training fold, there were 10 (our previously defined lower bound) or
more kinase substrates interacting with that protein. The data sets used to train and test the
model are available in the supplementary material.
2.3.5 Generating position weight matrices
For most kinases we were able to obtain position weight matrices (PWMs) from the Predikin
web-server, but for kinases CSNK2A1, CSNK2A2, ATM, ATR, CSNK2B and PRKDC we
constructed PWMs based on known phosphorylation sites from Phospho.ELM and HPRD. The
PWMs were constructed by taking a seven-residue window surrounding the phosphorylation
site as described previously (81), and calculating the weight of each amino acid within each
position in the window by calculating
w(a, j) = log2f(a, j)/0.05,
where w(a, j) represents the weight of amino acid a at position j, f(a, j) represents the fre-
quency, and 0.05 represents a uniform distribution of amino acids.
2.3.6 Setting non-query kinase nodes on the basis of sequence data
We tested the ability of the model to classify for a query kinase when the remaining kinase
variables in the model were set on the basis of sequence data. The PWMs were used to scan
the sequences and ascertain the highest scoring potential phosphorylation site for each kinase.
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For each training fold during cross-validation, we calculated the median scores for the kinases’
negative sequences (the proteins they are not known to be phosphorylating). When evaluating
the model on the test fold, we took the median of the negative scores and for each test substrate,
a kinase variable was set to false if its PWM score for that sequence was below the median
PWM score, and was left un-instantiated otherwise. This will result in a rough estimate of what
kinases are not phosphorylating a query protein, with the model able to infer the probability
of the remaining kinases phosphorylating the protein.
2.3.7 Testing the effect of STRING text mining on kinases
In order to test whether the use of text mining in the STRING database could be inflating the
performance of PhosphoPICK, we repeated our cross-validation tests for each kinase as follows.
When constructing a data file of input feature vectors for some kinase K, we first re-calculated
the STRING score as described in (56) for each association involving K, omitting the text
mining score. For each substrate Sub of K in the data file, if an interaction between Sub and
K had been observed (as defined in Section 2.3.2) previously, but now was not being observed,
the interaction between Sub and K was defined as null – the Bayesian network will consider
this to be unobserved.
2.3.8 Applying model to sequence-based predictions of phosphory-
lation sites
From our curated set of kinase substrates, we identified 2,964 kinase-specific phosphorylation
sites. In order to perform a fair comparison of how PhosphoPICK can improve the performance
for predictions of novel proteins, we again performed 15 fold cross-validation with 10 data set
splits, but retained the predictions for each protein in the test set. We then took the mean
kinase scores for each protein across the 10 data set splits. In order to measure the ability of the
methods being tested to predict phosphorylation sites, we took every potential phosphorylation
site (serine/threonine or tyrosine) in the substrate set, and tested the methods’ ability to predict
known kinase-specific phosphorylation sites out of all these potential sites. We compared the
performance of Predikin, GPS 2.1 and NetworKIN with the addition of PhosphoPICK by using
two metrics: the AUC50 (an ROC curve calculated up to the first 50 false positives), and the
sensitivity calculated at the threshold that yielded the fiftieth false positive. These metrics
indicate the performance of the methods at a false-positive rate of 0.0005 (i.e. specificity of
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0.9995) for serine/threonine kinases, and a false-positive rate of 0.002 (specificity of 0.998) for
tyrosine kinases.
Predikin:
To make predictions for potential phosphorylation sites using Predikin, we used the PWMs
that we were able to download from the Predikin web-server (95). The PWMs were used
to score each potential phosphorylation site in our substrate set. For the comparison with
PhosphoPICK, we first normalised the predictions on a per-kinase basis, by taking the minimum
(min) and maximum (max) scores for each kinase. Each kinase-specific phosphorylation site
prediction (pred), was then normalised by calculating score = pred − min/max − min. We
made two comparisons by taking the product and the sum of the normalised PWM score, and
the PhosphoPICK score for the substrate.
GPS:
We downloaded the current version of the GPS predictor (GPS 2.1) and adjusted the threshold
setting to “none” so that we could make predictions for all phosphorylation sites in our set. For
cases where GPS did not have a specific selection option for a kinase, we made predictions using
the sub-family of the kinase: Akt was selected for the prediction of AKT1 phosphorylation sites,
Abl for the prediction of ABL1 sites, and CK2a for predictions of CSNK2A1 and CSNK2A2
phosphorylation sites. The only kinase we were unable to make predictions for was PRKDC. For
comparison with PhosphoPICK, we again calculated the sum and the product of the normalised
site predictions (normalisation was performed as described above for Predikin) made by GPS,
and the substrate predictions given by PhosphoPICK.
NetworKIN:
We downloaded the NetworKIN 3.0 (97) software provided for running on a local machine.
We were able to make predictions for most kinases, with the exceptions of MAPK14, AKT1,
PDPK1, PRKG1, RSK1, CSK, JAK1, JAK2, RET, CHK1, MAPKAPK2, AURKB, CSNK2B,
PLK1 and PRKDC. As described above, to combined a NetworKIN score for a kinase, we first
normalised the scores (normalisation was performed as described above for Predikin), then took
alternatively the sum and the product of the PhosphoPICK score.
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2.3.9 GO term enrichment analyses
We first obtained a background set of human proteins from UniProt (http://www.uniprot.
org) by downloading all reviewed canonical human proteins. Of this set of 20,209 proteins,
we identified 18,469 that were annotated with GO terms in the QuickGO web-service (http:
//www.ebi.ac.uk/QuickGO). Statistical significance of GO term enrichments was determined
using Fisher’s exact test, with a Bonferroni correction.
2.3.10 Transcription factor analysis
To obtain a set of putative E2F binding sites, chromatin immunoprecipitation sequencing
(ChIP-Seq) data was downloaded from the ChIP-Seq experiment matrix provided by the EN-
CODE consortium (123). We downloaded ChIP-Seq narrow peak files for TFs E2F1, E2F4 and
E2F6 in HeLa cells – the same cell type used for generating the cell-cycle data used in this study
(28). In order to map the ChIP-Seq peaks to likely gene promoter regions, we also downloaded
refSeq annotated genes of human genome 19 with a 2000 base pair region upstream of each of
the genes. If a ChIP-Seq peak overlapped with an upstream region from a gene, the TF was
considered to be targeting that gene.
2.4 Results
2.4.1 Model performance for predicting kinase substrates
We generated five BN models by grouping kinases according to their family similarities (32):
CMGC, AGC, TK, CAMK and a combined model that incorporated kinases from the CK1,
STE, atypical and other families. We tested the ability of the model to classify kinase sub-
strates with varying numbers of protein interaction connections, and under three conditions.
To gauge the level of influence that substrate abundance during the cell cycle has on prediction
performance, we evaluated a version of the model excluding the cell-cycle variables (PPI only
model), and compared the performance to the full model. When making inferences about a
kinase-substrate phosphorylation event, the model relies on the knowledge of other potential
kinases phosphorylating that substrate. However, for the majority of proteins there is little, if
any, experimental information on any known kinase-specific phosphorylation events. Therefore,
to determine whether the model could be reliably extended to the wider proteome, we tested
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model performance when setting non-query kinase nodes to false on the basis of their sequence
binding motifs (Section 2.3.6).
Table 2.1: Evaluation of model performance with median AUC on all kinases in the model,
as tested under three different conditions: interactions only (int. only), full model, and kinase
variables approximated using sequence data (seq. approx.). Also shown is the number of
substrates (positive test set) that were identified for each kinase. Results are shown for 15-
fold cross validation across 10 data-set splits. The best result for each kinase is highlighted
in bold. CDK, MAPK and PRKC represent a family of kinases – the average values of their
family members are included in the table. Kinases are listed according to the family-specific
BN that they were incorporated into, where the “combined” model contained kinases from
the CK1, STE, atypical and other families of kinases.
kinase substrates int. only full model seq. approx.
C
M
G
C CDK 247 0.88±0.011 0.87±0.015 0.91±0.01
GSK3B 58 0.81±0.01 0.82±0.009 0.88±0.005
MAPK 136 0.84±0.016 0.88±0.016 0.92±0.015
AKT1 79 0.89±0.007 0.89±0.004 0.91±0.001
GRK2 14 0.86±0.022 0.87±0.035 0.87±0.01
PDPK1 23 0.95±0.011 0.94±0.011 0.91±0.021
A
G
C
PRKACA 154 0.94±0.003 0.93±0.006 0.96±0.002
PRKC 394 0.73±0.005 0.86±0.006 0.82±0.006
PRKG1 26 0.86±0.014 0.86±0.009 0.90±0.01
ROCK1 21 0.80±0.006 0.80±0.01 0.79±0.011
RSK1 27 0.91±0.027 0.89±0.019 0.93±0.008
RSK2 22 0.67±0.012 0.77±0.027 0.71±0.036
ABL1 40 0.89±0.017 0.88±0.014 0.97±0.006
BTK 14 0.79±0.056 0.83±0.091 0.69±0.11
CSK 18 0.87±0.012 0.95±0.034 0.91±0.036
EGFR 38 0.84±0.01 0.84±0.016 0.95±0.001
FYN 38 0.83±0.033 0.85±0.049 0.96±0.01
HCK 16 0.94±0.01 0.96±0.032 0.95±0.046
T
K
INSR 23 0.92±0.011 0.96±0.012 0.93±0.002
JAK1 11 0.65±0.12 0.69±0.078 0.76±0.098
JAK2 17 0.95±0.013 0.95±0.026 0.97±0.036
LCK 23 0.93±0.004 0.94±0.004 0.96±0.011
LYN 39 0.76±0.028 0.77±0.028 0.87±0.02
RET 16 0.60±0.11 0.82±0.07 0.69±0.096
SRC 125 0.85±0.01 0.87±0.009 0.89±0.003
SYK 27 1.00±0.0 1.00±0.0 0.98±0.004
ZAP70 12 0.95±0.064 0.92±0.019 0.94±0.059
Continued on next page
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kinase substrates int. only full model seq. approx.
Continued from previous page
CAMK1A 12 0.22±0.074 0.75±0.075 0.56±0.083
CAMK2A 41 0.84±0.014 0.89±0.022 0.81±0.021
C
A
M
K
CAMK2G 26 0.97±0.006 0.96±0.001 0.98±0.012
CHK1 11 0.88±0.045 0.52±0.05 0.91±0.038
LKB1 17 0.86±0.023 0.90±0.054 0.88±0.03
MAPKAPK2 21 0.91±0.008 0.93±0.025 0.93±0.01
ATM 46 0.99±0.001 0.99±0.001 0.98±0.003
ATR 14 0.99±0.029 0.98±0.018 0.92±0.047
AURKB 16 0.94±0.004 0.95±0.017 0.91±0.03
C
om
b
in
ed
CSNK1A1 25 0.88±0.014 0.89±0.011 0.86±0.017
CSNK1D 13 0.64±0.13 0.69±0.074 0.63±0.147
CSNK2A1 135 0.87±0.002 0.9±0.004 0.89±0.005
CSNK2A2 67 0.96±0.001 0.96±0.005 0.95±0.004
CSNK2B 20 0.86±0.005 0.88±0.017 0.87±0.012
PAK1 27 0.59±0.03 0.58±0.043 0.49±0.029
PAK2 12 0.21±0.13 0.53±0.12 0.40±0.115
PLK1 23 0.92±0.005 0.92±0.006 0.92±0.006
PRKDC 11 0.74±0.064 0.76±0.053 0.81±0.068
The AUC results (shown in Table 2.1, with averaged ROC curves for the five models and three
conditions shown in Figure 2.2) for 10 cross-validation runs evaluated on all 59 kinases in the
model for the three different conditions demonstrate that the prediction accuracy of the full
model is quite high, with most kinases having median AUCs surpassing 0.8. The average AUC
over all of the kinases is 0.86. The generally low standard deviation indicates that these results
are consistent regardless of the breakup of training/test data that is presented to the model.
We tested three different values for maximum number of protein interactions that could be
connected to a kinase variable (25, 40 and 50), but found that increasing the number of protein
interaction events connected to the kinase variables had very little effect on the performance
of the model (Table A.2), indicating the model’s ability to make classifications based on a
relatively small number of connections to the individual kinase nodes.
When comparing the performance of the PPI only model to the full model, we found that on
average the inclusion of protein abundance data collected across the cell cycle offered modest
improvements to prediction performance. For some kinases there was a greater performance
improvement – for example a 15% increase for PRKC kinases, a nearly 10% increase for the
tyrosine kinase CSK – but for many other kinases the inclusion of cell-cycle data seemed to
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have little effect. This demonstrates that while the protein-protein interaction data provides
the main source of information for the model, the use of cell-cycle data can offer improved
prediction performance for some kinases. This performance increase occurs despite the fact
that we only have cell-cycle data for less than half of the substrates in our set: the model infers
the cell-cycle profiles for the remaining proteins. This indicates that the model, when trained
on cell-cycle data, can still be applied to query proteins that have no associated cell-cycle data.
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Figure 2.2: ROC plots showing prediction accuracy of the Bayesian network model as tested
under the three different conditions: (a) interactions only, (b) full model, and (c) kinase
variables approximated using sequence data. ROC curves represent the averaged ROC values
of the kinases within each of the five Bayesian network models. Results are shown for 15-fold
cross validation across 10 data-set splits.
Table 2.1 also shows a comparison between setting the kinase nodes with database (“full model”)
versus sequence information (“seq. approx.”). We found that for many kinases, using sequence
to set the kinase nodes actually resulted in an increase in performance. The median AUC for
the CMGC kinases went from 0.87 using database information to 0.91 using sequence, and the
median AUC for the tyrosine kinases increased from 0.88 to 0.94.
The possibility was raised that as the kinase-substrate data from HPRD and Phospho.ELM
is sourced from the literature, and the STRING database also includes text mining from the
literature, a system of circular logic could be inflating the performance values. To determine
whether such an effect was occurring, we re-ran our simulations for each kinase with the text
mining information for that kinase removed (Section 2.3.7). We found that while for some
kinases this information appeared to have a large impact on prediction capability, it was not
the case for the majority of kinases (Table A.3).
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2.4.2 Improving sequence-based prediction of phosphorylation sites
For the remainder of this paper, the results were generated using the full model, with a PPI
count of 25, and setting non-query kinase nodes on the basis of their sequence binding motifs.
We tested the ability of PhosphoPICK to complement two phosphorylation site predictors that
operate on sequence data: Predikin (95) and GPS (80). We also tested NetworKIN (97), which
combines sequence scores with a context score generated on the basis of STRING associations.
Comparisons were made by normalising the values of the methods being tested against, and
summing the PhosphoPICK prediction (Section 2.3.8). Figure 2.3 shows the AUC50 (the AUC
obtained when calculating ROC up to the fiftieth false positive) comparison for Predikin, GPS
and NetworKIN across the five BNs, where the highest false-positive rate for serine/threonine
kinases was 0.0005, and the highest for tyrosine kinases was 0.002. Individual results for each
kinase are shown in Tables A.4–A.6. The results show that across all kinase families, there is
an average increase in performance when the Predikin and GPS scores are complemented with
PhosphoPICK predictions, with largest performance increases observed with kinases from the
CMGC family. We found that the performance of GPS improved by 2-fold for predicting CMGC
sites when combined with PhosphoPICK, and that the performance of Predikin was improved
by over 6-fold. The smallest performance increases were observed with tyrosine kinases, where
we found a 15% performance increase for GPS and a 40% increase for Predikin.
We found that in most cases, PhosphoPICK was unable to improve the performance of the
NetworKIN predictions. As Figure 2.3 shows, the differences in AUC50 between classifying
phosphorylation sites with NetworKIN alone and NetworKIN+PhosphoPICK are minor. How-
ever, as the NetworKIN score is already a combination of a STRING and sequence-based score,
it is possible that a simple summing of scores cannot yield further performance increases.
2.4.3 Understanding E2F and CDK2 regulation
To evaluate the ability of the predictions made by PhosphoPICK to provide biological insights,
we used CDK2 as a case study for a proteome-wide analysis. To determine whether predic-
tions were consistent with what is known about CDK2, several GO enrichment analyses were
performed (Section 2.3.9), comparing significantly over-represented GO terms (Fisher’s exact
test, Bonferroni correction, E-value<0.05) obtained for known CDK2 substrates with those ob-
tained for the predicted substrates. We found that the known CDK2 substrates were enriched
most strongly in various terms related to the G1/S transition of the cell cycle, such as DNA
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Figure 2.3: Comparison between predicting kinase-specific phosphorylation sites with three
alternative scoring methods, and when the methods are informed by PhosphoPICK. AUC50
was calculated for each kinase as a measure of the predictive performance at low false positive
levels. Shown here are the average values for each individual BN. The comparison is made by
normalising the scores of the alternative methods to a value between 0 and 1, then summing
this value with the PhosphoPICK prediction for a substrate.
damage response and DNA repair (Table A.7). This is consistent with the role of CDK2 in the
regulation of the transition from G1 to S phase in response to DNA damage (112).
To investigate the agreement of PhosphoPICK predictions with known CDK2 substrates, we
performed a proteome-wide scoring for CDK2 and took the top 300 novel predictions, excluding
known CDK2 substrates from the set of predicted substrates. We again performed a GO
enrichment analysis, and compared the values of the prediction terms with the significant terms
that were found during the analysis on the known substrates. Table A.7 shows the GO terms
found to be significantly over-represented among known CDK2 substrates, ranked from most
significant to least significant. Over half of the terms (31/59) were found to be significantly
over-represented among the novel substrates predicted by PhosphoPICK.
CDK2 is known to be a regulator of the TF E2F1 (124), a member of the E2F family, that is
known to play a role in the G1/S transition, and DNA replication during the S phase (125–127).
The E2F family is comprised of three classes of TFs: transcriptional activators, retinoblastoma
(Rb)-dependent repressors, and Rb-independent repressors. What is currently lacking is an
understanding of what specific roles in the S phase are controlled at transcriptional level by
E2F, and at the post-translational level by CDK2.
In order to investigate what overlapping functions may exist between E2F-regulated transcrip-
tion and CDK2-mediated phosphorylation, we took ChIP-Seq data (123) for E2F1 (activator),
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Figure 2.4: Venn diagram showing overlapping targets between E2F1, E2F4 and E2F6.
CDK2 substrates within the unique E2F1 and unique E2F6 target groups had an over-
representation of GO terms relating to apoptosis and ubiquitination. CDK2 substrates within
the central (all overlapping E2F targets) group were enriched in terms relating to DNA repli-
cation and DNA repair.
E2F4 (Rb-dependent repressor), and E2F6 (Rb-independent repressor). Figure 2.4 shows a
Venn diagram of the unique and overlapping gene targets that exist among the three TFs (Sec-
tion 2.3.10). It has been shown previously that overlapping targets between E2F1 and E2F4
are enriched in DNA replication and repair GO terms (128). We found that the overlapping
targets of all three TFs are also enriched in such GO terms.
We then combined our set of predicted CDK2 substrates with known CDK2 substrates and
identified proteins from this combined set of substrates that were in the unique and overlapping
groups of E2F targets. GO enrichment tests were performed with the CDK2 substrates as the
foreground and the remainder of the TF target group as the background. This allowed us to
detect what role CDK2 plays within these TF target groups. Tables A.8–A.14 contain the GO
terms found to be significantly over-represented (E-value<0.05) among CDK2 substrates in the
TF target groups. While we found significantly over-represented GO terms in all TF target
groups, we noticed a larger number of process-specific terms among the unique E2F1 targets
(Table A.8), unique E2F6 targets (Table A.10) and the overlapping targets among all three
TFs (Table A.11). We found that CDK2 substrates among unique E2F1 targets and unique
E2F6 targets were enriched in several terms relating to the regulation of apoptosis, as well as
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ubiquitination. Substrates in the overlapping group of targets of all three TFs were enriched
in terms relating to DNA replication and DNA damage repair.
2.5 Discussion
Protein phosphorylation is a highly regulated process, being controlled by the binding specificity
to the protein kinase catalytic site, as well as various cellular processes that further enhance the
kinase-substrate fidelity (27, 46). We have demonstrated how a probabilistic model of protein-
protein interactions and cell-cycle data can be used to accurately classify kinase substrates.
Importantly, we found that our model, when combined with sequence-operating methods, was
able to improve the accuracy of kinase-specific phosphorylation site prediction at false positive
levels below 0.002 for tyrosine kinases and below 0.0005 for serine/threonine kinases.
One potential point of concern in our current approach is that we only had access to cell-
cycle data for a single cell type, and whether this could result in a tissue-specific influence
that impeded predictions in some cell types. However, as the phosphorylation site data we
obtained from Phospho.ELM originates from multiple cell types (including, for example, HeLa
cells (129, 130), HEK 293T cells (131), MELN cells (132), and T98G glioma cells (133)),
the performance of the model across these varying cell types validates the appropriateness
of the data we used. We attribute this largely to the simple representation of the cell-cycle
data as four Boolean variables, which would be unlikely to result in a cell type-specific bias.
Somewhat counter-intuitively, we found that the cell-cycle data did not improve prediction
performance for the CDKs – kinases whose activity is strongly linked to cell-cycle progression
– while offering performance increase to other kinases. Though this work focussed on the use
of protein abundance data for representing protein cell-cycle profiles, we note that dynamic
gene-expression data across the cell-cycle also exists for human proteins (44). Further work
could investigate what influence dynamic gene-expression data can provide to kinase-substrate
prediction.
We observed some variation among the performance evaluations for the individual kinases,
indicating that the model works better on certain kinases. However, we found that the per-
formance for prediction of kinase substrates (Table 2.1) was not necessarily an indicator of
what improvement would be seen when applying the model to phosphorylation site prediction.
For example, the PhosphoPICK algorithm had excellent performance when classifying tyrosine
kinase substrates – in several cases with AUCs greater than 0.9. However, when predicting
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phosphorylation sites of tyrosine kinases using Predikin and GPS, we found that the prediction
of tyrosine kinase phosphorylation sites benefitted the least from the addition of the Phospho-
PICK score, and the score appeared to be detrimental to predictions made by NetworKIN.
The kinase family where PhosphoPICK consistently demonstrated the most powerful prediction
performance was the CMGC family - principally CDK and MAPK kinases. We found that
PhosphoPICK generally improved the prediction of phosphorylation sites for the CMGC kinases
as tested across each of the three methods, though there were some cases where PhosphoPICK
resulted in a decrease in the accuracy of NetworKIN predictions. As the kinases in these
families have very similar binding patterns, it is likely that mediating proteins captured by
the PhosphoPICK model make a greater contribution in the correct assignment of a kinase
to a substrate. These results lend support to the intuitive notion that the addition of context
information would support sequence-based predictions most powerfully when the kinase binding
patterns are less specific, or are very similar among family members – or both, as is the case
with CDK and MAPK kinases.
It was interesting to note that the putative CDK2 substrates within the overlapping E2F1, E2F4
and E2F6 targets groups were over-represented with GO terms related to DNA replication and
DNA damage repair. Considering this group of genes was itself already enriched in such terms
(when compared to the proteome), this underscores the importance that CDK2 has in regulating
DNA replication and DNA damage repair (134, 135). There are several potential responses to
DNA damage, but in some cases cells may undergo apoptosis (136, 137). We also noticed that
putative CDK2 substrates within the unique E2F1 and E2F6 target groups were both over-
represented with terms relating to the regulation of apoptosis and ubiquitination. These are
both processes that CDK2 has previously been implicated in (138, 139), and ubiquitination is
also known to play an important role in regulating apoptopic proteins (140). E2F1 is known to
be a regulator of apoptosis (141), and similarly E2F6 can negatively regulate apoptosis (142),
so it was interesting to find that the putative CDK2 substrates within the unique E2F1 and
E2F6 target groups were enriched in apoptosis and ubiquitination GO terms. These results
seem to suggest a dynamic regulatory interplay between the E2F family at the transcriptional
level, and the CDK2 kinase at the post-translational level.

Chapter 3
Cross-species differential
phosphorylation prediction: The sbv
IMPROVER species translation
challenge
3.1 Summary
In the previous chapter I demonstrated how context information such as protein-protein inter-
action networks could be used to predict phosphorylation substrates. An interesting application
that could be derived from a phosphorylation model is understanding how the phosphorylation
status of substrates change under different conditions; i.e. switching between phosphorylated
and unphosphorylated states. A dynamic representation of phosphorylation change under dif-
ferent conditions can be obtained with a method that integrates protein-protein interaction
information with condition-dependent protein expression levels.
The aim of the sbv IMPROVER (systems biology verification for Industrial Methodology for
PROcess VErification in Research) species translation challenge was to investigate whether,
after perturbing signalling pathways in rat, the effects on phosphorylation substrates can be
predicted in human (143). Challenge participants were provided with differential phosphoryla-
tion data sets (for a set of phosphoproteins), as well as gene expression data sets, as measured
under a range of conditions in rat and human epithelial cell lines. Participants were asked to
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design a models that could, firstly, predict phosphorylation change in rat cell lines from gene ex-
pression data, and secondly, predict phosphorylation change in human cell lines using rat data.
This challenge therefore provided a unique opportunity to investigate whether a phosphoryla-
tion model based on protein-protein interaction data could be used to predict phosphorylation
status in response to changes in gene expression levels. Furthermore, it allowed me to test
whether such a model would be able to predict phosphorylation change cross-species.
In this chapter I present a method that cross-references the protein-protein interaction networks
of the phosphoproteins analysed by sbv IMPROVER with genes found to be differentially
expressed under the same conditions as differentially phosphorylated phosphoproteins. Support
vector machine (SVM) and random forest (RF) classifiers were employed to train computational
models to predict phosphorylation status change based on the expression level of the identified
proteins. The hypothesis was that a model based on the protein-protein interaction network of a
phosphorylation substrate would predict phosphorylation status change more accurately than a
model based on randomly selected genes. I show that in 86% of the tests performed, the protein-
protein interactions models did indeed out-perform the random gene models, substantiating the
validity of the approach. Based on the challenge to predict rat phosphorylation status change
from gene expression, the method obtained an average balanced accuracy of 65% as measured
on a blind independent test set kept from the challenge participants by sbv IMPROVER. For
the first sub-challenge my method was ranked 6 of 21 participants, and 7 out of 13 for the second
sub-challenge. These results demonstrate that the PhosphoPICK method could be applied to
predicting change in the phosphorylation status of substrates based on condition-specific gene
expression levels.
3.2 Introduction
Phosphorylation is the main regulatory switch used for modulating protein function, where
change in the phosphorylation status of proteins can determine the activity of biological path-
ways. An example of such a pathway is the MAPK (mitogen-activated protein kinase) pathway,
which links extracellular signals to activity in the nucleus, and is activated by phosphorylation
(144). Understanding how the phosphorylation state of these pathways can change in response
to treatments is important for drug development and discovery, however limited availability of
data is a confounding difficulty. As a result, the development of predictive models that can
use more readily available high-throughput data such as gene expression levels to infer the
phosphorylation state of proteins is needed.
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A further consideration is the level to which observations made by such models can be translated
between species. Animal models are regularly used in a diverse range of biomedical settings,
where treatments for cancers and diseases are tested. Animal models such as mouse have proved
invaluable in gaining a greater understanding of tumour progression (145). While the purpose of
animal models is to be able to infer the response that may be seen in a human, there are severe
limitations on how much can be inferred between animal models and human. A treatment
may work in the animal model, but the results do not translate across in human clinical trials.
There are numerous reasons why translation between an animal model and human trials do not
work, but an important consideration is whether stimuli and treatments affect animal models
in comparable ways to how they affect humans.
The sbv IMPROVER Species Translation Challenge was created to probe the limits of trans-
latability of biological observations between rat and human. Of particular relevance, was the
focus of two of the challenges on predicting differential phosphorylation in response to stimuli.
Epithelial cell lines from rat and human were exposed to a series of identical treatments, with
gene expression (genome-wide) and phosphorylation levels of 16 important regulatory proteins
(kinases and transcription factors) measured under the various conditions. The first aim, or
challenge, of the competition was to create an algorithm that could predict the change of phos-
phorylation status of the given proteins based on gene expression data. The second challenge
concerned the “translatability” between rat and human – predicting phosphorylation status in
human proteins based on rat phosphorylation and gene expression data.
There are several ways that a treatment could result in differential protein phosphorylation. If
a treatment affects the expression of a kinase or a phosphatase, it is probable that the ordi-
nary phosphorylation of the kinase’s substrates will be perturbed. In the case of the kinase,
phosphorylation levels would be expected to decrease in response to down-regulation, and in
response to phosphatase down-regulation, substrate phosphorylation levels would be expected
to be higher than a control. Alternatively, if a key activator or mediator involved in regulating
kinase/phosphatase activity is differentially expressed, there is the potential for downstream
effects resulting in a change in phosphorylation levels. The aim is therefore to identify what
genes are relevant to modulating the phosphorylation of the proteins of interest – whether these
genes have a direct impact (kinases/phosphatases), or an indirect impact (activating/mediating
proteins). The PhosphoPICK algorithm presented in Chapter 2 introduced a method for using
protein-protein interaction and association networks to predict kinase substrates. A different
application of this would be to use the interaction networks to identify the proteins relevant
to determining a substrate’s phosphorylation status; changes in such proteins expression levels
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would be expected to effect the phosphorylation status of the substrate. Therefore, I hypoth-
esised that by leveraging protein-protein interaction and association networks in combination
with the data provided by sbv IMPROVER, a classification method could be trained to predict
changes in phosphorylation status from the gene expression data.
This chapter presents a method for identifying the genes most relevant to the phosphorylation
status of a phosphoprotein by cross-referencing differentially expressed genes with the protein-
protein interaction network of the phosphoprotein. By observing what genes (in the interaction
network) are differentially expressed under the same conditions that the phosphoprotein is
differentially phosphorylated, the identified gene set was used to train a machine learning clas-
sifier. I show that by incorporating these gene sets in support vector machine or random forest
classifiers, differential phosphorylation could be predicted with high accuracy as measured by
AUC. I also perform a statistical analysis to demonstrate that the use of our identified “relevant
genes” in a classifier performs significantly better than if a set of randomly selected genes are
trained on the same classifier.
A phosphoprotein classifier trained on gene expression data could be used to infer the phos-
phorylation status of the phosphoprotein under differing treatment conditions. I trained such
classifiers for the phosphoproteins in sub-challenge 1 (SC1), and used them to predict changing
phosphorylation status from the test gene expression data provided. For sub-challenge 2 (SC2)
I trained phosphoprotein classifiers on rat data, and used the classifiers to predict differential
phosphorylation in the test set of human data.
3.3 Methods
3.3.1 Data provided by sbv IMPROVER
A detailed description of the data generated for the competition is available at (146), but an
overview of the relevant data is provided here. The experiments were performed on normal
human bronchial epithelial (NHBE) and normal rat bronchial epithelial (NRBE) cell lines.
Phosphorylation levels of 16 phosphoproteins and genome-wide measurement of gene expression
were measured under 52 different stimuli, or Dulbecco’s Modified Eagle’s Medium (DME) as
a control condition. In order to divide the data into training data provided to competition
participants and hold-out data, the experiment was divided into two sets of stimuli: 26 for the
training set and 26 for the hold-out set.
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Gene expression was measured using an AffymetrixTM chip, six hours after the cells had been
exposed to a treatment. There were two or three biological replicates for each of the 52 treat-
ments, and 4 or 5 replicates for the DME control. The experiment yielded gene expression
levels for 13,841 rat genes and 20,110 human genes. Orthologs between rat and human proteins
(totalling 12,458 orthologs) were also provided to the competition participants based on HGNC
Comparison of Orthology Predictions.
Phosphorylation data was generated using the Luminex xMapTM technology (147), which uses
beads coated in antibodies that can bind specific proteins – in this case, phosphorylated pro-
teins. The phosphorylation status of the proteins was measured at two time intervals, 5 minutes
and 25 minutes. Phosphorylation signals at the two time intervals were measured in triplicates
for each stimulus, and in sextuplets for the DME control. As defined for the competition, a
phosphoprotein was considered “activated” (i.e. differentially phosphorylated) if the absolute
difference in Luminex xMapTM signal between the DME control and a treatment was greater
than 3. A distinction was not made between phosphoproteins being “down” phosphorylated or
“up” phosphorylated, however given the small number of differentially phosphorylated proteins
(61/416 of the measured rat phosphoproteins in the training data were differentially phosphory-
lated, and 35/416 of the human) it was not feasible to divide the differentially phosphorylated
proteins into two groups.
3.3.2 Additional data and classification tools
In addition to the data provided for the challenge, we sourced protein-protein interaction (PPI)
data for both human and rat from the BioGRID database (1), as well as protein-protein asso-
ciation data from the STRING database (148). BioGRID provides binary interactions between
proteins, while STRING scores associations between proteins based on multiple streams of
evidence such as gene co-expression and literature mining.
I made use of two machine learning tools that have had great success when applied to a variety
of biological problems: support vector machines (SVM) (98, 149) and random forest (RF). As
the prediction problem here is a two-class discriminatory one, I was interested in using machine
learning methods that could optimally separate the differentially phosphorylated samples from
the non-differentially phosphorylated samples. SVMs and RFs are better suited to such a task
than Bayesian networks, which are generative models. A description of SVMs is provided in
Section 1.5.2. The SVM models presented in this chapter use the radial basis kernel function,
which defines the distance between two input features x and x′ as
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ψ(x, x′) = exp(−α||x− x′||2), (3.1)
where α is a variable that can be adjusted.
RFs are based on decision classification trees. Employing a bootstrapping method, RFs con-
struct an ensemble of trees that establish classification rules as determined by training data. A
prediction on test data is made by averaging the results obtained across the ensemble of trees.
I used SVM and RF implementations from the Python machine learning toolkit (MILK, http:
//luispedro.org/software/milk/). Depending on the phosphoprotein, either the SVM or
RF classifier might provide the best performance. Therefore each phosphoprotein was trained
using both an SVM and an RF, and the optimal classifier was selected that obtained the
highest AUC from a cross-validation experiment. The classifier that was selected for each of
the phosphoproteins in SC1 and SC2 is listed in Table 3.1 and Table 3.2, respectively.
3.3.3 Predicting differential phosphorylation with gene expression
The purpose of sub-challenge 1 was to predict differential phosphorylation in the rat cell lines
using GEx data also generated from rat. I identified relevant genes to each phosphoprotein
by investigating the overlap between the protein-protein interaction and association networks
of the phosphoproteins, and the genes observed to be differentially expressed under the same
stimuli conditions that the phosphoproteins were differentially phosphorylated under.
Identification of genes relevant to phosphoproteins
To create vectors of gene expression values that could be used to train the SVM or RF, genes
relevant to a phosphoprotein of interest first needed to be identified. This was done according
to the following procedure. Firstly, the interaction network of the phosphoprotein was ex-
tracted from the BioGRID or STRING databases. As the rat BioGRID PPI network is limited
compared to the human one, the human PPI was used after converting the human proteins to
rat using the provided ortholog mappings. For the STRING database, scored associations were
converted into a binary format using a cut-off threshold: for each phosphoprotein an association
was retained if it obtained a score greater than 50%.
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Secondly, the phosphoprotein interaction network was cross-referenced with genes differentially
expressed under the same treatment conditions that the phosphoprotein was differentially phos-
phorylated (as defined in Section 3.3.1). To identify differential gene expression, Gaussian dis-
tributions of normalised (log-ratio of signal to control) gene expression values across treatment
conditions were constructed. Applying the cumulative distribution function with a threshold
probability γ, a gene was considered differentially expressed if the CDF-derived probability fell
below γ. The value of γ will yield differing numbers of significant genes; too few genes could
result in important information being missed, while too many could cause over-fitting of the
model. Therefore, for each phosphoprotein, different values of γ were tested to determine the
optimal value. Once the relevant gene set was identified for a phosphoprotein, feature vectors
of normalised gene expression values across the treatment conditions were constructed for use
as input features in training a classifier.
Model training and classification
Prediction accuracy of the classifiers was determined from leave-one-out cross-validation, and
measured by calculating area under the receiver operating characteristic curve (AUC). Three
of the phosphoproteins had zero or only one positive (differentially phosphorylated) samples
under any of the treatment conditions, and were excluded from the analysis. The 13 remaining
phosphoproteins were evaluated with different combinations of data source, classification tool
and γ value to determine the optimal configurations, which are listed in Table 3.1.
To determine whether the prediction accuracy of the classifiers was due to the gene selection
process, the accuracy was compared to a “random gene” model. A random gene model con-
tained the same number of genes and other model parameters, but the gene set was chosen
randomly. For each phosphoprotein, 1000 random gene models were generated, and a count
made of the number of times the random model outperformed the interactions-based model,
as measured by AUC. An empirical P-value was derived from the count divided by 1000 – the
number of tests run. The P-value was therefore an indication of the reliability of the accuracy
measure for a phosphoprotein model; i.e. a low P-value shows that the genes derived form the
interaction/association networks are enabling the model’s prediction accuracy.
Once the optimal configuration of classification method, data source and γ value was determined
for each of the phosphoproteins, the method was used to predict phosphorylation status from
the test gene expression data for SC1.
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Table 3.1: Parameters for the phosphoprotein models for predicting phosphorylation status
change in human proteins. If a phosphoprotein is marked as “N/A”, that indicates that there
were not sufficient (two or more) positive samples to train a model.
Protein Data source Classifier CDF sig. (γ)
AKT1 STRING SVM 0.00001
CREB1 STRING SVM 0.0001
FAK1 BioGRID SVM 0.001
GSK3B STRING RF 0.00001
HSPB1 N/A N/A N/A
IKBA BioGRID RF 0.0001
KS6A1 N/A N/A N/A
KS6B1 BioGRID SVM 0.001
MK03 BioGRID RF 0.001
MK09 STRING SVM 0.0001
MK14K11 N/A N/A N/A
MP2K1 BioGRID RF 0.0001
MP2K6 STRING SVM 0.001
PTN11 STRING RF 0.0001
TF65 BioGRID SVM 0.0001
WNK1 BioGRID SVM 0.001
3.3.4 Predicting human phosphorylation change from rat data
The goal of SC2 was to predict differential phosphorylation in human cell lines based on gene
expression and/or phosphorylation levels from the rat cell lines. SC2 therefore presented the
opportunity to test whether the method could work cross-species. Building on the method
presented in Section 3.3.3, my approach was to first use human data to identify genes relevant
to the human phosphoproteins, and then use the orthologous rat gene expression data to train
models on predicting human phosphorylation status change. In addition, at the completion
of SC1 participants were provided with the hold-out rat phosphorylation data. This provided
the opportunity to evaluate the impact of supplementing the gene expression models with rat
phosphorylation data in order to predict human phosphorylation status change.
Feature selection and model training
Human phosphoprotein gene sets were obtained based on the method described in Section 3.3.3,
with a few adjustments to account for predicting phosphorylation status in the human cell
line. Firstly, the human gene expression data was used to identify differentially expressed
genes. Secondly, as the human STRING association networks were much larger than their
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Table 3.2: Parameters for the phosphoprotein models for predicting phosphorylation status
change in human proteins from rat data. If a phospho-protein is marked as “N/A”, that
indicates that there were not sufficient (two or more) positive samples to train a model. “+
Phos” indicates that phosphorylation status from the gold standard rat phosphorylation data
was used.
Protein Data Source Classifier CDF Sig. (γ)
AKT1 BioGRID SVM 0.001
CREB1 BioGRID + Phos RF 0.001
FAK1 N/A N/A N/A
GSK3B BioGRID + Phos RF 1.0E-5
HSPB1 N/A N/A N/A
IKBA STRING (60) SVM 0.0001
KS6A1 BioGRID + Phos SVM 0.01
KS6B1 BioGRID + Phos SVM 0.01
MK03 STRING (70) + Phos RF 1.0E-9
MK09 N/A N/A N/A
MK14K11 N/A N/A N/A
MP2K1 BioGRID + Phos RF 0.01
MP2K6 N/A N/A N/A
PTN11 BioGRID + Phos RF 0.001
TF65 N/A N/A N/A
WNK1 N/A N/A N/A
rat counterparts, stricter cut-off thresholds of 60% or 70% were tested. For SC2 seven of the
phosphoproteins had zero or only one example of differential phosphorylation, meaning that
those phosphoproteins were excluded from the analysis.
Given a set of relevant genes for a phosphoprotein, the gene expression data from the rat or-
thologs was used to construct feature vectors for classifier training. The feature vectors could
also be extended to contain the median Luminex xMapTM signals (of protein phosphorylation
status) for the rat cells for the two time points, 5 and 25 minutes. Cross-validation evalua-
tion was used to determine if the phosphorylation data provided additional predictive power
compared to using the gene expression data alone (Table 3.2 ).
Table 3.2 details what data source, classifier algorithm and γ value were used for each of the
nine phosphoproteins in SC2. There were also parameters related to the SVM model that
were tuned. The level of flexibility allowed in the SVM margins is defined by a parameter, C,
which can be optimised. Cross-validation testing showed that setting the C value to 6 gave the
optimal prediction accuracy across the phosphoproteins. In addition, the α parameter in the
radial basis kernel function (Equation 3.1) was set to 2 after testing.
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Table 3.3: Prediction accuracy (measured using AUC) for the phosphoprotein classifiers of
phosphorylation status change for sub-challenge 1 and sub-challenge 2. P-values represent the
observed frequency of a random-gene model outperforming the model derived from phospho-
protein protein-protein interaction networks. If a phospho-protein is marked as “N/A”, that
indicates that there were not sufficient (two or more) positive samples to train a model.
Challenge 1 Challenge 2
Kinase AUC P-value AUC P-value
AKT1 0.86 0.075 0.88 0.01
CREB1 0.93 0.080 0.85 0.08
FAK1 0.65 0.30 N/A N/A
GSK3B 0.88 0.020 0.74 0.04
HSPB1 N/A N/A N/A N/A
IKBA 0.96 0.085 0.96 0.06
KS6A1 N/A N/A 0.96 0.10
KS6B1 0.71 0.060 1.00 0.00
MK03 0.77 0.200 0.86 0.08
MK09 0.86 0.200 N/A N/A
MK14K11 N/A N/A N/A N/A
MP2K1 0.71 0.090 0.93 0.02
MP2K6 0.71 0.200 N/A N/A
PTN11 1.00 0.090 0.96 0.02
TF65 0.91 0.180 N/A N/A
WNK1 0.94 0.01 N/A N/A
As a final step, the optimised phosphoproteins were evaluated on the test gene expression and
phosphorylation data to predict phosphorylation status in the human cell lines.
3.4 Results
3.4.1 Predicting phosphorylation status change in rat cells
I evaluated the method for its ability to predict differential phosphorylation for 13 out of 16 of
the phosphoproteins. Table 3.3 contains the set of AUC values found from performing leave-
one-out cross-validation on the training data for each of the phosphoproteins, as well as the
P-value representing the probability that the AUC value could be due to chance, rather than the
set of genes included in the model. The results showed promising performance, with an average
AUC of 0.84 across the proteins for the cross-validation test. For challenge 1, all but one of the
phosphoproteins obtained P-values < 0.2, though I only found two examples of phosphoproteins
(WNK1 and GSK3B) in sub-challenge 1 where the P-values obtained statistical significance (P
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< 0.05). The average P-value across the 13 phosphoproteins was 0.14, meaning that in 86%
of tests, the interaction models out-performed the random-gene models. The fact that the
interaction models had greater accuracy for the vast majority of tests is a strong indication
that the prediction accuracy of the method is mostly due to the gene selection process.
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Figure 3.1: Comparison between prediction accuracy as measured by AUC for cross-
validation testing, and the hold-out test set kept by SBV Improver.
I calculated the AUC values for each of the phosphoprotein test data sets provided after SC1,
and compare the prediction accuracy obtained from the cross-validation tests to the accuracy on
the blind test set (Figure 3.1). The method maintained a promising level of prediction accuracy,
obtaining an average AUC of 0.74 for the blind test set, down from an average AUC of 0.84
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Table 3.4: Rankings of participants in challenge 1. My entry is highlighted in bold font.
Prediction accuracy was measured with three metrics: area under the precision-recall curve
(AUPRC), Pearson correlation coefficient and balanced accuracy (BAC)
Rank Team AUPRC Pearson BAC
1 50 0.38 0.72 0.68
1 75 0.38 0.71 0.72
1 49 0.42 0.71 0.68
4 93 0.37 0.70 0.61
5 111 0.35 0.64 0.67
6 89 0.31 0.65 0.65
6 61 0.35 0.68 0.6
8 112 0.29 0.63 0.66
9 116 0.27 0.62 0.59
10 64 0.23 0.59 0.58
11 90 0.24 0.59 0.56
12 100 0.23 0.60 0.56
13 0.78 0.28 0.56 0.55
14 0.72 0.15 0.55 0.58
15 105 0.19 0.56 0.53
16 82 0.14 0.54 0.55
17 106 0.13 0.53 0.55
18 71 0.14 0.49 0.45
19 52 0.13 0.49 0.46
20 84 0.10 0.48 0.49
21 99 0.07 0.43 0.50
across the proteins for the cross-validation test. Many of the AUC values were fairly consistent
between the cross-validation and blind tests, with some notable exceptions. Interestingly, while
the prediction performance of some kinases decreased when tested on the blind test set – which
is expected – there were a few cases where the performance was observed to increase when
evaluated on the blind test set. MP2K6 was the most notable example, showing an increase in
AUC from 0.72 to 0.86. WNK1 showed the sharpest decrease in prediction performance, from an
AUC of 0.94 to a near-random value of 0.58. Surprisingly, WNK1 was also the phosphoprotein
with the most significant P-value obtained from comparing the gene-selection accuracy with the
random-gene model – this would intuitively make it the most likely phosphoprotein to maintain
a similar level of prediction accuracy on the hold-out set.
Table 3.4 shows the rankings from challenge 1, where prediction performance was measured us-
ing a variety of accuracy metrics. My method was ranked 6th place out of 21 teams that submit-
ted predictions to the competition. The ranking demonstrates that the method was nonetheless
amongst the best performing in the competition. Most importantly, as a proof of concept, the
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results demonstrate the potential for using context information such a protein-protein interac-
tion networks to inform the design of methods that can predict protein phosphorylation status
change.
3.4.2 Predicting human phosphorylation change from rat data
For sub-challenge 2, I evaluated the ability of the method to predict differential phosphorylation
in the human cell lines based on the rat data. Table 3.3 shows the AUC values (and level of
significance) for evaluating the prediction accuracy of the method through leave-one-out cross-
validation. The lack of differential phosphorylation examples in the human cell lines meant that
I was only able to obtain results for 9/16 of the phosphoproteins. I found that the prediction
performance for the 9 models was generally quite high, with all but one (GSK3B) of the phos-
phoproteins obtaining AUCs of greater than 0.85. Furthermore, for 8 of the phosphoproteins,
the AUCs I obtained were found to be significant (P < 0.05). The high level of prediction
accuracy and the confidence (based on low empirical P-values) that the performance is not due
to chance, is an indicator that the method can be used to predict human phosphorylation status
from observations made in rat cells.
For many of the phosphoproteins, the prediction accuracy observed for sub-challenge 1 was not
reflected in sub-challenge 2. KS6B1 provided a particularly stark example, with an AUC of
0.71 in sub-challenge 1, but perfect prediction accuracy (with an AUC of 1 and a P-value of 0)
for challenge 2. It is possible that the increased prediction accuracy is at least partly due to
the inclusion of rat phosphorylation data – it is certainly counter-intuitive that the prediction
accuracy for rat to human is generally higher than for sub-challenge 1 where the predictions
were only in rat. For the phosphoproteins where I did not include phosphorylation data (AKT1
and IKBA), the prediction accuracy (measured by AUC) remained almost identical between
sub-challenge 1 and sub-challenge 2 (Table 3.3).
While the competition participants were provided with the hold-out phosphorylation rat data
after SC1 was completed, the hold-out human phosphorylation data was not made available.
I was therefore unable to ascertain the prediction accuracy of the individual phosphoproteins
on the holdout data for challenge 2. Table 3.5 shows the overall rankings and accuracy metrics
that were provided by sbv IMPROVER. 13 teams entered SC2 and my method was ranked 7th.
The overall prediction accuracy of the method as measured on the test data was low compared
to SC1, with a balanced accuracy of 0.58. However this could partly be a reflection of the fact
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Table 3.5: Rankings of participants in challenge 2. My entry is highlighted in bold font.
Prediction accuracy was measured with three metrics: area under the precision-recall curve
(AUPRC), Pearson correlation coefficient and balanced accuracy (BAC)
Rank Team AUPRC Pearson BAC
1 50 0.54 0.75 0.77
2 111 0.41 0.68 0.76
3 49 0.33 0.72 0.68
4 61 0.34 0.70 0.66
5 52 0.31 0.69 0.71
6 93 0.29 0.67 0.59
7 89 0.18 0.57 0.58
7 116 0.28 0.68 0.55
9 112 0.13 0.55 0.56
10 97 0.10 0.54 0.57
11 90 0.12 0.55 0.53
12 105 0.06 0.47 0.45
13 84 0.06 0.45 0.42
that 7/16 of the phosphoproteins for SC2 did not have sufficient positive samples for training
classifiers.
3.5 Discussion
Phosphorylation is an important regulatory mechanism for controlling protein function. Being
able to predict changing phosphorylation states in proteins based on observation in gene expres-
sion level would be highly valuable; being able to infer the phosphorylation state of proteins in
human based on observations in a rodent model even more so. The sbv IMPROVER challenge
presented the opportunity to evaluate whether concepts underlying PhosphoPICK – that of
using cellular context in the form of protein-protein interaction networks to predict phospho-
rylation substrates – could be used to predict changes in protein phosphorylation status based
on gene expression. I have described in this chapter a method that can combine knowledge of
a phosphoprotein’s interaction and association networks with gene expression data to predict
the changing state of phosphorylation levels with promising accuracy. The results validate a
proof-of-concept that the interaction networks of phosphoproteins are useful features in de-
signing methods that can predict phosphorylation status change given the expression levels of
interacting proteins.
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It was noted that even the top teams were only able to achieve a balanced accuracy of 70%,
indicating that there are perhaps inherent limitations in the ability to predict phosphoryla-
tion status from gene expression (143). There were three teams that ranked first place in
sub-challenge 1: teams 49, 50 and 75. The three teams employed quite diverse methodologies
despite the similarity of their prediction accuracy on the test set. Team 49 ranked the gene
expression data in a phosphoprotein-specific manner according to a moderated t-test P-value
(143), identifying genes that underwent significant fold change in the same treatment conditions
as the phosphoproteins. They used a linear discriminant analysis (LDA) model, which was fit
to the training data by taking the top identified genes within a given fold change threshold –
the threshold was optimised through cross-validation runs. Similar to my approach, they did
not train classifiers for phosphoproteins with 1 or 0 examples of differential phosphorylation in
the training set – for those phosphoproteins, all samples in the test set were set to 0. Team 50
employed two methods; one involved the calculation of mutual information between the phos-
phorylation status of each of the 16 phosphoproteins, and differential gene expression (binarised
based on the results of a t-test). The second method employed a principal components analysis
(PCA) on the gene expression data to identify leading principal components (PCs). An LDA
model was fit to the training data as with team 49, with leave-one-out cross-validation used to
optimise the number of PCs in the model. The final prediction was a weighted average of the
scores generated from the two models. Team 75 created support vector regression models for
each of the 16 phosphoproteins, with a feature selection process to select genes that should be
included in the models. Cross-validation on the training set was used to identify the optimal
number of genes for inclusion in the models.
While these methods obtained moderately better prediction accuracy then our own method,
there are likely intrinsic limits to what can be achieved without considering additional infor-
mation about the proteins under study. This is similar to observations that have been made in
other areas of proteomics; for example it is recognised that only a small percentage of protein
abundance levels can be explained from gene expression levels alone. Rather, predicting pro-
tein abundance from gene expression benefits from additional information from the protein and
RNA level (150). Similarly, a method for predicting phosphorylation status that incorporates
additional relevant information from the protein level would provide a better description of how
phosphorylation levels can change in response to gene expression values.
The post-competition analysis also discussed the possibility that while it may be feasible to
predict human phosphorylation status from rat phosphorylation data, the current limitations in
computational tools mean that predictions do not benefit from the inclusion of gene expression
data (151). This is in agreement with our results, which found that almost all the human
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phosphoproteins benefited from the use of phosphorylation data in addition to gene expression
for predicting phosphorylation in human cell lines from rat cell lines. My results for predicting
human phosphorylation change from rat data seemed promising based on the training data,
but I was unable to determined the performance of the individual phosphoproteins on the hold-
out test data. As the data only allowed me to train models for half of the phosphoproteins,
it is difficult to gauge whether the low balanced accuracy (58%) obtained from the hold-out
evaluation performed by sbv IMPROVER is indicative of the accuracy of the trained models.
A major limitation in this study was the number of training samples available. We found that
for many of the phosphoproteins there were only a couple of positive examples of differential
phosphorylation that could be used for training. In challenge 2 there were 7 examples – nearly
half – of the phosphoproteins that did not have any examples of differential phosphorylation
associated with them. In such cases it was not possible to train and evaluate our model.
Nonetheless, even with the data limitations, the results presented in this chapter demonstrate
the potential for using methodology derived from PhosphoPICK to predict changes in protein
phosphorylation states.
Chapter 4
Prediction of kinase-specific
phosphorylation sites through an
integrative model of protein context
and sequence1
4.1 Abstract
The identification of kinase substrates and the specific phosphorylation sites they regulate is an
important factor in understanding protein function regulation and signalling pathways. Com-
putational prediction of kinase targets – assigning kinases to putative substrates, and selecting
from protein sequence the sites that kinases can phosphorylate – requires the consideration of
both the cellular context that kinases operate in, as well as their binding affinity.
We report here a novel probabilistic model for the classification of kinase-specific phosphoryla-
tion sites from sequence across three model organisms: human, mouse and yeast. The model
incorporates position-specific amino acid frequencies, and counts of co-occurring amino acids
from kinase binding sites in a kinase- and family-specific manner. We show how this model
can be seamlessly integrated with protein interactions and cell-cycle abundance profiles. When
evaluating the prediction accuracy of our method, PhosphoPICK, on an independent hold-out
set of kinase-specific phosphorylation sites, we found it achieved an average specificity of 97%
1Chapter reproduced from paper of the same name currently in submission.
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while correctly predicting 32% of true positives. We also compared PhosphoPICK’s ability,
through cross-validation, to predict kinase-specific phosphorylation sites with alternative meth-
ods, and found that at high levels of specificity PhosphoPICK outperforms alternative methods
for most comparisons made.
We investigated the relationship between experimentally confirmed phosphorylation sites and
predicted nuclear localisation signals by predicting the most likely kinases to be regulating the
phosphorylated residues immediately upstream or downstream from the localisation signal. We
show that kinases PKA, Akt1 and AurB have an over-representation of predicted binding sites
at particular positions downstream from predicted nuclear localisation signals, demonstrating
an important role for these kinases in regulating the nuclear import of proteins.
4.2 Introduction
Kinases regulate a wide variety of essential biological processes through protein phosphoryla-
tion, including transcription factor activity (152), the control of DNA damage repair pathways
(153), the progression of cells through mitosis (57), and protein import into the nucleus (154).
Knowledge of the kinases that regulate phosphorylation substrates is therefore a significant
factor in understanding the functional consequences of protein phosphorylation events. While
hundreds of thousands of phosphorylation sites have been identified across thousands of proteins
(4), the kinases that regulate these sites in most cases remain unknown. Computational meth-
ods that predict kinase-specific phosphorylation sites are therefore an important contributor to
understanding the role of phosphorylation events in biological processes (155). Such methods
contribute to the guidance of phosphorylation experiments (156) and provide information about
the likely signalling pathways that phosphorylation sites may be involved in (157).
Kinase-mediated phosphorylation is regulated by several important factors that can be lever-
aged to build predictive models. One is the sequence-level motifs surrounding phosphorylation
sites that interact with kinase binding domains. The protein sequence determines whether a
kinase can bind to the protein; previous studies have shown that local motifs surrounding a phos-
phorylation site interact with the binding domain of kinases to allow phosphorylation (25, 46).
There are numerous kinase-specific phosphorylation site predictors that take advantage of the
sequence specificity of kinases to predict kinase-specific phosphorylation sites (80, 95, 158) as
well as phosphorylation sites in a non-kinase specific manner (16, 104).
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The presence of valid kinase-binding motifs on a protein is no guarantee that a kinase will
phosphorylate a substrate however (27). The targeting of phosphorylation substrates by kinases
is subject to, and controlled by, a wide variety of processes within the cell – what may be called
the “context factors” that ensure kinase-substrate fidelity. Context factors can include proteins
that mediate the interaction between kinases and their substrates (20), activating proteins
such as cyclins (52), sub-cellular compartmentalisation (159) and the various stages within the
mitotic cell cycle (160).
We have shown previously that context information (in the form of protein-protein interaction
and association data, as well as protein abundance levels across the cell cycle) can be incorpo-
rated into a probabilistic model that maps kinases to putative substrates (161). This model
not only provides an accurate predictor of kinase substrates, but importantly, the sequence-
level prediction of kinase-specific phosphorylation sites can be greatly enhanced by the model’s
additional predictive power. While this model was able to use context alone to predict kinase
substrates, we hypothesised that the incorporation of sequence and context into a single model
would provide better explanatory power of the factors that describe kinase targets.
In this paper, we present a novel probabilistic method for predicting kinase-specific phosphory-
lation sites that incorporates position-specific amino acid frequencies and counts of co-occurring
neighbouring amino acids in a family-specific manner across three model organisms: human,
mouse and yeast. We demonstrate that this sequence model can be used as a module within a
larger Bayesian network that describes the context factors that influence how a kinase targets
a protein substrate. The seamless integration of these two domains of information – context
and sequence – allows for a comprehensive model of kinase-protein phosphorylation. We com-
pare the ability of our method, PhosphoPICK, to predict kinase-specific phosphorylation sites
against alternative phosphorylation predictors, and show that PhosphoPICK has a superior
ability to predict kinase-specific phosphorylation sites for most comparisons made.
As we now have a predictor that ably integrates the context and sequence conditions that reg-
ulate phosphorylation, we are in a position to investigate phosphorylation-dependent functions
and probe the kinases that are involved in regulating these functions. The nuclear import of
proteins is a highly-specific process, involving the binding of importin proteins to cargo pro-
teins that contain a relevant nuclear localisation signal (NLS) (162, 163). It has been shown
that the binding of importin proteins to their cargo can be controlled (promoted or inhibited)
by the presence of phosphorylation adjacent to the NLS (164). We therefore investigated the
relationship between nuclear localisation signals and phosphorylation by cross-referencing ex-
perimentally identified phosphorylation sites with predicted NLSs. We used PhosphoPICK to
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identify the most likely candidate kinases for NLS-adjacent phosphorylation sites, and per-
formed a statistical analysis to identify sites relative to NLSs that have an over-representation
of kinase binding sites. We identify several kinases as candidates to regulate phosphorylation
sites at sites downstream from the NLSs, most notably protein kinase A (PKA), Akt1 and
Aurora kinase B (AurB). We also identify kinases that regulate sites upstream from the NLS,
including cyclin dependent kinase 2 (CDK2). Gene ontology (GO) term enrichment analyses
indicate that the phosphorylation of specific sites close to the NLS by these kinases regulates
distinct biological functions.
4.3 Methods
4.3.1 Data resources
We obtained kinase-specific phosphorylation data for human and mouse from PhosphoSitePlusr,
www.phosphosite.org (4) and for yeast (Saccaromyces cerevisiae) from PhosphoGRID (73),
which is a database of in vivo phosphorylatio sites. For data collected from PhosphoSitePlusr,
we ensured that phosphorylation sites used were known to occur in vivo, but for both databases,
the kinase annotations are often informed by in vitro or in vivo experiments. We chose phos-
phorylation site data for kinases where there were greater than 5 unique kinase substrates,
resulting in 5,209 kinase-specific phosphorylation sites across 1,826 proteins for human, 956
kinases-specific phosphorylation sites across 417 proteins for mouse, and 2,219 kinase-specific
phosphorylation sites across 722 substrates for yeast. In order to have a more extensive back-
ground of phosphorylation events for training a sequence model, we also used phosphoryla-
tion sites that did not have a kinase assigned to them. We used phosphorylation sites from
PhosphoSitePlusr that were generated using low-throughput methods; similarly for Phospho-
GRID, sites were included if they were identified using more than one method, or if the single
detection method was not mass spectrometry. This resulted in an additional 5,939 phospho-
rylation sites for human, 2,865 additional phosphorylation sites for mouse and 674 additional
phosphorylation sites for yeast.
Protein-protein interaction (PPI) data was sourced from BioGRID (1), protein-protein associa-
tion data from STRING (148), and protein abundance data across the cell cycle from the work
by Olsen and colleagues (28). As the cell-cycle information was only available for human, cell-
cycle data was not incorporated into the mouse or yeast kinase models. A detailed description
of how this data was curated and processed is available in (161).
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In order to evaluate the prediction accuracy of our method on completely novel data, we created
a hold-out set for kinases for which there were more than 100 known substrates – there were
nine such human kinases. For each of the nine kinases, we selected a random set of substrates
equal to 10% of that kinase’s substrates that were not in the original set of substrates used for
developing the model (161). These substrates were excluded from all analyses and simulations,
and were used only for a final evaluation of model accuracy. This resulted in a hold-out set of
145 proteins – containing 416 phosphorylation sites specific to the nine kinases. After removing
the hold-out set, a set of 1,671 human proteins and 4,907 kinase-specific human phosphorylation
sites remained for training and testing.
In addition, we built similarity-reduced sets of the phospho-peptide sequences obtained from
PhosphoSitePlus and PhosphoGRID in order to determine whether sequence similarity could
be inflating prediction accuracy. The BLASTP program (165) was used to perform a pairwise
sequence similarity comparison of each of the phospho-peptides, using 15-residue sequences
centred on the phosphorylation site. All 15-residue pairs obtaining a BLASTP E-value under
0.05, with sequence identity of at least 30%, were retained. Similar pairs within the same
kinase category were reduced through the arbitrary removal of one of the phospho-peptides;
phospho-peptides that were similar, but phosphorylated by different kinases, were not reduced.
The similarity reduction was also applied to the background set of peptides.
4.3.2 PhosphoPICK method and workflow
Building on our existing context model, we developed a model for predicting kinase-specific
phosphorylation sites from sequence, as well as a model that incorporates this sequence model
into the context model described in our previous work.
Sequence model
We present a Bayesian network model for modelling various sequence features of a kinase binding
motif (Figure 4.1). We represent potential amino acid residues in an n length sequence motif
surrounding a phosphorylation site as discrete variables conditioned on two Boolean variables.
The first represents the event that some kinase of interest, K, binds to the site, the second
represents the event that a family member (i.e. any family member of K) binds to the site.
Each variable – R−m to R+m, where R0 represents the site for which phosphorylation is predicted
– contains three distributions of amino acid frequencies. These represent (1) the probability
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of each amino acid occurring at the position where K is seen to be phosphorylating, (2) the
amino acid frequencies for binding sites from the family members of K, and (3) the amino acid
frequency background as seen across all other phosphorylation sites in the training set.
In addition to position-specific amino acid frequencies, we included k-mers of k=2 (dimers) and
k=3 (trimers) to encode the frequency of co-occurring neighbouring amino acids. This should
allow the model to capture some paired dependencies that may exist between amino acids. In
order to avoid over-parameterising the sequence model with all possible combinations of dimers
and trimers, we only added the k-mers that were observed in some θ percentage of kinase
binding motifs from a training set. During cross-validation, the training set of kinase-binding
motifs was taken, and k-mers observed within the motifs were counted. If a k-mer occurred in
more than the θ percentage threshold of substrates, the k-mer was added to the model. We
tested three cut-offs of θ: 5, 10 and 20, and found that 5 gave the best prediction accuracy
across the full set of kinases (see Table B.1 for results across the set of human kinases, Table B.2
for mouse kinases and Table B.3 for yeast kinases). As shown in Figure 4.1, the k-mers are
represented as a series of n Boolean variables, Kmer1 to Kmern, where a k-mer is considered
to be true if it is observed in the amino acid motif surrounding the phosphorylation site. The
k-mer nodes were trained to capture the probability of each k-mer occurring within a kinase’s
binding motif, that of its family members and the background set of phosphorylation sites.
R0 R+1 R+mR-m R-1
Kinase
binds
..............
Family
binds
Kmer1 ....... Kmern
Figure 4.1: Sequence model. R nodes represent positions in a motif surrounding the phos-
phorylation site, where R0 is the potential phosphorylation site. Kmer1 to Kmern represent
the dimer and trimer configurations incorporated into the model.
It has been shown previously that varying the motif length in predicting kinase binding sites
improves prediction accuracy (80). Therefore, for each kinase we tested five different window
sizes centred around the phosphorylated residue: 7, 9, 11, 13 and 15. For each kinase we selected
the window size that gave the best prediction accuracy as measured within a cross-validation
test (Tables B.4, B.5 and B.6).
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Combined model
The combined model retains the structure of the “context” Bayesian network described previ-
ously (161), but with the sequence model incorporated into it. This model represents obser-
vations about kinase-substrate phosphorylation events, protein-protein interaction/association
events believed to be relevant to kinases encoded in the model, and cell-cycle profiles of sub-
strates as Boolean variables. A connection between a kinase and a PPI event is defined if the
protein is interacting with at least 5 of the kinase’s substrates. Up to 25 connections between
a kinase and a PPI event can be defined.
The sequence model was incorporated into the larger context model in a kinase-specific manner,
such that for each kinase the kinase target variable in the sequence model is conditioned on the
variable in the context model representing the kinase phosphorylating a substrate (Figure 4.2).
We created models based on sets of kinases as they are classified into family similarity (32).
For human, we created eight family-specific models comprising kinases from the CMGC (cyclin-
dependent, mitogen-activated, glycogen synthase and Cdc2-like), AGC (protein kinase A, G and
C families), CAMK (Ca2+/calmodulin-dependent kinase), TK (tyrosine kinase), “other”, STE,
CK1 (cell kinase 1) and atypical kinase families. For mouse, we created three models with
kinases from the CMGC, AGC and TK families; and for yeast we created four models from the
CMGC, AGC, CAMK and other kinase families.
4.3.3 Setting non-query kinase nodes
The model relies partly on the expected activity of alternative kinases that are encoded in the
Bayesian network. However, there is no experimental information on kinase binding events
for the majority of proteins, and negative evidence (a protein not being phosphorylated by a
particular kinase) is non-existent. Therefore we employ the amino acid sequence of a query
protein to estimate what kinases in the model will not bind to the protein, and can therefore
be set to false. In order to decide when kinase variables in the model should be set to false,
the following steps were followed for each non-query kinase. Within a training fold, the positive
training samples for that kinase were set aside. 75% of the substrates within the negative set
were selected randomly, and each phosphorylation site within this set was added to the training
data, while the remaining substrates were set aside as a test set.
The sequence model was trained using the selected training samples, and used to scan over
each of the substrates within the test set, with the highest score for each of the substrates
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recorded. The median value of these scores was then taken as a threshold representing the
highest expected score for a protein that is not phosphorylated by the kinase. When evaluating
the model on a test substrate, for each non-query kinase node, its sequence model was used
to scan the substrate and the highest score is recorded. If the score falls below the calculated
threshold value, that kinase node is set to false, otherwise it remains unspecified.
G1M S G2
K1 K2 .................. Ki
..................P1 P2 P3 Pk
Latent
K1 binds
R0
R+m
R-m
.....
.....
Kmern
Kmer1
.....
Family
binds
Figure 4.2: PhosphoPICK Bayesian network model incorporating both context and sequence
data. The bottom layer of nodes (P 1 to P k) represent protein interactions incorporated into
the model. These are conditioned on relevant kinases (K1 to Ki), which are themselves
conditioned on a latent node incorporating variables representing the four cell cycle stages.
The K1 binds “sequence” variable is conditioned on its corresponding K1 “context” variable.
Prediction workflow
A diagram illustrating the PhosphoPICK workflow for generating a prediction is shown in
Figure 4.3. To determine the probability of a query kinase phosphorylating a given substrate,
the relevant context data are queried and the corresponding nodes in the Bayesian network are
instantiated. As there is no experimental information on kinase binding events for the majority
of proteins, and negative evidence (a protein not being phosphorylated by a particular kinase)
is non-existent, the protein sequence is used to provide an estimate of what alternative kinases
will not phosphorylate the given substrate (Section 4.3.3).
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The model is then scanned over the substrate’s amino acid sequence, and for every potential
phosphorylation site, the n length motif corresponding to the query kinase surrounding the
phosphorylation site is used to set the sequence nodes in the network. For every potential
phosphorylation site, the node representing the kinase phosphorylating a substrate is queried,
and the highest probability for the scan is taken as the score for that substrate. Separately,
the potential phosphorylation sites within the substrate are scored using the sequence model.
The final score for a kinase-specific phosphorylation site prediction is equal to the average of
the substrate score from the combined model, and the site score from the sequence model.
4.3.4 Model training
Sequence model
The nodes in the sequence Bayesian network are defined using conditional probability tables
(CPTs), which learn from training data all possible values that a variable can take, given the
set of parents it is conditioned on. If a variable does not have parents, the CPT will represent
the observed frequency from the training data of it being true. As there may be amino acids
or k-mers that do not occur in some of the training data, we added a uniform pseudo-count of
0.05 to all the amino acid and k-mer nodes, ensuring that the model does not consider some
amino acids or k-mers impossible to occur.
Combined model
The nodes in the combined model are defined using CPTs and our variation on the NoisyOR
node (161), which allows for an approximation of a CPT. The protein interaction nodes were
defined using NoisyOR variables, allowing parameters to be inferred even in the case of data
sparsity. All other variables in the combined model were defined as CPTs.
As the combined model incorporates data representing different problems – that of predicting
kinase substrates, and predicting kinase binding sites, the model was trained in two stages.
First, the set of unique substrates was presented for expectation maximisation training (121)
in order to set the parameters for the protein-interaction, cell-cycle and kinase nodes in the
network. The parameters for these variables were then locked in place. Next, the sequence
module within the network was trained using the set of phosphorylation sites contained in the
training fold, with the position-specific amino acid nodes and k-mer nodes being set as for the
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sequence model. There will be some cases in the phosphorylation site data where a kinase will
be phosphorylating a substrate, but not the site. In these cases, the node representing the
kinase binding the substrate was set to false.
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Figure 4.3: Diagram showing the workflow involved when a kinase is queried for a protein
submitted to the model. BioGRID and STRING are queried to identify what proteins the
substrate interacts with, and the protein-interaction variables are set accordingly. If cell-cycle
data is available, it will be included also. The substrate sequence is used to estimate what
kinases in the model will not bind to the substrate, with the remainder left unspecified. The
model is then scanned across the sequence to identify the highest probability of the kinase
phosphorylating the substrate. Separately, the sequence model is used to score all potential
sites in the query substrate. The final prediction for a potential phosphorylation site is the
average of the substrate and site score.
4.3.5 Evaluating model prediction accuracy
The prediction accuracy of the models was evaluated across the 107 human kinases, 24 mouse
kinases and 26 yeast kinases using ten-fold cross-validation across ten randomised data-set
splits. The prediction accuracy of the sequence model was evaluated by its ability to correctly
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classify kinase-specific phosphorylation sites out of the set of known kinase-binding sites, and
the combined model was evaluated by its ability to correctly classify kinase substrates out of
the set of substrates.
To ascertain the effect that our sequence model features have on prediction accuracy, we evalu-
ated the accuracy of a simple baseline sequence model that only contained the position-specific
amino acid nodes conditioned on the kinase variable (the family variable was excluded). We
also evaluated the prediction accuracy of the context model (the combined model excluding the
sequence information) and compared its accuracy with the combined model to ascertain what
improvement may be gained from incorporating sequence and context information into a single
model. Prediction accuracy was determined using receiver operating characteristic (ROC) and
calculation of area under the ROC curve (AUC) as a measure of overall model performance
(122). We also calculated area under the ROC curve up to the fiftieth false positive (AUC50)
as a measure of performance at low false-positive levels.
Comparisons to alternative methods
We compared the ability of the complete PhosphoPICK work-flow to predict kinase-specific
phosphorylation sites out of all potential phosphorylation sites in the substrate sequences. The
comparison was performed firstly against the sequence model only, and secondly against three
alternative methods that have a larger number of kinases available for making predictions:
GPS 2.1 (80), NetPhorest 2.0 (97) and NetworKIN 3.0 (97). We downloaded the standalone
prediction software for each of the three methods and ran the set of 1,671 proteins through
them. For NetworKIN and NetPhorest, we did not specify the sites we wanted predictions
for. We used GPS’s batch prediction system to run GPS on the protein set, selecting the “no
threshold” option.
In order to compare PhosphoPICK predictions to the alternative methods, we again did a 10x
ten-fold cross-validation run of the combined model as well as of the sequence model. As most
of the potential phosphorylation sites in the substrates were not in the set of peptides used
for training the sequence model (and therefore not part of the cross-validation run), the fully
trained sequence model was used to score potential phosphorylation sites outside of the training
set.
Due to the large number of potential phosphorylation sites being scored (∼170,000 S/T sites
and ∼30,000 Y sites), we calculated sensitivity for two stringent levels of specificity – 99.9% and
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99%. The difference in sensitivity between PhosphoPICK and each alternative was calculated
across all ten cross-validation runs.
Calculating significance of predictions
Users of the PhosphoPICK web-server are provided with an option to include empirical P-
value calculations alongside their predictions, allowing for a measure of the significance of the
predictions. To obtain empirical P-values, we first calculated proteome-wide distributions of
predictions; i.e. for all kinases, substrate predictions were obtained for every protein in the
relevant proteome (human, mouse or yeast), and site predictions were made for all potential
phosphorylation sites in the proteome. To calculate a combined P-value for a prediction, Fisher’s
method for combining probabilities was applied such that:
X = −2(ln(Pcontext) + ln(Psite)),
where Pcontext and Psite represent the P-value value calculated for a context score given to a
substrate and a motif score given to a site respectively, and X follows a Chi squared distribution
with 4 degrees of freedom.
4.3.6 Evaluation on hold-out set
When evaluating the performance of the model on the hold-out set, the full sets of training
data was used to train the model. We predicted each potential phosphorylation site (all S/T
residues for serine/threonine kinases and all Y residues for the tyrosine kinase Src) in the hold-
out sequences, and evaluated the performance of the model for each kinase by its ability to
predict the kinases’ phosphorylation sites out of all potential sites. In order to evaluate how
well the method would be expected to perform using the P-value based thresholding system on
the web-server, P-values were calculated for the predictions, and if a P-value for a prediction
fell below 0.005 the prediction was considered to be true, and false otherwise.
We calculated sensitivity, specificity, balanced accuracy (BAC) and Matthews’ correlation co-
efficient (MCC). The metrics are defined as follows, where TP is the number of true positives,
FP the number of false positives, TN the number of true negatives, and FN the number of
false negatives.
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Sensitivity:
sens. =
TP
TP + FN
Specificity:
spec. =
TN
TN + FP
Balanced accuracy:
BAC =
sensitivity
specificity
Matthews’ correlation coefficient:
MCC =
TP × TN − FP × FN√
(TP + FP )(TP + FN)(TN + FP )(TN + FN)
4.4 Results
4.4.1 Sequence model for classifying kinase binding sites
The sequence model was evaluated by its ability to correctly classify, on a per-kinase basis,
kinase-specific phosphorylation sites out of the set of known kinase binding sites. Table 4.1
shows results for an example set of kinases (the CMGC family of kinases), and Table 4.2
contains the averaged prediction accuracy for each of the kinase families across the three tested
species. The full set of values are available in Tables B.7, B.8 and B.9. The sequence model has
good prediction accuracy over the kinases tested, with an average AUC of 0.79 across all human
kinases. We found that 66% of kinases obtained an AUC of greater than 0.75, demonstrating
that the model works well for the majority of kinases. We noticed particularly high accuracy
for the CMGC kinases, where 17/20 of the kinases in this family obtained an AUC of greater
than 0.8 (Table 4.1); and also the atypical kinases, where all of those kinases obtained an AUC
greater than 0.8, and 3/4 greater than 0.85 (Table B.7). The worst performing family appeared
to be the tyrosine kinase family, where we found an average AUC of 0.62 – substantially
lower than the overall average (of 0.79), and much lower than the accuracy from the various
serine/threonine kinase families.
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We compared the sequence model against a baseline model that only considered the position-
specific amino acid frequencies. While the sequence model outperforms the baseline in general,
we noticed that there was substantially higher accuracy at low false-positive levels as measured
by the AUC50. In the “other” family of kinases, there was a greater than 3-fold increase in the
AUC50, and in the CMGC and CK1 families we found a greater than 2-fold increase in AUC50.
Table 4.1: Comparison of prediction accuracy across human CMGC kinases between predict-
ing kinase-specific phosphorylation sites with a baseline model that only considers position-
specific amino acid frequencies, and the sequence model. Results were generated using ten-fold
cross-validation repeated across ten randomised data-set splits. Shown are the average and
standard deviation of the AUC and AUC50 values.
AUC AUC50
Kinase Baseline Sequence model Baseline Sequence model
CDK2 0.86±0.001 0.89±0.001 0.06±0.002 0.10±0.004
CDK1 0.88±0.002 0.89±0.002 0.09±0.004 0.07±0.008
ERK2 0.86±0.002 0.86±0.001 0.05±0.004 0.07±0.010
ERK1 0.86±0.005 0.86±0.005 0.04±0.005 0.07±0.012
GSK3B 0.77±0.009 0.81±0.006 0.09±0.007 0.13±0.014
P38A 0.79±0.007 0.81±0.007 0.12±0.016 0.15±0.017
JNK1 0.83±0.005 0.87±0.004 0.08±0.013 0.15±0.014
CDK5 0.84±0.012 0.84±0.009 0.07±0.009 0.05±0.007
JNK2 0.75±0.015 0.73±0.023 0.03±0.013 0.07±0.015
CDK7 0.77±0.017 0.88±0.019 0.16±0.044 0.31±0.032
GSK3A 0.89±0.014 0.90±0.026 0.26±0.020 0.46±0.045
CDK4 0.85±0.012 0.87±0.012 0.07±0.007 0.18±0.025
P38B 0.79±0.006 0.83±0.014 0.07±0.015 0.26±0.046
HIPK2 0.81±0.016 0.86±0.013 0.23±0.030 0.38±0.043
DYRK1A 0.77±0.034 0.83±0.033 0.01±0.024 0.26±0.043
CDK9 0.78±0.011 0.83±0.015 0.04±0.022 0.32±0.030
DYRK2 0.68±0.032 0.78±0.019 0.00±0.000 0.31±0.043
ERK5 0.79±0.015 0.83±0.016 0.02±0.014 0.32±0.034
CDK6 0.80±0.019 0.86±0.009 0.07±0.016 0.18±0.030
CDK3 0.69±0.031 0.76±0.050 0.00±0.000 0.36±0.045
On the mouse kinases, the model achieved a more moderate average AUC of 0.71, reflecting
the diminished availability of positive training data when compared to human or yeast kinases.
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Similar to the results seen in the human kinases, however, the CMGC kinases performed the
best, with an average AUC of 0.79, and the tyrosine kinases were again the worst performing,
with an average AUC of 0.63.
Table 4.2: Performance comparisons between predicting kinase-specific phosphorylation
sites with a baseline model that only considers position-specific amino acid frequencies, and
the sequence model. Results were generated using ten-fold cross-validation repeated across
ten randomised data-set splits. Shown are the average and standard deviation of the AUC
and AUC50 values.
AUC AUC50
Family Baseline Sequence Baseline Sequence
Human
CMGC 0.80±0.013 0.84±0.014 0.08±0.013 0.21±0.026
AGC 0.76±0.017 0.79±0.018 0.15±0.028 0.21±0.029
TK 0.56±0.022 0.62±0.025 0.11±0.021 0.18±0.024
CAMK 0.73±0.023 0.77±0.024 0.11±0.014 0.19±0.027
Other 0.69±0.019 0.80±0.021 0.07±0.013 0.32±0.038
STE 0.71±0.031 0.79±0.052 0.23±0.049 0.38±0.053
CK1 0.75±0.020 0.86±0.025 0.12±0.019 0.30±0.031
Atypical 0.84±0.009 0.87±0.008 0.18±0.008 0.20±0.030
Mouse
CMGC 0.74±0.016 0.79±0.016 0.14±0.017 0.24±0.029
AGC 0.72±0.025 0.75±0.032 0.17±0.034 0.26±0.051
TK 0.60±0.025 0.63±0.029 0.26±0.032 0.31±0.026
Yeast
CMGC 0.67±0.028 0.76±0.028 0.11±0.007 0.32±0.030
AGC 0.79±0.020 0.85±0.025 0.24±0.027 0.46±0.034
CAMK 0.64±0.024 0.78±0.024 0.05±0.017 0.34±0.037
Other 0.74±0.017 0.84±0.023 0.10±0.010 0.35±0.035
The yeast kinase models performed quite well, achieving an average AUC of 0.81. In yeast,
the best performing kinases were from the AGC family, with an average AUC of 0.85, and an
AUC50 exceeding any other kinase family from mouse or human. We noticed that the sequence
model had a substantial increase in accuracy when compared to the baseline – particularly at
the low false-positive rates as measured by AUC50. The CAMK kinases recorded the sharpest
increase, with an average AUC50 of over 6-fold greater than the baseline model. In general,
we found that the use of k-mers offered a great advantage over the simpler representation of
position-specific amino acid frequencies, and that this was particularly noticeable at low false-
positive levels. Our results indicate that our combination of features offers a highly accurate
model for predicting kinase phosphorylation sites across diverse kinase families and species.
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In order to test whether sequence similarity within the phospho-peptides could be inflating
prediction accuracy, we re-trained the sequence model on the similarity reduced data-set. Ta-
ble B.10, Table B.11 and Table B.12 contain a comparison of the fully trained sequence model
and the model trained on the reduced data-set. For the majority of kinases, the similarity
reduction did not result in a decrease in AUC. On average, there was a negligible difference
in AUC, with an average decrease across all kinases of 0.004 seen with the reduced data set.
Similarly, differences in the average AUC50 were slight, and within the margin of error. This
demonstrates that the prediction accuracy of the sequence model is not due to homologous
phospho-peptides in the training data, and can be applied to unseen samples.
4.4.2 Kinase substrate prediction
We compared the ability of the context model to predict kinase substrates against the combined
(context plus sequence) model. Table 4.3 shows AUC and AUC50 values from the CMGC family
of kinases, with averaged results across the kinase families summarised in Table 4.4, and the full
set of results for all kinases available in Tables B.13, B.14 and B.15. The results demonstrate
that across the kinase families, the incorporation of sequence data improved the ability of the
model to predict kinase substrates. We noticed larger increases in prediction accuracy for the
human CMGC, AGC and CAMK kinase families: the average AUC50 for CMGC increased
from 0.31 to 0.43, AGC saw a similar increase from 0.21 to 0.34 and CAMK the largest – from
0.25 to 0.40. Figure 4.4 shows ROC plots, calculated up to 50 false positives (representing the
AUC50 score), for kinases from the human CAMK family. ROC plots showing the prediction
accuracy of the combined vs context model for the full set of kinases is available in Figure B.1
– Figure B.15. The ROC curves in Figure 4.4 demonstrate that the combined model is able to
provide a substantial improvement in prediction accuracy at low false-positive rates for many
of the CAMK kinases, when compared to the context model.
Table 4.3: Combined model accuracy across human CMGC kinases when compared to
the context only model. Table shows accuracy values for classifying kinase substrates with
both models as determined by 10-fold cross-validation across 10 randomised data-set splits.
Prediction accuracy is measured using median and standard deviation of the AUC and AUC50
across the data-set splits.
AUC AUC50
Kinase Context model Combined model Context model Combined model
CDK2 0.69±0.003 0.76±0.002 0.097±0.0016 0.110±0.0024
Continued on next page
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Kinase Context model Combined model Context model Combined model
Continued from previous page
CDK1 0.77±0.002 0.79±0.002 0.088±0.0035 0.101±0.0036
ERK2 0.74±0.002 0.78±0.003 0.139±0.0022 0.155±0.0047
ERK1 0.78±0.003 0.81±0.003 0.125±0.0021 0.147±0.0048
GSK3B 0.74±0.002 0.79±0.005 0.151±0.0015 0.178±0.0032
P38A 0.80±0.003 0.80±0.006 0.132±0.0012 0.167±0.0115
JNK1 0.84±0.002 0.87±0.010 0.263±0.0021 0.310±0.0097
CDK5 0.78±0.006 0.82±0.007 0.183±0.0059 0.230±0.0081
JNK2 0.83±0.008 0.89±0.022 0.216±0.0113 0.313±0.0247
CDK7 0.93±0.034 0.95±0.048 0.560±0.0117 0.705±0.0327
GSK3A 0.81±0.042 0.91±0.028 0.378±0.0258 0.610±0.0551
CDK4 0.87±0.002 0.88±0.006 0.309±0.0263 0.494±0.0219
P38B 0.78±0.071 0.75±0.058 0.198±0.0330 0.410±0.0466
HIPK2 0.89±0.033 0.98±0.054 0.365±0.0155 0.780±0.0618
DYRK1A 0.92±0.032 0.90±0.015 0.698±0.0361 0.617±0.0257
CDK9 0.96±0.045 0.90±0.043 0.548±0.0175 0.656±0.0348
DYRK2 0.63±0.038 0.91±0.010 0.363±0.0098 0.849±0.0552
ERK5 0.82±0.078 0.97±0.141 0.549±0.0270 0.709±0.1387
CDK6 0.83±0.012 0.82±0.010 0.539±0.0201 0.698±0.0172
CDK3 0.54±0.047 0.57±0.064 0.284±0.0473 0.407±0.0822
While the context information accounts for the bulk of the accuracy, there were several exam-
ples of kinases where including the protein sequence in the model greatly improved prediction
accuracy. In a few instances, prediction accuracy was increased from low or even random to a
much higher value; for example the PKCI kinase improved from an AUC of 0.50 to an AUC
of 0.77 (Table B.13), and DYRK2 obtained a huge increase from an AUC of 0.63 to 0.91 (Ta-
ble 4.3). There were also several examples of substantial accuracy gains, even when the kinase
already had moderate to high accuracy in the context model; we observed that the prediction
accuracy of GSK3A increased from 0.81 to 0.91, tyrosine kinase Syk increased from 0.81 to 0.90
and CAMK kinase Pim1 increased from 0.8 to 0.94. While there were examples of prediction
accuracy decreasing when sequence information was added, these decreases were slight, indi-
cating that the accuracy gains for incorporating sequence and context information far outweigh
any potential losses.
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Table 4.4: Performance comparisons between predicting kinase substrates with the context
Bayesian network model, and with the combined sequence & context model. Results were gen-
erated using ten-fold cross-validation repeated across ten randomised data-set splits. Shown
are the average and standard deviation of the AUC and AUC50 values.
AUC AUC50
Context Combined Context Combined
Human
CMGC 0.80±0.023 0.84±0.027 0.31±0.015 0.43±0.032
AGC 0.74±0.025 0.79±0.029 0.21±0.015 0.34±0.035
TK 0.81±0.027 0.82±0.026 0.31±0.020 0.39±0.039
CAMK 0.66±0.039 0.76±0.032 0.25±0.016 0.40±0.034
Other 0.80±0.034 0.81±0.037 0.36±0.029 0.47±0.044
STE 0.73±0.059 0.80±0.063 0.40±0.043 0.57±0.072
CK1 0.79±0.035 0.81±0.028 0.39±0.032 0.41±0.042
Atypical 0.85±0.015 0.89±0.014 0.36±0.005 0.45±0.015
Mouse
CMGC 0.73±0.011 0.79±0.020 0.38±0.009 0.45±0.035
AGC 0.48±0.033 0.63±0.043 0.20±0.015 0.31±0.056
TK 0.61±0.045 0.78±0.052 0.25±0.020 0.46±0.052
Yeast
CMGC 0.65±0.032 0.76±0.042 0.22±0.020 0.44±0.050
AGC 0.57±0.043 0.71±0.048 0.26±0.036 0.48±0.048
CAMK 0.64±0.036 0.70±0.020 0.15±0.029 0.33±0.037
Other 0.60±0.036 0.75±0.045 0.21±0.019 0.40±0.033
In general, the accuracy for mouse kinases was more enhanced by the incorporation of sequence
when compared to the accuracy for human kinases (Table B.14). We noticed that the accuracy
for mouse AGC kinases was no greater than random for context alone, with a low AUC of
0.48. However, after the incorporation of sequence data, the AUC increased to a much higher
value of 0.63 (Table 4.4). This is likely due to the size of the mouse protein-interactome,
which is much smaller than the human version. The most substantial gains were made for the
tyrosine kinases, where the average AUC for the family increase from 0.61 to 0.78 – a near 30%
increase in prediction accuracy. There was a similar increase in the AUC50, from 0.25 to 0.46,
indicating that the incorporation of the sequence model also made an important contribution
at low false-positive levels.
The yeast kinases benefitted even more than the mouse kinases from the incorporation of
sequence, with substantial increases to prediction accuracy observed across the four yeast kinase
families (Table B.14). Prediction accuracy for yeast AGC and “other” kinases increased in AUC
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Figure 4.4: ROC plots showing the prediction accuracy of the combined and context models
for predicting kinases substrates from the human CAMK family of kinases. The ROC curves
are calculated up to the first 50 false positives from a 10-fold cross-validation run.
value by an average of 0.14 and 0.15 respectively, while CMGC kinases increased by an average
of 0.09. We also found that the AUC50 increased by approximately two-fold for each of the
four yeast kinase families. The results for mouse and yeast kinases indicate that the model is
able to offset the reduced availability of the context information through the sequence data.
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4.4.3 Comparisons to alternative methods
We tested the ability of PhosphoPICK (i.e. the full PhosphoPICK workflow described in section
“Prediction workflow”) to correctly classify the known kinase phosphorylation sites out of all
potential sites within our set of phosphorylation substrates. Due to the number of potential
phosphorylation sites (∼170,000 S/T sites and ∼30,000 Y sites), we tested prediction accuracy
at more stringent levels of specificity – 99.9% and 99%. We compared the prediction sensitivity
of PhosphoPICK with using sequence alone. We found that by combining the substrate score
from the combined model with the site score from the sequence model, we were consistently able
to improve prediction accuracy when compared to using the sequence model alone (Figure 4.5).
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Sensitivity difference for predicting kinase−specific phosphorylation sites
Figure 4.5: Sensitivity comparisons for predicting kinase-specific phosphorylation sites out
of all potential phosphorylation sites in the protein training set between PhosphoPICK and
alternative classification methods. Comparisons were made by performing cross-validation
across ten data-set splits for each of the kinases. Sensitivity was calculated for all methods
at two levels of specificity: 99.9% and 99%. Comparisons were made between PhosphoPICK
and the sequence method alone, and between PhosphoPICK and three alternative predictors:
GPS, NetPhorest and NetworKIN.
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On average, the use of the combined model offered the greatest level of accuracy increase to
kinases from the CMGC family, with an average sensitivity difference of 0.12 at 99.9% specificity
and 0.27 at 99% specificity. This is consistent from our previous findings that the use of context
offers greater support to phosphorylation site prediction from CMGC kinases. The CAMK
kinases gained a similar level of sensitivity at the higher specificity threshold, though there was
a smaller average sensitivity difference of 0.22 at the 99% specificity level. The AGC and TK
kinases appeared to benefit the least, with a sensitivity difference at 99.9% specificity of 0.045
and 0.042, respectively.
We also compared the ability of PhosphoPICK to predict kinase-specific phosphorylation sites
to three alternative methods: GPS 2.1 (80), NetPhorest 2.0 and NetworKIN 3.0 (97). We
compared the prediction sensitivity of the different methods at the specificity levels described
above. Figure 4.5 shows the sensitivity difference between PhosphoPICK and the compared
methods at two levels of specificity: 99.9% and 99%. Tables B.16 and B.17 contain the full
set of comparisons for individual kinases at specificity levels 99.9% and 99%, respectively. In
addition, Figure 4.6 shows a comparison against the various methods using MCC as the com-
parison metric. We found that at the stricter level of specificity, PhosphoPICK obtained an
increased level of sensitivity over the alternatives for most comparisons made. At the 99.9%
specificity level, PhosphoPICK gained an average sensitivity increase of 9% when compared to
NetworKIN, 10% compared to GPS and 22% compared to NetPhorest. At the 99% specificity
level, PhosphoPICK gained average sensitivity increases of 6%, 18% and 35% when compared
against NetworKIN, GPS and NetPhorest, respectively. While PhosphoPICK obtained greater
prediction accuracy on average, there were some cases where PhosphoPICK performed worse
than the alternatives – for example the tyrosine kinases, where we observed an average sen-
sitivity difference against GPS of -0.014 at the 99.9% specificity level. We also noticed that
PhosphoPICK performed worse on the atypical kinases when compared to NetworKIN, with a
small difference in sensitivity at 99.9% specificity of -0.004, and a larger difference of -0.076 at
99% specificity.
4.4.4 Evaluation using the hold-out set
PhosphoPICK contains the option to calculate P-values for predictions, representing the likeli-
hood of obtaining a given prediction by chance, given how predictions are distributed over the
proteome. To estimate the level of accuracy that is to be expected from using the fully trained
model underlying the web-server, we evaluated prediction accuracy using our hold-out set of
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Figure 4.6: MCC comparisons for predicting kinase-specific phosphorylation sites out of all
potential phosphorylation sites in the protein training set between PhosphoPICK and alter-
native classification methods. Comparisons were made according to the procedure described
for Figure 4.5, with MCC as the comparison metric.
145 substrates (of the kinases listed in Table 4.5) by calculating P-values of the predictions and
considering predictions that fell below a P-value threshold of 0.005 (Section 4.3.6).
We found that PhosphoPICK was generally able to maintain a high level of specificity, with
an average specificity of 97% across the 9 kinases represented in the hold-out set (Table 4.5).
There was a diverse range of sensitivity levels (from 3% for Src to 62% for CK2A1), with an
average of 32% – well above what would be expected by chance given the percentage of false-
positive predictions. This confident prediction accuracy on completely novel data indicates that
PhosphoPICK is a reliable method for uncovering new kinase substrates and kinase-specific
phosphorylation sites.
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Table 4.5: Prediction accuracy on hold-out set for predicting kinase-specific phosphorylation
sites (below a P-value threshold of 0.005) as measured by a variety of metrics – sensitivity,
specificity, balanced accuracy (BAC) and Matthews’ correlation coefficient (MCC). Results
were generated by training the model on the full training data set, and evaluating it on the
hold-out set. Results represent the ability of PhosphoPICK to correctly predict the known
kinase-specific phosphorylation sites out of all potential sites in the set of hold-out substrates.
In total there were 14,617 S/T sites and 2,324 Y sites.
Kinase Positives Sensitivity Specificity BAC MCC
CDK2 72 0.36 0.96 0.66 0.12
CDK1 39 0.51 0.93 0.72 0.09
ERK2 55 0.22 0.98 0.60 0.08
ERK1 56 0.29 0.98 0.63 0.12
PKACA 53 0.28 0.99 0.64 0.18
PKCA 40 0.15 0.97 0.56 0.04
Akt1 15 0.4 0.98 0.69 0.09
CK2A1 52 0.62 0.95 0.78 0.15
Src 34 0.03 0.99 0.51 0.02
4.4.5 Multiple kinases regulate nuclear localisation
We predicted NLSs using the NucImport predictor (119), a tool for predicting nuclear proteins
and the location of their NLSs on the basis of protein interaction and sequence data (NucImport
does not explicitly incorporate protein phosphorylation into its predictions). The complete
human proteome (including isoforms) was run through NucImport and all proteins that were
predicted to contain a type-1 classical NLS were retained – there were 4134 such proteins. The
type-1 classical NLS contains an optimal four residue amino acid configuration of KR(K/R)R
or K(K/R)RK (166). In order to investigate phosphorylation within a window surrounding
the NLS, we defined a centre position, P0, as the third residue within the predicted NLS (in
the literature, this position is usually designated “P4” (162)), and cross-referenced the location
of the signals with known phosphorylation sites from PhosphoSitePlusr. We identified 1,830
phosphorylation sites that were within a 20 residue window around P0. These phosphorylation
sites were submitted to PhosphoPICK for analysis (predicting all human kinases), and a P-value
threshold of 0.005 was used to return results with a high level of stringency.
In order to test for kinases that were regulating specific positions in relation to the NLS, we
counted the number of predicted binding events for kinases at each position within the 20 residue
window surrounding P0. To determine whether the number of predicted kinase binding sites
near an NLS was greater than would be expected by chance, we tested for over-representation
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against all known phosphorylation sites within the set of predicted nuclear proteins. Over-
representation was tested for using Fisher’s exact test with Bonferroni correction to obtain
E-values (the P-values for the Fisher’s exact test were corrected by the total number of tests
performed; i.e. the number of kinases multiplied by the number of sites – 2,247).
Figure 4.7 shows the distribution of predicted binding sites for several kinases around the P0
position of the NLS. We found that there was higher phosphorylation activity downstream from
the NLS, where protein kinase A (PKA), aurora kinase B (AurB), and Akt1 in particular were
found to have the most significantly over-represented binding locations. At position 3 (P3), the
most significant kinase was PKA (E = 2.03e−38), which was predicted to be phosphorylating
55/144 of the phosphorylation sites at that position. AurB had a pair of highly significant
binding sites at positions 2 (E = 7.32e−30) and 3 (E = 2.4e−21).
There were fewer observations of kinases over-represented at phosphorylation sites upstream
from the NLS, though we found that cyclic dependent kinase 2 (CDK2) and protein kinase C
alpha (PKCa) were significantly over-represented at several upstream positions. At positions -4,
-5 -6 and -7, CDK2 was found to have the most significant over-representation of sites compared
to any other kinase. CDK2 was predicted to target 28/50 (E = 9.42e−13) of the phosphorylation
sites at position -4, 31/61 (E = 2.1e−13) at position -5, 27/89 (E = 6.4e−10) at position -6 and
23/88 (E = 6.0e−07) at position -7.
To investigate whether the proteins being phosphorylated at these specific sites were involved in
similar biological processes, we performed gene ontology (GO) term enrichment analyses. We
performed the tests by taking a foreground set of proteins and testing for over-representation
(Fisher’s exact test, with Bonferroni multiple correction) of terms in the foreground set against
a background comprised of our set of phosphorylated nuclear proteins. Significant terms should
therefore not simply represent general phosphorylation or nuclear functions, but functions
specifically related to the kinase being tested.
We performed GO term enrichment tests on a kinase-specific basis, identifying substrates that
were predicted to be phosphorylated within the 20 residue window surrounding P0. We also
tested substrates that were predicted to be phosphorylated at the specific sites that were iden-
tified as being over-represented for the kinase being tested (Tables B.18 – B.25). We found
that AurB substrates were enriched in the GO terms “chromosome”, “nucleosome” and “nucle-
osome assembly”. Interestingly, while the proteins phosphorylated by AurB at the P3 position
were enriched in similar GO terms, the proteins phosphorylated at P2 returned no significant
GO terms. While CDK2 substrates obtained the significant terms “chromosome”, “cell cycle”,
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Figure 4.7: Distribution of predicted kinase phosphorylation sites surrounding NLSs.
The locations of predicted NLSs were cross-referenced with phosphorylation sites from
PhosphoSitePlusr and PhosphoPICK was used to assign kinases to the sites. Count rep-
resents the number of times a kinase was predicted to phosphorylate a specific site relative
to the NLS. Over-representation of a kinase for a particular site was assessed using a Fisher’s
exact test with a Bonferroni multiple correction. (*) indicates an E-value < 0.05 and (**) an
E-value < 1.0E−10.
“nucleus” and “DNA repair”, none of its significant binding site positions were found to be be
associated with enriched GO terms.
We noticed that kinases with an over-representation of binding events at P4 consistently ob-
tained a number of significant GO terms for substrates phosphorylated at that site. In addition
to AurB mentioned above, PKA P4 substrates had 10 enriched GO terms, Akt1 had 4, AMPKA1
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and p70S6K both had 11 and p90RSK had 8. We noticed that there was also some repetition of
enriched GO terms among these kinases at P4 – the term for “fibroblast growth factor receptor
(FGFR) signalling pathway” was the most significant P4 term for each of the AGC kinases
(PKA, Akt1, p70S6K and p90RSK), and was the second most significant for AMPKA1 kinase.
To determined whether phosphorylation at P4 in general was associated with specific functions
(such as the FGFR signalling pathway) we did a GO term enrichment test with all substrates
that were phosphorylated at that position, however no GO terms were found to be significant
(Table B.26). This would indicate that the phosphorylation of the site at P4 does not by itself
correspond to a particular function, rather this is dependent on the kinase regulating the site.
4.5 Discussion
The regulation of protein function through kinase-mediated phosphorylation is a complex pro-
cess involving numerous aspects of cellular behaviour on the systems biology level, and the
binding capacity of kinases to substrates on the molecular level. We have presented here a novel
method for probabilistically modelling the sequence features that determine kinase binding at a
molecular level. We have shown that PhosphoPICK is able to leverage these two diverse types
of information and seamlessly integrate them into a model that can identify kinase substrates
with high accuracy.
A benefit of the integration of sequence and context data into a single probabilistic model is
the ability to take into account interdependance between these heterogeneous sources of infor-
mation; i.e. the likelihood of seeing certain amino acids or k-mers in a protein may change
depending on the context information, and similarly, the expectation of certain protein inter-
actions can be influenced by the protein sequence. Indeed, we have found that the combined
model can be used to query expected kinase binding sequence motifs and generate correspond-
ing sequence logos (47) based on context information presented to the model (see Section B.1
for an example).
A counter-intuitive result seen as a part of the integration of sequence and context was that
the performance seen in the sequence was not necessarily reflected in the combined model.
The tyrosine kinases were a particularly interesting example; we found that while the tyrosine
sequence models (for both human and mouse) were the least accurate amongst the sequence
models, the mouse combined model benefited greatly from the incorporation of sequence, with
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a near two-fold increase seen in the AUC50. This is an indication that while the two individ-
ual systems – sequence and context – of predicting kinase binding events may be limited by
themselves, the integration of the two can result in a much more powerful predictive model.
It was interesting to note that though the sequence model obtained the greatest accuracy (for
phosphorylation site prediction) on the human kinases, the yeast kinases in general saw the high-
est increases in prediction accuracy (particularly as measured by AUC50) when the sequence
model was incorporated into the context model. While the availability of context data (e.g.
cell cycle data) is likely a factor in the observed differences in prediction performance between
organisms, a uni-cellular organism like yeast would be expected to require less sophistication
in the regulation of kinase activity than higher organisms. Consequently, the use of context
factors is no doubt more important for understanding kinase targets in higher organisms.
For more complex organisms such as human and mouse, an additional realm of biology to
consider in relation to phosphorylation and kinase activity is tissue and cell-type specificity.
Protein phosphorylation has the potential to change substantially depending on the cell type,
and the biological processes that kinases regulate can also vary depending on cell or tissue
type. While there is limited amounts of consolidated tissue-specific phosphorylation data,
there is growing amounts of tissue-specific protein expression data (167). In addition to protein
expression data, the FANTOM consortium has profiled vast cell-type specific gene expression
atlases (168). Such data resources could make it possible to infer more probable candidate
kinases based on which ones are available in the tissue or cell type of interest. While outside
the scope of the current study, this would certainly make for an interesting avenue of exploration
in future work.
A system-wide analysis of biological mechanisms has the potential to reveal functional trends
that may not otherwise be apparent. Our analysis of the overlap of NLSs and phosphorylation
events has shown that there are several kinases that may be implicated in the regulation of
nuclear localisation through the phosphorylation of specific sites close to the NLS. Phosphory-
lation is a well-documented mechanism of nuclear localisation (154, 163, 164, 169–172). Because
classical NLSs are positively charged, introduction of a negatively charged phosphate group in
the vicinity of the NLS would in general be expected to inhibit nuclear import, as previously
demonstrated for CDK1-mediated phosphorylation at positions “P0” and “P-1” (164) (inter-
estingly, these sites correspond to our P−4 and P−5 positions, which saw the most significant
over-representation of CDK2 binding sites.). However, the effect will depend on the specific
position that is phosphorylated, and in some positions phosphorylation can stimulate nuclear
import (154, 163, 169, 170, 172, 173).
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Several of the kinases identified in our study have previously been implicated in nuclear import.
For example, the import of sex-determining factor SOX9 is regulated by PKA, whereby the
phosphorylation of two phosphorylation sites (one next to the NLS) enhances SOX9 binding
to importin β (174). Adenomatus polyposis coli (APC) is another example of a protein where
nuclear import is regulated by phosphorylation (175). In this case, APC contains two identified
NLSs and a putative PKA-mediated phosphorylation site is positioned immediately after the
second NLS, which leads to a reduction in APC nuclear localisation when the site is active. As a
key regulator during mitosis, AurB is involved in several processes such as mitotic chromosome
condensation (176), and it has also been shown to phosphorylate residues within the vicinity of
NLSs (177). The Akt kinase has been shown to be a regulator of nuclear localisation (178), and
phosphorylation by Akt is able to impair the nuclear import of p27 in vitro (179). Similarly,
CDK2 is known to be a regulator of nuclear localisation (180). While these studies confirm that
these kinases are involved in nuclear localisation, our results shed light on specific mechanisms
whereby nuclear localisation is controlled by the phosphorylation of key residues close to the
NLS.
4.6 Availability
PhosphoPICK is freely available online as a web-server, and can be used in two ways. A user can
upload protein sequences, and select any number of kinases to obtain predictions for potential
phosphorylation sites on the proteins. Significance of predictions can be gauged through the
calculation of empirical P-values, and only results below a chosen level of significance returned.
Visualisation of results is also available through a “Protein Viewer” page based on the BioJS
(181) package pViz (182). Secondly, the web-server allows for the construction of downloadable
proteome-wide sets of kinase-substrate predictions for any of the kinases and species described
in this paper. A more detailed description of the web-server workflow is available in Section B.2.
Chapter 5
PhosphoPICK-SNP: Quantifying the
effect of nsSNPs on protein
phosphorylation1
5.1 Abstract
Genome-wide association studies are identifying single nucleotide polymorphisms (SNPs) linked
to various diseases, however the functional effect caused by these variants is often unknown.
One potential functional effect, the loss or gain of protein phosphorylation sites, can be induced
through variations in key amino acids that disrupt or introduce valid kinase binding patterns.
Current methods for predicting the effect of SNPs on phosphorylation operate on the sequence
content of reference and variant proteins. However, consideration of the amino acid sequence
alone is insufficient for predicting phosphorylation change, as context factors determine kinase-
substrate selection.
We present here a method for quantifying the effect of SNPs on protein phosphorylation through
an integrated system of motif analysis and context-based assessment of kinase targets. By
predicting the effect that known variants across the proteome have on phosphorylation, we are
able to use this background of proteome-wide variant effects to quantify the significance of novel
variants for modifying phosphorylation. We validate our method on a manually curated set of
phosphorylation change-causing variants from the primary literature, showing that the method
predicts known examples of phosphorylation change at high levels of specificity.
1Chapter reproduced from paper of the same name currently pending submission.
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5.2 Introduction
The identification of genetic variants linked to disease is transforming the biomedical research
landscape. Genome wide association studies (GWAS) have been identifying numerous single
nucleotide polymorphisms (SNPs) over-represented in patients with in a wide variety of diseases
including cancer. While many SNPs are being discovered, the precise effect that they have
on resultant RNA or protein products is generally not known. One of the potential effects
of non-synoymous SNPs (nsSNPs) on protein function is the disruption of post-translational
modifications (183). As phosphorylation is the most ubiquitous modification, the potential
for phosphorylation sites to be affected by amino acid variants is high. For example, the
PhosphoSitePlusr database (184) has identified numerous sequence variants that fall within the
immediate vicinity of a phosphorylation site, and the recent analysis of cancer driver mutations
has implicated phosphorylation as being a major factor in understanding the disruption of
signalling pathways caused by amino acid variations (185).
There have been numerous examples of disease-associated naturally occurring variants that
impact the phosphorylation status of proteins. The majority of such examples have involved a
variant disrupting a phosphorylation site in the reference protein, though there have been at
least two examples of missense mutations found to introduce phosphorylation sites (186, 187).
While there have been relatively few studies experimentally determining the effect of naturally
occurring variants on phosphorylation, there are tens of thousands of nsSNPs that have the
potential to impact phosphorylation. The PhosphoSitePlusr PTMVar dataset (184) , which is
comprised of missense mutations cross-referenced to post-translational modifications, contains
over 19,000 examples of variants falling within a 15-residue window surrounding a known phos-
phorylation site. Such variants have the potential to disrupt existing phosphorylation sites,
but there will be many additional variants with the potential to introduce new phosphorylation
sites. In addition to PhosphoSitePlusr, the PTM-SNP database collates SNPs that occur in
the vicinity of a number of post-translational modifications, including phosphorylation (183).
There have also been databases developed that catalogue the predicted effect of SNPs on po-
tential phosphorylation sites. Ryu and colleagues defined the term “phosphovariant” to refer
to a mutation that impacts the phosphorylation status of an amino acid (92). To predict
examples of phosphovariants, they developed PredPhospho, a support vector machine model
that predicts kinase-specific phosphorylation sites based on the amino acid motifs surrounding
potential phosphorylation sites. Applying PredPhospho to missense mutations obtained from
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Swiss-Prot, they predicted examples of phosphovariants and incorporated them into the Phos-
phoVariant database (92). The PhosSNP database is another example of cataloging variants
predicted to modify protein phosphorylation (188). Ren and colleagues employed the GPS
2.0 software, a kinase-specific phosphorylation site predictor that uses optimised substitution
matrices (79). The GPS 2.0 predictor was applied to variants from the dbSNP database (189),
with the ones predicted to cause a change in phosphorylation status or to cause a change in
the kinase targeting the phosphorylation site, were compiled into the PhosSNP database.
Most recently, the MIMP (mutation impact on phosphorylation) method has been developed,
which uses position weight matrices and Gaussian mixture models to score the probability that
a variant will cause loss or gain of phosphorylation (84). In contrast to the other methods,
MIMP provides a prediction service rather than a database. For the purpose of consistency
with the most recently published work, we will consider two classes of “phosphovariants”:
phosphorylation-loss causing variants and phosphorylation-gain causing variants.
The current methods for predicting the effect of nsSNPs on phosphorylation, described above,
operate on the sequence content surrounding a potential phosphorylation site. While methods
based on linear motifs can predict the potential for a kinase binding site to be disrupted (190),
the presence of a valid kinase-substrate binding motif on a protein is no guarantee that a
kinase will come into contact with the protein (27). We have previously developed a method,
PhosphoPICK, for predicting kinase substrates using protein-protein interaction networks and
protein abundance across the cell cycle. The use of such context information can improve the
prediction accuracy of kinase-specific phosphorylation site prediction from sequence by over two-
fold at low false-positive levels (161). An approach that integrates cellular context information
with sequence information should therefore be able to provide a more accurate assessment of
the effect of SNPs on phosphorylation than methods that operate on sequence alone.
Building on the properties of PhosphoPICK, we present here a method for quantifying the effect
of nsSNPs on protein phosphorylation status. Taking stock of known missense mutations across
the proteome, as collected in UniProt, we use PhosphoPICK to build kinase-specific, proteome-
wide sets of predicted variant effects on phosphorylation. These sets provide a “background
distribution” that can be used to calculate a measure of significance for the predicted effect
that a novel variant has on phosphorylation loss or gain.
In order to validate our approach, we searched the literature for naturally occurring variants
causing phosphorylation loss or gain, identifying 19 such variants. By comparing the threshold
at which our method detects true positives against that of the background, we demonstrate that
our method is able to detect over 50% of the known phosphovariants within the first 2% of the
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background distribution. This demonstrates the method’s reliability in detecting true examples
of differential phosphorylation from over one million potential phosphovariants. Applying the
method to variants in the vicinity of phosphorylation sites from the PhosphoSitePlusr PTM-
Var dataset (184), we find that the predicted phosphovariants are over-represented among the
ones with disease annotations. These results support the conclusion that our method, named
PhosphoPICK-SNP, is able to detect variants that have functional significance.
5.3 Methods
5.3.1 Data resources
Missense mutation data
We obtained the UniProt index of protein altering variants (191), which maps dbSNP variants
(189) to proteins within the UniProt database (downloaded March, 2015). This file contained
752,857 variants mapped to amino acid variants in UniProt proteins. The variants covered
89,909 protein sequences in the UniProt database.
Phosphorylation sites affected by naturally occurring variants
Through a manual search of the literature, we compiled a list of naturally occurring variants
that were found experimentally to either disrupt or introduce a phosphorylation site. For
the purpose of this work we included variants that were shown either in vivo or in vitro to
affect the phosphorylation of a specific site; although there are examples of studies showing
changing phosphorylation levels on the protein, we only recorded examples where the precise
phosphorylation site was known. Table 5.1 contains the list of identified genes, with variant and
phosphorylation site affected. We found 17 examples of phosphorylation loss and 2 examples of
phosphorylation gain in response to nsSNPs. Of the 17 loss-causing variants, 6 of the mutations
are on the phosphorylation site.
5.3.2 Building distributions of variant effects
We built distributions of predicted variant effects on phosphorylation in a kinase-specific basis
across all protein altering variants. PhosphoPICK employs two Bayesian network models to
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Table 5.1: Naturally occurring variants that have been shown through in vivo or in vitro
experiments to affect a phosphorylation site either adjacent to, or at the site of, the variant.
The effect can be to disrupt an existing phosphorylation site (loss), or introduce a new one
(gain).
Gene Variant Phos. site Effect Reference
Cyclin D1 T286R T286 loss (192)
hOG1 S326C S326 loss (193)
p53 P47S S46 loss (194)
BDNF V66M T62 loss (195)
CDKN1A D149G S146 loss (196)
hERG1 K897T T897 gain (186)
PPARγ2 P113Q S112 loss (197)
PTP-1B P387L S386 loss (198)
UBE3A T485A T485 loss (199)
PER2 S662G S662 loss (200)
MeCP2 R306C T308 loss (201)
NKX3-1 R52C S48 loss (202)
PLN R14C S16 loss (203)
ABCB4 T34M T34 loss (204)
MAF P59H T58 loss (205)
GLUT1 R223W S226 loss (206)
AR R405S S405 gain (187)
Gab1 T387N T387 loss (207)
STAT1 L706S Y701 loss (208)
make predictions. The first model classifies kinase-substrate binding sites from sequence, and
incorporates position-specific amino acid frequencies and counts of co-occurring neighbouring
amino acids within some m length window surrounding a potential phosphorylation site (paper
in submission). This model is henceforth referred to as the sequence model. Separately, a
Bayesian network model integrates the sequence model with protein-protein interaction and
association data sourced from BioGRID (209) and STRING (148), as well as protein abundance
data across the cell cycle (28), in order to calculate the probability that a kinase ordinarily
targets a given protein. This model is henceforth referred to as the combined model. When
scoring the effect of a variant we use PhosphoPICK to generate three scores: (1) Rsubstrate, the
prior probability based on the combined model that the kinase would be expected to target the
reference protein, (2) Rsite the probability according to the sequence model that the kinase will
phosphorylate the site of interest on the reference protein, and (3) Vsite the probability that the
kinase will target the site of interest on the variant protein.
Kinases within PhosphoPICK contain different optimal binding site windows that are considered
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when making a prediction for a potential phosphorylation site. Therefore, given a query kinase,
we checked for variants that fell within a window surrounding a potential phosphorylation site.
For each potential phosphorylation site, we recorded a reference peptide and a variant peptide
containing the missense mutation. We then used the sequence model to obtain the Rsite and
Vsite scores from the reference and variant peptides respectively. If the central residue for a
peptide is not a valid phosphorylation site (for example a threonine is mutated to an arginine)
it will be scored 0. We defined a score difference,
Dsite = Vsite −Rsite (5.1)
where a negative value of Dsite indicates the variant is predicted to cause decreased probability
of phosphorylation, and a positive value represents an increased probability of phosphorylation.
We calculated distributions of Dsite values in a kinase-specific manner across all potential phos-
phorylation sites that contained a missense mutation within the window for the query kinase.
A potential phosphorylation site is defined as any serine (S) or threonine (T) residue for S/T
kinases, any tyrosine (Y) residue for Y kinases, or any S/T/Y residue for dual specificity kinases.
5.3.3 Calculating variant significance
The significance of the effect on phosphorylation by a variant is calculated in a kinase-specific
manner, as described by the following procedure. Given some kinase K, an m length window
corresponding to K is centred on potential phosphorylation sites within the protein sequence,
where if the variant falls within a window, m length reference and variant peptides are retained.
Dsite is then calculated from the reference and variant peptides using Equation 5.1. The dif-
ference is then compared to the background distribution and a P-value from both tails of the
distribution is calculated – representing whether the difference is greater (increased probability
of phosphorylation) or less (decreased probability of phosphorylation) than would be expected
by chance. The P-values are calculated such that
Ploss =
1
n
n∑
i=1
I(Di ≤ Dsite) (5.2)
Pgain =
1
n
n∑
i=1
I(Di ≥ Dsite) (5.3)
Chapter 5. Quantifying the effect of nsSNPs on protein phosphorylation 99
where n is the number of variants contained in the background distribution for kinase K and
I(·) is the indicator function. The final P-value representing the site, Psite, is calculated as the
minimum of Ploss and Pgain.
The Rsubstrate context score for the query protein is then retrieved. As for the Dsite scores, we
have distributions of context scores across the proteome for each kinase. We therefore calculate
an empirical P-value for the Rsubstrate score, Psubstrate, based on a count of the proteome-wide
context scores that are greater than or equal to Rsubstrate, using the same form as Equation 5.3.
We then use Fisher’s method to combine the two P-values into a combined P-value that repre-
sents the confidence of the variant effect size given both the difference in sequence scores and
likelihood that the reference protein would ordinarily be a substrate of the query kinase. Given
the P-values Psite and Psubstrate, we calculate:
X = −2(ln(Psubstrate) + ln(Psite)) (5.4)
where X follows a Chi squared distribution with 4 degrees of freedom. The combined P-
value, Pcombined, can then be derived from X. As a single phosphovariant can be scored with
all kinases available to PhosphoPICK (currently numbering 107), we correct the P-value for
multiple testing using a Bonferroni multiple correction on Psite and Pcombined to obtain Esite and
Ecombined.
5.3.4 Evaluating method accuracy on known variants
In order to calculate an estimate of the number of potential phosphorylation sites that were
affected by the presence of a nearby variation, we used a 10-fold cross-validation approach
to build a set of predicted background values. The proteins within the background set were
split into 10 partitions, where 9 of the partitions were used to construct distributions for both
the context scores and the Dsite values. These distributions were then used to evaluate and
obtain E-values for the variants in the remaining partition. For each variant the lowest E-value
was retained as representing the greatest liklihood that the mutation resulted in a change in
phosphorylation status.
To evaluate our method on its ability to detect the examples of differential phosphorylation
recorded in Table 5.1, we evaluated the known variants on our method using each of the 10
partitions from the cross-validation test to construct the background distributions. For each
variant we calculated the median of the E-values generated across the cross-validation runs;
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similar to the background, the final E-value assigned to a variant was the minimum of the
E-values for all potential kinases. As there is no obvious way to define a true negative set,
we compared to the background set the E-value thresholds at which the true positives were
identified; i.e. at each E-value threshold calculated for a true positive, we calculated the number
and percentage of variants in the background set that were also identified at that threshold. We
performed this test using both Esite and Ecombined values to understand the influence of context
on predicting phosphorylation change.
We compared our method’s ability to detect the known variants against that of the MIMP
predictor (84). We downloaded the local version of the software, and ran the background set
of protein sequences and variants through it, specifying probability and log thresholds of 0 to
enable a comparison over all thresholds.
5.4 Results
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Figure 5.1: Line-curves showing the tradeoff between the percentage of positive differential
phosphorylation examples identified and the number of variants considered (as the E-value
cut-off decreases). Comparison is made between predicting phosphorylation change using
sequence alone, and combining sequence with context. Shown is the tradeoff until all positive
examples are detected (a), as well as the tradeoff up until 10% of the background variants are
detected (b).
The experimentally determined examples of differential phosphorylation listed in Table 5.1 were
used to gauge how well our method performed in identifying real examples of phosphorylation
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gain and loss. Figure 5.1 shows a tradeoff between the percentage of known positives detected
and the background at each E-value threshold a positive was discovered at. When predicting
phosphovariants using the combined E-value, we found that the majority (over 50%) of the
known positives could be identified within the first 2% of the background distribution. We were
able to identify 79% of the experimental examples at an E-value threshold corresponding to
14% of the background. These results demonstrate that the method can identify true positive
examples of phosphovariants at high levels of specificity, which represent candidates of real
interest to biologists.
We also evaluated the use of sequence only for predicting phosphovariants (i.e. using the Esite
value), in order to determine if the incorporation of context information was providing an
increase in prediction accuracy. When using sequence alone, the majority of variants were
not detected until 7% of the background distribution was reached (Figure 5.1). Given the
combined method detected the majority of variants at 2% of the background, this represents
a 3-fold increase when using the combined E-value. As can be seen from Figure 5.1(a), at
the more liberal E-value thresholds there was less difference between sequence alone and the
combined E-values. However, these results show that the approach of combining context and
sequence information provides the greatest benefit for identifying true variants at higher levels
of specificity.
5.4.1 Estimating phosphorylation sites affected by SNPs
In order to investigate the effect of context on predicting differential phosphorylation, we used
the methods for calculating Esite and Ecombined to estimate the number of putative phosphory-
lation sites affected by the nsSNPs contained in the UniProt index of protein altering variants.
We performed two tests: firstly, we identified predicted differentially-phosphorylated sites on
the basis of Esite, where if Esite fell below 0.05 the variant was considered to cause differential
phosphorylation; i.e. a phosphovariant. In the second test, the Ecombined value was applied
as a filter, where only variants with Ecombined and Esite falling below 0.05 were classified as a
phosphovariant.
Based on our cross-validated analysis of the background distribution, we identified the variants
that were predicted to be causing differential phosphorylation. In total we found 65,203 variants
that were predicted, based on their Esite value, to cause differential phosphorylation. When
requiring that a variant obtain an E-value < 0.05 for both Esite and Ecombined, the number
dropped to 41,075. Figure 5.2 shows a histogram of the Ecombined values calculated for all the
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Figure 5.2: Histogram showing combined E-value (Ecombined) scores for all variants consid-
ered to be significantly likely (E-value < 0.05) to result in differential phosphorylation based
on sequence alone.
variants that were found to be significant based on Esite alone. While the majority maintain
a high level of significance when context is included, nearly 40% of the variants obtained an
E-value > 0.05 after context is included. These results illustrate the effect that context has in
filtering out spurious examples of phosphovariants where the kinase is unlikely to target the
query protein.
5.4.2 Comparison with alternative method
We compared the ability of the MIMP method (84) to predict the set of positives out of
the background to our combined method. As MIMP was unable to make predictions for the
two phosphorylation gain sites (due to the centre residue of the reference protein being non-
phosphorylatable) we performed the comparison using the 17 phosphorylation loss-causing vari-
ants. As can be seen from Figure 5.3, at stricter cut-off thresholds our method is able to detect
greater numbers of the true positive examples. Within 2% of the background distribution our
method is able to detect 47% of the 17 positives, however MIMP does not reach 47% until 3.6%
of the background – this corresponds approximately to an additional 17,000 variants.
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Figure 5.3: Line-curves showing a comparison of detecting experimentally confirmed phos-
phovariants between the combined PhosphoPICK-SNP method and MIMP (84). Shown is
the tradeoff until all positive examples are detected (a), as well as the tradeoff up until 10%
of the background variants are detected (b).
5.4.3 Phosphorylation loss in disease
We used our method to determine whether the variants that were most confidently predicted
to result in a change in phosphorylation status were over-represented among disease-associated
variants. We used the PTMVar database from PhosphoSitePlusr, which cross-references post-
translational modification information from PhosphoSitePlusr with variant information from
the UniProt human variation database. The PTMVar database annotates sites with the clas-
sification ‘Disease’, ‘Polymorphism’ or ‘Unclassified’. Variants that were within the vicinity of
phosphorylation sites and were annotated with either ‘Disease’ or ‘Polymorphism’ were selected.
We then counted the number of times that a variant in each of these classes was predicted to be
differentially phosphorylated with a decreased probability of phosphorylation (i.e. it obtained
an Ecombined value < 0.05 in a test for decreased probability), and counted the number of times
the variants in both classes were not predicted to be differentially down-phosphorylated.
Fisher’s exact test was used to determine the over-representation. We found that variants anno-
tated as disease-associated were significantly over-represented among the variants predicted to
result in down-phosphorylation, with a P-value of 0.0002. This indicates that while the presence
of a variant in the vicinity of a phosphorylation does not necessarily result in phosphorylation
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disruption, our method is able to detect the disease-associated variants that will have a strong
impact on phosphorylation.
5.4.4 Prediction of phosphorylation disruption in disease-associated
sites
Given that our methods is reliably able to detect phosphorylation loss events, we used it to
identify the most likely examples of phosphorylation loss in the PhosphoSitePlusr PTMVar
database that were associated with at least one of five cancer types: ovarian, breast, colorectal,
liver and pancreatic. These variants were run through our method, and variants that obtained
E-values below 0.05 for both Esite and Ecombined were retained. Table 5.2 lists top scoring
variants with their disease associations, where the variant has been mapped to the vicinity of
a phosphorylation site. The full list of variants is available in Table C.1. In total, we found 52
examples of predicted phosphorylation loss caused by variants related to ovarian cancer, 12 for
breast cancer, 8 for colorectal cancer, 19 for liver cancer and 9 for pancreatic cancer.
Table 5.2: Cancer-associated variants predicted to cause loss of phosphorylation. Variants
are listed according to the cancer or disease they are associated with. Each row contains
protein name as UniProt accession, the location of the variant and phosphorylation site, the
kinase predicted to target the site, the reference and variant scores for the peptide.
Protein Variant Phos Kinase Rsubst. Rsite Vsite Ecombined Peptide
P35222 G555A T551 Akt2 1.0 1.0 4.95E-05 9.36E-09 QDTQRRTpSMG[G/A]TQ
O
v
a
ri
a
n P26010 Y753H Y753 FAK 1.0 1.0 0.0 2.23E-08 YRLSVEI[Yp/H]DRREYSR
Q7KZI7 S197N S197 NEK6 1.0 1.0 0.0 2.3E-07 KIADFGF[Sp/N]NEFTFGN
P51813 S212R S212 GSK3B 0.998 1 0 1.33e-07 PPSSST[Sp/R]LAQYDS
P46939 M1256R T1259 MARK2 1 0.914 0.0005 4.47e-05 R[M/R]KSTpEVLP
P14859 S88F S88 DNAPK 1.0 1.0 0.0 8.6E-06 SQQPSQP[Sp/F]QQPSVQA
B
re
a
st
P43355 K278T Y276 Brk 0.998 1 0.000491 0.000103 RALAETSYpV[K/T]VLEYV
P03372 H6Y T2 VRK1 0.0492 0.0792 0.00421 0.00111 MTpMTL[H/Y]TKA
Q99490 D816Y S818 P38B 0.0186 0.587 0.000173 0.00126 CTPSG[D/Y]LSpPLSREPP
P54646 S523G S527 p90RSK 0.36 0.78 0.00501 0.00214 LTG[S/G]TLSSpVSPRLGS
P04637 E271K S269 CAMK2A 1 0.781 0.011 0.000131 NLLGRNSpF[E/K]VRVC
C
o
lo
re
ct
a
l
Q9P253 A913S S912 ERK5 0.495 0.848 0.0394 0.00475 APPPAKGSp[A/S]RAKEAE
Q9NPD5 I292M S293 CaMK4 0.832 0.524 3.21e-08 0.00785 ERK[I/M]SpLSLH
Q6ZMN7 G784R S783 CaMK4 0.792 0.454 1.52e-06 0.00954 TQSSSp[G/R]QSS
Q92953 V450I S448 ROCK1 0.326 0.845 0.00479 0.012 RAKRNGSpI[V/I]SMNL
P35222 T41A T41 GSK3A 1 1 0 2.28e-09 GIHSGAT[Tp/A]TAPSLSG
L
iv
er
P35222 S37F S37 GSK3A 1 1 0 2.28e-09 YLDSGIH[Sp/F]GATTTAP
P35222 T41A T41 IKKA 1 1 0 7.97e-09 GIHSGAT[Tp/A]TAPSLSG
P35222 S37F S37 IKKA 1 1 0 7.97e-09 YLDSGIH[Sp/F]GATTTAP
P35222 T41A T41 GSK3B 1 0.997 0 8.13e-06 IHSGAT[Tp/A]TAPSLS
Continued on next page
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Protein Variant Phos Kinase Rsubst. Rsite Vsite Ecombined Peptide
Continued from previous page
Q9BYV9 T519I T519 p70S6K 1 1 0 1.14e-08 LETRTR[Tp/I]SSSCSS
P
a
n
cr
ea
ti
c
P04637 E271K S269 CAMK2A 1 0.781 0.011 0.000131 NLLGRNSpF[E/K]VRVC
Q9BYV9 T519I S525 p70S6K 1 0.84 0.0917 0.000294 [T/I]SSSCSSpYSYAED
P56715 A135V S137 MARK2 0.848 0.987 2.83e-06 0.000418 IS[A/V]HSpPPHP
P05129 P524R Y521 Brk 0.356 0.227 0.000117 0.000629 TFCGTPDYIA[P/R]EIIA
We found several examples of predicted phosphorylation loss on the β-catenin protein (Uniprot
accession number P35222), which was a top candidate for phosphorylation loss for both ovarian
and liver cancer. The T41 phosphorylation site, which has been previously identified as a
GSK3B target (210), is a known site mutated in cancers (211). It is predicted by PhosphopICK-
SNP that the T41A mutation would abolish a GSK3B phosphorylation site at T41 (Table 5.2)
There was also an example of predicted phosphorylation loss on tumour suppressor protein p53
(Uniprot accession number P04637), which has been shown previously to lose phosphorylation
as a consequence of a P47S mutation (194). The E271K variant, which was associated with both
pancreatic and colorectal cancer (212), was found to have a significant likelihood of disrupting
the phosphorylation site at S269. The phosphorylation site at S269 is known to be an important
regulator of p53 transcriptional activity (213).
5.5 Discussion
With increasing numbers of disease-associated variants being catalogued, the need for reliable
functional annotations is only going to continue to grow. While there are many potential
functional effects of gene-coding variants on protein function, such as the perturbation of protein
structure or the disruption of one of the many post-translational modifications that proteins
undergo, phosphorylation is a high-probability target of disruption due to the ubiquitous nature
of this protein modification process. We have presented here a method for quantifying the
expected effect of nsSNPs on protein phosphorylation, and have demonstrated that it detects
experimentally confirmed examples of phosphovariants at high levels of specificity.
An advantage of our approach is the consideration of the cellular context that kinases and their
substrates operate in. We have shown that by incorporating context into the prediction of phos-
phovariants, we can identify positive examples of phosphovariants at higher levels of specificity
than if using sequence alone. There are examples of phosphovariants that represent a trivial loss
of phosphorylation; the removal of a phosphorylated serine, threonine or tyrosine residue will
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by definition cause loss of phosphorylation. A method that operates only on sequence may be
able to correctly predict such cases, but introduce false-positive predictions for cases where the
mutation occurs on a residue adjacent to the phosphorylation site. Given the small number of
trivial losses contained in our test set, the specificity increase gained by incorporating context
into predictions indicates that our method is able to predict a broader spectrum of potential
phosphovariants than by using sequence alone. In addition, when comparing our method to
an alternative method of predicting the effect of variants on phosphorylation, MIMP, we found
that we could predict positive examples of phosphorylation loss at stricter specificity levels than
the MIMP method.
While there are over 19,000 examples of missense mutations in the vicinity of a phospho-
rylation site according to the PhosphoSitePlusr PTMVar dataset (184), we found that the
mutations with the strongest propensity for causing phosphorylation loss were associated sig-
nificantly with disease annotations. While computational analysis of variants has predicted
both phosphorylation loss and gain to be associated with disease (214), this study represents
an analysis of the predicted effect of variants on experimentally determined phosphorylation
sites. However, a greater availability of phosphorylation-gain examples in response to variants
would enable a similar analysis to be performed examining the link between phosphorylation
gain and disease. There are key residues within a kinase-substrate binding motif that determine
the ability of a kinase to catalyse a phosphorylation modification (25, 46). The mutation of
these key residues can disrupt the phosphorylation site, and specific effects will depend on the
associated kinase. For example, the loss of a proline at the +1 position relative to a phosphory-
lation site in a proline-directed kinase-substrate binding motif will cause loss of phosphorylation
(194, 197, 205). However, the mutation of alternative, non-key, residues within the motif would
not be expected to disrupt the phosphorylation site the same extent. As a result, it is to be
expected that many missense mutations, even if they are in the vicinity of a phosphorylation
site, will not cause a loss of phosphorylation. Our results indicate that PhosphoPICK-SNP is
able to detect the mutations that do have an impact on phosphorylation, and therefore have a
greater likelihood of being associated with disease.
5.6 Availability
The PhosphoPICK-SNP web-service takes as input protein sequences in Fasta format, and
information defining the mutation occurring in the proteins. This follows the format used for
missense mutations in Tables 5.1 and 5.2, for example S523G. Users choose which kinases to
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make predictions for, and select an E-value threshold for returning results; results that obtain
both Esite and Ecombined values below the threshold will be returned. The output is an interactive
table of results which details the context score provided to the protein (Rsubstrate), the reference
and variant scores (Rsite and Vsite) obtained from the potential phosphorylation peptide, the
Ecombined value and the peptide itself. More comprehensive information regarding the variant
is available in a downloadable tab-delimited text file of the results.

Chapter 6
Conclusion
6.1 Summary
The regulation of much of the molecular functions that proteins are involved in is determined
by complex sets of factors. Kinase-mediated protein phosphorylation is a prime example of this,
where the determinants of kinase targets can be seen at multiple levels. At the sequence level,
protein substrates must contain amino acid sequences suitable to binding by a kinase’s catalytic
domain. At the cellular level a wide array of processes – localisation, expression, mediating
and activating proteins – all contribute towards ensuring kinase-substrate fidelity. The main
hypothesis of this thesis was that computational methods for predicting phosphorylation would
benefit from a computational framework that can seamlessly integrate the context and sequence
determinants of protein phosphorylation. Such a framework would not be unique however, but
have the capacity to translate to additional post-translational modifications or protein functions
that are regulated through motifs and cellular context.
I this thesis I have proposed a novel computational framework, based on probabilistic graphi-
cal modelling, for integrating the sequence and context factors that regulate phosphorylation.
Chapter 2 showed how protein context, in the form of protein-protein interaction and associ-
ation networks, as well as protein abundance across the cell cycle, could be incorporated into
a Bayesian network model that predicts kinase substrates. The model, named PhosphoPICK,
showed reliable prediction accuracy, with an average AUC of 0.86 across the 59 human kinases
tested. An important question at this point was, do the kinase-substrate predictions provide
additional predictive power to a sequence-operating method of phosphorylation prediction?
By complementing kinase-specific phosphorylation site predictions from existing methods with
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PhosphoPICK substrate scores, I found that PhosphoPICK could indeed improve the prediction
accuracy of sequence-operating predictors. For some kinases the improvement was substantial:
in particular, when the PhosphoPICK model complemented scores from the Predikin and GPS
methods, it improved the prediction of CMGC kinase phosphorylation sites by over two-fold.
This was therefore a demonstration that the context model could be used to supplement se-
quence methods of phosphorylation prediction, and improve prediction accuracy.
While Chapter 2 showed that the PhosphoPICK context model could supplement independent
sequence models, the main question of the thesis was how to integrate context and sequence
information – diverse data types – into a single model of phosphorylation. Chapter 4 presented
a probabilistic model of kinase-binding motifs, that incorporates position-specific amino acid
frequencies and k-mer frequencies in a way that captures motif sequence context in a kinase-
and family-specific manner. The chapter demonstrated how this sequence model could be in-
corporated into the context model presented in Chapter 2. This seamless integration of features
meant that the context information had the capacity to influence the model’s expectation of
the sequence, and vice versa. Importantly, the combination of context and sequence was found
to greatly increase the prediction accuracy of the model when applied to kinase-substrate pre-
diction, with an average 50% increase in prediction accuracy at low false-positive levels (as
measured by AUC50). This result was a validation of the driving hypothesis behind the the-
sis, that phosphorylation prediction methods would gain increased accuracy using a combined
model of context and sequence, rather than considering them in isolation. The power of this
approach was seen clearly in the improved prediction accuracy of PhosphoPICK compared to
alternative methods GPS, NetPhorest and NetworKIN. A comparison of kinase-specific phos-
phorylation site prediction showed that PhosphoPICK obtained an average sensitivity increase
of between 9 and 22% at a 99.9% specificity level; a substantial improvement.
Chapter 4 further demonstrated that the PhosphoPICK methodology is generalisable across
species, after it was applied to kinases from mouse and yeast. I found that the combined model
was particularly effective with mouse, greatly increasing its prediction accuracy from context
alone. The size of available mouse protein-protein interaction networks is much smaller than
in human, which indicated a major advantage of the combined model: When one aspect of
the data is more limited, such as mouse protein-protein interaction networks, the sequence
module within the Bayesian network has the capacity to compensate for the uncertain context
information.
One of the potential uses for a model of phosphorylation is to understand how the phospho-
rylation status of proteins or specific sites can be altered. I have shown at two levels how the
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theory underpinning PhosphoPICK, or the algorithm itself, can be used to predict changes in
protein phosphorylation status from gene expression, and the effect of SNPs on phosphoryla-
tion, respectively. In Chapter 3 I investigated the feasibility of applying the PhosphoPICK
method from Chapter 2 to predicting changes in protein phosphorylation status from gene
expression. The sbv IMPROVER species translation challenge, which provided participants
with gene expression and phosphorylation data collected under various treatment conditions,
presented a unique opportunity to evaluate whether PhosphoPICK could be used to predict
protein phosphorylation change. Chapter 3 detailed a method to identify genes that explain
the changing phosphorylation status of phosphoproteins in response to treatments. By cross-
referencing the protein-protein interaction networks of phosphoproteins with genes differentially
expressed under the same treatment conditions as differentially phosphorylated proteins, a can-
didate set of genes could be identified. Using the expression of these genes as input features
into SVM and RF classifiers, phosphorylation status change could be predicted from gene ex-
pression with promising accuracy. From the first sub-challenge in the competition, the method
was able to predict phosphorylation status change in rat cells from rat gene expression with
an average AUC of 0.74 on a blind hold-out set, and an average AUC of 0.86 as measured by
cross-validation on training data. The method was also ranked 6 out of 21 in the competition,
further demonstrating the utility of the approach. These results were an indicator that the
PhosphoPICK approach can be extended to predict protein phosphorylation status change in
response to treatment conditions.
Building on from the methods for predicting kinase targets (at both the substrate level, and
site level) presented in Chapter 4, Chapter 5 showed how PhosphoPICK could be used to
analyse the effect of amino acid variations on phosphorylation sites. Non-synonymous single
nucleotide polymorphisms (nsSNPs) have the capacity to cause loss or gain of phosphoryla-
tion through the modification of key amino acids that determine kinase binding affinity. The
studies that have identified examples of phosphorylation change resulting from nsSNPs have
invariably found them in the context of disease-associated variants, highlighting the importance
of identifying the variants that do cause loss or gain of phosphorylation. Chapter 5 presented
a method that uses PhosphoPICK to construct a background of variant effects, based on score
differences between a reference and variant peptide according to the sequence model, across
missense mutations collected in the UniProt database. Comparing a novel variant against the
background allowed a level of significance, as determined by an empirical P-value to be calcu-
lated. Combining this with context scores generated by the combined PhosphoPICK Bayesian
network model, the method was able to score the effect of a variant based not only on the
difference in sequence scores caused by the mutation, but the prior belief of the query kinase
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targeting the protein. Comparing this “combined score” with using sequence alone, as well
as an alternative method, MIMP, I demonstrated that PhophoPICK is able to identify true
positive examples of phosphovariants at higher threshold stringency than either MIMP or the
sequence method alone. This demonstrates that just as predicting phosphorylation sites under
ordinary circumstances benefits from the combination of context and sequence, understanding
the effect of amino acid variants on phosphorylation also benefits from protein context.
6.2 A framework for modelling biological systems
An overarching goal in this work was to design a method that could integrate the sequence
and context factors that regulate phosphorylation. This is a concept that is not unique to
phosphorylation – there are many biological processes that rely on a combination of linear
motifs and interacting proteins to maintain specificity. The method that has been presented
here should be considered a framework that could be applied to different biological processes,
with alternative post-translational modifications being an obvious choice for candidate studies.
There are many different types of post-translational modifications that proteins can undergo;
these can involve structural change to the protein (such as proteolytic cleavage), chemical mod-
ifications like phosphorylation, or the linkage of an additional protein. SUMO (short ubiquitin-
like modifier) is a modification involving the addition of the small SUMO protein to a lysine
residue on a protein, and is involved in the regulation of a diverse range of molecular functions
(215). The importance of SUMOylation can be seen in its regulation of protein promyelocytic
leukemia (PML) nuclear body (NB) formation. The PML-NB is an important sub-nuclear
compartment, found in many tissues, and appears to have a highly dynamic role in regulating
an array of processes, including DNA repair and transcription, in response to cellular stresses
(216, 217). The importance of the PML-NB is illustrated by the link between its aberrant
function and leukaemia, as well as tumours (216). A critical regulatory component of PML-NB
is SUMO: PML-NB function is regulated by SUMO (218), and the SUMOylation of PML-
NB proteins is required for their localisation to the nucleus, and the correct formation of the
PML-NB (219).
There are four SUMO protein paralogues that can be covalently attached to a lysine residue on
a substrate protein (220). The process of SUMOylation follows a cascade of enzymes, whereby
an activating enzyme (E1) first activates the SUMO protein, which is then transferred to a
substrate protein by the E2 enzyme. The conjugation of the SUMO protein to the substrate is
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often performed by the E2 enzyme in conjunction with the ligase enzyme, E3. The regulation of
SUMO targets is complex, and involves a combination of context and sequence characteristics, as
for phosphorylation. SUMOylation by specific SUMO paralogues is regulated by factors such as
sub-cellular location and cell-cycle stage (221); in addition, SUMOylation can occur in response
to cellular stress (222). The binding of SUMO to a target protein is known to occur within
a set of well-defined motifs – some of which are phosphorylation-dependent. The best known
consensus motif for SUMO is the ψKXE motif, where K is the SUMOylated lysine residue, ψ
is a hydrophobic residue and X is any amino acid (223). An example of a phosphorylation-
dependent motif follows the form ψKXEXXSpP, where Sp is the phosphorylation site (224).
Even more so than the predictors that have been built for phosphorylation, the existing methods
for predicting protein SUMOylation sites operate primarily on sequence motif data (225–229).
There are parallels that can be made between phosphorylation and SUMOylation; the modifi-
cations are both regulated by the presence of valid motifs and context factors. These parallels
are a strong indication that the modelling framework presented in this thesis could feasibly be
applied to the SUMO modification. While the number of known protein SUMOylation sites is
small compared to phosphorylation, there are sufficient to train and evaluate a predictive model,
with over 850 sites currently recorded in the PhosphoSitePlusr database (184). Furthermore,
the protein-protein interaction and association databases used in this thesis, BioGRID (209)
and STRING (148), should provide the context information necessary to form the basis of a
SUMOylation predictor that follows the framework underlying PhosphoPICK. Based on the
results presented in this thesis, a SUMOylation predictor that captures the sequence and con-
text conditions that determine SUMOylation would be expected to gain substantial increases
in prediction accuracy over the methods that operate on sequence alone.
There are many more examples of PTMs, and motif-based PTM predictors that could be given.
Sequence-operating methods have been developed for a variety of post-translational modifica-
tions, such as methylation (230, 231), glycosylation (232) and acetylation (233). This thesis has
illustrated the power of leveraging not only the sequence information intrinsic to proteins, but
the context that the proteins operate in, for predicting kinase-substrate phosphorylation events.
But more than that, it has presented a computational framework to enable a comprehensive
modelling of the complex factors that regulate the diversity of protein modifications.
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Table A.1: Model prediction accuracy (measured using AUC) when varying STRING thresh-
olds are used to add protein interactors to the model.
kinase 40 60 80
CDK1 0.86±0.004 0.87±0.004 0.75±0.004
CDK2 0.89±0.004 0.91±0.004 0.79±0.006
CDK5 0.92±0.006 0.96±0.004 0.74±0.018
C
M
G
C
CDK7 0.92±0.022 0.91±0.029 0.83±0.029
GSK3B 0.87±0.006 0.88±0.005 0.83±0.011
MAPK1 0.86±0.003 0.89±0.004 0.8±0.004
MAPK3 0.88±0.006 0.90±0.011 0.78±0.014
MAPK8 0.90±0.009 0.92±0.008 0.84±0.009
MAPK9 0.89±0.05 0.94±0.043 0.65±0.083
MAPK14 0.94±0.003 0.95±0.008 0.89±0.005
AKT1 0.88±0.002 0.91±0.001 0.91±0.004
GRK2 0.87±0.01 0.87±0.01 0.43±0.13
PDPK1 0.91±0.012 0.91±0.021 0.75±0.027
PRKACA 0.97±0.003 0.96±0.002 0.58±0.009
PRKCA 0.77±0.006 0.76±0.005 0.55±0.007
PRKCB 0.86±0.017 0.86±0.011 0.55±0.045
A
G
C
PRKCD 0.85±0.008 0.86±0.012 0.56±0.011
PRKCE 0.82±0.024 0.83±0.027 0.52±0.107
PRKCG 0.90±0.014 0.90±0.01 0.55±0.035
PRKCH 0.54±0.113 0.52±0.098 0.54±0.13
PRKCT 0.91±0.028 0.93±0.031 0.39±0.103
PRKCZ 0.90±0.011 0.90±0.009 0.47±0.025
Continued on next page
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kinase 40 60 80
Continued from previous page
PRKG1 0.90±0.013 0.90±0.01 0.81±0.011
ROCK1 0.89±0.01 0.79±0.011 0.29±0.042
RSK1 0.93±0.009 0.93±0.008 0.77±0.026
RSK2 0.71±0.048 0.71±0.036 0.36±0.066
ABL1 0.96±0.003 0.97±0.006 0.90±0.004
BTK 0.72±0.106 0.69±0.11 0.52±0.104
CSK 0.89±0.04 0.91±0.036 0.57±0.088
EGFR 0.94±0.032 0.95±0.001 0.93±0.004
FYN 0.94±0.002 0.96±0.01 0.82±0.017
HCK 0.95±0.023 0.96±0.046 0.82±0.059
T
K
INSR 0.95±0.015 0.93±0.017 0.92±0.033
JAK1 0.75±0.124 0.76±0.098 0.52±0.143
JAK2 0.92±0.034 0.97±0.036 0.83±0.085
LCK 0.97±0.01 0.96±0.011 0.93±0.014
LYN 0.86±0.024 0.87±0.02 0.82±0.016
RET 0.68±0.073 0.69±0.096 0.55±0.083
SRC 0.87±0.004 0.89±0.003 0.86±0.003
SYK 0.98±0.007 0.98±0.004 0.89±0.009
ZAP70 0.95±0.06 0.94±0.059 0.58±0.1
CAMK1A 0.60±0.081 0.56±0.083 0.61±0.1
C
A
M
K
CAMK2A 0.85±0.01 0.81±0.021 0.53±0.031
CAMK2G 0.99±0.006 0.98±0.012 0.70±0.046
CHK1 0.92±0.041 0.91±0.038 0.91±0.036
LKB1 0.96±0.022 0.88±0.03 0.73±0.056
MAPKAPK2 0.93±0.007 0.93±0.01 0.89±0.02
ATM 0.97±0.005 0.98±0.003 0.98±0.004
ATR 0.93±0.033 0.92±0.047 0.72±0.105
AURKB 1.00±0.002 0.91±0.03 0.93±0.015
C
om
b
in
ed
CSNK1A1 0.86±0.025 0.86±0.017 0.41±0.048
CSNK1D 0.63±0.143 0.63±0.147 0.41±0.041
CSNK2A1 0.87±0.004 0.89±0.005 0.69±0.008
CSNK2A2 0.95±0.007 0.95±0.004 0.60±0.012
CSNK2B 0.88±0.012 0.87±0.012 0.37±0.04
PAK1 0.54±0.023 0.49±0.025 0.52±0.021
PAK2 0.38±0.127 0.40±0.115 0.39±0.128
PLK1 0.92±0.004 0.92±0.006 0.89±0.012
PRKDC 0.81±0.07 0.81±0.068 0.63±0.131
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Table A.2: Model prediction accuracy (measured using AUC) for varying numbers of inter-
action connections to kinase variables in Bayesian network models.
kinase 25 40 50
CDK1 0.87±0.004 0.87±0.003 0.86±0.004
CDK2 0.91±0.004 0.89±0.006 0.88±0.007
CDK5 0.96±0.004 0.96±0.004 0.96±0.001
C
M
G
C
CDK7 0.91±0.029 0.92±0.021 0.91±0.035
GSK3B 0.88±0.005 0.87±0.008 0.87±0.007
MAPK1 0.89±0.004 0.88±0.004 0.87±0.004
MAPK3 0.90±0.011 0.86±0.016 0.83±0.017
MAPK8 0.92±0.008 0.92±0.009 0.92±0.011
MAPK9 0.94±0.043 0.94±0.044 0.94±0.043
MAPK14 0.95±0.008 0.95±0.009 0.95±0.008
AKT1 0.91±0.001 0.90±0.002 0.90±0.002
GRK2 0.87±0.01 0.88±0.027 0.89±0.022
PDPK1 0.91±0.021 0.91±0.021 0.91±0.021
PRKACA 0.96±0.002 0.95±0.002 0.95±0.002
PRKCA 0.76±0.005 0.76±0.006 0.77±0.005
PRKCB 0.86±0.011 0.85±0.011 0.85±0.011
A
G
C
PRKCD 0.86±0.012 0.86±0.011 0.86±0.011
PRKCE 0.83±0.027 0.84±0.024 0.84±0.028
PRKCG 0.90±0.01 0.91±0.014 0.91±0.01
PRKCH 0.52±0.098 0.55±0.013 0.57±0.13
PRKCT 0.93±0.031 0.90±0.042 0.92±0.037
PRKCZ 0.90±0.009 0.90±0.011 0.90±0.011
PRKG1 0.90±0.01 0.89±0.015 0.91±0.008
ROCK1 0.79±0.011 0.80±0.011 0.79±0.011
RSK1 0.93±0.008 0.94±0.01 0.94±0.012
RSK2 0.71±0.036 0.70±0.029 0.70±0.031
ABL1 0.97±0.006 0.97±0.006 0.97±0.006
BTK 0.69±0.11 0.77±0.088 0.76±0.1
CSK 0.91±0.036 0.91±0.028 0.91±0.046
EGFR 0.95±0.001 0.95±0.001 0.95±0.001
FYN 0.96±0.01 0.96±0.008 0.96±0.007
HCK 0.95±0.046 0.94±0.029 0.94±0.034
T
K
INSR 0.93±0.017 0.92±0.023 0.94±0.024
JAK1 0.76±0.098 0.71±0.101 0.74±0.13
JAK2 0.97±0.036 0.96±0.042 0.92±0.033
LCK 0.96±0.01 0.97±0.009 0.96±0.009
LYN 0.87±0.02 0.86±0.022 0.86±0.016
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kinase 25 40 50
Continued from previous page
RET 0.69±0.096 0.72±0.09 0.67±0.05
SRC 0.89±0.003 0.89±0.003 0.88±0.004
SYK 0.98±0.004 0.98±0.004 0.87±0.003
ZAP70 0.94±0.059 0.96±0.055 0.93±0.058
CAMK1A 0.56±0.083 0.58±0.09 0.57±0.1
C
A
M
K
CAMK2A 0.81±0.021 0.82±0.017 0.81±0.019
CAMK2G 0.98±0.012 0.98±0.011 0.99±0.009
CHK1 0.91±0.038 0.92±0.037 0.91±0.04
LKB1 0.88±0.03 0.89±0.034 0.89±0.031
MAPKAPK2 0.93±0.01 0.93±0.011 0.93±0.007
ATM 0.98±0.003 0.97±0.001 0.97±0.004
ATR 0.92±0.047 0.97±0.053 0.95±0.049
AURKB 0.91±0.03 0.93±0.024 0.93±0.021
C
om
b
in
ed
CSNK1A1 0.86±0.017 0.89±0.016 0.87±0.02
CSNK1D 0.63±0.147 0.61±0.113 0.64±0.05
CSNK2A1 0.89±0.005 0.89±0.006 0.86±0.003
CSNK2A2 0.95±0.004 0.96±0.004 0.95±0.004
CSNK2B 0.87±0.012 0.87±0.015 0.88±0.013
PAK1 0.49±0.025 0.57±0.058 0.49±0.026
PAK2 0.40±0.115 0.49±0.099 0.43±0.127
PLK1 0.92±0.006 0.92±0.005 0.94±0.018
PRKDC 0.81±0.068 0.77±0.047 0.80±0.071
Table A.3: Comparison of model prediction accuracy (measured using AUC) between using
STRING with all data sources (normal) and when STRING text mining influence for a test
kinase has been removed.
kinase normal text mining removed
CDK1 0.87±0.004 0.76±0.004
CDK2 0.91±0.004 0.88±0.005
CDK5 0.96±0.004 0.94±0.015
C
M
G
C
CDK7 0.91±0.029 0.89±0.027
GSK3B 0.88±0.005 0.82±0.008
MAPK1 0.89±0.004 0.84±0.005
MAPK3 0.90±0.011 0.73±0.014
MAPK8 0.92±0.008 0.91±0.012
MAPK9 0.94±0.043 0.92±0.02
MAPK14 0.95±0.008 0.94±0.01
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kinase normal text mining removed
Continued from previous page
AKT1 0.91±0.001 0.89±0.003
GRK2 0.87±0.01 0.86±0.024
PDPK1 0.91±0.021 0.76±0.026
PRKACA 0.96±0.002 0.96±0.003
PRKCA 0.76±0.005 0.65±0.007
PRKCB 0.86±0.011 0.63±0.022
A
G
C
PRKCD 0.86±0.012 0.66±0.012
PRKCE 0.83±0.027 0.72±0.066
PRKCG 0.90±0.01 0.87±0.016
PRKCH 0.52±0.098 0.54±0.132
PRKCT 0.93±0.031 1.00±0.008
PRKCZ 0.90±0.009 0.86±0.008
PRKG1 0.90±0.01 0.88±0.005
ROCK1 0.79±0.011 0.50±0.012
RSK1 0.93±0.008 0.86±0.018
RSK2 0.71±0.036 0.44±0.054
ABL1 0.97±0.006 0.94±0.006
BTK 0.69±0.11 0.70±0.13
CSK 0.91±0.036 0.80±0.058
EGFR 0.95±0.001 0.92±0.008
FYN 0.96±0.01 0.91±0.019
HCK 0.95±0.046 0.79±0.058
T
K
INSR 0.93±0.017 0.80±0.042
JAK1 0.76±0.098 0.73±0.11
JAK2 0.97±0.036 0.92±0.053
LCK 0.96±0.011 0.97±0.006
LYN 0.87±0.02 0.87±0.018
RET 0.69±0.096 0.65±0.135
SRC 0.89±0.003 0.88±0.004
SYK 0.98±0.004 0.94±0.016
ZAP70 0.94±0.059 0.88±0.128
CAMK1A 0.56±0.083 0.59±0.056
C
A
M
K
CAMK2A 0.81±0.021 0.66±0.015
CAMK2G 0.98±0.012 0.92±0.036
CHK1 0.91±0.038 0.96±0.03
LKB1 0.88±0.03 0.88±0.034
MAPKAPK2 0.93±0.01 0.83±0.01
ATM 0.98±0.001 0.96±0.007
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kinase normal text mining removed
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ATR 0.92±0.047 0.94±0.048
AURKB 0.91±0.03 0.85±0.022
C
o
m
b
in
ed
CSNK1A1 0.86±0.017 0.69±0.049
CSNK1D 0.63±0.147 0.62±0.105
CSNK2A1 0.89±0.005 0.88±0.004
CSNK2A2 0.95±0.004 0.93±0.006
CSNK2B 0.87±0.012 0.81±0.013
PAK1 0.49±0.025 0.50±0.022
PAK2 0.40±0.115 0.38±0.12
PLK1 0.92±0.006 0.93±0.018
PRKDC 0.81±0.068 0.82±0.044
Table A.4: Comparison between classifying phosphorylation sites using Predikin, and clas-
sifying phosphorylation sites when Predikin score is combined with PhosphoPICK predictions
using two methods – sum and product. Comparisons were made using AUC50 (area under
an ROC curve calculated up to the first 50 false positives), and sensitivity (predicted true
positives/total true positives) at the threshold that yielded the fiftieth false positive. In case
of a tie, an arbitrary order is used to determine the top fifty false positives.
AUC50 Sensitivity
Kinase Predikin Combined Predikin Combined
Sum Product Sum Product
CDK1 0.018 0.060 0.061 0.030 0.090 0.090
CDK2 0.009 0.065 0.068 0.017 0.116 0.124
CDK5 0.006 0.115 0.084 0.013 0.160 0.120
C
M
G
C CDK7 0.000 0.009 0.000 0.000 0.059 0.000
GSK3B 0.010 0.028 0.018 0.025 0.042 0.025
MAPK1 0.004 0.012 0.014 0.010 0.030 0.030
MAPK3 0.005 0.017 0.019 0.035 0.035 0.043
MAPK8 0.006 0.056 0.064 0.018 0.091 0.091
MAPK9 0.011 0.150 0.024 0.036 0.286 0.071
MAPK14 0.015 0.022 0.021 0.021 0.053 0.053
AKT1 0.018 0.048 0.046 0.048 0.114 0.095
GRK2 0.000 0.029 0.000 0.000 0.080 0.000
PDPK1 0.206 0.182 0.103 0.286 0.262 0.143
A
G
C
PRKACA 0.008 0.051 0.041 0.018 0.076 0.058
PRKCA 0.013 0.012 0.013 0.019 0.019 0.023
PRKCB 0.000 0.032 0.050 0.000 0.063 0.079
PRKCD 0.025 0.053 0.045 0.048 0.071 0.060
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Kinase Predikin Combined Predikin Combined
Continued from previous page
PRKCE 0.027 0.038 0.000 0.038 0.038 0.000
A
G
C
PRKCG 0.000 0.017 0.025 0.000 0.050 0.075
PRKCH 0.058 0.058 0.000 0.083 0.083 0.000
PRKCT 0.000 0.140 0.000 0.000 0.400 0.000
PRKCZ 0.000 0.068 0.073 0.000 0.103 0.103
PRKG1 0.000 0.088 0.085 0.000 0.128 0.128
ROCK1 0.000 0.077 0.073 0.000 0.130 0.130
RSK1 0.000 0.058 0.055 0.000 0.091 0.091
RSK2 0.000 0.000 0.000 0.000 0.000 0.000
ABL1 0.012 0.060 0.056 0.022 0.089 0.111
BTK 0.002 0.020 0.000 0.048 0.048 0.000
CSK 0.000 0.000 0.000 0.000 0.000 0.000
EGFR 0.062 0.118 0.119 0.107 0.161 0.161
FYN 0.016 0.018 0.009 0.049 0.033 0.016
HCK 0.011 0.000 0.000 0.032 0.000 0.000
T
K
INSR 0.049 0.172 0.160 0.094 0.226 0.189
JAK1 0.000 0.000 0.000 0.000 0.000 0.000
JAK2 0.027 0.008 0.000 0.030 0.030 0.000
LCK 0.062 0.134 0.146 0.099 0.225 0.239
LYN 0.043 0.027 0.030 0.088 0.035 0.053
RET 0.000 0.000 0.000 0.000 0.000 0.000
SRC 0.024 0.037 0.038 0.045 0.072 0.072
SYK 0.204 0.193 0.182 0.283 0.245 0.226
ZAP70 0.201 0.235 0.023 0.280 0.400 0.040
CAMK1A 0.177 0.180 0.000 0.333 0.333 0.000
C
A
M
K
CAMK2A 0.000 0.059 0.031 0.000 0.118 0.044
CAMK2G 0.000 0.044 0.000 0.000 0.095 0.000
CHK1 0.090 0.138 0.000 0.105 0.158 0.000
LKB1 0.205 0.448 0.000 0.308 0.538 0.000
MAPKAPK2 0.023 0.224 0.192 0.031 0.281 0.219
AURKB 0.056 0.124 0.037 0.081 0.243 0.081
co
m
b
in
ed
CSNK1A1 0.000 0.047 0.033 0.000 0.104 0.083
CSNK1D 0.000 0.000 0.000 0.000 0.000 0.000
PAK1 0.004 0.014 0.000 0.026 0.053 0.000
PAK2 0.028 0.027 0.000 0.057 0.057 0.000
PLK1 0.000 0.029 0.029 0.000 0.051 0.051
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Table A.5: Comparison between classifying phosphorylation sites using Predikin, and clas-
sifying phosphorylation sites when GPS score is combined with PhosphoPICK predictions
using two methods – sum and product. Comparisons were made using AUC50 (area under
an ROC curve calculated up to the first 50 false positives), and sensitivity (predicted true
positives/total true positives) at the threshold that yielded the fiftieth false positive. In case
of a tie, an arbitrary order is used to determine the top fifty false positives.
AUC50 Sensitivity
Kinase GPS Combined GPS Combined
Sum Product Sum Product
CDK1 0.000 0.022 0.019 0.000 0.059 0.040
CDK2 0.000 0.070 0.068 0.000 0.137 0.137
CDK5 0.000 0.094 0.087 0.000 0.173 0.147
C
M
G
C CDK7 0.291 0.323 0.526 0.389 0.333 0.778
GSK3B 0.015 0.015 0.018 0.042 0.034 0.034
MAPK1 0.006 0.035 0.035 0.015 0.049 0.049
MAPK3 0.008 0.039 0.039 0.009 0.087 0.087
MAPK8 0.000 0.043 0.043 0.000 0.109 0.109
MAPK9 0.017 0.099 0.098 0.0357 0.179 0.179
MAPK14 0.020 0.051 0.053 0.021 0.104 0.094
AKT1 0.073 0.265 0.265 0.114 0.352 0.352
GRK2 0.080 0.204 0.613 0.111 0.370 0.815
PDPK1 0.3940 0.388 0.496 0.476 0.429 0.667
PRKACA 0.010 0.102 0.099 0.026 0.174 0.174
PRKCA 0.005 0.021 0.021 0.013 0.032 0.039
PRKCB 0.005 0.040 0.040 0.016 0.047 0.047
A
G
C
PRKCD 0.027 0.070 0.080 0.047 0.094 0.118
PRKCE 0.147 0.158 0.060 0.192 0.192 0.077
PRKCG 0.125 0.149 0.020 0.125 0.200 0.025
PRKCH 0.156 0.153 0.000 0.167 0.167 0.000
PRKCT 0.000 0.040 0.108 0.000 0.400 0.200
PRKCZ 0.148 0.190 0.196 0.172 0.207 0.241
PRKG1 0.159 0.164 0.110 0.231 0.231 0.180
ROCK1 0.073 0.125 0.131 0.152 0.152 0.174
RSK1 0.254 0.160 0.162 0.273 0.182 0.182
RSK2 0.711 0.653 0.138 0.778 0.778 0.222
ABL1 0.235 0.270 0.276 0.311 0.378 0.378
BTK 0.230 0.232 0.050 0.286 0.286 0.190
CSK 0.245 0.370 0.090 0.500 0.500 0.286
EGFR 0.221 0.339 0.333 0.339 0.482 0.464
FYN 0.086 0.053 0.062 0.115 0.098 0.098
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Kinase GPS Combined GPS Combined
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HCK 0.195 0.028 0.001 0.290 0.065 0.032
T
K
INSR 0.121 0.249 0.282 0.170 0.302 0.358
JAK1 0.368 0.368 0.082 0.368 0.368 0.263
JAK2 0.116 0.122 0.083 0.212 0.212 0.182
LCK 0.091 0.229 0.221 0.141 0.352 0.296
LYN 0.216 0.198 0.212 0.263 0.333 0.351
RET 0.464 0.461 0.195 0.571 0.571 0.429
SRC 0.077 0.086 0.089 0.126 0.212 0.167
SYK 0.288 0.458 0.452 0.434 0.585 0.585
ZAP70 0.533 0.557 0.305 0.720 0.760 0.480
CAMK1A 0.653 0.647 0.000 0.667 0.667 0.000
C
A
M
K
CAMK2A 0.021 0.117 0.146 0.074 0.221 0.235
CAMK2G 0.005 0.083 0.024 0.048 0.238 0.143
CHK1 0.148 0.202 0.051 0.211 0.263 0.105
LKB1 0.722 0.706 0.511 0.769 0.769 0.538
MAPKAPK2 0.044 0.344 0.348 0.093 0.375 0.375
ATM 0.033 0.148 0.146 0.088 0.221 0.221
ATR 0.000 0.025 0.019 0.000 0.054 0.054
AURKB 0.112 0.178 0.169 0.162 0.243 0.243
CSNK1A1 0.341 0.227 0.200 0.354 0.271 0.229
co
m
b
in
ed
CSNK1D 0.016 0.012 0.000 0.056 0.056 0.000
CSNK2A1 0.016 0.055 0.052 0.031 0.094 0.100
CSNK2A2 0.039 0.187 0.195 0.069 0.276 0.302
CSNK2B 0.066 0.069 0.074 0.094 0.094 0.094
PAK1 0.023 0.025 0.000 0.026 0.026 0.0
PAK2 0.108 0.102 0.018 0.200 0.200 0.057
PLK1 0.093 0.296 0.299 0.128 0.462 0.462
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Table A.6: Comparison between classifying phosphorylation sites using NetworKIN, and
classifying phosphorylation sites when NetworKIN score is combined with PhosphoPICK pre-
dictions using two methods – sum and product. Comparisons were made using AUC50 (area
under an ROC curve calculated up to the first 50 false positives), and sensitivity (predicted
true positives/total true positives) at the threshold that yielded the fiftieth false positive.
In case of a tie, an arbitrary order is used to determine the top fifty false predictions. The
specificity at this threshold is 0.9995 for serine/threonine kinases, and 0.998 for the tyrosine
kinases.
AUC50 Sensitivity
Kinase NetworKIN Combined NetworKIN Combined
Sum Product Sum Product
CDK1 0.031 0.034 0.034 0.056 0.061 0.061
CDK2 0.125 0.159 0.159 0.242 0.274 0.274
CDK5 0.047 0.173 0.169 0.080 0.240 0.240
C
M
G
C CDK7 0.109 0.000 0.000 0.222 0.000 0.000
GSK3B 0.008 0.045 0.045 0.017 0.067 0.067
MAPK1 0.051 0.081 0.076 0.104 0.129 0.129
MAPK3 0.047 0.049 0.052 0.096 0.078 0.087
MAPK8 0.004 0.013 0.013 0.036 0.018 0.018
MAPK9 0.024 0.017 0.000 0.036 0.036 0.000
GRK2 0.018 0.000 0.000 0.037 0.000 0.000
PRKACA 0.046 0.067 0.065 0.093 0.111 0.115
PRKCA 0.015 0.011 0.010 0.026 0.016 0.013
PRKCB 0.000 0.064 0.064 0.000 0.079 0.079
A
G
C
PRKCD 0.000 0.000 0.000 0.000 0.000 0.000
PRKCE 0.000 0.000 0.000 0.000 0.000 0.000
PRKCG 0.039 0.025 0.003 0.077 0.026 0.026
PRKCH 0.040 0.040 0.000 0.083 0.083 0.000
PRKCT 0.176 0.176 0.176 0.200 0.200 0.200
PRKCZ 0.017 0.000 0.000 0.034 0.034 0.034
ROCK1 0.032 0.019 0.019 0.065 0.065 0.065
RSK2 0.054 0.000 0.029 0.111 0.000 0.111
ABL1 0.090 0.060 0.060 0.178 0.111 0.089
BTK 0.023 0.000 0.000 0.048 0.000 0.000
EGFR 0.135 0.161 0.161 0.250 0.268 0.268
FYN 0.068 0.050 0.048 0.131 0.082 0.082
T
K
HCK 0.047 0.000 0.000 0.097 0.000 0.000
INSR 0.072 0.092 0.119 0.151 0.132 0.170
LCK 0.118 0.125 0.125 0.169 0.155 0.155
LYN 0.106 0.088 0.086 0.175 0.158 0.158
SRC 0.043 0.047 0.046 0.081 0.095 0.095
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Kinase NetworKIN Combined NetworKIN Combined
Continued from previous page
SYK 0.020 0.023 0.023 0.058 0.077 0.077
ZAP70 0.120 0.065 0.000 0.200 0.080 0.000
C
A
M
K
CAMK1A 0.203 0.227 0.133 0.333 0.333 0.333
CAMK2A 0.072 0.031 0.007 0.147 0.118 0.015
CAMK2G 0.138 0.123 0.114 0.238 0.238 0.238
LKB1 0.113 0.278 0.278 0.231 0.308 0.308
ATM 0.100 0.101 0.101 0.204 0.204 0.204
ATR 0.040 0.000 0.000 0.081 0.000 0.000
co
m
b
in
ed
CSNK1A1 0.008 0.010 0.014 0.021 0.021 0.021
CSNK1D 0.000 0.000 0.000 0.000 0.000 0.000
CSNK2A1 0.062 0.053 0.052 0.102 0.109 0.102
CSNK2A2 0.071 0.100 0.101 0.273 0.327 0.282
PAK1 0.026 0.011 0.000 0.053 0.026 0.000
PAK2 0.388 0.386 0.378 0.400 0.400 0.400
Table A.7: Gene ontology (GO) term enrichment analysis for known CDK2 substrates and
predicted substrates. The first two columns in the table show GO terms and their descriptions
that were found to be significantly over-represented (Fisher’s exact test, Bonferroni correction,
E-value<0.05) in known CDK2 substrates, with the E-values shown in the third column. The
terms are ordered from most to least significant. The final column contains the E-values for the
terms that were found when performing the same enrichment test on the top 300 predictions
for PhosphoPICK. If a value is listed as “N/A”, then the term was not identified with any
protein in the set of predictions.
GO term Description Substrates PhosphoPICK
GO:0005654 nucleoplasm 4.38e-20 8.74e-144
GO:0007049 cell cycle 3.62e-14 4.18e-125
GO:0000278 mitotic cell cycle 9.35e-12 6.95e-214
GO:0005634 nucleus 9.91e-11 8.22e-78
GO:0000082 G1/S transition of mitotic cell cycle 2.92e-10 1.95e-126
GO:0005515 protein binding 1.94e-08 2.00e-52
GO:0045893 positive regulation of transcription, DNA-templated 4.09e-07 0.155
GO:0006974 cellular response to DNA damage stimulus 3.70e-06 4.55e-25
GO:0007050 cell cycle arrest 4.92e-06 0.0010
GO:0006978 DNA damage response, signal transduction by p53 class 1.08e-05 259.34
mediator resulting in transcription of p21 class mediator
GO:0031625 ubiquitin protein ligase binding 1.94e-05 0.08
GO:0006260 DNA replication 2.86e-05 1.10e-59
GO:0051726 regulation of cell cycle 3.10e-05 1.80e-28
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GO term Description Substrates PhosphoPICK
Continued from previous page
GO:0008285 negative regulation of cell proliferation 4.83e-05 524.32
GO:0019901 protein kinase binding 7.20e-05 2.76e-09
GO:0000083 regulation of transcription involved in G1/S transition
of mitotic cell cycle
7.82e-05 8.14e-13
GO:0000079 regulation of cyclin-dependent protein serine/threonine
kinase activity
8.54e-05 1.69e-19
GO:0005730 nucleolus 0.0001 7.06e-34
GO:0005667 transcription factor complex 0.0001 0.0007
GO:0003700 sequence-specific DNA binding transcription factor ac-
tivity
0.0002 390.26
GO:0005737 cytoplasm 0.0003 1.43e-21
GO:0000307 cyclin-dependent protein kinase holoenzyme complex 0.0003 1.84e-06
GO:0000785 chromatin 0.0003 5.75e-15
GO:0006281 DNA repair 0.0003 8.41e-37
GO:0051301 cell division 0.0003 6.49e-72
GO:0071850 mitotic cell cycle arrest 0.0004 N/A
GO:0031571 mitotic G1 DNA damage checkpoint 0.0006 210.79
GO:0050681 androgen receptor binding 0.0007 179.82
GO:0008134 transcription factor binding 0.0007 1.06e-12
GO:0030521 androgen receptor signaling pathway 0.001 811.58
GO:0008284 positive regulation of cell proliferation 0.002 4.85
GO:0030308 negative regulation of cell growth 0.003 506.21
GO:0000086 G2/M transition of mitotic cell cycle 0.003 2.82e-26
GO:0003682 chromatin binding 0.003 1.35e-08
GO:0071158 positive regulation of cell cycle arrest 0.004 41.04
GO:0043433 negative regulation of sequence-specific DNA binding
transcription factor activity
0.004 97.84
GO:0006351 transcription, DNA-templated 0.004 114.1
GO:0006357 regulation of transcription from RNA polymerase II pro-
moter
0.004 247.83
GO:0003713 transcription coactivator activity 0.005 284.81
GO:0006977 DNA damage response, signal transduction by p53 0.007 5.06e-56
class mediator resulting in cell cycle arrest
GO:0008156 negative regulation of DNA replication 0.009 57.94
GO:0043550 regulation of lipid kinase activity 0.009 55.29
GO:0045944 positive regulation of transcription from RNA poly-
merase II promoter
0.01 0.001
GO:0006270 DNA replication initiation 0.01 1.14e-22
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GO term Description Substrates PhosphoPICK
Continued from previous page
GO:0000122 negative regulation of transcription from RNA poly-
merase II promoter
0.01 0.01
GO:0007265 Ras protein signal transduction 0.01 46.02
GO:0001836 release of cytochrome c from mitochondria 0.01 N/A
GO:0005829 cytosol 0.01 4.07e-42
GO:0003677 DNA binding 0.01 1.34e-12
GO:0044212 transcription regulatory region DNA binding 0.02 270.76
GO:0043234 protein complex 0.02 0.007
GO:0004860 protein kinase inhibitor activity 0.02 614.09
GO:0000790 nuclear chromatin 0.03 2.24e-09
GO:0007369 gastrulation 0.03 701.09
GO:0045892 negative regulation of transcription, DNA-templated 0.03 2.06
GO:0045668 negative regulation of osteoblast differentiation 0.03 701.09
GO:0006355 regulation of transcription, DNA-templated 0.04 133.62
GO:0043353 enucleate erythrocyte differentiation 0.045 108.82
GO:0090344 negative regulation of cell aging 0.045 N/A
Table A.8: Gene ontology (GO) term enrichment analysis for CDK2 substrates within
unique E2F1 targets.
GO term Description E-value
GO:0051439 regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle 2.81e-11
GO:0051437 positive regulation of ubiquitin-protein ligase activity involved in mitotic cell
cycle
2.81e-11
GO:0051436 negative regulation of ubiquitin-protein ligase activity involved in mitotic cell
cycle
2.81e-11
GO:0031145 anaphase-promoting complex-dependent proteasomal 2.81e-11
ubiquitin-dependent protein catabolic process
GO:0006977 DNA damage response, signal transduction by 2.23e-10
p53 class mediator resulting in cell cycle arrest
GO:0000082 G1/S transition of mitotic cell cycle 7.79e-10
GO:0000278 mitotic cell cycle 9.90e-09
GO:0005654 nucleoplasm 1.62e-08
GO:0002474 antigen processing and presentation of peptide antigen via MHC class I 7.40e-08
GO:0002479 antigen processing and presentation of exogenous 7.40e-08
peptide antigen via MHC class I, TAP-dependent
GO:0042590 antigen processing and presentation of exogenous peptide antigen via MHC
class I
2.20e-07
GO:0006521 regulation of cellular amino acid metabolic process 2.39e-07
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GO term Description E-value
Continued from previous page
GO:0043066 negative regulation of apoptotic process 8.78e-07
GO:0000502 proteasome complex 1.42e-06
GO:0000209 protein polyubiquitination 2.35e-06
GO:0042981 regulation of apoptotic process 8.43e-06
GO:0010467 gene expression 1.78e-05
GO:0016032 viral process 4.70e-05
GO:0016071 mRNA metabolic process 0.0003
GO:0006915 apoptotic process 0.0003
GO:0016070 RNA metabolic process 0.0004
GO:0034641 cellular nitrogen compound metabolic process 0.0009
GO:0022624 proteasome accessory complex 0.0015
GO:0005634 nucleus 0.0088
GO:0005829 cytosol 0.0130
GO:0000079 regulation of cyclin-dependent protein serine/threonine kinase activity 0.0151
GO:0005637 nuclear inner membrane 0.0300
Table A.9: Gene ontology (GO) term enrichment analysis for CDK2 substrates within
unique E2F4 targets.
GO term Description E-value
GO:0007049 cell cycle 3.29e-16
GO:0000278 mitotic cell cycle 8.16e-14
GO:0051301 cell division 3.39e-11
GO:0007067 mitotic nuclear division 3.39e-11
GO:0005819 spindle 6.60e-07
GO:0031145 anaphase-promoting complex-dependent proteasomal 6.21e-05
ubiquitin-dependent protein catabolic process
GO:0005654 nucleoplasm 6.41e-05
GO:0007094 mitotic spindle assembly checkpoint 7.82e-05
GO:0019901 protein kinase binding 0.0001
GO:0051439 regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle 0.0005
GO:0051437 positive regulation of ubiquitin-protein ligase activity involved in mitotic cell
cycle
0.0005
GO:0005856 cytoskeleton 0.0016
GO:0005829 cytosol 0.0039
GO:0005524 ATP binding 0.0042
GO:0000082 G1/S transition of mitotic cell cycle 0.0062
GO:0005737 cytoplasm 0.0067
GO:0008283 cell proliferation 0.0072
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GO term Description E-value
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GO:0000086 G2/M transition of mitotic cell cycle 0.0072
GO:0007080 mitotic metaphase plate congression 0.0078
GO:0000922 spindle pole 0.0133
GO:0007059 chromosome segregation 0.0185
GO:0030496 midbody 0.0430
GO:0051436 negative regulation of ubiquitin-protein ligase activity involved in mitotic cell
cycle
0.0430
Table A.10: Gene ontology (GO) term enrichment analysis for CDK2 substrates within
unique E2F6 targets.
GO term Description E-value
GO:0000278 mitotic cell cycle 4.61e-16
GO:0051439 regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle 5.02e-16
GO:0031145 anaphase-promoting complex-dependent proteasomal 5.02e-16
ubiquitin-dependent protein catabolic process
GO:0051437 positive regulation of ubiquitin-protein ligase activity involved in mitotic cell
cycle
5.02e-16
GO:0051436 negative regulation of ubiquitin-protein ligase activity involved in mitotic cell
cycle
5.02e-16
GO:0000082 G1/S transition of mitotic cell cycle 8.36e-10
GO:0006977 DNA damage response, signal transduction by 5.50e-09
p53 class mediator resulting in cell cycle arrest
GO:0042590 antigen processing and presentation of exogenous peptide antigen via MHC
class I
3.28e-08
GO:0006521 regulation of cellular amino acid metabolic process 3.28e-08
GO:0002479 antigen processing and presentation of exogenous 3.28e-08
peptide antigen via MHC class I, TAP-dependent
GO:0005654 nucleoplasm 7.04e-08
GO:0002474 antigen processing and presentation of peptide antigen via MHC class I 1.14e-07
GO:0000502 proteasome complex 6.81e-07
GO:0000209 protein polyubiquitination 6.81e-07
GO:0042981 regulation of apoptotic process 2.47e-06
GO:0005829 cytosol 4.09e-05
GO:0016071 mRNA metabolic process 4.44e-05
GO:0016032 viral process 4.44e-05
GO:0016070 RNA metabolic process 7.97e-05
GO:0034641 cellular nitrogen compound metabolic process 0.0001
GO:0022624 proteasome accessory complex 0.0001
Continued on next page
Appendix A. Chapter 2 supplementary material 130
GO term Description E-value
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GO:0007094 mitotic spindle assembly checkpoint 0.0004
GO:0005680 anaphase-promoting complex 0.0004
GO:0010467 gene expression 0.0006
GO:0070979 protein K11-linked ubiquitination 0.0011
GO:0043066 negative regulation of apoptotic process 0.0015
GO:0007049 cell cycle 0.0044
GO:0051301 cell division 0.0156
GO:0006915 apoptotic process 0.0232
GO:0044281 small molecule metabolic process 0.0324
GO:0030163 protein catabolic process 0.0432
Table A.11: Gene ontology (GO) term enrichment analysis for CDK2 substrates within
overlapping E2F1, E2F4 and E2F6 targets.
GO term Description E-value
GO:0000278 mitotic cell cycle 1.02e-34
GO:0006260 DNA replication 3.13e-25
GO:0005654 nucleoplasm 2.35e-24
GO:0000082 G1/S transition of mitotic cell cycle 2.47e-21
GO:0007049 cell cycle 8.60e-21
GO:0005634 nucleus 5.73e-14
GO:0006271 DNA strand elongation involved in DNA replication 1.04e-12
GO:0007067 mitotic nuclear division 9.91e-09
GO:0006281 DNA repair 4.87e-08
GO:0051301 cell division 8.35e-08
GO:0006270 DNA replication initiation 2.91e-07
GO:0032201 telomere maintenance via semi-conservative replication 1.40e-06
GO:0000722 telomere maintenance via recombination 5.61e-06
GO:0005515 protein binding 7.18e-06
GO:0000775 chromosome, centromeric region 7.29e-06
GO:0031145 anaphase-promoting complex-dependent 1.36e-05
proteasomal ubiquitin-dependent protein catabolic process
GO:0003677 DNA binding 1.50e-05
GO:0051439 regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle 2.79e-05
GO:0051436 negative regulation of ubiquitin-protein ligase activity involved in mitotic cell
cycle
2.79e-05
GO:0000777 condensed chromosome kinetochore 9.98e-05
GO:0005694 chromosome 0.0001
GO:0000723 telomere maintenance 0.0001
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GO term Description E-value
Continued from previous page
GO:0017111 nucleoside-triphosphatase activity 0.0003
GO:0051437 positive regulation of ubiquitin-protein ligase activity involved in mitotic cell
cycle
0.0004
GO:0006974 cellular response to DNA damage stimulus 0.0007
GO:0000776 kinetochore 0.0009
GO:0005524 ATP binding 0.0010
GO:0006297 nucleotide-excision repair, DNA gap filling 0.0011
GO:0007094 mitotic spindle assembly checkpoint 0.0011
GO:0051726 regulation of cell cycle 0.0019
GO:0008283 cell proliferation 0.0037
GO:0005819 spindle 0.0054
GO:0000083 regulation of transcription involved in G1/S transition of mitotic cell cycle 0.0104
GO:0006302 double-strand break repair 0.0204
GO:0003690 double-stranded DNA binding 0.0409
Table A.12: Gene ontology (GO) term enrichment analysis for predicted CDK2 substrates
overlapping with E2F1 and E2F4 targets but not E2F6 targets.
GO term Description E-value
GO:0007049 cell cycle 6.26e-20
GO:0000278 mitotic cell cycle 2.33e-15
GO:0000082 G1/S transition of mitotic cell cycle 8.67e-11
GO:0051301 cell division 2.05e-10
GO:0007067 mitotic nuclear division 7.50e-08
GO:0005634 nucleus 6.05e-06
GO:0006260 DNA replication 7.18e-06
GO:0005515 protein binding 1.97e-05
GO:0031145 anaphase-promoting complex-dependent proteasomal 4.91e-05
ubiquitin-dependent protein catabolic process
GO:0006977 DNA damage response, signal transduction by 0.0001
p53 class mediator resulting in cell cycle arrest
GO:0051439 regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle 0.0005
GO:0048015 phosphatidylinositol-mediated signaling 0.0005
GO:0005654 nucleoplasm 0.0007
GO:0005694 chromosome 0.0020
GO:0007051 spindle organization 0.0057
GO:0051437 positive regulation of ubiquitin-protein ligase activity involved in mitotic cell
cycle
0.0057
GO:0051726 regulation of cell cycle 0.0127
Continued on next page
Appendix A. Chapter 2 supplementary material 132
GO term Description E-value
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GO:0006281 DNA repair 0.0152
GO:0006974 cellular response to DNA damage stimulus 0.0152
GO:0005874 microtubule 0.0215
GO:0005876 spindle microtubule 0.0351
GO:0005667 transcription factor complex 0.0351
GO:0043066 negative regulation of apoptotic process 0.0432
Table A.13: Gene ontology (GO) term enrichment analysis for predicted CDK2 substrates
overlapping with E2F1 and E2F6 targets but not E2F4 targets.
GO term Description E-value
GO:0019905 syntaxin binding 0.0119
GO:0042770 signal transduction in response to DNA damage 0.0119
GO:0006974 cellular response to DNA damage stimulus 0.0375
GO:0006281 DNA repair 0.0375
Table A.14: Gene ontology (GO) term enrichment analysis for predicted CDK2 substrates
overlapping with E2F4 and E2F6 targets but not E2F1 targets.
GO term Description E-value
GO:0000278 mitotic cell cycle 9.44e-09
GO:0007049 cell cycle 8.01e-05
GO:0051301 cell division 0.0004
GO:0007067 mitotic nuclear division 0.0021
GO:0000082 G1/S transition of mitotic cell cycle 0.0028
GO:0000775 chromosome, centromeric region 0.0238
GO:0005654 nucleoplasm 0.0296
GO:0005694 chromosome 0.0360
GO:0007059 chromosome segregation 0.0371
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Table B.1: Sequence model accuracy across human kinases when different percentages of ki-
nase phosphorylation peptides were used to determine the set of k-mers added to the sequence
model. Table shows median AUC and AUC50 values for classifying kinase phosphorylation
sites with the sequence model as determined by 10-fold cross-validation across 10 randomised
data-set splits. Kinases are grouped according to their family, with the average prediction
accuracy for each family shown.
AUC AUC50
Kinase 5% 10% 20% 5% 10% 20%
CDK2 0.89±0.001 0.89±0.001 0.89±0.001 0.100±0.004 0.105±0.003 0.086±0.003
CDK1 0.89±0.002 0.89±0.001 0.89±0.002 0.071±0.008 0.081±0.011 0.105±0.009
ERK2 0.86±0.001 0.86±0.001 0.87±0.002 0.067±0.010 0.063±0.007 0.084±0.009
ERK1 0.86±0.005 0.85±0.005 0.84±0.005 0.066±0.012 0.035±0.006 0.036±0.007
GSK3B 0.81±0.006 0.80±0.007 0.80±0.007 0.132±0.014 0.137±0.011 0.107±0.007
P38A 0.81±0.007 0.81±0.007 0.80±0.007 0.151±0.017 0.150±0.018 0.131±0.017
JNK1 0.87±0.004 0.85±0.005 0.84±0.005 0.155±0.014 0.074±0.013 0.082±0.014
CDK5 0.84±0.009 0.85±0.009 0.84±0.011 0.050±0.007 0.086±0.011 0.054±0.011
C
M
G
C
JNK2 0.73±0.023 0.71±0.022 0.71±0.018 0.068±0.015 0.054±0.011 0.055±0.007
CDK7 0.88±0.019 0.78±0.017 0.76±0.018 0.310±0.032 0.270±0.018 0.235±0.052
GSK3A 0.90±0.026 0.88±0.017 0.85±0.022 0.458±0.045 0.351±0.041 0.219±0.033
CDK4 0.87±0.012 0.85±0.012 0.83±0.014 0.179±0.025 0.055±0.017 0.065±0.021
P38B 0.83±0.014 0.81±0.014 0.81±0.014 0.260±0.046 0.217±0.040 0.105±0.049
HIPK2 0.86±0.013 0.84±0.017 0.84±0.017 0.380±0.043 0.224±0.031 0.229±0.034
DYRK1A 0.83±0.033 0.80±0.039 0.81±0.030 0.260±0.043 0.147±0.070 0.041±0.035
CDK9 0.83±0.015 0.80±0.010 0.78±0.011 0.320±0.030 0.227±0.056 0.057±0.018
DYRK2 0.78±0.019 0.76±0.024 0.72±0.029 0.306±0.043 0.197±0.061 0.000±0.006
ERK5 0.83±0.016 0.81±0.011 0.82±0.009 0.317±0.034 0.148±0.034 0.073±0.026
CDK6 0.86±0.009 0.85±0.011 0.82±0.011 0.183±0.030 0.163±0.026 0.029±0.010
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Kinase 5% 10% 20% 5% 10% 20%
Continued from previous page
CDK3 0.76±0.050 0.76±0.050 0.66±0.059 0.357±0.045 0.357±0.045 0.000±0.036
Average 0.84±0.014 0.82±0.014 0.81±0.015 0.21±0.026 0.157±0.027 0.09±0.02
PKACA 0.89±0.003 0.89±0.003 0.89±0.003 0.120±0.008 0.126±0.007 0.126±0.007
PKCA 0.84±0.001 0.83±0.002 0.83±0.002 0.133±0.009 0.129±0.006 0.109±0.008
Akt1 0.92±0.004 0.91±0.004 0.91±0.005 0.181±0.017 0.169±0.014 0.167±0.008
PKCD 0.70±0.009 0.69±0.009 0.68±0.010 0.043±0.006 0.026±0.006 0.027±0.005
PKG1 0.86±0.027 0.86±0.026 0.87±0.026 0.203±0.020 0.226±0.014 0.201±0.021
p90RSK 0.80±0.010 0.77±0.012 0.74±0.015 0.173±0.037 0.024±0.021 0.035±0.013
PKCE 0.67±0.017 0.65±0.020 0.64±0.020 0.100±0.006 0.098±0.015 0.092±0.022
PKCZ 0.63±0.020 0.59±0.027 0.56±0.029 0.143±0.029 0.014±0.011 0.015±0.014
PKCB 0.71±0.019 0.67±0.022 0.65±0.023 0.127±0.028 0.110±0.019 0.136±0.020
A
G
C
RSK2 0.71±0.023 0.72±0.023 0.69±0.028 0.124±0.017 0.095±0.022 0.069±0.016
ROCK1 0.76±0.012 0.75±0.011 0.74±0.010 0.146±0.032 0.110±0.025 0.136±0.019
PDK1 0.84±0.018 0.84±0.018 0.85±0.019 0.499±0.024 0.450±0.015 0.414±0.011
PKCT 0.77±0.041 0.78±0.030 0.80±0.026 0.125±0.047 0.070±0.045 0.089±0.044
PKCG 0.65±0.024 0.62±0.026 0.63±0.026 0.108±0.064 0.037±0.013 0.027±0.013
p70S6K 0.83±0.010 0.82±0.013 0.80±0.014 0.284±0.029 0.155±0.026 0.114±0.016
SGK1 0.83±0.018 0.82±0.017 0.83±0.022 0.328±0.011 0.270±0.030 0.258±0.025
Akt2 0.87±0.012 0.89±0.018 0.87±0.020 0.159±0.020 0.169±0.026 0.101±0.034
GRK2 0.86±0.014 0.84±0.014 0.77±0.017 0.529±0.033 0.371±0.028 0.144±0.015
ROCK2 0.77±0.015 0.69±0.033 0.76±0.020 0.171±0.002 0.175±0.003 0.140±0.011
PKCI 0.81±0.023 0.73±0.043 0.78±0.027 0.160±0.049 0.198±0.066 0.227±0.055
PKCH 0.90±0.026 0.85±0.028 0.83±0.037 0.561±0.038 0.345±0.051 0.327±0.065
PKN1 0.79±0.058 0.79±0.058 0.65±0.095 0.202±0.108 0.202±0.108 0.150±0.103
Average 0.79±0.018 0.77±0.021 0.76±0.022 0.21±0.029 0.162±0.026 0.141±0.025
Src 0.56±0.006 0.57±0.007 0.55±0.005 0.102±0.005 0.081±0.007 0.084±0.007
Abl 0.62±0.009 0.60±0.011 0.60±0.012 0.149±0.016 0.124±0.010 0.108±0.013
Fyn 0.59±0.009 0.57±0.011 0.56±0.012 0.121±0.009 0.067±0.014 0.084±0.010
Lck 0.53±0.012 0.54±0.011 0.54±0.013 0.063±0.016 0.050±0.014 0.062±0.015
Lyn 0.48±0.016 0.48±0.016 0.47±0.017 0.048±0.012 0.053±0.011 0.061±0.014
EGFR 0.56±0.023 0.53±0.022 0.54±0.021 0.050±0.018 0.024±0.010 0.054±0.016
Syk 0.81±0.018 0.82±0.016 0.80±0.015 0.266±0.025 0.308±0.024 0.290±0.019
InsR 0.69±0.026 0.67±0.029 0.67±0.028 0.352±0.025 0.177±0.017 0.156±0.022
T
K
JAK2 0.58±0.028 0.52±0.029 0.52±0.033 0.155±0.030 0.107±0.025 0.072±0.025
FAK 0.67±0.050 0.50±0.033 0.40±0.017 0.360±0.067 0.071±0.039 0.041±0.014
Ret 0.54±0.023 0.52±0.018 0.52±0.015 0.193±0.025 0.166±0.020 0.166±0.021
Arg 0.67±0.036 0.53±0.041 0.66±0.034 0.154±0.017 0.070±0.040 0.193±0.030
Brk 0.60±0.021 0.53±0.034 0.49±0.032 0.197±0.007 0.079±0.044 0.066±0.018
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kinase 5% 10% 20% 5% 10% 20%
Continued from previous page
ALK 0.57±0.032 0.57±0.032 0.50±0.031 0.000±0.000 0.000±0.000 0.000±0.000
Btk 0.71±0.033 0.70±0.028 0.70±0.031 0.311±0.053 0.205±0.047 0.152±0.043
PDGFRB 0.61±0.033 0.60±0.019 0.51±0.017 0.255±0.040 0.143±0.033 0.047±0.019
JAK3 0.81±0.032 0.72±0.046 0.72±0.056 0.398±0.063 0.158±0.054 0.161±0.051
Hck 0.58±0.025 0.51±0.032 0.50±0.029 0.089±0.017 0.063±0.017 0.057±0.017
Pyk2 0.62±0.033 0.62±0.033 0.45±0.076 0.173±0.019 0.173±0.019 0.000±0.000
Average 0.21±0.0246 0.59±0.025 0.56± 0.026 0.181±0.024 0.112±0.023 0.098±0.019
CAMK2A 0.68±0.011 0.67±0.011 0.64±0.011 0.119±0.012 0.093±0.014 0.084±0.014
Chk1 0.71±0.017 0.70±0.020 0.69±0.022 0.062±0.022 0.055±0.014 0.060±0.019
AMPKA1 0.72±0.016 0.74±0.018 0.75±0.018 0.079±0.014 0.087±0.012 0.094±0.013
MAPKAPK2 0.78±0.019 0.79±0.014 0.80±0.016 0.141±0.028 0.089±0.015 0.076±0.021
PKD1 0.76±0.010 0.75±0.010 0.74±0.012 0.088±0.012 0.089±0.016 0.063±0.016
LKB1 0.81±0.009 0.80±0.011 0.79±0.015 0.579±0.018 0.497±0.005 0.486±0.010
C
A
M
K
MSK1 0.86±0.032 0.83±0.061 0.79±0.048 0.333±0.076 0.259±0.076 0.109±0.050
Chk2 0.62±0.020 0.61±0.023 0.59±0.021 0.027±0.010 0.018±0.008 0.017±0.007
Pim1 0.84±0.025 0.84±0.029 0.74±0.026 0.353±0.031 0.249±0.054 0.042±0.033
AMPKA2 0.86±0.028 0.82±0.028 0.81±0.033 0.116±0.037 0.051±0.018 0.057±0.021
MARK2 0.80±0.024 0.73±0.042 0.75±0.030 0.245±0.002 0.267±0.022 0.237±0.047
CAMK1A 0.83±0.016 0.83±0.016 0.82±0.019 0.423±0.065 0.423±0.065 0.345±0.062
DAPK3 0.67±0.035 0.55±0.054 0.49±0.038 0.194±0.065 0.000±0.016 0.000±0.013
CaMK4 0.79±0.032 0.79±0.032 0.71±0.085 0.000±0.000 0.000±0.000 0.000±0.000
PKD2 0.80±0.054 0.80±0.054 0.81±0.108 0.075±0.040 0.075±0.040 0.016±0.017
CAMK2D 0.83±0.041 0.83±0.041 0.81±0.095 0.250±0.000 0.250±0.000 0.176±0.036
Average 0.77±0.024 0.75±0.029 0.73±0.037 0.193±0.027 0.156±0.023 0.117±0.024
CK2A1 0.93±0.001 0.93±0.001 0.93±0.001 0.386±0.004 0.374±0.004 0.374±0.004
PLK1 0.78±0.007 0.76±0.009 0.73±0.010 0.121±0.016 0.102±0.014 0.091±0.010
AurB 0.79±0.010 0.78±0.009 0.77±0.010 0.086±0.010 0.077±0.018 0.035±0.005
AurA 0.74±0.012 0.74±0.016 0.74±0.015 0.101±0.012 0.038±0.018 0.015±0.012
PLK3 0.66±0.039 0.61±0.032 0.61±0.020 0.212±0.039 0.040±0.014 0.000±0.000
O
th
er
IKKA 0.69±0.013 0.67±0.015 0.62±0.011 0.241±0.046 0.077±0.028 0.029±0.009
IKKB 0.75±0.021 0.68±0.016 0.63±0.016 0.374±0.022 0.176±0.016 0.123±0.017
TBK1 0.76±0.032 0.73±0.026 0.68±0.027 0.296±0.041 0.218±0.036 0.098±0.030
CK2A2 0.91±0.036 0.85±0.022 0.82±0.020 0.441±0.063 0.188±0.057 0.021±0.015
IKKE 0.96±0.011 0.95±0.015 0.90±0.024 0.690±0.088 0.408±0.043 0.203±0.048
TTK 0.82±0.036 0.66±0.033 0.65±0.037 0.355±0.057 0.049±0.012 0.067±0.020
NEK6 0.78±0.021 0.78±0.021 0.76±0.026 0.309±0.035 0.309±0.035 0.160±0.050
NEK2 0.76±0.041 0.68±0.064 0.69±0.036 0.493±0.064 0.386±0.052 0.283±0.093
Average 0.80±0.021 0.76±0.022 0.73±0.02 0.32±0.038 0.19±0.027 0.12±0.024
Continued on next page
Appendix B. Supplementary material for Chapter 4 136
kinase 5% 10% 20% 5% 10% 20%
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PAK1 0.70±0.013 0.66±0.018 0.65±0.020 0.038±0.009 0.005±0.003 0.011±0.006
Cot 0.84±0.020 0.80±0.018 0.80±0.026 0.502±0.086 0.462±0.077 0.459±0.088
MST1 0.75±0.042 0.69±0.032 0.65±0.041 0.204±0.028 0.055±0.022 0.000±0.000
S
T
E
ASK1 0.82±0.021 0.70±0.028 0.69±0.035 0.392±0.061 0.142±0.059 0.135±0.055
MKK4 0.90±0.038 0.79±0.014 0.79±0.018 0.642±0.029 0.534±0.009 0.544±0.009
MST2 0.72±0.052 0.66±0.072 0.64±0.073 0.192±0.047 0.124±0.038 0.121±0.037
PAK2 0.73±0.074 0.53±0.069 0.45±0.048 0.360±0.078 0.087±0.049 0.000±0.000
MKK7 0.96±0.084 0.96±0.084 0.84±0.051 0.799±0.054 0.807±0.057 0.629±0.006
MEK1 0.72±0.050 0.72±0.050 0.66±0.041 0.466±0.009 0.468±0.007 0.478±0.009
Average 0.79±0.044 0.73±0.043 0.69±0.039 0.40±0.044 0.30±0.036 0.26±0.023
CK1A 0.78±0.009 0.75±0.009 0.73±0.013 0.195±0.011 0.097±0.018 0.085±0.016
C
K
1 CK1D 0.90±0.006 0.88±0.008 0.87±0.009 0.232±0.029 0.131±0.023 0.045±0.018
CK1E 0.87±0.018 0.82±0.026 0.76±0.018 0.415±0.059 0.188±0.050 0.023±0.020
VRK1 0.87±0.068 0.83±0.075 0.65±0.045 0.348±0.027 0.353±0.030 0.346±0.045
Average 0.86±0.025 0.82±0.029 0.75±0.021 0.30±0.03 0.19±0.03 0.12±0.025
ATM 0.95±0.002 0.95±0.002 0.95±0.002 0.277±0.017 0.267±0.011 0.308±0.015
A
ty
p
ic
al ATR 0.86±0.009 0.86±0.008 0.85±0.012 0.114±0.014 0.102±0.009 0.114±0.009
DNAPK 0.86±0.005 0.86±0.004 0.85±0.005 0.170±0.012 0.161±0.010 0.147±0.011
mTOR 0.81±0.017 0.77±0.014 0.77±0.016 0.220±0.040 0.091±0.018 0.077±0.019
Average 0.87±0.008 0.86±0.007 0.85±0.009 0.195±0.021 0.155±0.012 0.162±0.014
Table B.2: Sequence model accuracy across mouse kinases when different percentages of ki-
nase phosphorylation peptides were used to determine the set of k-mers added to the sequence
model. Table shows median AUC and AUC50 values for classifying kinase phosphorylation
sites with the sequence model as determined by 10-fold cross-validation across 10 randomised
data-set splits. Kinases are grouped according to their family, with the average prediction
accuracy for each family shown.
AUC AUC50
Kinase 5% 10% 20% 5% 10% 20%
ERK2 0.83±0.006 0.83±0.006 0.83±0.005 0.194±0.017 0.220±0.016 0.241±0.017
ERK1 0.82±0.010 0.80±0.011 0.80±0.012 0.164±0.021 0.131±0.013 0.118±0.015
CDK5 0.80±0.013 0.78±0.013 0.76±0.014 0.167±0.016 0.145±0.013 0.093±0.010
C
M
G
C CDK1 0.79±0.013 0.77±0.013 0.78±0.015 0.184±0.030 0.160±0.026 0.138±0.021
JNK1 0.78±0.014 0.76±0.014 0.76±0.017 0.219±0.040 0.169±0.027 0.173±0.025
P38A 0.74±0.017 0.72±0.015 0.69±0.018 0.226±0.028 0.202±0.031 0.117±0.021
CDK2 0.74±0.034 0.69±0.033 0.68±0.023 0.340±0.033 0.154±0.042 0.075±0.014
GSK3B 0.83±0.021 0.77±0.020 0.71±0.021 0.414±0.049 0.152±0.035 0.108±0.020
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Kinase 5% 10% 20% 5% 10% 20%
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Average 0.79±0.016 0.77±0.016 0.75±0.016 0.239±0.029 0.167±0.025 0.133±0.018
PKACA 0.81±0.007 0.79±0.006 0.79±0.006 0.245±0.014 0.242±0.015 0.251±0.009
PKCA 0.72±0.010 0.70±0.013 0.69±0.012 0.253±0.016 0.198±0.018 0.192±0.013
Akt1 0.81±0.011 0.82±0.011 0.81±0.010 0.383±0.047 0.413±0.052 0.348±0.060
PKCD 0.75±0.028 0.64±0.051 0.68±0.029 0.113±0.037 0.068±0.025 0.080±0.021
A
G
C p90RSK 0.87±0.013 0.81±0.020 0.90±0.009 0.216±0.037 0.175±0.044 0.371±0.041
RSK2 0.79±0.042 0.79±0.042 0.68±0.087 0.283±0.085 0.283±0.085 0.280±0.084
PKG1 0.66±0.042 0.66±0.042 0.36±0.043 0.000±0.000 0.000±0.000 0.000±0.000
p70S6K 0.88±0.029 0.88±0.029 0.76±0.045 0.394±0.062 0.394±0.062 0.326±0.078
PKCZ 0.69±0.095 0.69±0.095 0.47±0.108 0.286±0.114 0.286±0.114 0.071±0.110
PKCE 0.54±0.043 0.54±0.043 0.47±0.033 0.444±0.102 0.444±0.102 0.000±0.066
Average 0.75±0.032 0.73±0.035 0.66±0.038 0.262±0.052 0.25±0.052 0.192±0.048
Src 0.61±0.012 0.55±0.016 0.54±0.018 0.267±0.013 0.191±0.020 0.178±0.016
Fyn 0.64±0.018 0.63±0.013 0.66±0.015 0.307±0.027 0.253±0.037 0.335±0.038
T
K Abl 0.52±0.042 0.42±0.040 0.49±0.039 0.151±0.008 0.135±0.013 0.111±0.026
Lyn 0.65±0.027 0.66±0.028 0.65±0.028 0.286±0.029 0.298±0.026 0.247±0.025
Lck 0.64±0.060 0.53±0.072 0.64±0.050 0.271±0.056 0.177±0.066 0.265±0.070
Syk 0.71±0.014 0.60±0.029 0.61±0.022 0.601±0.024 0.299±0.073 0.336±0.026
Average 0.627±0.029 0.56±0.033 0.60±0.029 0.314±0.026 0.226±0.039 0.245±0.033
Table B.3: Sequence model accuracy across yeast kinases when different percentages of ki-
nase phosphorylation peptides were used to determine the set of k-mers added to the sequence
model. Table shows median AUC and AUC50 values for classifying kinase phosphorylation
sites with the sequence model as determined by 10-fold cross-validation across 10 randomised
data-set splits. Kinases are grouped according to their family, with the average prediction
accuracy for each family shown.
AUC AUC50
Kinase 5% 10% 20% 5% 10% 20%
CDC28 0.93±0.001 0.93±0.001 0.93±0.001 0.295±0.012 0.297±0.013 0.346±0.009
CTK1 0.70±0.008 0.69±0.008 0.69±0.007 0.434±0.000 0.432±0.001 0.432±0.000
MCK1 0.83±0.009 0.80±0.011 0.74±0.016 0.348±0.024 0.230±0.022 0.127±0.025
C
M
G
C PHO85 0.71±0.018 0.64±0.014 0.61±0.013 0.172±0.010 0.113±0.023 0.043±0.013
SSN3 0.74±0.057 0.67±0.051 0.63±0.041 0.295±0.064 0.027±0.016 0.000±0.000
HOG1 0.79±0.047 0.73±0.040 0.67±0.040 0.301±0.052 0.099±0.031 0.080±0.028
KNS1 0.93±0.038 0.83±0.032 0.69±0.065 0.591±0.056 0.333±0.085 0.083±0.055
SLT2 0.68±0.037 0.58±0.062 0.40±0.040 0.271±0.048 0.215±0.060 0.000±0.032
FUS3 0.54±0.035 0.54±0.035 0.53±0.052 0.217±0.004 0.217±0.004 0.048±0.040
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Kinase 5% 10% 20% 5% 10% 20%
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Average 0.76±0.028 0.71±0.028 0.65±0.03 0.325±0.03 0.218±0.028 0.129±0.022
TPK1 0.95±0.003 0.95±0.003 0.95±0.003 0.383±0.011 0.336±0.017 0.391±0.010
TPK3 0.81±0.036 0.76±0.033 0.71±0.039 0.595±0.058 0.426±0.040 0.359±0.048
A
G
C YPK1 0.74±0.043 0.68±0.061 0.62±0.046 0.443±0.087 0.327±0.073 0.167±0.078
PKH2 0.75±0.037 0.75±0.037 0.72±0.100 0.250±0.003 0.250±0.003 0.040±0.048
PKH1 0.98±0.006 0.98±0.006 0.88±0.026 0.750±0.000 0.750±0.000 0.500±0.037
PKC1 0.88±0.024 0.84±0.052 0.85±0.037 0.346±0.045 0.338±0.067 0.228±0.088
Average 0.85±0.025 0.83±0.032 0.79±0.042 0.461±0.034 0.405±0.033 0.281±0.051
SNF1 0.78±0.014 0.71±0.014 0.66±0.015 0.162±0.032 0.023±0.009 0.022±0.010
C
A
M
K FRK1 0.75±0.021 0.70±0.043 0.60±0.047 0.424±0.048 0.367±0.087 0.019±0.015
PSK2 0.74±0.047 0.58±0.026 0.51±0.029 0.413±0.055 0.016±0.013 0.004±0.014
DUN1 0.85±0.013 0.83±0.018 0.79±0.023 0.379±0.012 0.256±0.015 0.182±0.050
Average 0.78±0.024 0.71±0.026 0.64±0.029 0.345±0.037 0.167±0.031 0.057±0.023
CKA1 0.89±0.005 0.89±0.006 0.88±0.006 0.313±0.015 0.294±0.017 0.212±0.010
CKA2 0.91±0.007 0.91±0.007 0.90±0.007 0.355±0.017 0.314±0.011 0.251±0.013
O
th
er
MPS1 0.86±0.016 0.84±0.014 0.83±0.015 0.231±0.036 0.142±0.025 0.111±0.017
PTK1 0.67±0.015 0.64±0.025 0.56±0.024 0.139±0.020 0.047±0.010 0.029±0.010
PTK2 0.89±0.046 0.76±0.037 0.64±0.024 0.755±0.065 0.263±0.043 0.000±0.011
IPL1 0.91±0.009 0.91±0.008 0.92±0.012 0.276±0.018 0.298±0.028 0.236±0.020
BUD32 0.73±0.063 0.70±0.072 0.49±0.052 0.385±0.071 0.335±0.064 0.000±0.000
Average 0.84±0.023 0.81±0.024 0.74±0.02 0.351±0.035 0.242±0.028 0.12±0.012
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Table B.4: Sequence model accuracy for varying window sizes in human kinases, where kinases are grouped according to family.
Table shows accuracy values for classifying kinase phosphorylation sites with the sequence model as determined by 10-fold cross-
validation across 10 randomised data-set splits. Prediction accuracy is shown using median and standard deviation of the AUC and
AUC50 across the data-set splits. Varying window sizes were applied to determine the optimal window size on a kinase-specific basis.
The window size determined for a kinase is highlighted through bold text. Optimal window size was determined primarily through
AUC50 as a measure of the model’s accuracy at low false-positive rates. If accuracy did not increase through increasing window size,
the lower window size was chosen.
AUC AUC50
Kinase 7 9 11 13 15 7 9 11 13 15
CDK2 0.89±0.001 0.89±0.001 0.89±0.001 0.89±0.001 0.89±0.001 0.066±0.008 0.073±0.003 0.088±0.006 0.100±0.004 0.100±0.006
CDK1 0.89±0.002 0.89±0.001 0.89±0.001 0.89±0.001 0.89±0.002 0.071±0.008 0.053±0.008 0.055±0.005 0.045±0.004 0.059±0.007
ERK2 0.87±0.001 0.87±0.001 0.87±0.002 0.86±0.002 0.86±0.001 0.048±0.006 0.040±0.003 0.046±0.007 0.044±0.005 0.067±0.010
ERK1 0.87±0.003 0.86±0.004 0.86±0.004 0.86±0.004 0.86±0.005 0.034±0.011 0.045±0.009 0.042±0.012 0.059±0.014 0.066±0.012
GSK3B 0.72±0.006 0.80±0.005 0.81±0.007 0.81±0.006 0.81±0.008 0.031±0.004 0.096±0.008 0.127±0.014 0.132±0.014 0.117±0.013
P38A 0.83±0.005 0.83±0.005 0.82±0.004 0.81±0.006 0.81±0.007 0.091±0.020 0.142±0.017 0.145±0.016 0.135±0.015 0.151±0.017
JNK1 0.87±0.004 0.87±0.005 0.86±0.004 0.85±0.005 0.87±0.004 0.092±0.018 0.123±0.021 0.134±0.015 0.118±0.012 0.155±0.014
CDK5 0.85±0.007 0.85±0.009 0.84±0.009 0.84±0.008 0.84±0.007 0.016±0.007 0.037±0.007 0.050±0.007 0.027±0.006 0.026±0.010
C
M
G
C
JNK2 0.79±0.009 0.77±0.012 0.72±0.016 0.69±0.022 0.73±0.023 0.045±0.012 0.049±0.014 0.051±0.013 0.048±0.013 0.068±0.015
CDK7 0.70±0.031 0.76±0.024 0.84±0.022 0.89±0.018 0.88±0.019 0.094±0.039 0.254±0.067 0.326±0.052 0.307±0.040 0.310±0.032
GSK3A 0.85±0.023 0.90±0.022 0.89±0.022 0.90±0.028 0.90±0.026 0.281±0.032 0.405±0.034 0.446±0.033 0.438±0.031 0.458±0.045
CDK4 0.87±0.008 0.87±0.009 0.88±0.010 0.86±0.012 0.87±0.012 0.085±0.015 0.078±0.008 0.098±0.024 0.099±0.015 0.179±0.025
P38B 0.83±0.005 0.86±0.010 0.86±0.008 0.85±0.012 0.83±0.014 0.097±0.019 0.168±0.022 0.226±0.034 0.222±0.047 0.260±0.046
HIPK2 0.84±0.011 0.85±0.011 0.86±0.010 0.85±0.010 0.86±0.013 0.206±0.029 0.222±0.032 0.245±0.039 0.300±0.039 0.380±0.043
DYRK1A 0.76±0.021 0.78±0.020 0.83±0.026 0.84±0.029 0.83±0.033 0.000±0.013 0.107±0.017 0.206±0.028 0.248±0.038 0.260±0.043
CDK9 0.77±0.011 0.79±0.009 0.80±0.013 0.83±0.015 0.84±0.015 0.220±0.031 0.275±0.023 0.287±0.039 0.320±0.030 0.306±0.039
DYRK2 0.73±0.023 0.76±0.028 0.79±0.021 0.80±0.019 0.78±0.019 0.066±0.015 0.159±0.032 0.242±0.053 0.297±0.050 0.306±0.043
ERK5 0.73±0.027 0.79±0.024 0.82±0.020 0.83±0.017 0.83±0.016 0.000±0.000 0.043±0.020 0.257±0.045 0.272±0.038 0.317±0.034
CDK6 0.83±0.012 0.84±0.014 0.83±0.014 0.84±0.014 0.86±0.009 0.075±0.018 0.077±0.027 0.093±0.030 0.138±0.029 0.183±0.030
CDK3 0.76±0.039 0.77±0.039 0.73±0.031 0.77±0.051 0.76±0.050 0.000±0.000 0.065±0.005 0.152±0.035 0.235±0.003 0.357±0.045
PKACA 0.89±0.003 0.89±0.003 0.89±0.003 0.89±0.003 0.89±0.003 0.112±0.007 0.112±0.008 0.120±0.008 0.115±0.009 0.111±0.006
PKCA 0.81±0.004 0.83±0.003 0.83±0.003 0.84±0.001 0.84±0.001 0.118±0.006 0.120±0.005 0.107±0.009 0.133±0.009 0.123±0.009
Akt1 0.88±0.003 0.87±0.003 0.92±0.004 0.92±0.004 0.92±0.003 0.071±0.012 0.077±0.008 0.170±0.014 0.181±0.017 0.186±0.013
PKCD 0.69±0.007 0.70±0.004 0.71±0.006 0.70±0.009 0.69±0.008 0.032±0.011 0.039±0.007 0.038±0.009 0.043±0.006 0.034±0.008
PKG1 0.84±0.020 0.86±0.027 0.86±0.027 0.84±0.026 0.83±0.027 0.202±0.023 0.203±0.020 0.208±0.022 0.209±0.020 0.216±0.023
p90RSK 0.83±0.016 0.81±0.016 0.81±0.014 0.81±0.011 0.80±0.010 0.065±0.010 0.073±0.015 0.131±0.031 0.161±0.037 0.173±0.037
PKCE 0.68±0.015 0.65±0.014 0.65±0.015 0.63±0.015 0.67±0.017 0.085±0.013 0.097±0.013 0.096±0.004 0.096±0.000 0.101±0.006
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Kinase 7 9 11 13 15 7 9 11 13 15
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PKCZ 0.57±0.016 0.61±0.020 0.62±0.021 0.63±0.020 0.61±0.022 0.021±0.011 0.067±0.026 0.098±0.029 0.143±0.029 0.138±0.026
PKCB 0.72±0.022 0.71±0.019 0.68±0.016 0.70±0.017 0.73±0.016 0.099±0.025 0.127±0.028 0.099±0.025 0.122±0.029 0.116±0.023
A
G
C
RSK2 0.70±0.024 0.66±0.022 0.68±0.020 0.71±0.023 0.67±0.025 0.071±0.025 0.044±0.019 0.084±0.026 0.124±0.017 0.140±0.025
ROCK1 0.79±0.008 0.77±0.005 0.78±0.007 0.76±0.012 0.75±0.014 0.127±0.030 0.109±0.039 0.133±0.029 0.146±0.032 0.155±0.027
PDK1 0.84±0.018 0.81±0.012 0.78±0.011 0.78±0.011 0.78±0.012 0.499±0.024 0.476±0.014 0.472±0.017 0.465±0.017 0.461±0.016
PKCT 0.77±0.041 0.71±0.035 0.70±0.039 0.67±0.047 0.62±0.050 0.125±0.047 0.124±0.040 0.124±0.039 0.124±0.036 0.124±0.037
PKCG 0.61±0.022 0.63±0.022 0.65±0.029 0.64±0.029 0.65±0.024 0.000±0.025 0.004±0.050 0.035±0.059 0.067±0.054 0.108±0.064
p70S6K 0.79±0.015 0.79±0.014 0.82±0.008 0.83±0.010 0.82±0.009 0.037±0.010 0.117±0.023 0.228±0.027 0.284±0.029 0.271±0.024
SGK1 0.83±0.018 0.78±0.019 0.84±0.016 0.81±0.016 0.81±0.017 0.328±0.011 0.324±0.005 0.299±0.005 0.292±0.005 0.295±0.002
Akt2 0.84±0.019 0.82±0.012 0.85±0.014 0.87±0.012 0.85±0.013 0.162±0.034 0.151±0.026 0.141±0.021 0.159±0.020 0.120±0.029
GRK2 0.80±0.013 0.82±0.013 0.85±0.015 0.86±0.016 0.86±0.014 0.301±0.038 0.410±0.036 0.468±0.031 0.510±0.031 0.529±0.033
ROCK2 0.77±0.015 0.71±0.018 0.67±0.016 0.65±0.011 0.69±0.009 0.171±0.002 0.171±0.002 0.174±0.002 0.173±0.002 0.171±0.002
PKCI 0.81±0.023 0.80±0.021 0.80±0.018 0.82±0.017 0.80±0.018 0.160±0.049 0.162±0.048 0.158±0.048 0.158±0.051 0.170±0.047
PKCH 0.86±0.024 0.86±0.023 0.87±0.022 0.89±0.023 0.90±0.026 0.388±0.052 0.378±0.050 0.484±0.049 0.488±0.033 0.560±0.039
PKN1 0.76±0.048 0.79±0.058 0.74±0.054 0.69±0.063 0.68±0.057 0.140±0.079 0.202±0.108 0.158±0.090 0.202±0.103 0.258±0.130
Src 0.55±0.006 0.56±0.006 0.56±0.006 0.57±0.006 0.57±0.008 0.082±0.004 0.102±0.005 0.082±0.007 0.096±0.006 0.087±0.006
Abl 0.62±0.012 0.62±0.009 0.61±0.008 0.62±0.011 0.63±0.011 0.132±0.014 0.149±0.016 0.132±0.015 0.134±0.012 0.142±0.012
Fyn 0.59±0.009 0.60±0.013 0.59±0.016 0.59±0.017 0.60±0.018 0.121±0.009 0.108±0.007 0.114±0.010 0.108±0.014 0.116±0.019
Lck 0.54±0.012 0.55±0.012 0.53±0.012 0.54±0.017 0.56±0.016 0.044±0.009 0.032±0.009 0.063±0.016 0.042±0.015 0.039±0.014
Lyn 0.45±0.010 0.46±0.016 0.45±0.019 0.46±0.019 0.48±0.016 0.000±0.002 0.027±0.009 0.027±0.010 0.041±0.010 0.048±0.012
EGFR 0.51±0.017 0.50±0.019 0.51±0.024 0.56±0.023 0.54±0.026 0.022±0.009 0.032±0.012 0.036±0.012 0.050±0.018 0.030±0.013
Syk 0.73±0.016 0.74±0.015 0.77±0.020 0.79±0.018 0.81±0.018 0.174±0.019 0.178±0.023 0.216±0.024 0.235±0.026 0.266±0.025
InsR 0.68±0.024 0.69±0.026 0.64±0.020 0.63±0.014 0.64±0.016 0.229±0.014 0.351±0.025 0.349±0.022 0.346±0.020 0.340±0.017
T
K
JAK2 0.52±0.014 0.53±0.021 0.52±0.021 0.56±0.024 0.58±0.028 0.086±0.019 0.153±0.033 0.140±0.027 0.135±0.024 0.156±0.030
FAK 0.58±0.056 0.69±0.046 0.65±0.049 0.67±0.045 0.67±0.050 0.206±0.039 0.286±0.054 0.316±0.056 0.307±0.063 0.360±0.067
Ret 0.41±0.024 0.44±0.022 0.46±0.019 0.49±0.016 0.54±0.023 0.149±0.027 0.159±0.031 0.162±0.031 0.195±0.035 0.192±0.024
Arg 0.57±0.027 0.57±0.041 0.52±0.036 0.63±0.037 0.67±0.036 0.107±0.008 0.046±0.017 0.036±0.020 0.122±0.021 0.154±0.017
Brk 0.57±0.019 0.57±0.014 0.56±0.020 0.53±0.021 0.60±0.021 0.204±0.017 0.192±0.011 0.198±0.005 0.194±0.003 0.197±0.007
ALK 0.40±0.029 0.57±0.032 0.54±0.030 0.46±0.027 0.45±0.024 0.000±0.000 0.000±0.000 0.000±0.000 0.000±0.000 0.000±0.006
Btk 0.68±0.034 0.71±0.033 0.67±0.045 0.67±0.044 0.65±0.038 0.315±0.055 0.311±0.053 0.320±0.057 0.307±0.053 0.297±0.058
PDGFRB 0.64±0.031 0.61±0.034 0.62±0.032 0.64±0.031 0.61±0.033 0.165±0.013 0.162±0.031 0.154±0.031 0.206±0.036 0.255±0.040
JAK3 0.71±0.028 0.78±0.030 0.80±0.032 0.81±0.032 0.78±0.032 0.259±0.041 0.362±0.045 0.381±0.063 0.398±0.063 0.369±0.063
Hck 0.55±0.027 0.51±0.023 0.49±0.025 0.49±0.032 0.58±0.025 0.086±0.013 0.078±0.015 0.072±0.017 0.041±0.020 0.089±0.017
Pyk2 0.55±0.041 0.62±0.033 0.56±0.025 0.58±0.026 0.44±0.026 0.000±0.000 0.173±0.019 0.157±0.023 0.011±0.017 0.000±0.000
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CAMK2A 0.73±0.011 0.74±0.010 0.72±0.009 0.68±0.011 0.69±0.012 0.069±0.015 0.056±0.006 0.100±0.013 0.119±0.012 0.112±0.013
Chk1 0.69±0.023 0.67±0.030 0.68±0.023 0.68±0.022 0.71±0.017 0.048±0.012 0.046±0.011 0.055±0.013 0.058±0.020 0.062±0.022
AMPKA1 0.65±0.021 0.68±0.021 0.72±0.016 0.70±0.013 0.73±0.015 0.053±0.017 0.065±0.018 0.079±0.014 0.070±0.016 0.076±0.012
MAPKAPK2 0.81±0.020 0.79±0.020 0.78±0.019 0.78±0.021 0.77±0.023 0.080±0.026 0.082±0.027 0.141±0.028 0.132±0.020 0.121±0.017
PKD1 0.70±0.018 0.71±0.018 0.76±0.010 0.73±0.011 0.70±0.011 0.016±0.010 0.021±0.012 0.088±0.012 0.087±0.017 0.085±0.021
LKB1 0.82±0.008 0.81±0.008 0.81±0.009 0.82±0.010 0.81±0.009 0.504±0.022 0.532±0.015 0.561±0.018 0.569±0.017 0.579±0.017
C
A
M
K
MSK1 0.77±0.033 0.80±0.028 0.83±0.027 0.85±0.031 0.86±0.032 0.187±0.046 0.193±0.072 0.238±0.077 0.313±0.082 0.333±0.076
Chk2 0.56±0.022 0.59±0.027 0.61±0.023 0.59±0.020 0.62±0.020 0.000±0.000 0.009±0.007 0.018±0.009 0.017±0.007 0.027±0.010
Pim1 0.69±0.021 0.75±0.031 0.85±0.025 0.84±0.024 0.84±0.025 0.180±0.055 0.277±0.046 0.324±0.045 0.338±0.035 0.352±0.032
AMPKA2 0.75±0.026 0.79±0.031 0.84±0.028 0.86±0.028 0.85±0.029 0.004±0.006 0.038±0.016 0.051±0.017 0.116±0.037 0.118±0.040
MARK2 0.75±0.026 0.80±0.024 0.76±0.022 0.76±0.032 0.74±0.031 0.243±0.008 0.245±0.002 0.247±0.019 0.245±0.004 0.247±0.013
CAMK1A 0.82±0.021 0.81±0.016 0.83±0.016 0.76±0.018 0.74±0.018 0.397±0.067 0.396±0.067 0.423±0.064 0.426±0.044 0.425±0.064
DAPK3 0.44±0.033 0.60±0.059 0.68±0.038 0.66±0.038 0.67±0.035 0.000±0.000 0.005±0.012 0.068±0.034 0.089±0.054 0.194±0.065
CaMK4 0.78±0.018 0.79±0.032 0.74±0.028 0.70±0.027 0.65±0.036 0.000±0.000 0.000±0.000 0.000±0.000 0.000±0.000 0.000±0.000
PKD2 0.83±0.040 0.75±0.045 0.83±0.037 0.79±0.039 0.80±0.054 0.000±0.000 0.000±0.003 0.029±0.016 0.051±0.026 0.075±0.040
CAMK2D 0.73±0.031 0.70±0.033 0.71±0.038 0.80±0.034 0.83±0.041 0.144±0.019 0.240±0.004 0.245±0.002 0.250±0.000 0.250±0.000
CK2A1 0.92±0.001 0.93±0.001 0.93±0.001 0.93±0.001 0.93±0.001 0.316±0.004 0.356±0.003 0.374±0.004 0.386±0.004 0.370±0.004
PLK1 0.78±0.012 0.76±0.012 0.78±0.010 0.78±0.008 0.78±0.007 0.098±0.010 0.093±0.012 0.077±0.016 0.087±0.014 0.121±0.016
AurB 0.79±0.010 0.77±0.008 0.76±0.009 0.77±0.011 0.77±0.010 0.086±0.010 0.075±0.010 0.067±0.011 0.084±0.011 0.073±0.008
AurA 0.74±0.012 0.74±0.010 0.73±0.011 0.75±0.011 0.72±0.014 0.101±0.012 0.093±0.013 0.082±0.019 0.079±0.017 0.070±0.015
PLK3 0.65±0.032 0.64±0.037 0.64±0.041 0.62±0.039 0.66±0.039 0.031±0.020 0.020±0.025 0.066±0.023 0.140±0.031 0.212±0.039
O
t
h
e
r
IKKA 0.68±0.019 0.64±0.014 0.64±0.011 0.66±0.012 0.69±0.013 0.040±0.012 0.060±0.016 0.110±0.024 0.131±0.028 0.241±0.046
IKKB 0.62±0.013 0.68±0.013 0.73±0.010 0.76±0.018 0.75±0.021 0.026±0.006 0.135±0.014 0.243±0.030 0.313±0.026 0.374±0.022
TBK1 0.73±0.029 0.76±0.032 0.77±0.030 0.76±0.032 0.74±0.032 0.162±0.018 0.182±0.023 0.269±0.031 0.296±0.041 0.298±0.041
CK2A2 0.88±0.021 0.86±0.019 0.86±0.024 0.89±0.026 0.91±0.036 0.241±0.040 0.391±0.069 0.389±0.061 0.426±0.059 0.441±0.063
IKKE 0.96±0.015 0.97±0.012 0.96±0.010 0.96±0.012 0.96±0.011 0.206±0.027 0.489±0.080 0.663±0.087 0.669±0.090 0.690±0.088
TTK 0.61±0.025 0.72±0.026 0.82±0.031 0.82±0.036 0.81±0.047 0.045±0.019 0.098±0.025 0.266±0.026 0.355±0.057 0.351±0.052
NEK6 0.84±0.016 0.80±0.015 0.79±0.020 0.82±0.015 0.78±0.021 0.095±0.032 0.190±0.057 0.173±0.053 0.230±0.056 0.309±0.035
NEK2 0.72±0.032 0.69±0.032 0.66±0.051 0.68±0.045 0.76±0.041 0.144±0.022 0.371±0.070 0.356±0.046 0.463±0.054 0.493±0.064
PAK1 0.73±0.007 0.70±0.013 0.66±0.014 0.70±0.014 0.69±0.012 0.023±0.004 0.038±0.009 0.023±0.009 0.037±0.007 0.038±0.008
Cot 0.82±0.014 0.80±0.017 0.81±0.020 0.84±0.020 0.83±0.025 0.496±0.091 0.500±0.088 0.500±0.089 0.502±0.086 0.497±0.088
MST1 0.73±0.028 0.77±0.028 0.76±0.025 0.74±0.040 0.75±0.042 0.115±0.001 0.118±0.001 0.161±0.016 0.165±0.018 0.205±0.028
S
T
E
ASK1 0.73±0.018 0.78±0.022 0.79±0.017 0.82±0.020 0.82±0.021 0.251±0.055 0.313±0.056 0.362±0.056 0.377±0.059 0.392±0.061
MKK4 0.88±0.030 0.86±0.035 0.89±0.042 0.90±0.038 0.87±0.040 0.601±0.004 0.602±0.007 0.618±0.018 0.646±0.029 0.652±0.035
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MST2 0.75±0.055 0.65±0.052 0.65±0.047 0.70±0.052 0.72±0.052 0.123±0.035 0.161±0.038 0.161±0.037 0.159±0.037 0.192±0.047
PAK2 0.72±0.056 0.76±0.060 0.79±0.068 0.75±0.073 0.73±0.074 0.035±0.019 0.080±0.035 0.180±0.042 0.289±0.068 0.360±0.078
MKK7 0.96±0.084 0.98±0.089 0.98±0.088 0.96±0.083 0.96±0.084 0.547±0.016 0.719±0.034 0.736±0.045 0.747±0.053 0.799±0.057
MEK1 0.71±0.050 0.73±0.056 0.72±0.050 0.74±0.044 0.75±0.032 0.497±0.040 0.485±0.011 0.466±0.010 0.476±0.009 0.476±0.006
CK1A 0.76±0.014 0.76±0.014 0.77±0.013 0.78±0.011 0.78±0.009 0.058±0.010 0.066±0.012 0.100±0.014 0.166±0.013 0.195±0.011
C
K
1 CK1D 0.85±0.007 0.86±0.010 0.87±0.008 0.88±0.007 0.90±0.006 0.047±0.017 0.128±0.028 0.118±0.026 0.183±0.030 0.232±0.029
CK1E 0.82±0.021 0.82±0.018 0.83±0.021 0.83±0.019 0.87±0.018 0.157±0.027 0.205±0.056 0.303±0.055 0.346±0.047 0.415±0.059
VRK1 0.54±0.024 0.68±0.022 0.77±0.026 0.81±0.051 0.87±0.068 0.265±0.011 0.266±0.006 0.342±0.031 0.345±0.017 0.348±0.027
ATM 0.95±0.002 0.95±0.001 0.95±0.001 0.95±0.002 0.95±0.001 0.233±0.015 0.270±0.016 0.273±0.014 0.277±0.017 0.275±0.015
A
t
y
p
i
c
a
l
ATR 0.90±0.007 0.88±0.007 0.86±0.009 0.85±0.011 0.82±0.012 0.106±0.008 0.106±0.014 0.114±0.014 0.103±0.010 0.099±0.016
DNAPK 0.87±0.004 0.87±0.004 0.87±0.005 0.86±0.005 0.86±0.005 0.125±0.008 0.132±0.010 0.159±0.010 0.155±0.010 0.170±0.012
mTOR 0.69±0.015 0.74±0.016 0.76±0.018 0.77±0.020 0.81±0.017 0.113±0.034 0.156±0.040 0.184±0.039 0.186±0.040 0.220±0.040
Table B.5: Sequence model accuracy for varying window sizes in mouse kinases, where kinases are grouped according to family.
Table shows accuracy values for classifying kinase phosphorylation sites with the sequence model as determined by 10-fold cross-
validation across 10 randomised data-set splits. Prediction accuracy is shown using median and standard deviation of the AUC and
AUC50 across the data-set splits. Varying window sizes were applied to determine the optimal window size on a kinase-specific basis.
The window size determined for a kinase is highlighted through bold text. Optimal window size was determined primarily through
AUC50 as a measure of the model’s accuracy at low false-positive rates. If accuracy did not increase through increasing window size,
the lower window size was chosen.
AUC AUC50
Kinase 7 9 11 13 15 7 9 11 13 15
ERK2 0.85±0.006 0.84±0.006 0.83±0.007 0.83±0.007 0.83±0.006 0.165±0.019 0.163±0.022 0.224±0.024 0.224±0.024 0.222±0.028
ERK1 0.82±0.006 0.81±0.009 0.82±0.009 0.82±0.009 0.82±0.010 0.102±0.015 0.152±0.018 0.147±0.021 0.147±0.021 0.164±0.021
CDK5 0.81±0.006 0.80±0.012 0.77±0.010 0.77±0.010 0.72±0.009 0.141±0.014 0.128±0.014 0.172±0.013 0.172±0.013 0.184±0.014
C
M
G
C CDK1 0.79±0.013 0.79±0.017 0.78±0.016 0.78±0.016 0.76±0.017 0.184±0.030 0.171±0.023 0.165±0.020 0.165±0.020 0.138±0.011
JNK1 0.73±0.012 0.78±0.014 0.74±0.018 0.74±0.018 0.71±0.023 0.187±0.029 0.219±0.040 0.222±0.024 0.222±0.024 0.202±0.020
P38A 0.73±0.018 0.72±0.026 0.70±0.020 0.70±0.020 0.74±0.017 0.184±0.023 0.136±0.018 0.180±0.017 0.180±0.017 0.226±0.028
CDK2 0.76±0.025 0.77±0.030 0.77±0.034 0.77±0.034 0.74±0.034 0.110±0.024 0.192±0.022 0.314±0.041 0.314±0.041 0.340±0.033
GSK3B 0.67±0.018 0.76±0.021 0.85±0.020 0.85±0.020 0.83±0.021 0.106±0.020 0.196±0.032 0.391±0.059 0.391±0.059 0.414±0.049
PKACA 0.81±0.007 0.79±0.009 0.79±0.009 0.78±0.008 0.78±0.008 0.245±0.014 0.182±0.012 0.149±0.016 0.163±0.012 0.180±0.013
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PKCA 0.70±0.014 0.72±0.010 0.69±0.007 0.71±0.010 0.71±0.013 0.146±0.012 0.253±0.016 0.251±0.021 0.239±0.015 0.244±0.014
Akt1 0.80±0.019 0.81±0.022 0.81±0.011 0.81±0.014 0.81±0.020 0.187±0.027 0.222±0.042 0.383±0.047 0.373±0.059 0.358±0.052
PKCD 0.75±0.028 0.74±0.033 0.72±0.037 0.65±0.041 0.69±0.046 0.113±0.037 0.087±0.032 0.098±0.034 0.097±0.040 0.052±0.031
A
G
C
p90RSK 0.87±0.013 0.80±0.013 0.76±0.012 0.73±0.016 0.76±0.016 0.216±0.037 0.236±0.044 0.237±0.037 0.241±0.049 0.290±0.031
RSK2 0.79±0.042 0.75±0.051 0.68±0.069 0.64±0.073 0.60±0.067 0.283±0.085 0.286±0.086 0.284±0.085 0.284±0.085 0.284±0.085
PKG1 0.66±0.042 0.66±0.040 0.56±0.035 0.58±0.024 0.67±0.024 0.000±0.000 0.000±0.001 0.000±0.000 0.000±0.000 0.000±0.004
p70S6K 0.81±0.035 0.79±0.039 0.84±0.033 0.88±0.029 0.86±0.035 0.393±0.062 0.396±0.064 0.391±0.039 0.394±0.062 0.377±0.074
PKCZ 0.64±0.076 0.66±0.070 0.69±0.098 0.63±0.087 0.69±0.095 0.087±0.041 0.134±0.055 0.137±0.057 0.277±0.111 0.286±0.114
PKCE 0.51±0.032 0.53±0.039 0.55±0.049 0.55±0.052 0.54±0.043 0.251±0.072 0.222±0.066 0.324±0.087 0.432±0.100 0.444±0.102
Src 0.54±0.016 0.57±0.014 0.61±0.012 0.60±0.014 0.57±0.011 0.160±0.019 0.215±0.022 0.267±0.013 0.273±0.012 0.248±0.013
Fyn 0.64±0.018 0.66±0.016 0.66±0.015 0.62±0.013 0.63±0.014 0.307±0.027 0.284±0.031 0.262±0.034 0.265±0.025 0.283±0.039
T
K
Abl 0.52±0.042 0.39±0.039 0.38±0.023 0.38±0.030 0.40±0.029 0.151±0.008 0.155±0.004 0.154±0.005 0.151±0.007 0.166±0.005
Lyn 0.58±0.027 0.61±0.022 0.64±0.021 0.65±0.027 0.64±0.031 0.191±0.025 0.281±0.025 0.279±0.026 0.286±0.029 0.248±0.028
Lck 0.65±0.040 0.64±0.056 0.64±0.060 0.64±0.070 0.62±0.070 0.199±0.060 0.193±0.059 0.270±0.056 0.228±0.059 0.186±0.048
Syk 0.65±0.035 0.71±0.025 0.69±0.023 0.72±0.015 0.71±0.014 0.261±0.025 0.311±0.025 0.411±0.055 0.576±0.037 0.601±0.024
Table B.6: Sequence model accuracy for varying window sizes in yeast kinases, where kinases are grouped according to family.
Table shows accuracy values for classifying kinase phosphorylation sites with the sequence model as determined by 10-fold cross-
validation across 10 randomised data-set splits. Prediction accuracy is shown using median and standard deviation of the AUC and
AUC50 across the data-set splits. Varying window sizes were applied to determine the optimal window size on a kinase-specific basis.
The window size determined for a kinase is highlighted through bold text. Optimal window size was determined primarily through
AUC50 as a measure of the model’s accuracy at low false-positive rates. If accuracy did not increase through increasing window size,
the lower window size was chosen.
AUC AUC50
Kinase 7 9 11 13 15 7 9 11 13 15
CDC28 0.93±0.001 0.93±0.001 0.93±0.001 0.93±0.001 0.93±0.001 0.243±0.008 0.242±0.008 0.234±0.010 0.262±0.013 0.295±0.012
CTK1 0.72±0.011 0.70±0.012 0.70±0.012 0.70±0.008 0.71±0.009 0.418±0.001 0.417±0.002 0.421±0.002 0.434±0.000 0.430±0.002
MCK1 0.73±0.021 0.79±0.014 0.80±0.012 0.82±0.007 0.83±0.009 0.141±0.020 0.209±0.027 0.261±0.026 0.324±0.016 0.348±0.024
C
M
G
C
PHO85 0.66±0.013 0.70±0.013 0.72±0.018 0.71±0.023 0.71±0.018 0.097±0.014 0.094±0.023 0.124±0.010 0.154±0.010 0.172±0.010
SSN3 0.69±0.053 0.72±0.051 0.76±0.042 0.73±0.052 0.74±0.057 0.044±0.027 0.204±0.051 0.230±0.052 0.296±0.063 0.295±0.064
HOG1 0.66±0.042 0.66±0.046 0.70±0.049 0.75±0.046 0.79±0.047 0.042±0.015 0.048±0.027 0.063±0.024 0.208±0.065 0.301±0.052
KNS1 0.88±0.031 0.92±0.024 0.93±0.028 0.92±0.032 0.93±0.038 0.268±0.023 0.431±0.044 0.506±0.047 0.521±0.055 0.591±0.056
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Kinase 7 9 11 13 15 7 9 11 13 15
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SLT2 0.61±0.030 0.62±0.043 0.61±0.036 0.63±0.032 0.68±0.037 0.008±0.016 0.059±0.002 0.089±0.030 0.263±0.041 0.271±0.048
FUS3 0.54±0.025 0.54±0.035 0.51±0.031 0.45±0.025 0.47±0.029 0.108±0.036 0.217±0.004 0.220±0.002 0.222±0.000 0.222±0.000
TPK1 0.95±0.003 0.95±0.003 0.95±0.004 0.94±0.004 0.93±0.005 0.355±0.017 0.383±0.011 0.373±0.010 0.360±0.010 0.382±0.013
TPK3 0.72±0.045 0.74±0.034 0.78±0.039 0.76±0.032 0.81±0.036 0.206±0.046 0.309±0.062 0.440±0.071 0.525±0.074 0.595±0.058
A
G
C
YPK1 0.76±0.037 0.80±0.039 0.80±0.045 0.74±0.043 0.68±0.037 0.241±0.052 0.303±0.076 0.352±0.091 0.443±0.087 0.398±0.083
PKH2 0.74±0.054 0.75±0.037 0.72±0.053 0.68±0.048 0.64±0.048 0.240±0.004 0.250±0.003 0.250±0.000 0.250±0.000 0.249±2.776e-17
PKH1 0.95±0.020 0.96±0.014 0.97±0.007 0.98±0.006 0.96±0.010 0.738±0.003 0.745±0.003 0.749±0.002 0.750±0.000 0.750±0.000
PKC1 0.88±0.024 0.89±0.017 0.87±0.010 0.90±0.016 0.87±0.020 0.346±0.045 0.269±0.058 0.192±0.044 0.228±0.044 0.232±0.045
SNF1 0.73±0.013 0.73±0.013 0.74±0.020 0.76±0.018 0.78±0.014 0.040±0.009 0.040±0.009 0.078±0.027 0.153±0.035 0.162±0.032
C
A
M
K FRK1 0.68±0.026 0.68±0.026 0.68±0.027 0.73±0.021 0.75±0.021 0.181±0.038 0.181±0.038 0.371±0.050 0.404±0.050 0.424±0.048
PSK2 0.71±0.027 0.71±0.027 0.73±0.040 0.73±0.047 0.74±0.047 0.374±0.044 0.374±0.044 0.393±0.049 0.402±0.050 0.413±0.055
DUN1 0.87±0.012 0.87±0.012 0.85±0.013 0.85±0.015 0.87±0.015 0.273±0.016 0.273±0.016 0.379±0.012 0.374±0.011 0.358±0.009
CKA1 0.90±0.003 0.90±0.003 0.90±0.003 0.89±0.005 0.89±0.005 0.200±0.019 0.210±0.013 0.248±0.014 0.287±0.018 0.313±0.015
CKA2 0.92±0.005 0.91±0.006 0.91±0.006 0.91±0.006 0.91±0.007 0.154±0.015 0.199±0.011 0.276±0.015 0.334±0.014 0.355±0.017
O
t
h
e
r
MPS1 0.83±0.013 0.83±0.016 0.83±0.020 0.86±0.015 0.86±0.016 0.078±0.017 0.122±0.017 0.155±0.032 0.174±0.033 0.231±0.036
PTK1 0.61±0.015 0.63±0.017 0.62±0.020 0.67±0.013 0.67±0.015 0.024±0.011 0.050±0.009 0.048±0.011 0.088±0.013 0.139±0.020
PTK2 0.79±0.027 0.81±0.034 0.86±0.045 0.86±0.042 0.89±0.046 0.302±0.049 0.419±0.033 0.517±0.049 0.640±0.049 0.755±0.065
IPL1 0.91±0.009 0.89±0.013 0.87±0.013 0.83±0.012 0.83±0.016 0.276±0.018 0.200±0.027 0.232±0.041 0.158±0.031 0.139±0.027
BUD32 0.61±0.076 0.63±0.070 0.72±0.070 0.73±0.063 0.74±0.069 0.020±0.029 0.177±0.044 0.315±0.067 0.385±0.071 0.310±0.071
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Table B.7: Comparison of prediction accuracy across human kinases between predicting
kinase-specific phosphorylation sites with a baseline model that only considers position-specific
amino acid frequencies, and the sequence model. Kinases are grouped according to their
family, with the average prediction accuracy for each family included. Results were generated
using ten-fold cross-validation repeated across ten randomised data-set splits. Shown are the
average and standard deviation of the AUC and AUC50 values.
AUC AUC50
Kinase Baseline Sequence model Baseline Sequence model
CDK2 0.86±0.001 0.89±0.001 0.06±0.002 0.10±0.004
CDK1 0.88±0.002 0.89±0.002 0.09±0.004 0.07±0.008
ERK2 0.86±0.002 0.86±0.001 0.05±0.004 0.07±0.010
ERK1 0.86±0.005 0.86±0.005 0.04±0.005 0.07±0.012
GSK3B 0.77±0.009 0.81±0.006 0.09±0.007 0.13±0.014
P38A 0.79±0.007 0.81±0.007 0.12±0.016 0.15±0.017
JNK1 0.83±0.005 0.87±0.004 0.08±0.013 0.15±0.014
CDK5 0.84±0.012 0.84±0.009 0.07±0.009 0.05±0.007
C
M
G
C
JNK2 0.75±0.015 0.73±0.023 0.03±0.013 0.07±0.015
CDK7 0.77±0.017 0.88±0.019 0.16±0.044 0.31±0.032
GSK3A 0.89±0.014 0.90±0.026 0.26±0.020 0.46±0.045
CDK4 0.85±0.012 0.87±0.012 0.07±0.007 0.18±0.025
P38B 0.79±0.006 0.83±0.014 0.07±0.015 0.26±0.046
HIPK2 0.81±0.016 0.86±0.013 0.23±0.030 0.38±0.043
DYRK1A 0.77±0.034 0.83±0.033 0.01±0.024 0.26±0.043
CDK9 0.78±0.011 0.83±0.015 0.04±0.022 0.32±0.030
DYRK2 0.68±0.032 0.78±0.019 0.00±0.000 0.31±0.043
ERK5 0.79±0.015 0.83±0.016 0.02±0.014 0.32±0.034
CDK6 0.80±0.019 0.86±0.009 0.07±0.016 0.18±0.030
CDK3 0.69±0.031 0.76±0.050 0.00±0.000 0.36±0.045
Average 0.80±0.013 0.84±0.014 0.078±0.013 0.21±0.026
PKACA 0.89±0.003 0.89±0.003 0.10±0.005 0.12±0.008
PKCA 0.82±0.004 0.84±0.001 0.10±0.004 0.13±0.009
Akt1 0.91±0.005 0.92±0.004 0.23±0.014 0.18±0.017
PKCD 0.67±0.011 0.70±0.009 0.05±0.007 0.04±0.006
PKG1 0.86±0.019 0.86±0.027 0.25±0.035 0.20±0.020
p90RSK 0.74±0.022 0.80±0.010 0.05±0.010 0.17±0.037
PKCE 0.59±0.015 0.67±0.017 0.07±0.018 0.10±0.006
PKCZ 0.55±0.022 0.63±0.020 0.01±0.007 0.14±0.029
PKCB 0.64±0.025 0.71±0.019 0.11±0.018 0.13±0.028
A
G
C
RSK2 0.68±0.031 0.71±0.023 0.08±0.012 0.12±0.017
ROCK1 0.71±0.008 0.76±0.012 0.15±0.023 0.15±0.032
PDK1 0.85±0.020 0.84±0.018 0.46±0.009 0.50±0.024
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Kinase Baseline Sequence model Baseline Sequence model
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PKCT 0.80±0.025 0.77±0.041 0.11±0.037 0.12±0.047
PKCG 0.62±0.023 0.65±0.024 0.01±0.007 0.11±0.064
p70S6K 0.78±0.013 0.83±0.010 0.11±0.026 0.28±0.029
SGK1 0.83±0.018 0.83±0.018 0.28±0.045 0.33±0.011
Akt2 0.82±0.023 0.87±0.012 0.11±0.036 0.16±0.020
GRK2 0.73±0.014 0.86±0.014 0.09±0.028 0.53±0.033
ROCK2 0.78±0.015 0.77±0.015 0.13±0.012 0.17±0.002
PKCI 0.82±0.017 0.81±0.023 0.28±0.049 0.16±0.049
PKCH 0.83±0.027 0.90±0.026 0.32±0.059 0.56±0.038
PKN1 0.77±0.021 0.79±0.058 0.29±0.148 0.20±0.108
Average 0.76±0.017 0.79±0.018 0.154±0.028 0.21±0.029
Src 0.53±0.004 0.56±0.006 0.07±0.004 0.10±0.005
Abl 0.58±0.011 0.62±0.009 0.11±0.007 0.15±0.016
Fyn 0.54±0.011 0.59±0.009 0.10±0.008 0.12±0.009
Lck 0.54±0.014 0.53±0.012 0.05±0.009 0.06±0.016
Lyn 0.50±0.017 0.48±0.016 0.08±0.011 0.05±0.012
EGFR 0.54±0.015 0.56±0.023 0.06±0.005 0.05±0.018
Syk 0.78±0.018 0.81±0.018 0.27±0.020 0.27±0.025
InsR 0.61±0.030 0.69±0.026 0.21±0.020 0.35±0.025
T
K
JAK2 0.50±0.018 0.58±0.028 0.10±0.016 0.16±0.030
FAK 0.44±0.025 0.67±0.050 0.09±0.030 0.36±0.067
Ret 0.43±0.026 0.54±0.023 0.17±0.027 0.19±0.025
Arg 0.66±0.039 0.67±0.036 0.15±0.022 0.15±0.017
Brk 0.56±0.016 0.60±0.021 0.15±0.026 0.20±0.007
ALK 0.49±0.021 0.57±0.032 0.04±0.020 0.00±0.000
Btk 0.60±0.036 0.71±0.033 0.14±0.044 0.31±0.053
PDGFRB 0.59±0.017 0.61±0.033 0.09±0.043 0.25±0.040
JAK3 0.63±0.040 0.81±0.032 0.19±0.053 0.40±0.063
Hck 0.51±0.026 0.58±0.025 0.08±0.022 0.09±0.017
Pyk2 0.64±0.027 0.62±0.033 0.00±0.021 0.17±0.019
Average 0.56±0.022 0.62±0.025 0.11±0.021 0.18±0.024
CAMK2A 0.64±0.011 0.68±0.011 0.10±0.011 0.12±0.012
Chk1 0.69±0.022 0.71±0.017 0.07±0.017 0.06±0.022
AMPKA1 0.75±0.019 0.72±0.016 0.10±0.014 0.08±0.014
MAPKAPK2 0.79±0.016 0.78±0.019 0.08±0.020 0.14±0.028
C
A
M
K PKD1 0.75±0.015 0.76±0.010 0.08±0.014 0.09±0.012
LKB1 0.77±0.013 0.81±0.009 0.47±0.003 0.58±0.018
MSK1 0.76±0.044 0.86±0.032 0.10±0.049 0.33±0.076
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Chk2 0.59±0.023 0.62±0.020 0.03±0.008 0.03±0.010
Pim1 0.72±0.018 0.84±0.025 0.01±0.010 0.35±0.031
AMPKA2 0.81±0.031 0.86±0.028 0.07±0.024 0.12±0.037
MARK2 0.80±0.024 0.80±0.024 0.26±0.020 0.24±0.002
CAMK1A 0.86±0.015 0.83±0.016 0.41±0.017 0.42±0.065
DAPK3 0.47±0.035 0.67±0.035 0.00±0.010 0.19±0.065
CaMK4 0.76±0.028 0.79±0.032 0.00±0.000 0.00±0.000
PKD2 0.84±0.038 0.80±0.054 0.02±0.011 0.07±0.040
CAMK2D 0.72±0.022 0.83±0.041 0.00±0.000 0.25±0.000
Average 0.73±0.023 0.77±0.024 0.11±0.014 0.19±0.027
CK2A1 0.93±0.002 0.93±0.001 0.36±0.005 0.39±0.004
PLK1 0.72±0.010 0.78±0.007 0.07±0.013 0.12±0.016
AurB 0.77±0.010 0.79±0.010 0.05±0.008 0.09±0.010
AurA 0.73±0.016 0.74±0.012 0.02±0.012 0.10±0.012
PLK3 0.55±0.019 0.66±0.039 0.00±0.000 0.21±0.039
O
th
er
IKKA 0.53±0.010 0.69±0.013 0.00±0.005 0.24±0.046
IKKB 0.52±0.017 0.75±0.021 0.01±0.010 0.37±0.022
TBK1 0.59±0.038 0.76±0.032 0.04±0.016 0.30±0.041
CK2A2 0.81±0.015 0.91±0.036 0.08±0.022 0.44±0.063
IKKE 0.82±0.038 0.96±0.011 0.09±0.015 0.69±0.088
TTK 0.60±0.025 0.82±0.036 0.05±0.016 0.35±0.057
NEK6 0.77±0.020 0.78±0.021 0.08±0.033 0.31±0.035
NEK2 0.63±0.024 0.76±0.041 0.00±0.019 0.49±0.064
Average 0.69±0.019 0.8±0.021 0.066±0.013 0.32±0.038
PAK1 0.69±0.012 0.70±0.013 0.03±0.007 0.04±0.009
Cot 0.79±0.022 0.84±0.020 0.48±0.098 0.50±0.086
MST1 0.61±0.035 0.75±0.042 0.00±0.014 0.20±0.028
S
T
E
ASK1 0.64±0.048 0.82±0.021 0.14±0.047 0.39±0.061
MKK4 0.86±0.012 0.90±0.038 0.54±0.035 0.64±0.029
MST2 0.64±0.035 0.72±0.052 0.12±0.035 0.19±0.047
PAK2 0.64±0.031 0.73±0.074 0.00±0.000 0.36±0.078
MKK7 0.78±0.032 0.96±0.084 0.54±0.004 0.80±0.054
MEK1 0.83±0.039 0.72±0.050 0.50±0.115 0.47±0.009
Average 0.71±0.031 0.79±0.052 0.228±0.049 0.38±0.053
CK1A 0.70±0.014 0.78±0.009 0.08±0.014 0.19±0.011
C
K
1 CK1D 0.84±0.008 0.90±0.006 0.07±0.019 0.23±0.029
CK1E 0.72±0.027 0.87±0.018 0.05±0.021 0.42±0.059
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VRK1 0.72±0.032 0.87±0.068 0.29±0.022 0.35±0.027
Average 0.75±0.02 0.86±0.025 0.124±0.019 0.30±0.031
ATM 0.95±0.002 0.95±0.002 0.37±0.014 0.28±0.017
A
ty
p
ic
al ATR 0.86±0.008 0.86±0.009 0.14±0.009 0.11±0.014
DNAPK 0.83±0.008 0.86±0.005 0.13±0.005 0.17±0.012
mTOR 0.72±0.019 0.81±0.017 0.08±0.003 0.22±0.040
Average 0.84±0.009 0.87±0.008 0.18±0.008 0.20±0.029
Table B.8: Comparison of prediction accuracy across mouse kinases between predicting
kinase-specific phosphorylation sites with a baseline model that only considers position-specific
amino acid frequencies, and the sequence model. Kinases are grouped according to their
family, with the average prediction accuracy for each family included. Results were generated
using ten-fold cross-validation repeated across ten randomised data-set splits. Shown are the
average and standard deviation of the AUC and AUC50 values.
AUC AUC50
Kinase Baseline Sequence model Baseline Sequence model
ERK2 0.81±0.006 0.83±0.006 0.27±0.011 0.19±0.017
ERK1 0.78±0.011 0.82±0.010 0.19±0.018 0.16±0.021
CDK5 0.73±0.013 0.80±0.013 0.09±0.015 0.17±0.016
C
M
G
C CDK1 0.76±0.022 0.79±0.013 0.17±0.018 0.18±0.030
JNK1 0.74±0.019 0.78±0.014 0.13±0.018 0.22±0.040
P38A 0.67±0.021 0.74±0.017 0.10±0.022 0.23±0.028
CDK2 0.76±0.020 0.74±0.034 0.10±0.020 0.34±0.033
GSK3B 0.70±0.018 0.83±0.021 0.07±0.011 0.41±0.049
Average 0.74±0.016 0.79±0.016 0.14±0.017 0.24±0.029
PKACA 0.78±0.006 0.81±0.007 0.22±0.014 0.25±0.014
PKCA 0.67±0.014 0.72±0.010 0.15±0.011 0.25±0.016
Akt1 0.82±0.015 0.81±0.011 0.34±0.049 0.38±0.047
PKCD 0.71±0.014 0.75±0.028 0.13±0.024 0.11±0.037
A
G
C p90RSK 0.90±0.015 0.87±0.013 0.31±0.048 0.22±0.037
RSK2 0.80±0.056 0.79±0.042 0.29±0.087 0.28±0.085
PKG1 0.70±0.023 0.66±0.042 0.12±0.049 0.00±0.000
p70S6K 0.82±0.032 0.88±0.029 0.18±0.062 0.39±0.062
PKCZ 0.61±0.050 0.69±0.095 0.00±0.000 0.29±0.114
PKCE 0.38±0.028 0.54±0.043 0.00±0.000 0.44±0.102
Average 0.72±0.025 0.75±0.032 0.17±0.034 0.26±0.051
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Src 0.52±0.021 0.61±0.012 0.17±0.024 0.27±0.013
Fyn 0.66±0.018 0.64±0.018 0.33±0.030 0.31±0.027
T
K Abl 0.49±0.035 0.52±0.042 0.15±0.025 0.15±0.008
Lyn 0.66±0.023 0.65±0.027 0.25±0.026 0.29±0.029
Lck 0.72±0.030 0.64±0.060 0.32±0.046 0.27±0.056
Syk 0.57±0.023 0.71±0.014 0.33±0.041 0.60±0.024
Average 0.60±0.025 0.63±0.029 0.26±0.032 0.31±0.026
Table B.9: Comparison of prediction accuracy across yeast kinases between predicting
kinase-specific phosphorylation sites with a baseline model that only considers position-specific
amino acid frequencies, and the sequence model. Kinases are grouped according to their
family, with the average prediction accuracy for each family included. Results were generated
using ten-fold cross-validation repeated across ten randomised data-set splits. Shown are the
average and standard deviation of the AUC and AUC50 values.
AUC AUC50
Kinase Baseline Sequence model Baseline Sequence model
CDC28 0.93±0.001 0.93±0.001 0.30±0.003 0.29±0.012
CTK1 0.75±0.009 0.70±0.008 0.47±0.004 0.43±0.000
MCK1 0.69±0.026 0.83±0.009 0.06±0.009 0.35±0.024
C
M
G
C PHO85 0.64±0.014 0.71±0.018 0.06±0.010 0.17±0.010
SSN3 0.54±0.035 0.74±0.057 0.00±0.000 0.29±0.064
HOG1 0.62±0.034 0.79±0.047 0.07±0.022 0.30±0.052
KNS1 0.78±0.038 0.93±0.038 0.01±0.008 0.59±0.056
SLT2 0.56±0.039 0.68±0.037 0.00±0.011 0.27±0.048
FUS3 0.51±0.055 0.54±0.035 0.00±0.000 0.22±0.004
Average 0.67±0.028 0.76±0.028 0.11±0.007 0.32±0.03
TPK1 0.94±0.004 0.95±0.003 0.39±0.013 0.38±0.011
TPK3 0.63±0.040 0.81±0.036 0.19±0.014 0.60±0.058
A
G
C YPK1 0.63±0.018 0.74±0.043 0.03±0.024 0.44±0.087
PKH2 0.77±0.028 0.75±0.037 0.07±0.046 0.25±0.003
PKH1 0.91±0.013 0.98±0.006 0.55±0.024 0.75±0.000
PKC1 0.87±0.014 0.88±0.024 0.19±0.039 0.35±0.045
Average 0.79±0.02 0.85±0.025 0.24±0.027 0.46±0.034
SNF1 0.68±0.011 0.78±0.014 0.01±0.004 0.16±0.032
T
K FRK1 0.57±0.032 0.75±0.021 0.00±0.000 0.42±0.048
PSK2 0.59±0.026 0.74±0.047 0.12±0.043 0.41±0.055
DUN1 0.73±0.027 0.85±0.013 0.07±0.020 0.38±0.012
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Average 0.64±0.024 0.78±0.024 0.05±0.017 0.34±0.037
CKA1 0.90±0.003 0.89±0.005 0.18±0.014 0.31±0.015
CKA2 0.91±0.006 0.91±0.007 0.17±0.014 0.36±0.017
O
th
er
MPS1 0.82±0.017 0.86±0.016 0.09±0.021 0.23±0.036
PTK1 0.58±0.014 0.67±0.015 0.00±0.005 0.14±0.020
PTK2 0.66±0.019 0.89±0.046 0.00±0.000 0.75±0.065
IPL1 0.91±0.010 0.91±0.009 0.28±0.017 0.28±0.018
BUD32 0.39±0.049 0.73±0.063 0.00±0.000 0.39±0.071
Average 0.74±0.017 0.84±0.023 0.10±0.01 0.35±0.035
Table B.10: Comparison of prediction accuracy across human kinases between predicting
kinase-specific phosphorylation sites using the sequence model trained on the full data-set,
and when the model is trained on the similarity-reduced data-set. Prediction accuracy is
calculated on the similarity-reduced data-set. If a kinase could not be trained on the reduced
data-set due to too few positive training samples it was marked as “N/A”. Kinases are grouped
according to their family, with the average prediction accuracy for each family included.
Results were generated using ten-fold cross-validation repeated across ten randomised data-
set splits. Shown are the average and standard deviation of the AUC and AUC50 values.
AUC AUC50
Kinase Full set Reduced set Full set Reduced set
CDK2 0.89±0.001 0.89±0.001 0.10±0.003 0.10±0.009
CDK1 0.89±0.002 0.90±0.001 0.08±0.008 0.09±0.007
ERK2 0.86±0.002 0.86±0.002 0.07±0.011 0.06±0.007
ERK1 0.85±0.005 0.85±0.002 0.06±0.010 0.05±0.008
GSK3B 0.81±0.006 0.81±0.004 0.14±0.016 0.13±0.007
P38A 0.81±0.008 0.80±0.007 0.14±0.015 0.11±0.022
JNK1 0.86±0.005 0.86±0.006 0.17±0.016 0.16±0.023
CDK5 0.84±0.010 0.83±0.008 0.04±0.004 0.03±0.006
C
M
G
C
JNK2 0.72±0.023 0.71±0.017 0.05±0.012 0.02±0.013
CDK7 0.86±0.022 0.85±0.023 0.23±0.038 0.25±0.060
GSK3A 0.89±0.028 0.91±0.023 0.46±0.050 0.45±0.052
CDK4 0.87±0.012 0.86±0.010 0.18±0.025 0.15±0.029
P38B 0.83±0.014 0.84±0.014 0.26±0.045 0.27±0.022
HIPK2 0.85±0.015 0.85±0.009 0.34±0.046 0.27±0.044
DYRK1A 0.83±0.033 0.84±0.027 0.26±0.045 0.27±0.065
CDK9 0.82±0.017 0.80±0.017 0.34±0.033 0.31±0.033
DYRK2 0.78±0.019 0.80±0.028 0.31±0.042 0.28±0.066
ERK5 0.82±0.017 0.84±0.024 0.31±0.034 0.34±0.036
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Kinase Full set Reduced set Full set Reduced set
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CDK6 0.85±0.009 0.83±0.012 0.17±0.027 0.09±0.033
CDK3 0.73±0.057 0.66±0.061 0.28±0.054 0.14±0.012
Average 0.84±0.015 0.83±0.015 0.198±0.027 0.178±0.027
PKACA 0.89±0.003 0.89±0.002 0.12±0.007 0.11±0.004
PKCA 0.84±0.001 0.83±0.002 0.12±0.009 0.13±0.006
Akt1 0.91±0.004 0.91±0.003 0.18±0.018 0.18±0.012
PKCD 0.70±0.009 0.69±0.007 0.04±0.007 0.04±0.009
PKG1 0.84±0.026 0.82±0.013 0.12±0.023 0.07±0.018
PKCB 0.71±0.020 0.70±0.029 0.12±0.022 0.12±0.021
PKCE 0.66±0.018 0.64±0.025 0.06±0.006 0.02±0.012
p90RSK 0.78±0.011 0.76±0.012 0.16±0.036 0.19±0.041
PKCZ 0.62±0.020 0.64±0.034 0.13±0.026 0.14±0.022
ROCK1 0.74±0.012 0.73±0.016 0.15±0.030 0.09±0.024
GRK2 0.86±0.015 0.85±0.011 0.52±0.034 0.51±0.044
A
G
C
RSK2 0.72±0.021 0.72±0.028 0.11±0.014 0.11±0.021
PDK1 0.79±0.024 0.75±0.026 0.35±0.023 0.32±0.014
p70S6K 0.82±0.010 0.83±0.021 0.26±0.029 0.25±0.052
PKCG 0.65±0.023 0.62±0.025 0.11±0.064 0.13±0.042
PKCT 0.77±0.045 0.75±0.020 0.14±0.052 0.14±0.002
SGK1 0.81±0.020 0.77±0.020 0.27±0.009 0.23±0.029
Akt2 0.86±0.015 0.84±0.021 0.19±0.023 0.20±0.015
ROCK2 0.76±0.015 0.77±0.019 0.18±0.000 0.18±0.071
PKCH 0.88±0.030 0.89±0.034 0.51±0.047 0.49±0.074
PKCI 0.81±0.022 0.80±0.034 0.16±0.049 0.16±0.064
PKN1 N/A N/A N/A N/A
Average 0.78±0.017 0.77±0.019 0.19±0.025 0.181±0.028
Src 0.55±0.006 0.55±0.006 0.09±0.004 0.08±0.009
Abl 0.62±0.009 0.62±0.011 0.14±0.015 0.15±0.012
Fyn 0.59±0.009 0.57±0.012 0.12±0.010 0.12±0.008
Lck 0.53±0.013 0.50±0.016 0.06±0.013 0.05±0.013
EGFR 0.55±0.023 0.52±0.011 0.04±0.015 0.06±0.020
InsR N/A N/A N/A N/A
Lyn 0.48±0.016 0.48±0.021 0.03±0.008 0.02±0.008
Syk 0.81±0.018 0.81±0.013 0.28±0.027 0.27±0.019
T
K
JAK2 0.57±0.027 0.55±0.021 0.14±0.027 0.14±0.016
Ret 0.50±0.027 0.53±0.026 0.12±0.026 0.18±0.036
PDGFRB 0.61±0.033 0.63±0.048 0.26±0.040 0.26±0.051
Hck 0.53±0.028 0.54±0.023 0.07±0.018 0.11±0.023
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Btk 0.74±0.039 0.73±0.024 0.28±0.046 0.20±0.025
FAK 0.67±0.050 0.63±0.032 0.36±0.067 0.35±0.067
Arg 0.67±0.037 0.67±0.033 0.16±0.018 0.18±0.054
JAK3 0.82±0.031 0.79±0.035 0.40±0.062 0.33±0.072
Brk 0.60±0.021 0.61±0.045 0.20±0.007 0.19±0.052
ALK 0.57±0.033 0.55±0.069 0.00±0.000 0.00±0.006
Pyk2 0.62±0.033 0.61±0.091 0.18±0.019 0.18±0.062
Average 0.61±0.025 0.60±0.03 0.163±0.023 0.160±0.03
CAMK2A 0.66±0.011 0.63±0.026 0.11±0.011 0.10±0.022
Chk1 0.70±0.018 0.68±0.011 0.04±0.019 0.03±0.013
AMPKA1 0.72±0.015 0.70±0.018 0.09±0.014 0.09±0.017
MAPKAPK2 0.77±0.019 0.78±0.011 0.09±0.026 0.12±0.013
Chk2 0.62±0.020 0.63±0.026 0.03±0.010 0.02±0.011
C
A
M
K PKD1 0.77±0.011 0.76±0.020 0.07±0.013 0.06±0.021
LKB1 0.73±0.013 0.73±0.026 0.41±0.027 0.43±0.035
MSK1 0.85±0.026 0.84±0.047 0.36±0.085 0.41±0.055
CAMK1A 0.81±0.018 0.79±0.022 0.37±0.037 0.24±0.002
Pim1 0.85±0.024 0.87±0.012 0.39±0.036 0.40±0.032
CaMK4 0.79±0.036 0.80±0.054 0.00±0.000 0.00±0.000
DAPK3 0.67±0.035 0.71±0.028 0.19±0.065 0.22±0.052
AMPKA2 0.86±0.030 0.87±0.021 0.13±0.040 0.14±0.025
MARK2 0.76±0.029 0.67±0.021 0.10±0.001 0.01±0.017
PKD2 0.79±0.054 0.79±0.025 0.08±0.042 0.08±0.027
CAMK2D 0.83±0.041 0.84±0.035 0.25±0.000 0.25±0.100
Average 0.76±0.025 0.76±0.025 0.169±0.026 0.16±0.028
CK2A1 0.93±0.001 0.93±0.002 0.38±0.003 0.38±0.003
PLK1 0.78±0.007 0.77±0.009 0.12±0.016 0.12±0.016
AurB 0.79±0.010 0.78±0.008 0.07±0.010 0.06±0.009
AurA 0.75±0.013 0.74±0.012 0.11±0.013 0.11±0.016
PLK3 0.66±0.039 0.66±0.025 0.22±0.040 0.21±0.044
O
th
er
IKKA 0.69±0.013 0.68±0.015 0.24±0.046 0.23±0.030
IKKB 0.75±0.021 0.75±0.015 0.37±0.022 0.37±0.017
TBK1 0.79±0.034 0.81±0.014 0.31±0.043 0.33±0.053
CK2A2 0.91±0.036 0.92±0.022 0.44±0.063 0.48±0.030
IKKE 0.96±0.011 0.95±0.016 0.69±0.088 0.68±0.038
TTK 0.84±0.038 0.84±0.026 0.38±0.061 0.41±0.041
NEK6 0.78±0.021 0.78±0.016 0.32±0.035 0.33±0.028
NEK2 0.76±0.041 0.77±0.029 0.49±0.065 0.50±0.050
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Kinase Full set Reduced set Full set Reduced set
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Average 0.80±0.022 0.80±0.021 0.32±0.039 0.324±0.029
PAK1 0.69±0.013 0.67±0.013 0.04±0.010 0.03±0.009
Cot 0.82±0.024 0.80±0.061 0.43±0.083 0.37±0.054
S
T
E
MST1 0.75±0.042 0.75±0.027 0.20±0.028 0.21±0.029
ASK1 0.79±0.024 0.77±0.045 0.36±0.056 0.40±0.053
MKK4 0.82±0.068 0.83±0.015 0.44±0.067 0.42±0.005
MST2 0.70±0.046 0.62±0.029 0.14±0.034 0.09±0.048
PAK2 0.73±0.074 0.77±0.082 0.36±0.078 0.37±0.094
MKK7 0.93±0.152 0.94±0.093 0.76±0.114 0.80±0.121
MEK1 0.63±0.067 0.67±0.086 0.31±0.006 0.29±0.088
Average 0.76±0.057 0.76±0.05 0.339±0.053 0.332±0.056
CK1A 0.77±0.009 0.77±0.010 0.19±0.011 0.17±0.015
C
K
1 CK1D 0.90±0.006 0.90±0.006 0.23±0.029 0.23±0.033
CK1E 0.87±0.018 0.87±0.032 0.42±0.059 0.43±0.066
VRK1 0.87±0.058 0.89±0.032 0.39±0.021 0.32±0.023
Average 0.85±0.023 0.86±0.02 0.306±0.03 0.288±0.034
ATM 0.95±0.002 0.95±0.002 0.29±0.017 0.28±0.015
A
ty
p
ic
al ATR 0.86±0.009 0.86±0.008 0.12±0.014 0.11±0.016
DNAPK 0.86±0.005 0.85±0.006 0.17±0.012 0.19±0.011
mTOR 0.81±0.018 0.78±0.021 0.22±0.038 0.17±0.039
Average 0.87±0.008 0.86±0.009 0.201±0.02 0.186±0.02
Table B.11: Comparison of prediction accuracy across mouse kinases between predicting
kinase-specific phosphorylation sites using the sequence model trained on the full data-set,
and when the model is trained on the similarity-reduced data-set. Prediction accuracy is
calculated on the similarity-reduced data-set. If a kinase could not be trained on the reduced
data-set due to too few positive training samples it was marked as “N/A”. Kinases are grouped
according to their family, with the average prediction accuracy for each family included.
Results were generated using ten-fold cross-validation repeated across ten randomised data-
set splits. Shown are the average and standard deviation of the AUC and AUC50 values.
AUC AUC50
Kinase Full set Reduced set Full set Reduced set
ERK2 0.83±0.006 0.83±0.009 0.19±0.017 0.19±0.019
ERK1 0.82±0.010 0.83±0.019 0.16±0.021 0.18±0.030
CDK5 0.79±0.013 0.79±0.011 0.15±0.016 0.13±0.032
C
M
G
C CDK1 0.79±0.013 0.78±0.018 0.19±0.031 0.17±0.026
JNK1 0.77±0.014 0.78±0.020 0.22±0.040 0.26±0.039
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Kinase Full set Reduced set Full set Reduced set
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P38A 0.74±0.017 0.73±0.021 0.23±0.028 0.21±0.025
CDK2 0.74±0.034 0.76±0.031 0.34±0.033 0.34±0.044
GSK3B 0.83±0.021 0.83±0.016 0.41±0.045 0.36±0.037
Average 0.79±0.016 0.79±0.018 0.237±0.029 0.229±0.031
PKACA 0.81±0.007 0.81±0.007 0.25±0.014 0.24±0.023
PKCA 0.72±0.010 0.70±0.014 0.25±0.016 0.25±0.027
Akt1 0.82±0.012 0.80±0.022 0.40±0.049 0.43±0.037
PKCD 0.75±0.028 0.73±0.043 0.11±0.037 0.11±0.026
A
G
C p90RSK 0.87±0.014 0.82±0.019 0.24±0.041 0.22±0.035
RSK2 0.76±0.043 0.79±0.040 0.17±0.050 0.00±0.000
PKG1 0.66±0.042 0.68±0.015 0.00±0.000 0.00±0.000
p70S6K 0.88±0.029 0.89±0.033 0.39±0.062 0.39±0.063
PKCZ 0.69±0.095 0.68±0.057 0.29±0.114 0.29±0.086
PKCE 0.54±0.043 0.53±0.057 0.44±0.102 0.44±0.089
Average 0.75±0.032 0.74±0.031 0.254±0.049 0.237±0.039
Src 0.59±0.012 0.57±0.014 0.24±0.014 0.22±0.020
Fyn 0.64±0.019 0.63±0.013 0.31±0.027 0.30±0.024
T
K Abl 0.52±0.041 0.49±0.036 0.15±0.008 0.15±0.038
Lyn 0.65±0.027 0.65±0.016 0.29±0.030 0.28±0.027
Lck 0.65±0.064 0.64±0.044 0.31±0.065 0.30±0.061
Syk 0.71±0.014 0.70±0.024 0.60±0.024 0.57±0.055
Average 0.63±0.03 0.61±0.024 0.318±0.028 0.302±0.038
Table B.12: Comparison of prediction accuracy across mouse kinases between predicting
kinase-specific phosphorylation sites using the sequence model trained on the full data-set,
and when the model is trained on the similarity-reduced data-set. Prediction accuracy is
calculated on the similarity-reduced data-set. If a kinase could not be trained on the reduced
data-set due to too few positive training samples it was marked as “N/A”. Kinases are grouped
according to their family, with the average prediction accuracy for each family included.
Results were generated using ten-fold cross-validation repeated across ten randomised data-
set splits. Shown are the average and standard deviation of the AUC and AUC50 values.
AUC AUC50
Kinase Full set Reduced set Full set Reduced set
CDC28 0.93±0.001 0.93±0.001 0.30±0.012 0.30±0.010
CTK1 0.53±0.012 0.68±0.018 0.15±0.000 0.16±0.014
MCK1 0.83±0.009 0.81±0.015 0.35±0.024 0.33±0.041
C
M
G
C PHO85 0.71±0.018 0.69±0.023 0.17±0.010 0.18±0.013
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Kinase Full set Reduced set Full set Reduced set
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SSN3 0.73±0.058 0.74±0.051 0.29±0.064 0.29±0.066
HOG1 0.79±0.046 0.82±0.024 0.30±0.052 0.35±0.030
KNS1 0.93±0.038 0.95±0.038 0.59±0.056 0.68±0.088
SLT2 0.68±0.037 0.69±0.041 0.27±0.047 0.28±0.029
FUS3 0.54±0.035 0.54±0.046 0.22±0.004 0.22±0.065
Average 0.74±0.028 0.76±0.028 0.293±0.03 0.31±0.04
TPK1 0.96±0.002 0.96±0.002 0.38±0.012 0.38±0.015
TPK3 0.80±0.038 0.82±0.034 0.57±0.062 0.62±0.047
A
G
C YPK1 0.76±0.049 0.74±0.061 0.49±0.095 0.49±0.068
PKH2 0.74±0.037 0.74±0.040 0.25±0.003 0.25±0.074
PKH1 0.98±0.006 0.98±0.030 0.75±0.000 0.75±0.075
PKC1 0.88±0.024 0.88±0.040 0.35±0.045 0.37±0.062
Average 0.85±0.026 0.85±0.034 0.464±0.036 0.476±0.057
SNF1 0.78±0.014 0.78±0.019 0.16±0.032 0.16±0.027
T
K FRK1 0.75±0.021 0.74±0.043 0.42±0.048 0.42±0.054
PSK2 0.74±0.047 0.74±0.035 0.41±0.055 0.45±0.066
DUN1 0.85±0.013 0.85±0.013 0.38±0.012 0.35±0.051
Average 0.78±0.024 0.78±0.027 0.34±0.037 0.35±0.049
CKA1 0.89±0.005 0.90±0.007 0.31±0.015 0.32±0.019
CKA2 0.91±0.007 0.91±0.004 0.36±0.017 0.36±0.023
O
th
er
MPS1 0.86±0.016 0.86±0.021 0.23±0.036 0.22±0.038
PTK1 0.67±0.015 0.67±0.024 0.14±0.020 0.15±0.012
PTK2 0.89±0.046 0.87±0.028 0.75±0.065 0.75±0.087
IPL1 0.91±0.009 0.91±0.016 0.28±0.018 0.29±0.023
BUD32 0.73±0.063 0.78±0.043 0.39±0.071 0.40±0.059
Average 0.86±0.023 0.84±0.021 0.351±0.035 0.355±0.037
Table B.13: Combined model accuracy across human kinases when compared to the context
only model. Kinases are grouped according to their family, with the average prediction accu-
racy for each family included. Table shows accuracy values for classifying kinase substrates
with both models as determined by 10-fold cross-validation across 10 randomised data-set
splits. Prediction accuracy is shown using median and standard deviation of the AUC and
AUC50 across the data-set splits.
AUC AUC50
Kinase Context model Combined model Context model Combined model
CDK2 0.69±0.003 0.76±0.002 0.097±0.0016 0.110±0.0024
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Kinase Context model Combined model Context model Combined model
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CDK1 0.77±0.002 0.79±0.002 0.088±0.0035 0.101±0.0036
ERK2 0.74±0.002 0.78±0.003 0.139±0.0022 0.155±0.0047
ERK1 0.78±0.003 0.81±0.003 0.125±0.0021 0.147±0.0048
GSK3B 0.74±0.002 0.79±0.005 0.151±0.0015 0.178±0.0032
P38A 0.80±0.003 0.80±0.006 0.132±0.0012 0.167±0.0115
JNK1 0.84±0.002 0.87±0.010 0.263±0.0021 0.310±0.0097
CDK5 0.78±0.006 0.82±0.007 0.183±0.0059 0.230±0.0081
C
M
G
C
JNK2 0.83±0.008 0.89±0.022 0.216±0.0113 0.313±0.0247
CDK7 0.93±0.034 0.95±0.048 0.560±0.0117 0.705±0.0327
GSK3A 0.81±0.042 0.91±0.028 0.378±0.0258 0.610±0.0551
CDK4 0.87±0.002 0.88±0.006 0.309±0.0263 0.494±0.0219
P38B 0.78±0.071 0.75±0.058 0.198±0.0330 0.410±0.0466
HIPK2 0.89±0.033 0.98±0.054 0.365±0.0155 0.780±0.0618
DYRK1A 0.92±0.032 0.90±0.015 0.698±0.0361 0.617±0.0257
CDK9 0.96±0.045 0.90±0.043 0.548±0.0175 0.656±0.0348
DYRK2 0.63±0.038 0.91±0.010 0.363±0.0098 0.849±0.0552
ERK5 0.82±0.078 0.97±0.141 0.549±0.0270 0.709±0.1387
CDK6 0.83±0.012 0.82±0.010 0.539±0.0201 0.698±0.0172
CDK3 0.54±0.047 0.57±0.064 0.284±0.0473 0.407±0.0822
Average 0.80±0.023 0.84±0.027 0.31±0.015 0.43±0.032
PKACA 0.65±0.002 0.68±0.003 0.060±0.0004 0.064±0.0027
PKCA 0.69±0.002 0.71±0.004 0.070±0.0017 0.086±0.0046
Akt1 0.78±0.002 0.81±0.004 0.181±0.0037 0.225±0.0035
PKCD 0.65±0.004 0.65±0.008 0.116±0.0023 0.135±0.0053
PKG1 0.83±0.010 0.84±0.020 0.335±0.0064 0.421±0.0342
p90RSK 0.88±0.004 0.88±0.010 0.242±0.0083 0.334±0.0205
PKCE 0.70±0.009 0.76±0.012 0.030±0.0051 0.205±0.0255
PKCZ 0.71±0.005 0.68±0.012 0.136±0.0084 0.199±0.0182
PKCB 0.68±0.009 0.76±0.018 0.166±0.0121 0.194±0.0214
A
G
C
RSK2 0.77±0.006 0.82±0.016 0.290±0.0041 0.364±0.0378
ROCK1 0.84±0.008 0.89±0.016 0.392±0.0097 0.571±0.0458
PDK1 0.94±0.029 0.97±0.030 0.402±0.0171 0.767±0.0231
PKCT 0.80±0.013 0.78±0.011 0.225±0.0056 0.312±0.0499
PKCG 0.72±0.027 0.79±0.011 0.199±0.0325 0.270±0.0474
p70S6K 0.89±0.018 0.91±0.030 0.398±0.0035 0.502±0.0234
SGK1 0.83±0.015 0.87±0.028 0.254±0.0139 0.342±0.0209
Akt2 0.84±0.049 0.80±0.029 0.119±0.0212 0.237±0.0614
GRK2 0.88±0.014 0.68±0.050 0.323±0.0113 0.385±0.0874
ROCK2 0.48±0.061 0.66±0.067 0.181±0.0195 0.193±0.0194
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PKCI 0.50±0.112 0.77±0.114 0.101±0.0604 0.541±0.0872
PKCH 0.72±0.042 0.98±0.053 0.376±0.0294 0.738±0.0460
PKN1 0.46±0.102 0.58±0.085 0.130±0.0507 0.330±0.0777
Average 0.74±0.025 0.79±0.029 0.21±0.015 0.34±0.035
Src 0.75±0.002 0.78±0.002 0.062±0.0018 0.063±0.0023
Abl 0.85±0.003 0.86±0.005 0.153±0.0026 0.171±0.0043
Fyn 0.78±0.005 0.81±0.007 0.110±0.0018 0.118±0.0048
Lck 0.84±0.004 0.85±0.007 0.172±0.0082 0.190±0.0089
Lyn 0.77±0.010 0.83±0.010 0.104±0.0031 0.169±0.0188
EGFR 0.76±0.010 0.84±0.017 0.110±0.0143 0.145±0.0253
Syk 0.81±0.015 0.90±0.009 0.324±0.0060 0.444±0.0354
InsR 0.82±0.019 0.87±0.007 0.378±0.0182 0.456±0.0263
T
K
JAK2 0.83±0.019 0.84±0.018 0.422±0.0111 0.476±0.0209
FAK 0.81±0.033 0.83±0.040 0.295±0.0291 0.533±0.0554
Ret 0.91±0.001 0.91±0.003 0.493±0.0127 0.598±0.0558
Arg 0.77±0.068 0.74±0.044 0.400±0.0391 0.434±0.0757
Brk 0.81±0.038 0.81±0.042 0.613±0.0624 0.556±0.0583
ALK 0.80±0.104 0.76±0.120 0.296±0.0183 0.375±0.1237
Btk 0.79±0.010 0.81±0.013 0.469±0.0223 0.654±0.0304
PDGFRB 0.86±0.010 0.89±0.021 0.532±0.0125 0.764±0.0482
JAK3 0.71±0.050 0.73±0.033 0.511±0.0549 0.606±0.0430
Hck 0.84±0.090 0.79±0.054 0.291±0.0205 0.389±0.0408
Pyk2 0.84±0.014 0.76±0.037 0.243±0.0458 0.320±0.0555
Average 0.81±0.027 0.82±0.026 0.31±0.02 0.39±0.039
CAMK2A 0.67±0.015 0.69±0.011 0.057±0.0108 0.153±0.0212
Chk1 0.77±0.008 0.78±0.007 0.161±0.0028 0.172±0.0128
AMPKA1 0.76±0.010 0.79±0.009 0.132±0.0111 0.217±0.0064
MAPKAPK2 0.81±0.007 0.83±0.013 0.302±0.0062 0.365±0.0313
PKD1 0.68±0.009 0.70±0.018 0.145±0.0086 0.197±0.0177
LKB1 0.86±0.009 0.97±0.005 0.446±0.0073 0.840±0.0089
C
A
M
K
MSK1 0.78±0.057 0.72±0.031 0.354±0.0399 0.433±0.0538
Chk2 0.86±0.009 0.89±0.011 0.314±0.0154 0.382±0.0172
Pim1 0.80±0.039 0.94±0.068 0.422±0.0231 0.564±0.0522
AMPKA2 0.31±0.075 0.64±0.024 0.000±0.0000 0.291±0.0295
MARK2 0.88±0.058 0.91±0.060 0.478±0.0236 0.608±0.0464
CAMK1A 0.72±0.082 0.61±0.056 0.495±0.0482 0.283±0.0429
DAPK3 0.71±0.063 0.88±0.036 0.442±0.0155 0.825±0.0776
CaMK4 0.43±0.060 0.62±0.046 0.226±0.0396 0.424±0.0050
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Kinase Context model Combined model Context model Combined model
Continued from previous page
PKD2 0.42±0.081 0.62±0.081 0.000±0.0000 0.284±0.0693
CAMK2D 0.16±0.046 0.57±0.038 0.000±0.0000 0.332±0.0495
Average 0.66±0.039 0.76±0.032 0.25±0.016 0.40±0.034
CK2A1 0.73±0.003 0.77±0.002 0.116±0.0013 0.156±0.0043
PLK1 0.81±0.010 0.82±0.007 0.143±0.0055 0.131±0.0067
AurB 0.78±0.014 0.85±0.010 0.183±0.0139 0.168±0.0177
AurA 0.73±0.011 0.74±0.015 0.175±0.0104 0.198±0.0136
PLK3 0.89±0.026 0.84±0.025 0.419±0.0230 0.688±0.0414
O
th
er
IKKA 0.84±0.023 0.81±0.022 0.515±0.0052 0.583±0.0093
IKKB 0.89±0.005 0.87±0.019 0.322±0.0075 0.530±0.0323
TBK1 0.99±0.004 0.99±0.001 0.735±0.0329 0.752±0.0320
CK2A2 0.83±0.071 0.75±0.056 0.324±0.0162 0.625±0.0500
IKKE 0.78±0.135 0.85±0.125 0.557±0.1298 0.554±0.1165
TTK 0.69±0.107 0.71±0.108 0.201±0.0920 0.579±0.1296
NEK6 0.55±0.011 0.67±0.058 0.447±0.0042 0.321±0.0415
NEK2 0.93±0.028 0.91±0.036 0.552±0.0404 0.762±0.0805
Average 0.80±0.034 0.81±0.037 0.36±0.029 0.47±0.044
PAK1 0.76±0.025 0.73±0.011 0.191±0.0104 0.182±0.0121
Cot 0.84±0.103 0.85±0.116 0.159±0.0380 0.593±0.1458
MST1 0.63±0.047 0.65±0.036 0.436±0.0289 0.307±0.0396
S
T
E
ASK1 0.88±0.109 0.94±0.118 0.681±0.0982 0.784±0.1428
MKK4 0.70±0.033 0.90±0.036 0.428±0.0445 0.868±0.0556
MST2 0.85±0.038 0.84±0.046 0.780±0.0466 0.697±0.0595
PAK2 0.66±0.053 0.80±0.051 0.143±0.0488 0.423±0.0513
MKK7 0.65±0.094 0.85±0.129 0.375±0.0615 0.820±0.1301
MEK1 0.60±0.026 0.60±0.026 0.451±0.0057 0.455±0.0114
Average 0.73±0.059 0.80±0.063 0.40±0.043 0.57±0.072
CK1A 0.76±0.019 0.78±0.016 0.290±0.0236 0.204±0.0333
C
K
1 CK1D 0.75±0.051 0.83±0.031 0.315±0.0278 0.379±0.0544
CK1E 0.80±0.055 0.95±0.037 0.364±0.0592 0.560±0.0664
VRK1 0.85±0.014 0.68±0.028 0.583±0.0184 0.493±0.0157
Average 0.79±0.035 0.81±0.028 0.39±0.032 0.41±0.042
ATM 0.83±0.011 0.86±0.013 0.242±0.0042 0.302±0.0054
A
ty
p
ic
al ATR 0.90±0.024 0.89±0.027 0.391±0.0081 0.478±0.0161
DNAPK 0.92±0.003 0.93±0.005 0.314±0.0050 0.404±0.0120
mTOR 0.75±0.020 0.88±0.011 0.504±0.0037 0.624±0.0275
Average 0.85±0.015 0.89±0.014 0.36±0.005 0.45±0.015
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Table B.14: Combined model accuracy across mouse kinases when compared to the context
only model. Kinases are grouped according to their family, with the average prediction accu-
racy for each family included. Table shows accuracy values for classifying kinase substrates
with both models as determined by 10-fold cross-validation across 10 randomised data-set
splits. Prediction accuracy is shown using median and standard deviation of the AUC and
AUC50 across the data-set splits.
AUC AUC50
Kinase Context model Combined model Context model Combined model
ERK2 0.73±0.010 0.77±0.012 0.269±0.0030 0.280±0.0113
ERK1 0.73±0.013 0.70±0.014 0.301±0.0064 0.341±0.0141
CDK5 0.61±0.015 0.70±0.017 0.329±0.0076 0.246±0.0333
C
M
G
C CDK1 0.79±0.013 0.79±0.013 0.413±0.0061 0.496±0.0234
JNK1 0.71±0.009 0.76±0.015 0.414±0.0048 0.453±0.0428
P38A 0.72±0.011 0.80±0.027 0.350±0.0189 0.446±0.0445
CDK2 0.86±0.003 0.92±0.047 0.608±0.0223 0.724±0.0795
GSK3B 0.69±0.015 0.86±0.016 0.377±0.0044 0.576±0.0331
Average 0.73±0.011 0.79±0.02 0.38±0.009 0.45±0.035
PKACA 0.45±0.022 0.61±0.009 0.107±0.0044 0.128±0.0209
PKCA 0.44±0.020 0.54±0.014 0.070±0.0102 0.118±0.0217
Akt1 0.73±0.006 0.83±0.012 0.141±0.0154 0.459±0.0443
PKCD 0.65±0.028 0.61±0.029 0.270±0.0141 0.296±0.0441
A
G
C p90RSK 0.28±0.052 0.61±0.020 0.000±0.0000 0.222±0.0020
RSK2 0.49±0.021 0.58±0.079 0.346±0.0056 0.427±0.0852
PKG1 0.19±0.052 0.41±0.067 0.000±0.0000 0.167±0.0500
p70S6K 0.42±0.094 0.65±0.094 0.287±0.0865 0.292±0.0965
PKCZ 0.56±0.020 0.74±0.039 0.435±0.0051 0.490±0.0829
PKCE 0.55±0.016 0.76±0.070 0.385±0.0101 0.489±0.1074
Average 0.48±0.033 0.63±0.043 0.20±0.015 0.31±0.056
Src 0.79±0.012 0.85±0.011 0.311±0.0039 0.362±0.0068
Fyn 0.64±0.011 0.78±0.031 0.151±0.0273 0.553±0.0550
T
K Abl 0.41±0.025 0.62±0.036 0.176±0.0086 0.211±0.0517
Lyn 0.83±0.044 0.81±0.033 0.460±0.0269 0.595±0.0354
Lck 0.81±0.114 0.94±0.162 0.434±0.0521 0.731±0.1625
Syk 0.18±0.062 0.68±0.037 0.000±0.0000 0.332±0.0000
Average 0.61±0.045 0.78±0.052 0.26±0.02 0.46±0.052
Appendix B. Supplementary material for Chapter 4 160
Table B.15: Combined model accuracy across yeast kinases when compared to the context
only model. Kinases are grouped according to their family, with the average prediction accu-
racy for each family included. Table shows accuracy values for classifying kinase substrates
with both models as determined by 10-fold cross-validation across 10 randomised data-set
splits. Prediction accuracy is shown using median and standard deviation of the AUC and
AUC50 across the data-set splits.
AUC AUC50
Kinase Context model Combined model Context model Combined model
CDC28 0.63±0.003 0.76±0.003 0.148±0.0033 0.274±0.0082
CTK1 0.46±0.021 0.48±0.027 0.041±0.0119 0.079±0.0188
MCK1 0.73±0.038 0.84±0.034 0.303±0.0104 0.427±0.0264
C
M
G
C PHO85 0.83±0.012 0.81±0.012 0.449±0.0207 0.396±0.0387
SSN3 0.54±0.018 0.85±0.035 0.176±0.0180 0.667±0.0531
HOG1 0.85±0.003 0.79±0.020 0.463±0.0121 0.551±0.0375
KNS1 0.41±0.044 0.77±0.054 0.000±0.0000 0.500±0.0573
SLT2 0.78±0.116 0.79±0.135 0.211±0.0710 0.571±0.1434
FUS3 0.66±0.040 0.71±0.055 0.161±0.0299 0.500±0.0667
Average 0.65±0.033 0.76±0.042 0.22±0.02 0.44±0.05
TPK1 0.75±0.007 0.73±0.006 0.349±0.0092 0.333±0.0138
TPK3 0.16±0.026 0.70±0.045 0.000±0.0000 0.583±0.0472
A
G
C YPK1 0.46±0.033 0.74±0.033 0.000±0.0000 0.390±0.0367
PKH2 0.41±0.131 0.44±0.125 0.236±0.0953 0.097±0.0462
PKH1 0.84±0.048 0.84±0.048 0.820±0.0513 0.818±0.0456
PKC1 0.81±0.015 0.81±0.029 0.129±0.0609 0.665±0.0991
Average 0.57±0.043 0.71±0.048 0.26±0.036 0.48±0.048
SNF1 0.64±0.018 0.72±0.027 0.183±0.0149 0.217±0.0244
C
A
M
K FRK1 0.57±0.085 0.68±0.021 0.109±0.0350 0.301±0.0387
PSK2 0.80±0.016 0.77±0.023 0.143±0.0408 0.488±0.0643
DUN1 0.55±0.025 0.61±0.014 0.150±0.0243 0.328±0.0187
Average 0.64±0.036 0.70±0.021 0.15±0.029 0.33±0.036
CKA1 0.76±0.033 0.77±0.024 0.253±0.0177 0.280±0.0192
CKA2 0.79±0.018 0.78±0.011 0.226±0.0074 0.307±0.0257
O
th
er
MPS1 0.80±0.020 0.79±0.017 0.372±0.0069 0.397±0.0082
PTK1 0.42±0.025 0.62±0.023 0.036±0.0140 0.165±0.0249
PTK2 0.54±0.066 0.99±0.084 0.201±0.0605 0.888±0.0651
IPL1 0.71±0.056 0.72±0.100 0.373±0.0234 0.371±0.0462
BUD32 0.21±0.037 0.60±0.054 0.000±0.0000 0.426±0.0424
Average 0.60±0.036 0.75±0.045 0.21±0.019 0.40±0.033
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Table B.16: Sensitivity differences for kinases at 99.9% specificity, where kinases are
grouped according to their family, with the average sensitivity difference for each family in-
cluded. The sensitivity difference between PhosphoPICK and each alternative method was
measured for predicting kinase-specific phosphorylation sites out of all potential phosphory-
lation sites in our set of substrates. If we were unable to identify predictions for a kinase, it
was marked as “N/A”.
Sensitivity difference between PhosphoPICK and alternative
Kinase Sequence model GPS NetPhorest NetworKIN
CDK2 0.0009±0.0031 0.0371±0.0126 0.0205±0.0126 -0.0329±0.0126
CDK1 0.0625±0.0057 0.0920±0.0115 0.0684±0.0115 -0.0523±0.0115
ERK2 0.0166±0.0132 0.0238±0.0111 0.0151±0.0111 -0.0746±0.0111
ERK1 0.0341±0.0193 0.0606±0.0197 0.0312±0.0197 -0.0512±0.0197
GSK3B 0.0558±0.0114 0.0240±0.0161 0.0473±0.0161 0.0085±0.0161
P38A 0.0405±0.0186 0.1230±0.0202 0.1500±0.0202 0.1390±0.0202
JNK1 0.0624±0.0311 0.1680±0.0253 0.1800±0.0253 0.1090±0.0253
CDK5 0.0161±0.0161 0.0500±0.0168 -0.0145±0.0168 -0.1270±0.0168
C
M
G
C JNK2 -0.0143±0.0293 0.0171±0.0229 0.0457±0.0229 -0.0114±0.0229
CDK7 0.0160±0.0408 -0.1840±0.0408 -0.0240±0.0408 -0.1440±0.0408
GSK3A 0.1120±0.0176 0.3820±0.0474 0.3240±0.0474 0.3820±0.0474
CDK4 0.1520±0.0307 0.1740±0.0307 0.3040±0.0307 0.3040±0.0307
P38B 0.1830±0.0660 0.2610±0.0660 0.3720±0.0660 0.3720±0.0660
HIPK2 0.1300±0.0812 N/A 0.5050±0.0723 0.4380±0.0723
DYRK1A 0.3200±0.0400 0.440±0.0327 N/A N/A
CDK9 0.0407±0.0452 N/A N/A N/A
DYRK2 0.4870±0.0875 N/A N/A N/A
ERK5 0.2140±0.0714 0.1140±0.0857 0.3520±0.0857 0.1620±0.0857
CDK6 0.2830±0.0428 0.3500±0.0373 0.4500±0.0373 0.3830±0.0373
CDK3 0.2250±0.0935 N/A 0.5620±0.0839 0.3120±0.0839
Average 0.1220±0.0382 0.1330±0.0310 0.1990±0.0365 0.1250±0.0365
PKACA 0.0398±0.0121 0.0587±0.0095 0.0180±0.00947 -0.1070±0.0095
PKCA 0.0104±0.0064 0.0367±0.0138 0.0033±0.0138 -0.0004±0.0138
Akt1 0.0732±0.0222 N/A 0.0098±0.0147 -0.0098±0.0147
PKCD 0.0156±0.0124 0.0156±0.0124 0.0267±0.0124 0.0267±0.0124
PKG1 0.0533±0.0371 0.0400±0.0359 0.1730±0.0359 0.0400±0.0359
p90RSK 0.0632±0.0268 0.2130±0.0415 0.1610±0.0415 0.1340±0.0415
PKCE 0.0025±0.0075 -0.0225±0.0075 0.1020±0.0075 0.0275±0.0075
PKCZ 0.0178±0.0133 -0.0244±0.0306 0.1310±0.0306 0.0867±0.0306
PKCB 0.0103±0.0235 0.0538±0.0179 0.0538±0.0179 0.0795±0.0179
RSK2 0.0968±0.0323 -0.0226±0.0355 0.1710±0.0355 -0.0226±0.0355
A
G
C ROCK1 0.0260±0.0180 -0.0200±0.0390 0.0800±0.0390 0.0200±0.0390
PDK1 0.0276±0.0207 -0.0552±0.0442 0.2900±0.0442 -0.0207±0.0442
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Kinase Sequence model GPS NetPhorest NetworKIN
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PKCT 0.0000±0.0000 -0.0708±0.0458 0.0542±0.0458 -0.0708±0.0458
PKCG 0.0231±0.0188 -0.1040±0.0517 0.0885±0.0517 0.0500±0.0517
p70S6K 0.0636±0.0370 0.1940±0.0411 0.1330±0.0411 -0.0182±0.0411
SGK1 -5e-14±0.0421 0.2230±0.0414 0.0692±0.0414 -0.1230±0.0414
Akt2 0.2000±0.0516 0.0333±0.0683 0.1000±0.0683 0.1000±0.0683
GRK2 0.0026±0.0079 0.4890±0.0376 0.4630±0.0376 0.1740±0.0376
ROCK2 0.0000±0.0000 N/A 0.1820±0.0000 0.0909±1.39e-17
PKCI -0.0167±0.0333 N/A 0.0500±0.0553 0.1330±0.0553
PKCH 0.2330±0.0745 0.3070±0.0680 0.7070±0.0680 0.5070±0.0680
PKN1 0.0500±0.0764 N/A N/A N/A
Average 0.0451±0.0261 0.0747±0.0356 0.1460±0.0339 0.0522±0.0339
Src 0.0081±0.0079 -0.0152±0.0084 -0.0011±0.0084 -0.0187±0.0084
Abl 0.0176±0.0164 -0.0228±0.0130 0.0327±0.0130 0.0438±0.0130
Fyn 0.0056±0.0124 0.0022±0.00667 0.0022±0.0067 -0.0200±0.0067
Lck 0.0260±0.0114 -0.0151±0.0207 0.0260±0.0207 -0.0699±0.0207
Lyn -0.0020±0.0163 -0.0863±0.00961 0.0314±0.0096 -0.0078±0.0096
EGFR 0.0122±0.0100 -0.1860±0.0143 0.0184±0.0143 -0.1240±0.0143
Syk 0.1160±0.0329 -0.0047±0.0357 0.2740±0.0357 0.2740±0.0357
InsR 0.0343±0.0308 0.2460±0.0343 0.3600±0.0343 0.3310±0.0343
T
K
JAK2 0.0000±0.0000 0.0129±0.0214 N/A N/A
FAK 0.1190±0.0519 0.3750±0.0791 N/A N/A
Ret 0.0370±0.0331 -0.3110±0.0474 N/A N/A
Arg 0.2000±0.0408 0.0182±0.0408 0.1090±0.0408 -0.0727±0.0408
Brk 0.0000±0.0000 0.0000±0.0000 0.1430±0.0000 -0.0714±1.39e-17
ALK 0.0000±0.0000 -0.2220±0.0000 N/A N/A
Btk -0.1380±0.0462 -0.2310±2.78e-17 0.0000±0.0000 -0.0769±1.39e-17
PDGFRB 0.0261±0.0288 0.1610±0.0552 0.1610±0.0552 0.1170±0.0552
JAK3 0.0312±0.0576 0.1500±0.0800 N/A N/A
Hck 0.0850±0.0391 -0.2150±0.0391 0.0850±0.0391 0.0850±0.0391
Pyk2 0.2290±0.1140 0.0857±0.1140 N/A N/A
Average 0.0424±0.0289 -0.0136±0.0326 0.0955±0.0214 0.0300±0.0214
CAMK2A 0.0397±0.0191 0.0159±0.0159 0.0450±0.0159 -0.0697±0.0159
Chk1 0.0102±0.0137 -0.0204±0.0241 N/A N/A
AMPKA1 0.0511±0.0195 0.0170±0.0266 -0.0255±0.0266 -0.0894±0.0266
MAPKAPK2 0.0364±0.0253 -0.0545±0.0396 N/A N/A
PKD1 0.0511±0.0217 -0.0319±0.0238 0.0957±0.0238 0.0532±0.0238
LKB1 0.0290±0.0097 0.1840±0.0207 0.5970±0.0207 0.3660±0.0207
C
A
M
K
MSK1 0.3000±0.0856 N/A N/A N/A
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Kinase Sequence model GPS NetPhorest NetworKIN
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Chk2 0.0560±0.0215 -0.056±0.0307 N/A N/A
Pim1 0.0609±0.0651 N/A 0.2700±0.0696 0.1390±0.0696
AMPKA2 0.2120±0.0288 0.2060±0.0395 0.2060±0.0395 0.2650±0.0395
MARK2 0.1080±0.0534 N/A N/A N/A
CAMK1A 0.0222±0.0667 0.4440±0.0000 0.4440±0.0000 0.4440±0.0000
DAPK3 0.4310±0.0705 0.2850±0.0846 0.5150±0.0846 0.2300±0.0846
CaMK4 0.0500±0.0829 -0.2000±0.0829 -0.2000±0.0829 -0.0750±0.0829
PKD2 0.2250±0.0500 N/A 0.2250±0.0500 -0.0250±0.0500
CAMK2D 0.2120±0.0800 N/A 0.3380±0.0800 0.4630±0.0800
Average 0.1180±0.0446 0.0717±0.0353 0.2280±0.0449 0.1550±0.0449
CK2A1 0.0206±0.0036 0.0714±0.0052 0.0775±0.0052 -0.0435±0.0052
PLK1 0.0284±0.0120 0.0157±0.0118 N/A N/A
AurB 0.0480±0.0148 -0.0040±0.0104 N/A N/A
AurA 0.0056±0.0208 -0.0056±0.0299 -0.0056±0.0299 -0.0611±0.0299
PLK3 0.1320±0.0516 N/A N/A N/A
O
th
er
IKKA 0.0759±0.0371 0.0241±0.0438 0.2310±0.0438 0.0387±0.0438
IKKB 0.0333±0.0282 0.2130±0.0345 0.3130±0.0345 0.2860±0.0345
TBK1 0.1690±0.0462 N/A N/A N/A
CK2A2 0.1880±0.0559 0.6130±0.0468 0.5500±0.0468 0.1750±0.0468
IKKE -0.0889±0.1430 N/A N/A N/A
TTK 0.2440±0.1660 N/A 0.481±0.1650 0.4810±0.1650
NEK6 0.1800±0.0748 0.1000±1.39e-17 N/A N/A
NEK2 -0.2420±0.1310 0.1170±0.0667 0.1170±0.0667 0.0333±0.0667
Average 0.0610±0.0605 0.1270±0.0277 0.2520±0.0560 0.1300±0.0560
PAK1 0.0107±0.0143 0.0179±0.0080 0.0357±0.0080 -0.1790±0.0080
Cot 0.0778±0.0509 0.4830±0.1290 N/A N/A
MST1 0.1180±0.0372 N/A 0.2650±0.0395 0.1740±0.0395
S
T
E
ASK1 0.1070±0.0659 N/A N/A N/A
MKK4 0.3120±0.1010 N/A 0.7750±0.1220 0.1500±0.1220
MST2 0.1500±0.0500 N/A 0.2630±0.0673 0.0403±0.0673
PAK2 0.1690±0.0576 0.1920±0.1050 0.4230±0.1050 0.3460±0.1050
MKK7 0.0500±0.0829 -0.0250±0.0500 0.8500±0.0500 0.4750±0.0500
MEK1 0.0000±0.0000 0.2000±2.78e-17 0.4000±5.55e-17 -0.2000±2.78e-17
Average 0.1110±0.0511 0.1740±0.0584 0.4300±0.0560 0.1150±0.0560
CK1A 0.0133±0.0109 -0.0267±0.0133 0.1510±0.0133 0.1400±0.0133
C
K
1 CK1D 0.0216±0.0162 0.1860±0.0351 0.2410±0.0351 0.1860±0.0351
CK1E 0.0652±0.0446 -0.0565±0.0516 0.4220±0.0516 0.0739±0.0516
VRK1 0.2640±0.0636 0.4360±0.0545 N/A N/A
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Average 0.0910±0.0338 0.1350±0.0387 0.2710±0.0334 0.1330±0.0334
ATM 0.0866±0.0223 0.0779±0.0312 0.1420±0.0312 -0.0616±0.0312
A
ty
p
ic
al ATR 0.0885±0.0167 0.1180±0.0161 0.0689±0.0161 -0.0623±0.0161
DNAPK 0.0242±0.0146 -0.0088±0.0176 0.1230±0.0176 0.1120±0.0176
mTOR 0.0526±0.0235 0.1950±0.0443 N/A N/A
Average 0.0630±0.0193 0.0955±0.0273 0.1110±0.0216 -0.0040±0.0216
Table B.17: Sensitivity differences for kinases at 99% specificity, where kinases are
grouped according to their family, with the average sensitivity difference for each family
included. The sensitivity difference between PhosphoPICK and each alternative method was
measured for predicting kinase-specific phosphorylation sites out of all potential phosphory-
lation sites in our set of substrates. If we were unable to identify predictions for a kinase, it
was marked as “N/A”.
sensitivity difference between PhosphoPICK and alternative
Kinase Sequence model GPS NetPhorest NetworKIN
CDK2 0.0406±0.0081 0.0878±0.0242 -0.0023±0.0242 0.0023±0.0242
CDK1 0.1850±0.0270 0.3290±0.0144 0.1510±0.0144 -0.0318±0.0144
ERK2 0.1030±0.0173 -0.0570±0.0303 0.0355±0.0303 -0.1180±0.0303
ERK1 0.1070±0.0244 -2e-15±0.0268 0.1120±0.0268 -0.1290±0.0268
GSK3B 0.0775±0.0147 0.0814±0.0233 0.0581±0.0233 -0.0349±0.0233
P38A 0.0910±0.0256 0.0748±0.0304 0.3160±0.0304 0.0743±0.0304
JNK1 0.2250±0.0309 0.3530±0.0361 0.4820±0.0361 0.0824±0.0361
CDK5 0.0548±0.0207 0.1060±0.0308 -0.1350±0.0308 -0.3130±0.0308
C
M
G
C JNK2 0.2400±0.0343 0.1110±0.0469 0.3110±0.0469 -0.2890±0.0469
CDK7 0.4360±0.0631 0.1880±0.0256 0.3880±0.0256 0.2280±0.0256
GSK3A 0.2530±0.0459 0.4180±0.0668 0.4180±0.0668 0.3000±0.0668
CDK4 0.4370±0.0471 0.4130±0.0466 0.7610±0.0466 0.6740±0.0466
P38B 0.2830±0.0678 0.2940±0.0434 0.5720±0.0434 0.5100±0.0434
HIPK2 0.3100±0.0700 N/A 0.8400±0.0539 0.5730±0.0539
DYRK1A 0.3730±0.0680 0.5270±0.0200 N/A N/A
CDK9 0.3960±0.0598 N/A N/A N/A
DYRK2 0.6190±0.0763 N/A N/A N/A
ERK5 0.5240±0.1280 0.3430±0.1490 0.6760±0.1490 0.0095±0.1490
CDK6 0.5170±0.0522 0.6070±0.0133 0.8070±0.0133 0.4400±0.0133
CDK3 0.1750±0.0612 N/A 0.0625±0.0839 -0.1880±0.0839
Average 0.272±0.0471 0.242±0.0392 0.344±0.0439 0.105±0.0439
PKACA -0.0031±0.0163 -0.0938±0.0184 -0.0548±0.0184 -0.1390±0.0184
PKCA 0.0263±0.0099 0.0230±0.0158 0.0304±0.0158 -0.0437±0.0158
Akt1 0.0458±0.0155 N/A -0.0856±0.0264 -0.0268±0.0264
PKCD 0.0789±0.0153 -0.0322±0.0246 0.0122±0.0246 -0.0433±0.0246
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Kinase Sequence model GPS NetPhorest NetworKIN
Continued from previous page
PKG1 0.0900±0.0473 -0.0667±0.0365 0.200±0.0365 -0.0333±0.0365
p90RSK 0.1500±0.0457 0.2110±0.0372 0.1320±0.0372 0.1580±0.0372
PKCE 0.1950±0.0245 0.1130±0.0301 0.2120±0.0301 0.0125±0.0301
PKCZ 0.0578±0.0178 0.0133±0.0267 0.0800±0.0267 -0.0089±0.0267
PKCB 0.0872±0.0515 0.1900±0.0576 0.0615±0.0576 0.2670±0.0576
RSK2 0.1900±0.0488 0.1740±0.0413 0.2390±0.0413 0.0774±0.0413
A
G
C ROCK1 0.3120±0.0634 0.1020±0.0648 0.3420±0.0648 0.0220±0.0648
PDK1 0.1480±0.0269 0.0448±0.0269 0.1480±0.0269 -0.0241±0.0269
PKCT 0.0958±0.0267 -0.0833±0.0527 0.0833±0.0527 -0.2080±0.0527
PKCG 0.3310±0.0734 0.1620±0.0985 0.3150±0.0985 0.3150±0.0985
p70S6K 0.1640±0.0545 0.1580±0.0182 0.0364±0.0182 0.0667±0.0182
SGK1 0.1190±0.0607 0.0423±0.0607 0.0808±0.0607 -0.1120±0.0607
Akt2 0.1930±0.0629 -0.0800±0.0653 -0.2800±0.0653 -0.0133±0.0653
GRK2 0.2320±0.0349 0.4500±0.0299 0.7130±0.0299 0.1610±0.0299
ROCK2 0.0909±1.39e-17 N/A 0.1820±0.0000 -0.2730±5.55e-17
PKCI 0.4170±0.1180 N/A 0.4250±0.1260 0.4250±0.1260
PKCH 0.1670±0.1090 0.4330±0.0683 0.6330±0.0683 0.3000±0.0683
PKN1 0.0833±0.1540 N/A N/A N/A
Average 0.1490±0.0489 0.0977±0.0430 0.1670±0.0441 0.0419±0.0441
Src 0.0403±0.0117 -0.0929±0.0163 0.0131±0.0163 -0.0364±0.0163
Abl 0.0319±0.0199 -0.0995±0.0294 0.0560±0.0294 0.0560±0.0294
Fyn 0.0411±0.0186 -0.0011±0.0256 0.0433±0.0256 -0.1120±0.0256
Lck 0.0795±0.0279 -0.1600±0.0253 0.0726±0.0253 -0.2420±0.0253
Lyn 0.0333±0.0197 -0.2220±0.0197 0.0529±0.0197 -0.0647±0.0197
EGFR 0.0449±0.0327 -0.3370±0.0345 -0.0306±0.0345 -0.3370±0.0345
Syk 0.2860±0.0642 0.0140±0.0599 0.6420±0.0599 0.2520±0.0599
InsR 0.0429±0.0263 0.0143±0.0367 0.3290±0.0367 0.0429±0.0367
T
K
JAK2 0.1290±0.0289 0.0774±0.0214 N/A N/A
FAK 0.3190±0.0763 0.5750±0.0673 N/A N/A
Ret 0.1040±0.0363 -0.2070±0.0602 N/A N/A
Arg 0.4830±0.0972 0.2770±0.1070 0.2770±0.1070 0.0046±0.1070
Brk 0.4930±0.0500 0.5430±0.0350 0.6860±0.0350 0.1140±0.0350
ALK 0.4560±0.1160 0.2330±0.1160 N/A N/A
Btk 0.4150±0.0923 0.1620±0.0803 0.4690±0.0803 0.2380±0.0803
PDGFRB 0.2090±0.0543 0.2090±0.0543 0.2520±0.0543 -0.0522±0.0543
JAK3 0.2870±0.0893 0.1380±0.0545 N/A N/A
Hck 0.5000±0.0316 0.1300±0.0400 0.5300±0.0400 0.2300±0.0400
Pyk2 0.3860±0.0915 0.2430±0.0915 N/A N/A
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Kinase Sequence model GPS NetPhorest NetworKIN
Continued from previous page
Average 0.2310±0.0518 0.0787±0.0513 0.2610±0.0434 0.0072±0.0434
CAMK2A 0.0302±0.0132 -0.2680±0.0218 -0.0221±0.0218 -0.1040±0.0218
Chk1 0.1140±0.0410 0.0449±0.0363 N/A N/A
AMPKA1 0.0723±0.0255 -0.0447±0.0322 0.0617±0.0322 -0.0872±0.0322
MAPKAPK2 0.2480±0.0400 0.0250±0.0561 N/A N/A
PKD1 0.1040±0.0461 0.1280±0.0404 0.1700±0.0404 -0.0638±0.0404
C
A
M
K LKB1 0.1190±0.0521 0.2030±0.0541 0.5210±0.0541 0.1750±0.0541
MSK1 0.2000±0.0789 N/A N/A N/A
Chk2 0.1560±0.0496 -0.0700±0.0361 N/A N/A
Pim1 0.2870±0.0758 N/A 0.3780±0.0675 0.2480±0.0675
AMPKA2 0.3410±0.0634 0.1650±0.0353 0.3410±0.0353 0.2240±0.0353
MARK2 0.2830±0.0764 N/A N/A N/A
CAMK1A 0.0000±0.0000 0.4440±0.0000 0.4440±0.0000 -0.1110±0.0000
DAPK3 0.6540±0.0788 0.4310±0.0510 0.8920±0.0510 -0.1080±0.0510
CaMK4 0.4750±0.0500 -0.1250±0.0000 0.1250±0.0000 0.1250±0.0000
PKD2 0.1380±0.1180 N/A 0.0500±0.1000 -0.0750±0.1000
CAMK2D 0.2250±0.0750 N/A 0.3500±0.0750 0.3500±0.0750
Average 0.2150±0.0552 0.0848±0.0330 0.3010±0.0434 0.0520±0.0434
CK2A1 -0.0009±0.0070 0.0206±0.0073 0.0575±0.0073 -0.0348±0.0073
PLK1 0.0873±0.0203 0.0725±0.0229 N/A N/A
AurB 0.1290±0.0260 -0.0080±0.0208 N/A N/A
AurA 0.0778±0.0408 0.0556±0.0329 0.1110±0.0329 0.1110±0.0329
PLK3 0.4730±0.0649 N/A N/A N/A
O
th
er
IKKA 0.2690±0.0530 0.1860±0.0229 0.4540±0.0229 -0.0074±0.0229
IKKB 0.3380±0.0377 0.5380±0.0324 0.6640±0.0324 0.3130±0.0324
TBK1 0.4960±0.0631 N/A N/A N/A
CK2A2 0.3440±0.0504 0.4250±0.0375 0.4250±0.0375 0.2370±0.0375
IKKE 0.0833±0.0756 N/A N/A N/A
TTK 0.3440±0.2440 N/A 0.5750±0.2270 0.4500±0.2270
NEK6 0.1300±0.0458 0.0000±0.0000 N/A N/A
NEK2 0.3170±0.1280 0.7000±0.1190 0.6170±0.1190 0.2830±0.1190
Average 0.2370±0.0659 0.2210±0.0329 0.4150±0.0684 0.1930±0.0684
PAK1 0.1050±0.0168 -0.0536±0.0179 0.0000±0.0179 -0.2320±0.0179
Cot 0.1330±0.0619 0.4170±0.1300 N/A N/A
MST1 0.2410±0.0412 N/A 0.3740±0.0176 0.1920±0.0176
S
T
E
ASK1 0.3070±0.0848 N/A N/A N/A
MKK4 0.3620±0.0375 N/A 0.7750±0.1220 -0.1000±0.1220
MST2 0.5060±0.0813 N/A 0.6810±0.0187 0.2370±0.0188
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Kinase Sequence model GPS NetPhorest NetworKIN
Continued from previous page
PAK2 0.2850±0.0913 0.4460±0.0462 0.5230±0.0462 0.2920±0.0462
MKK7 0.0250±0.0750 0.0000±0.0000 0.8750±0.0000 0.0000±0.0000
MEK1 0.1200±0.0980 0.1200±0.0980 0.5200±0.0980 -0.0800±0.0980
Average 0.2320±0.0653 0.1860±0.0583 0.5350±0.0458 0.0441±0.0458
CK1A 0.0378±0.0218 0.0100±0.0265 0.1990±0.0265 0.0211±0.0265
C
K
1 CK1D 0.2920±0.0315 0.5220±0.0343 0.4950±0.0343 0.1700±0.0343
CK1E 0.3040±0.0802 0.2610±0.0550 0.6520±0.0550 0.2170±0.0550
VRK1 0.3090±0.0833 0.4270±0.0582 N/A N/A
Average 0.2360±0.0542 0.3050±0.0435 0.4490±0.0386 0.1360±0.0386
ATM 0.0895±0.0258 0.0959±0.0203 0.2350±0.0203 -0.1250±0.0203
A
ty
p
ic
al ATR 0.3690±0.0499 0.2480±0.0405 0.3300±0.0405 -0.1790±0.0405
DNAPK 0.1560±0.0343 0.0659±0.0269 0.3960±0.0269 0.0769±0.0269
mTOR 0.3840±0.0591 0.4890±0.0542 N/A N/A
Average 0.2500±0.0423 0.2250±0.0355 0.3200±0.0292 -0.0756±0.0292
Table B.18: Gene ontology (GO) term enrichment analysis for predicted Akt1 substrates.
Shown are all positions that the kinase was found to be significantly over-represented at.
position GO term Description E-value
All GO:0019901 protein kinase binding 0.0007
2 N/A N/A N/A
3 GO:0010907 positive regulation of glucose metabolic process 0.013
3 GO:0002053 positive regulation of mesenchymal cell proliferation 0.013
4 GO:0008543 fibroblast growth factor receptor signaling pathway 0.0017
4 GO:0019901 protein kinase binding 0.002
4 GO:0007173 epidermal growth factor receptor signalling pathway 0.022
4 GO:0032000 positive regulation of fatty acid beta-oxidation 0.007
5 GO:0090343 positive regulation of cell ageing 0.006
6 GO:0005158 insulin receptor binding 0.003
6 GO:0010907 positive regulation of glucose metabolic process 0.006
6 GO:0032000 positive regulation of fatty acid beta-oxidation 0.037
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Table B.19: Gene ontology (GO) term enrichment analysis for predicted AMPKA1 sub-
strates. Shown are all positions that the kinase was found to be significantly over-represented
at.
position GO term Description E-value
All GO:0019901 protein kinase binding 0.0001
All GO:0008543 fibroblast growth factor receptor signaling pathway 0.001
All GO:0005829 cytosol 0.001
All GO:0048011 neurotrophin TRK receptor signaling pathway 0.003
All GO:0008286 insulin receptor signaling pathway 0.003
All GO:0097149 centralspindlin complex 0.006
All GO:0005158 insulin receptor binding 0.022
All GO:0005737 cytoplasm 0.026
All GO:0007173 epidermal growth factor receptor signaling pathway 0.036
All GO:0006302 double-strand break repair 0.037
All GO:0007049 cell cycle 0.039
All GO:0007265 Ras protein signal transduction 0.042
All GO:0005515 protein binding 0.048
3 GO:0010907 positive regulation of glucose metabolic process 0.014
3 GO:0002053 positive regulation of mesenchymal cell proliferation 0.014
4 GO:0019901 protein kinase binding 4.26e-05
4 GO:0008543 fibroblast growth factor receptor signaling pathway 0.0004
4 GO:0007173 epidermal growth factor receptor signaling pathway 0.0008
4 GO:0048011 neurotrophin TRK receptor signaling pathway 0.0011
4 GO:0038095 Fc-epsilon receptor signaling pathway 0.0014
4 GO:0048015 phosphatidylinositol-mediated signaling 0.0016
4 GO:0008286 insulin receptor signaling pathway 0.0029
4 GO:0060397 JAK-STAT cascade involved in growth hormone signaling pathway 0.007
4 GO:0005158 insulin receptor binding 0.023
4 GO:0010907 positive regulation of glucose metabolic process 0.029
4 GO:0005829 cytosol 0.036
Table B.20: Gene ontology (GO) term enrichment analysis for predicted AurB substrates.
Shown are all positions that the kinase was found to be significantly over-represented at.
position GO term Description E-value
All GO:0005694 chromosome 1.47e-05
All GO:0000786 nucleosome 0.0003
All GO:0006334 nucleosome assembly 0.011
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position GO term Description E-value
Continued from previous page
All GO:0043065 positive regulation of apoptotic process 0.02
2 N/A N/A N/A
3 GO:0005694 chromosome 7.59e-08
3 GO:0000786 nucleosome 1.17e-06
3 GO:0006334 nucleosome assembly 2.49e-05
3 GO:0046982 protein heterodimerization activity 0.011
4 GO:0019886 antigen processing and presentation of 0.0007
exogenous peptide antigen via MHC class II
4 GO:0007018 microtubule-based movement 0.003
4 GO:0097149 centralspindlin complex 0.022
4 GO:0051256 mitotic spindle midzone assembly 0.022
4 GO:0005874 microtubule 0.032
Table B.21: Gene ontology (GO) term enrichment analysis for predicted CDK2 substrates.
Shown are all positions that the kinase was found to be significantly over-represented at.
position GO term Description E-value
All GO:0005694 chromosome 5.68e-05
All GO:0007049 cell cycle 0.0008
All GO:0005634 nucleus 0.011
All GO:0006281 DNA repair 0.022
-4 N/A N/A N/A
-5 N/A N/A N/A
-6 N/A N/A N/A
-7 N/A N/A N/A
Table B.22: Gene ontology (GO) term enrichment analysis for predicted p70S6K substrates.
Shown are all positions that the kinase was found to be significantly over-represented at.
position GO term Description E-value
All GO:0048011 neurotrophin TRK receptor signalling pathway 0.0002
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position GO term Description E-value
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All GO:0008286 insulin receptor signalling pathway 0.003
All GO:0007173 epidermal growth factor receptor signalling pathway 0.003
All GO:0008543 fibroblast growth factor receptor signalling pathway 0.013
All GO:0019901 protein kinase binding 0.037
3 GO:0010907 positive regulation of glucose metabolic process 0.008
3 GO:0008286 insulin receptor signalling pathway 0.01
4 GO:0008543 fibroblast growth factor receptor signalling pathway 2.78e-05
4 GO:0007173 epidermal growth factor receptor signalling pathway 6.85e-05
4 GO:0008286 insulin receptor signalling pathway 0.0002
4 GO:0038095 Fc-epsilon receptor signalling pathway 0.0027
4 GO:0048015 phosphatidylinositol-mediated signalling 0.0027
4 GO:0019901 protein kinase binding 0.018
4 GO:0048011 neurotrophin TRK receptor signalling pathway 0.031
4 GO:0005158 insulin receptor binding 0.033
4 GO:0090343 positive regulation of cell ageing 0.036
4 GO:0010907 positive regulation of glucose metabolic process 0.036
4 GO:0004871 signal transducer activity 0.049
5 GO:0006974 cellular response to DNA damage stimulus 0.0005
5 GO:0090343 positive regulation of cell ageing 0.0079
5 GO:0031465 Cul4B-RING E3 ubiquitin ligase complex 0.0079
5 GO:0006281 DNA repair 0.049
6 GO:0010907 positive regulation of glucose metabolic process 0.003
6 GO:0032000 positive regulation of fatty acid beta-oxidation 0.015
6 GO:0045725 positive regulation of glycogen biosynthetic process 0.025
6 GO:0043548 phosphatidylinositol 3-kinase binding 0.025
6 GO:0048011 neurotrophin TRK receptor signalling pathway 0.032
6 GO:0046326 positive regulation of glucose import 0.038
6 GO:0008286 insulin receptor signalling pathway 0.048
Table B.23: Gene ontology (GO) term enrichment analysis for predicted p90RSK substrates.
Shown are all positions that the kinase was found to be significantly over-represented at.
position GO term Description E-value
All GO:0019901 protein kinase binding 0.0002
All GO:0045087 innate immune response 0.003
All GO:0048011 neurotrophin TRK receptor signalling pathway 0.018
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position GO term Description E-value
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All GO:0038095 Fc-epsilon receptor signalling pathway 0.033
All GO:0006974 cellular response to DNA damage stimulus 0.033
3 GO:0010907 positive regulation of glucose metabolic process 0.018
3 GO:0019901 protein kinase binding 0.0196
3 GO:0002053 positive regulation of mesenchymal cell proliferation 0.02
3 GO:0042169 SH2 domain binding 0.02
4 GO:0008543 fibroblast growth factor receptor signalling pathway 0.0012
4 GO:0007173 epidermal growth factor receptor signalling pathway 0.0027
4 GO:0019901 protein kinase binding 0.0033
4 GO:0048015 phosphatidylinositol-mediated signalling 0.0042
4 GO:0008286 insulin receptor signalling pathway 0.0077
4 GO:0006974 cellular response to DNA damage stimulus 0.027
4 GO:0010907 positive regulation of glucose metabolic process 0.041
4 GO:0005158 insulin receptor binding 0.042
-5 N/A N/A N/A
Table B.24: Gene ontology (GO) term enrichment analysis for predicted PAK1 substrates.
Shown are all positions that the kinase was found to be significantly over-represented at.
position GO term Description E-value
All GO:0019901 protein kinase binding 1.1e-05
All GO:0006915 apoptotic process 0.0003
All GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation 0.014
-2 N/A N/A N/A
3 GO:0010907 positive regulation of glucose metabolic process 0.016
3 GO:0002053 positive regulation of mesenchymal cell proliferation 0.018
4 GO:0019901 protein kinase binding 3.8e-05
4 GO:0032000 positive regulation of fatty acid beta-oxidation 0.0003
4 GO:0005158 insulin receptor binding 0.0078
4 GO:0048015 phosphatidylinositol-mediated signalling 0.01
4 GO:0010907 positive regulation of glucose metabolic process 0.013
4 GO:0032467 positive regulation of cytokinesis 0.014
4 GO:0008286 insulin receptor signalling pathway 0.017
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position GO term Description E-value
Continued from previous page
4 GO:0051256 mitotic spindle midzone assembly 0.039
4 GO:0097149 centralspindlin complex 0.039
4 GO:0008543 fibroblast growth factor receptor signalling pathway 0.041
Table B.25: Gene ontology (GO) term enrichment analysis for predicted PKA substrates.
Shown are all positions that the kinase was found to be significantly over-represented at.
position GO term Description E-value
All GO:0004871 signal transducer activity 3.33e-05
All GO:0048011 neurotrophin TRK receptor signalling pathway 0.0001
All GO:0007165 signal transduction 0.0005
All GO:0005737 cytoplasm 0.0017
All GO:0005515 protein binding 0.004
All GO:0043065 positive regulation of apoptotic process 0.01
All GO:0019901 protein kinase binding 0.029
All GO:0007399 nervous system development 0.049
2 GO:0042301 phosphate ion binding 0.0302
3 N/A N/A N/A
4 GO:0008543 fibroblast growth factor receptor signalling pathway 0.0001
4 GO:0007173 epidermal growth factor receptor signalling pathway 0.0003
4 GO:0019901 protein kinase binding 0.0006
4 GO:0032000 positive regulation of fatty acid beta-oxidation 0.002
4 GO:0048015 phosphatidylinositol-mediated signaling 0.0073
4 GO:0048011 neurotrophin TRK receptor signalling pathway 0.0087
4 GO:0008286 insulin receptor signalling pathway 0.013
4 GO:0060397 JAK-STAT cascade involved in growth hormone signalling pathway 0.019
4 GO:0042593 glucose homeostasis 0.032
4 GO:0005829 cytosol 0.034
5 GO:0097149 centralspindlin complex 0.015
5 GO:0048008 platelet-derived growth factor receptor signaling pathway 0.049
5 GO:0090399 replicative senescence 0.049
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Table B.26: Gene ontology (GO) term enrichment analysis for substrates predicted to con-
tain an NLS and a phosphorylation site at the specific position relative to the NLS.
position GO term Description E-value
-10 GO:0005694 chromosome 0.0017
-10 GO:0000786 nucleosome 0.024
Continued on next page
position GO term Description E-value
Continued from previous page
-9 GO:0005730 nucleolus 0.045
-8 N/A N/A N/A
-7 N/A N/A N/A
-6 N/A N/A N/A
-5 N/A N/A N/A
-4 N/A N/A N/A
-3 N/A N/A N/A
-2 N/A N/A N/A
-1 N/A N/A N/A
0 N/A N/A N/A
1 N/A N/A N/A
2 N/A N/A N/A
3 GO:0005694 chromosome 0.0039
4 N/A N/A N/A
5 GO:0006974 cellular response to DNA damage stimulus 0.0025
5 GO:0008274 gamma-tubulin ring complex 0.015
5 GO:0097149 centralspindlin complex 0.015
6 GO:0048011 neurotrophin TRK receptor signaling pathway 0.025
7 GO:0000786 nucleosome 5.31e-10
7 GO:0006334 nucleosome assembly 2.02e-08
7 GO:0032982 myosin filament 1.53e-05
7 GO:0005694 chromosome 2.90e-05
7 GO:0005859 muscle myosin complex 0.0001
7 GO:0046982 protein heterodimerization activity 0.0007
7 GO:0030016 myofibril 0.002
7 GO:0016459 myosin complex 0.015
7 GO:0000146 microfilament motor activity 0.019
7 GO:0042742 defense response to bacterium 0.019
7 GO:0005925 focal adhesion 0.041
7 GO:0030049 muscle filament sliding 0.041
8 GO:0000786 nucleosome 1.98e-07
8 GO:0006334 nucleosome assembly 2.42e-06
Continued on next page
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position GO term Description E-value
Continued from previous page
8 GO:0005694 chromosome 0.00027
8 GO:0046982 protein heterodimerization activity 0.0087
8 GO:0042742 defense response to bacterium 0.009
9 GO:0006334 nucleosome assembly 8.68e-08
9 GO:0000786 nucleosome 2.12e-07
9 GO:0005694 chromosome 0.0004
10 N/A N/A N/A
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Figure B.1: ROC plots showing the prediction accuracy of the combined and context models
for predicting kinases substrates from the human CMGC family of kinases. The ROC curves
are calculated up to the first 50 false positives from a 10-fold cross-validation run.
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Figure B.2: ROC plots showing the prediction accuracy of the combined and context models
for predicting kinases substrates from the human AGC family of kinases. The ROC curves
are calculated up to the first 50 false positives from a 10-fold cross-validation run.
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Figure B.3: ROC plots showing the prediction accuracy of the combined and context models
for predicting kinases substrates from the human TK family of kinases. The ROC curves are
calculated up to the first 50 false positives from a 10-fold cross-validation run.
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Figure B.4: ROC plots showing the prediction accuracy of the combined and context models
for predicting kinases substrates from the human CAMK family of kinases. The ROC curves
are calculated up to the first 50 false positives from a 10-fold cross-validation run.
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Figure B.5: ROC plots showing the prediction accuracy of the combined and context models
for predicting kinases substrates from the human ’other’ family of kinases. The ROC curves
are calculated up to the first 50 false positives from a 10-fold cross-validation run.
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Figure B.6: ROC plots showing the prediction accuracy of the combined and context models
for predicting kinases substrates from the human STE family of kinases. The ROC curves are
calculated up to the first 50 false positives from a 10-fold cross-validation run.
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Figure B.7: ROC plots showing the prediction accuracy of the combined and context models
for predicting kinases substrates from the human CK1 family of kinases. The ROC curves are
calculated up to the first 50 false positives from a 10-fold cross-validation run.
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Figure B.8: ROC plots showing the prediction accuracy of the combined and context models
for predicting kinases substrates from the human atypical family of kinases. The ROC curves
are calculated up to the first 50 false positives from a 10-fold cross-validation run.
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Figure B.9: ROC plots showing the prediction accuracy of the combined and context models
for predicting kinases substrates from the mouse CMGC family of kinases. The ROC curves
are calculated up to the first 50 false positives from a 10-fold cross-validation run.
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Figure B.10: ROC plots showing the prediction accuracy of the combined and context
models for predicting kinases substrates from the mouse TK family of kinases. The ROC
curves are calculated up to the first 50 false positives from a 10-fold cross-validation run.
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Figure B.11: ROC plots showing the prediction accuracy of the combined and context
models for predicting kinases substrates from the mouse AGC family of kinases. The ROC
curves are calculated up to the first 50 false positives from a 10-fold cross-validation run.
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Figure B.12: ROC plots showing the prediction accuracy of the combined and context
models for predicting kinases substrates from the yeast CMGC family of kinases. The ROC
curves are calculated up to the first 50 false positives from a 10-fold cross-validation run.
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Figure B.13: ROC plots showing the prediction accuracy of the combined and context
models for predicting kinases substrates from the yeast AGC family of kinases. The ROC
curves are calculated up to the first 50 false positives from a 10-fold cross-validation run.
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Figure B.14: ROC plots showing the prediction accuracy of the combined and context
models for predicting kinases substrates from the yeast ’other’ family of kinases. The ROC
curves are calculated up to the first 50 false positives from a 10-fold cross-validation run.
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Figure B.15: ROC plots showing the prediction accuracy of the combined and context
models for predicting kinases substrates from the yeast CAMK family of kinases. The ROC
curves are calculated up to the first 50 false positives from a 10-fold cross-validation run.
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B.1 Identifying expected sequence motifs from context
As the Bayesian network combined two diverse types of information, we were interested in
observing what the model “expects” from a kinase binding motif in response to the protein
interaction and cell-cycle data that is presented to it. To do this we took the full set of human
proteins from Uniprot (canonical plus isoforms) and obtained their relevant context information.
For each protein, we first set the context parameters in the Bayesian network: the protein
interaction nodes, cell-cycle nodes and kinase nodes (except the kinase being queried). We used
the most probable explanation (MPE) form of inference to determine the most likely value for
the query kinase phosphorylating the substrate, as well as the expected values of the dimer and
trimer nodes. If the model at this point did not believe the query kinase to be phosphorylating
the protein, the protein was discarded. Otherwise, we then used the expected values of the
k-mer variables to set their respective nodes, and queried each of the position-specific amino
acid nodes, inferring the probability of each potential amino acid.
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Figure B.16: Comparison of sequence logos for PKA kinase. Left logo shows amino acid
probabilities expected by the combined model for PKA binding sites when context information
for a query substrate indicates that PKA will target the protein. Right logo was made using
peptides from actual PKA phosphorylation substrates. Logo generated using WebLogo3 (47).
For each position in the motif, we then took the sum of probabilities for each amino acid across
the samples predicted to be phosphorylated by the kinase. This resulted in a position-specific
matrix of counts across the 20 amino acids for the kinase. In order to visualise the position-
specific amino acid counts we used WebLogo 3 (47) to generate sequence logos from the count
matrix.
Figure B.16 shows a sequence logo generated from the probability distributions of amino acids
from proteins predicted to be PKA substrates, based only on context data being provided to
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the model. We compared this to a sequence logo generated from actual PKA substrates from
PhosphoSitePlusr. The comparison shows that there is a high level of similarity between
the expected amino acids, given the context information, and the amino acid frequencies from
actual PKA substrates. This demonstrates that the model is able to have a prior expectation
about what binding site to expect on a protein sequence, before actually seeing the sequence.
B.2 Web-server workflow
Uniprot reviewed (Swissprot) proteins were downloaded for human (July, 2014), mouse (Febru-
ary, 2015) and yeast (February, 2015). The full set of canonical and isoform proteins were
downloaded for the three species. For each kinase, the combined model was trained on the full
set of training data. Each protein in the relevant proteome was submitted to the model and
the probability of it being a substrate of the kinase was queried. The kinase predictions for
each substrate were stored in an SQLite3 database.
When a user uploads a Fasta file of protein sequences, they are submitted for a BLASTP query
against the proteome of the chosen species (human, mouse or yeast). If an exact match is
made for a protein in the database, that protein is retrieved. We also wanted to allow for users
to submit isoforms or homologs that are not in the database; i.e. such proteins would obtain
a substrate prediction based on the closest relative protein in the database. Therefore, if an
exact match is not made, proteins in the database that obtain an E-value < 0.001, and have
a sequence identity of at least 90% will be considered. The highest E-value is taken, and all
proteins in the database that obtain the E-value are returned. Once proteins in the database
have been identified from the BLASTP search, the requested kinase predictions are retrieved.
The user’s sequences are then scanned using the sequence model and each potential phospho-
rylation site is scored. If the user has requested that their predictions be thresholded according
to P-value, only the results that fall below the chosen P-value threshold will be returned. The
output is an interactive table of results for each potential phosphorylation site in the user’s
submitted proteins for each kinase that was queried. Users can filter their results by providing
a list of protein names, or protein names and sites. The results can also be downloaded as a
tab-delimited text file. The results for each protein can be viewed separately by clicking on a
desired protein to be redirected to the “Protein Viewer” page, which presents an interactive
view of the protein annotated with predicted phosphorylation sites.
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In addition to submitting protein sequences for analysis, the option exists to download proteome-
wide sets of kinase-substrate predictions. Similar to the submission page, users are able to select
sets of kinases from either human, mouse of yeast, though instead of uploading protein sequence,
there is an option to choose between downloading predictions for the set of Swissprot canonical
or isoform proteins. P-values for predictions can also be calculated.
Results visualisation
In order to create a way for visualising the potential kinase binding sites on a protein, we
implemented a “Protein Viewer” page. This was based on the BioJS (181) package pViz
(182), which allows the zoomable visualisation of an amino acid sequence with multiple rows
of annotations on specified positions on the sequence. For a protein, the visualisation consists
of a row of annotations representing potential phosphorylation sites for each kinase that a user
queries. Phosphorylation site predictions are presented as coloured circles, where the shade of
the circle indicates the strength of the context prediction and the size of the circle indicates the
strength of the sequence prediction for that site. When a user clicks on a site, an information
box is displayed showing the details of that prediction.
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Table C.1: Variants are listed according to the cancer or disease they are associated with.
Each row contains protein name as UniProt accession, the location of the variant and phos-
phorylation site, the kinase predicted to target the site, the reference and variant scores for
the peptide.
Cancer Protein Variant Phos. Kinase Rsubst. Rsite Vsite Ecombined Peptide
Ovarian P35222 G555A T551 Akt2 1 1 4.95e-05 9.36e-09 QDTQRRTpSMG[G/A]TQ
P26010 Y753H Y753 FAK 1 1 0 2.23e-08 YRLSVEI[Yp/H]DRREYSR
Q7KZI7 S197N S197 NEK6 1 1 0 2.3e-08 KIADFGF[Sp/N]NEFTFGN
P51813 S212R S212 GSK3B 0.998 1 0 1.33e-07 PPSSST[Sp/R]LAQYDS
P46939 M1256R T1259 MARK2 1 0.914 0.0005 4.47e-05 R[M/R]KSTpEVLP
P43355 K278I Y276 Brk 0.998 1 0.000979 0.000103 RALAETSYpV[K/I]VLEYV
P18846 L71I S72 MSK1 1 0.0525 0.00138 0.000107 RKILKD[L/I]SpSEDTRGR
P35222 G555A T556 Akt2 1 0.0694 7.46e-09 0.000108 RTSMG[G/A]TpQQQFVE
Q96BY6 T1347M T1347 CAMK2D 0.681 0.351 0 0.00011 CFLHIMK[Tp/M]ISYETLI
Q13009 S170F S170 PKCA 1 0.982 0 0.00013 SFKKKR[Sp/F]KSADIW
Q9BQQ3 R106C S109 MAPKAPK2 0.486 0.999 0.00399 0.000331 SF[R/C]RASpEQVWH
Q08999 P547A T541 CDK7 1 0.21 0.0142 0.000577 ACCLEVVTpFSYKP[P/A]G
Q96KQ7 S119F S118 CDK2 0.711 0.964 0.00256 0.0013 ATKSFPSp[S/F]PSKGG
P50747 S83N S83 MARK2 0.321 0.87 0 0.00131 SASG[Sp/N]EPAG
O94988 R648Q S650 AMPKA1 0.207 0.978 0.0507 0.00132 FMR[R/Q]RSpSSLGS
O94988 R648Q S651 AMPKA1 0.207 0.942 0.0156 0.00132 MR[R/Q]RSSpSLGSY
Q96KQ7 S119F S119 CDK5 0.091 0.806 0 0.00154 KSFPS[Sp/F]PSKGG
O75182 S130L S126 IKKB 0.0176 0.979 0.000183 0.0016 NIQSPLTSpQEN[S/L]HNH
Q13136 R137Q S138 MARK2 0.214 0.752 7.89e-09 0.00199 RHE[R/Q]SpLRMT
Q8N9Q2 T47R T47 CK2A1 1 1 0 0.002 VLDVSS[Tp/R]SSEDSD
Q96D09 F508C S512 PKG1 0.98 0.975 0.0982 0.00226 [F/C]RSTSpPFGI
P55209 K276Q T269 MST1 0.458 0.267 0.0983 0.00233 WKKGKNVTpLKTIKK[K/Q]
P04198 P358L S355 CDK6 0.000617 0.55 0.000508 0.00236 KKIKSEASpPR[P/I]LKSV
Q2M1Z3 N776T S778 CDK4 0.0007 0.959 0.037 0.00246 VGGPG[N/T]LSpPPLPPAP
P20338 A208T S204 MAPKAPK2 0.0707 0.953 0.00571 0.00268 LRQLRSpPRR[A/T]Q
Q14149 V872I T874 GRK2 0.995 0.982 0.14 0.00279 QTATD[V/I]STSpSNIEES
Q14149 V872I S875 GRK2 0.995 0.999 0.167 0.00291 TATD[V/I]STSSpNIEESV
Q14686 S1349A S1349 CDK2 0.538 0.939 0 0.0031 SPGRQN[Sp/A]KAPKLT
Q04206 E127Q S131 ATR 0.889 0.87 0.0366 0.0032 L[E/Q]QAISpQRIQT
Q86UR5 R1113W S1116 Akt1 0.473 0.991 0.024 0.00324 DRA[R/W]SASpTNCLRP
O75182 S130L T125 IKKB 0.0176 0.924 0.00019 0.00438 LNIQSPLTpSQEN[S/L]HN
O75182 S130L S130 IKKB 0.0176 0.921 0 0.00447 PLTSQEN[Sp/L]HNHGDGA
Q14517 S157P S150 NEK6 0.00491 0.00376 0.000213 0.00461 NDLRPLFSpPTSYSV[S/P]
Q92610 T1024N S1027 PKCG 0.42 0.885 0.0502 0.00488 QSFH[T/N]PNSpLRKHIRN
Q92766 S1140F S1140 ERK5 0.404 0.795 0 0.00567 ASSPEAA[Sp/F]PTEQGPA
Q15361 S240W S240 ATR 0.00249 0.949 0 0.00612 AMPEG[Sp/W]QAGRE
A0PJX4 Q132H S130 DNAPK 0.0411 0.995 0.0237 0.00672 CLRPKEPSpQ[Q/H]PIRFS
Q8TDJ6 L964P S960 CaMK4 0.865 0.804 0.316 0.00742 PHSSSpIAN[L/P]
Continued on next page
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P12235 R188K Y187 ALK 0.827 0.754 5.87e-08 0.0075 GIIIYp[R/K]AAY
P08151 R637Q S640 PKD1 0.205 0.855 0.0074 0.00754 VT[R/Q]RASpDPAQA
P62995 R62G S64 AurB 0.102 0.998 0.00645 0.00762 R[R/G]SSpRRH
O94988 R648Q S650 CAMK1A 0.0375 0.0134 9.08e-06 0.00912 FMR[R/G]RSpSSLGS
Q86VZ2 S240R T247 PKCG 0.206 0.751 0.0191 0.00996 [S/R]RGRCLKTpYTGHKNE
P17020 S129Y S129 RSK2 0.00935 0.82 0 0.0105 GRRLPQ[Sp/Y]LSQEGD
P09848 V971L Y974 Lyn 0.0304 0.961 0.163 0.0107 RALK[V/L]KAYpFSISWS
Q15047 S504C S504 GSK3B 0.174 0.928 0 0.011 SVGSGH[Sp/C]SPTSPA
P20930 R2018K S2017 P38B 0.000651 0.0439 6.53e-06 0.0115 QLQSADSSp[R/K]HSGIGH
Q9BQQ3 R106C S104 PKCD 0.0198 0.892 0.0153 0.0121 ASVRFCSpF[R/C]RASE
O60237 G422V S421 CaMK4 0.734 0.316 2.35e-05 0.0122 RRFSSp[G/V]LFN
Q8WXG6 R1643W S1646 PKD2 0.000201 6.86e-05 5.97e-08 0.0125 RTPP[R/W]PVSpS
Q8IWI9 S645R S645 ERK2 0.013 0.802 0 0.0128 STKNTPV[Sp/R]PGSTFPD
P18583 S1782F S1780 p70S6K 0.00452 0.903 0.0084 0.0132 SMPERASpE[S/F]SSEE
Q14653 E137K T135 DNAPK 0.138 0.893 0.0187 0.0137 GGGSTSDTpQ[E/K]DILDE
Q9NQL9 S382R S381 AMPKA1 0.098 0.945 0.268 0.0151 LARSQSp[S/R]PFLP
O14717 G155V S150 P38B 0.000301 0.0272 3.02e-06 0.0164 QYQEFLLSpPTSL[G/V]IP
Q9NUQ6 I136K S135 CaMK4 0.515 0.204 0.00342 0.0182 EKKISp[I/K]LEE
Q96AV8 S160R S160 CDK3 1.08e-05 5.36e-06 0 0.0192 KFLARYP[Sp/R]YPLSTEK
P78312 V259M S261 mTOR 0.00387 0.955 0.0271 0.0212 RSPPS[V/M]SSpASSGSGS
Q9BTC0 S660N S660 DNAPK 0.00101 0.967 0 0.022 PGRLGAM[Sp/N]AAPSQPN
P30533 Q244K S242 PKG1 0.706 0.656 0.0731 0.0237 LRRVSpH[Q/K]GY
P52948-2 R538H T536 CDK6 2.12e-06 0.234 0.0634 0.0237 TPTHYKLTpP[R/H]PATRV
Q9BYJ9 V200I T202 PKCE 0.0236 0.771 0.0258 0.0249 VSSSA[V/I]KTpVGSVVSS
Q8N3K9 T2592I T2592 PLK1 0.000765 0.842 0 0.0263 SFSLVKA[Tp/I]SVTEKSE
P50052 R350Q S353 p90RSK 0.000294 0.586 0.0953 0.0317 SMSC[R/Q]KSSpSLREMET
Q86UR5 R1113W S1116 AMPKA1 0.0404 0.604 0.0128 0.0336 RA[R/W]SASpTNCLR
Q6W4X9 T1911M T1911 GSK3B 0.0328 0.882 0 0.0347 SPSSFS[Tp/M]AKTSTS
Q8N4N8 R110C T113 SGK1 0.17 0.976 0.000545 0.0352 [R/C]TATpKWV
P18583 S1782F S1782 CK2A1 0.994 1 0 0.0391 PERASE[Sp/F]SSEEKD
Q5M775 S312P S312 CK1A 0.323 0.985 0 0.0395 HGNALRT[Sp/P]GSSSSDV
Q9ULE3 S310A S310 mTOR 0.00139 0.885 0 0.0427 PPPPLPS[Sp/A]PPPSSVN
Q9UL68 S237R S237 CK2A1 0.998 1 0 0.0438 NSLEDD[Sp/R]DKNENL
O94988 R648Q S650 AurA 0.0837 0.963 0.0028 0.0456 R[R/Q]RSpSSL
Q9ULE3 S310A S310 GSK3B 0.00684 0.921 0 0.0465 PPPLPS[Sp/A]PPPSSV
Breast P14859 S88F S88 DNAPK 1 1 0 1.95e-06 SQQPSQP[Sp/F]QQPSVQA
P14859-5 S111F S111 DNAPK 1 1 0 8.66e-06 SQQPSQP[Sp/F]QQPSVQA
P43355 K278T Y276 Brk 0.998 1 0.000491 0.000103 RALAETSYpV[K/T]VLEYV
P03372 H6Y T2 VRK1 0.0492 0.0792 0.00421 0.00111 MTpMTL[H/Y]TKA
Q99490 D816Y S818 P38B 0.0186 0.587 0.000173 0.00126 CTPSG[D/Y]LSpPLSREPP
P54646 S523G S527 p90RSK 0.36 0.78 0.00501 0.00214 LTG[S/G]TLSSpVSPRLGS
P43487 E16D T13 CK2A2 0.0196 0.135 0.021 0.00259 DTHEDHDTpST[E/D]NTDE
Q9NTX9 S95G S95 CK2A1 1 1 0 0.00313 ADEDSA[Sp/G]DLSDSE
Q9NTX9 S95G S95 CK1D 0.697 0.993 0 0.00354 NADEDSA[Sp/G]DLSDSER
P54646 S523G S529 p90RSK 0.36 0.693 0.175 0.00412 G[S/G]TLSSVSpPRLGSHT
P43487 E16D S14 CK2A2 0.0196 0.02 0.0116 0.00597 THEDHDTSpT[E/D]NTDES
O14681 T319A S326 CDK6 1.96e-05 0.451 0.0093 0.00642 [T/A]SAEKFPSpPHPSPAK
Q96RK0 E104K S105 JNK1 0.00186 0.98 0.182 0.0112 PGATCP[E/K]SpPGPGPPH
Q702N8 L929H S925 PKD2 0.000176 6.29e-05 1.54e-08 0.0134 SKASERSSpVQL[L/H]ASC
Q9H8V3 T833P T833 PKCA 0.699 0.951 0 0.0173 SRAIKK[Tp/P]SKKVTR
Q9NTX9 S95G S93 CK1D 0.697 0.953 0.0528 0.0178 KENADEDSpA[S/G]DLSDS
Q86UP2 T1316P T1316 GRK2 0.19 0.736 0 0.0304 NSDVSPE[Tp/P]ESSEKET
Q86UP2 T1316P S1319 GRK2 0.19 0.678 0.000182 0.0357 VSPE[T/P]ESSpEKETMSV
Colorectal P04637 E271K S269 CAMK2A 1 0.781 0.011 0.000131 NLLGRNSpF[E/K]VRVC
Q9P253 A913S S912 ERK5 0.495 0.848 0.0394 0.00475 APPPAKGSp[A/S]RAKEAE
Q9NPD5 I292M S293 CaMK4 0.832 0.524 3.21e-08 0.00785 ERK[I/M]SpLSLH
Q6ZMN7 G784R S783 CaMK4 0.792 0.454 1.52e-06 0.00954 TQSSSp[G/R]QSS
Q92953 V450I S448 ROCK1 0.326 0.845 0.00479 0.012 RAKRNGSpI[V/I]SMNL
Q6ZMN7 G784R S781 CaMK4 0.792 0.171 1.38e-05 0.0131 AATQSpSS[G/R]Q
Q92729 R856C S853 CDK1 0.0472 0.903 0.0725 0.0164 LGGSpPR[R/C]
P17936 T7M T7 PKACA 0.311 0.903 0 0.0205 QRARP[Tp/M]LWAAA
Q9BTA9 S475L S475 CDK2 0.055 0.919 0 0.0275 ISTPPV[Sp/L]SQPKVS
Liver P35222 T41A T41 GSK3A 1 1 0 2.28e-09 GIHSGAT[Tp/A]TAPSLSG
P35222 S37F S37 GSK3A 1 1 0 2.28e-09 YLDSGIH[Sp/F]GATTTAP
P35222 T41A T41 IKKA 1 1 0 7.97e-09 GIHSGAT[Tp/A]TAPSLSG
P35222 S37F S37 IKKA 1 1 0 7.97e-09 YLDSGIH[Sp/F]GATTTAP
P35222 T41A T41 GSK3B 1 0.997 0 8.13e-06 IHSGAT[Tp/A]TAPSLS
Continued on next page
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P35222 S37F S37 JNK1 1 0.984 0 1.33e-05 YLDSGIH[Sp/F]GATTTAP
P35222 T41A S45 GSK3A 1 0.11 1.16e-06 2e-05 GAT[T/A]TAPSpLSGKGNP
P35222 S37F T40 GSK3A 1 1 0.923 2.14e-05 SGIH[S/F]GATTTAPSLS
P35222 T41A T41 JNK1 1 0.961 0 2.15e-05 GIHSGATp[T/A]TAPSLSG
P35222 T41A S47 GSK3A 1 0.0535 1.43e-06 2.48e-05 T[T/A]TAPSLSpGKGNPEE
P35222 T41A T40 GSK3A 1 1 0.965 2.95e-05 SGIHSGATp[T/A]TAPSLS
P35222 S37F S33 CK2A2 1 0.0545 0.00319 4.62e-05 QQQSYLDSpGIH[S/F]GAT
P35222 T41A T40 JNK1 1 0.896 0.0106 4.69e-05 SGIHSGATp[T/A]TAPSLS
Q13950 V203F T205 Pim1 1 1 0.0302 4.7e-05 TLTIT[V/F]FTpNPPQVAT
Q9Y6B2 S8C S2 MSK1 0.717 0.799 0.00184 7.28e-05 MSpEMAEL[S/C]E
Q9Y463 K47N S42 CAMK1A 0.981 0.948 0.00136 8.16e-05 FRDATSpAPLR[K/N]
P35222 T41A S47 IKKA 1 0.882 0.21 0.000184 T[T/A]TAPSLSpGKGNPEE
P35222 S37F T40 JNK1 1 0.896 0.198 0.000188 SGIH[S/F]GATTTAPSLS
P04083 E139V T132 CK2A2 0.431 0.773 0.494 0.000875 AAMKGLGTpDEDTLI[E/V]
Q92997 S188G S188 CK1D 0.999 0.954 0 0.00164 SSELETT[Sp/G]FFDSDED
Q8IXF0 T461I S458 p70S6K 0.27 0.964 0.00343 0.00173 PEKTSESpSE[T/I]SDS
Q8IXF0 T461I S464 GRK2 0.998 0.999 0.175 0.00208 ESSE[T/I]SDSpESDSKDT
Q8IXF0 T461I S459 p70S6K 0.27 0.927 0.00059 0.00262 EKTSESSpE[T/I]SDSE
Q8IXF0 T461I T461 GRK2 0.998 0.763 0 0.00273 KTSESSE[Tp/I]SDSESDS
P27816 S867G S867 MSK1 0.0005 0.00983 0 0.0057 RPKSTST[Sp/G]SMKKTTT
Q8IXF0 T461I T461 CK2A1 0.998 1 0 0.0212 TSESSE[Tp/I]SDSESD
O14647 E167G S165 CK1D 0.282 0.962 0.0494 0.0265 DEQEQGTSpA[E/G]SEPEQ
O43347 L308Q T304 NEK6 8.54e-05 6.19e-05 8.07e-11 0.0291 PGSTPSRTpGGF[L/Q]GTT
Q01081 R202H S206 PAK1 0.0227 0.915 0.0301 0.0359 [R/H]RSRSpRDRG
Q9Y463 K47N S49 PKG1 0.51 0.454 0.000119 0.0395 LR[K/N]LSpVDLI
Q9Y463 L48F S49 PKG1 0.51 0.454 0.00388 0.0398 LRK[L/F]SpVDLI
Pancreatic Q9BYV9 T519I T519 p70S6K 1 1 0 1.14e-08 LETRTR[Tp/I]SSSCSS
P04637 E271K S269 CAMK2A 1 0.781 0.011 0.000131 NLLGRNSpF[E/K]VRVC
Q9BYV9 T519I S525 p70S6K 1 0.84 0.0917 0.000294 [T/I]SSSCSSpYSYAED
P56715 A135V S137 MARK2 0.848 0.987 2.83e-06 0.000418 IS[A/V]HSpPPHP
P05129 P524R Y521 Brk 0.356 0.227 0.000117 0.000629 TFCGTPDYIA[P/R]EIIA
P05129 P524R T518 LKB1 1 0.156 0.000956 0.00106 TTRTFCGTpPDYIA[P/R]E
P16333 R63W S66 CDK3 0.000153 0.000188 4.82e-05 0.00365 KNSA[R/W]KASpIVKNLKD
O95954 R446W S449 PKD1 0.184 0.982 0.0623 0.00366 LR[R/W]AVSpVPLTL
Q6P0Q8 K1420N S1418 CAMK1A 0.145 0.0533 0.00125 0.00433 AALAASpE[K/N]KLA
Q8NEV4 R1358L S1355 PKCB 0.831 0.995 0.0408 0.00473 VFIQSpKY[R/L]G
Q9UQ35 R2530Q S2532 AurB 0.413 0.993 0.00288 0.00483 E[R/Q]RSpSSS
Q9NZ56 R446Q S450 RSK2 0.0283 0.934 0.107 0.00676 KR[R/Q]PEPSpLSRGSR
O95935 P122L S121 CDK1 0.0235 0.821 0.00407 0.0343 PKGSp[P/L]AR
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